Insufficent data points (0) to generate a histogram of RSD values

( Species:Human)
ANOVA results for this metabolite where p-value <=0.05

Name	Study_id	Analysis_id	ANOVA p-Value	FDR	Experimental Conditions (factors)
isohydroxybutyric acid	ST000092	AN000146	3.930E-230	7.460E-229	Solution Added;N/A;None;Urease;Water
Nicotine-1-N-oxide	ST001048	AN001716	3.070E-167	2.260E-165	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
L-Glutamic Acid / N-Methyl-D-aspartic acid	ST001048	AN001716	3.810E-154	1.870E-152	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
glucosylglycerol	ST000092	AN000146	2.800E-139	3.550E-138	Solution Added;N/A;None;Urease;Water
Disaccharide	ST000589	AN000904	3.570E-126	1.800E-125	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
3-Indolelactic acid	ST000589	AN000904	7.810E-121	3.550E-120	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
OH-MiNP (7-OH-(Mono-methyl-octyl) phthalate / Mono-(4-methyl-7-hydroxyloctyl) phthalate)	ST001048	AN001717	3.460E-118	2.940E-116	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
Methyl eicosatrienoate	ST000589	AN000904	3.390E-116	1.260E-115	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
Phenylglycine	ST001048	AN001716	9.020E-109	2.040E-107	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
ZEATIN [ISTD] (M+Cl)-	ST000818	AN001296	1.990E-105	1.890E-103	Categorization;Amhara;Dizi;Hadza_settled;Hadza_traditional;H...
ZEATIN [ISTD] (M-H)-	ST000818	AN001296	4.610E-101	2.190E-99	Categorization;Amhara;Dizi;Hadza_settled;Hadza_traditional;H...
GAB-13C0	ST000114	AN000194	1.430E-94	9.960E-93	Oxygen Condition;hypoxia;normoxia
GAB-ALL	ST000114	AN000194	1.430E-94	9.960E-93	Oxygen Condition;hypoxia;normoxia
glycodeoxycholate/glycochenodeoxycholate	ST001142	AN001876	7.320E-81	2.160E-79	Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
6-Deoxyhexose	ST000589	AN000904	3.150E-80	8.530E-80	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
glucosylglycerol	ST000092	AN000146	1.440E-79	2.740E-78	Volume Urine (µL);100;10;25;50;5
isohydroxybutyric acid	ST000092	AN000146	2.000E-77	2.840E-76	Volume Urine (µL);100;10;25;50;5
cis-Cyclo[L-ala-L-Pro]	ST000974	AN001595	3.890E-75	3.020E-73	REGION;AHRI;MRC;SUN
cis/trans-hydroxyproline	ST001142	AN001875	2.010E-74	1.030E-73	Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
2-Ketoleucine	ST000589	AN000904	3.070E-72	7.600E-72	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
ZEATIN [ISTD] (M+Cl)-	ST000818	AN001296	4.770E-70	4.530E-68	Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
ZEATIN [ISTD] (M-H)-	ST000818	AN001296	1.690E-68	8.050E-67	Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
BOC-ALA-OH	ST000016	AN000033	1.210E-67	3.030E-65	Material;Cells;Media
Ovothiol A-cysteine disulfide	ST001201	AN001998	9.400E-65	3.680E-62	cell_type;iRBC;unRBC
2-Ketovaline	ST000589	AN000904	9.360E-62	2.060E-61	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
Methyl palmitate	ST000589	AN000904	6.410E-61	1.390E-60	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
Trisaccharide	ST000589	AN000904	7.830E-61	1.670E-60	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
gamma-thiomethyl glutamate	ST001202	AN002000	9.020E-59	1.820E-56	cell_type;iRBC;unRBC
psicoselysine	ST001201	AN001998	7.260E-57	9.460E-55	cell_type;iRBC;unRBC
Asp-Val-Pro-Ser	ST001201	AN001999	1.260E-56	4.500E-55	cell_type;iRBC;unRBC
Mevalolactone	ST001048	AN001716	4.310E-56	6.330E-55	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
2-chloro-3-methyl-maleylacetate	ST001201	AN001998	4.340E-56	3.390E-54	cell_type;iRBC;unRBC
Trp-Trp-Tyr-Tyr	ST001202	AN002000	8.160E-56	1.100E-53	cell_type;iRBC;unRBC
3-Pyridinebutanoic acid	ST000356	AN000583	1.940E-53	1.110E-51	Diagnosis;breast cancer;control
methylsuccinoylcarnitine (1)	ST000974	AN001595	2.270E-53	1.130E-51	REGION;AHRI;MRC;SUN
ZEATIN [ISTD] (M+H)+	ST000842	AN001357	3.400E-53	3.940E-51	Sample type;Muscles;Plasma;Pooled sample
glucosylglycerol	ST000092	AN000146	1.500E-51	5.710E-50	Gender;N/A;Female;Male
D/L N-Acetylglucosamine / D/L N-Acetylgalactosamine / D/L N-Acetylmannosamine	ST001048	AN001716	5.780E-51	7.720E-50	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
2-oxo-5-methylthiopentanoic-acid	ST001201	AN001998	2.050E-50	6.680E-49	cell_type;iRBC;unRBC
Tartronic acid	ST000589	AN000904	4.310E-50	8.090E-50	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
L-Valine/Methyl 4-Aminobutyrate	ST001317	AN002192	8.944E-50	1.252E-48	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
L-Valine/Methyl 4-Aminobutyrate	ST001317	AN002192	8.944E-50	1.252E-48	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
HEPES	ST001202	AN002001	1.250E-49	7.990E-48	cell_type;iRBC;unRBC
glucosylglycerol	ST000092	AN000146	3.050E-49	1.160E-47	Ethnicity;N/A;Asian;Black;Caucasian;Hispanic
methiin	ST001202	AN002000	3.350E-49	1.500E-47	cell_type;iRBC;unRBC
L-methioninamide	ST001204	AN002005	3.860E-48	5.120E-46	cell_type;iRBC;unRBC
L-Zeatine	ST000614	AN000939	3.870E-48	2.980E-46	Diagonsis;Benign;Cancer;Normal
S-Methyl-5-thio-D-ribose 1-phosphate	ST001201	AN001999	5.200E-48	6.980E-47	cell_type;iRBC;unRBC
L-Zeatine	ST000614	AN000939	2.100E-47	1.620E-45	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
hexoses (HILIC neg)	ST001142	AN001876	3.470E-47	4.100E-46	Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
Ala-Ala-Asp-Tyr	ST001201	AN001999	4.300E-47	5.320E-46	cell_type;iRBC;unRBC
C8-Ceramide m+13	ST000644	AN000976	2.330E-46	9.470E-45	tracer;13C-glucose;13C-glutamine;No label
hexoses (HILIC neg)	ST001142	AN001876	7.600E-46	4.480E-44	Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
C8-Ceramide m+15	ST000644	AN000976	1.790E-45	6.340E-44	tracer;13C-glucose;13C-glutamine;No label
5-Amino-6-ribitylamino uracil	ST000356	AN000583	1.610E-44	4.580E-43	Diagnosis;breast cancer;control
L-cysteine sulfinate	ST001201	AN001999	4.040E-44	4.200E-43	cell_type;iRBC;unRBC
gamma-thiomethyl glutamate	ST001201	AN001998	2.430E-43	5.580E-42	cell_type;iRBC;unRBC
hexoses (HILIC pos)	ST001142	AN001875	3.470E-43	1.340E-42	Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
C8-Ceramide m+11	ST000644	AN000976	2.320E-42	6.590E-41	tracer;13C-glucose;13C-glutamine;No label
Hexose Monophosphate Pool	ST000450	AN000706	2.610E-42	1.460E-40	gender;Female;Male
Biflorin	ST000356	AN000583	3.570E-42	7.620E-41	Diagnosis;breast cancer;control
biphosphoglyceric acid	ST000608	AN000931	9.730E-42	1.670E-40	Sample_Type;blotter;serum
3-Phosphonopyruvate	ST001201	AN001999	1.020E-41	9.100E-41	cell_type;iRBC;unRBC
Gluconic acid or similar sugar acid	ST000586	AN000901	1.190E-41	4.470E-40	Plasma Volume;0 uL;150 uL;700 uL
L-Glutamyl 5-phosphate	ST001201	AN001998	1.290E-41	2.650E-40	cell_type;iRBC;unRBC
Allothreonine/L-Threonine	ST001317	AN002192	1.776E-41	1.658E-40	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Allothreonine/L-Threonine	ST001317	AN002192	1.776E-41	1.658E-40	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
FA oxo(21:0)	ST001201	AN001998	2.710E-41	5.290E-40	cell_type;iRBC;unRBC
methylhexadecanoic acid	ST000385	AN000620	7.320E-41	6.180E-40	Organ;Plasma;Serum;Serum or Plasma
N2-(D-1-Carboxyethyl)-L-arginine	ST001202	AN002000	1.500E-40	2.630E-39	cell_type;iRBC;unRBC
Ala-Lys-Asp-Gly	ST001201	AN001998	4.530E-40	8.430E-39	cell_type;iRBC;unRBC
Crotanecine	ST001202	AN002000	1.500E-39	2.420E-38	cell_type;iRBC;unRBC
C8-Ceramide m+9	ST000644	AN000976	1.830E-39	3.460E-38	tracer;13C-glucose;13C-glutamine;No label
melibionate	ST001202	AN002001	4.960E-39	1.270E-37	cell_type;iRBC;unRBC
deacetylcolchicine	ST001202	AN002000	2.500E-38	3.600E-37	cell_type;iRBC;unRBC
3-deoxy-D-galactose	ST001201	AN001998	4.830E-38	8.580E-37	cell_type;iRBC;unRBC
Allopregnanalone sulfate	ST000566	AN000869	5.090E-38	1.120E-36	Time point;Post;Pre;Baseline
Ala-Asp-Cys-Ser	ST001202	AN002000	5.710E-38	7.430E-37	cell_type;iRBC;unRBC
nonulose 9-phosphate	ST001202	AN002001	9.490E-38	2.020E-36	cell_type;iRBC;unRBC
2-Ketoleucine/ketoisoleucine	ST000586	AN000901	2.300E-37	1.960E-36	Plasma Volume;0 uL;150 uL;700 uL
2-Methylmaleate/Itaconate	ST001317	AN002193	5.539E-37	5.601E-36	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
2-Methylmaleate/Itaconate	ST001317	AN002193	5.539E-37	5.601E-36	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Disaccharide	ST000586	AN000901	5.980E-37	4.570E-36	Plasma Volume;0 uL;150 uL;700 uL
[13C]-PROLINE	ST000016	AN000033	1.060E-36	2.780E-35	Material;Cells;Media
Aldopentoses	ST000589	AN000904	2.110E-36	3.340E-36	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
1-(14-methyl-pentadecanoyl)-2-(8-[3]-ladderane-octanyl)-sn-glycerol	ST001202	AN002000	3.320E-36	3.530E-35	cell_type;iRBC;unRBC
L-Erythrulose	ST001201	AN001999	3.350E-36	2.630E-35	cell_type;iRBC;unRBC
Cohibin C	ST001202	AN002000	5.620E-36	5.660E-35	cell_type;iRBC;unRBC
Myoinositol-2-phosphate	ST000589	AN000904	5.880E-36	9.210E-36	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
3-Deoxy-D-manno-octulosonate 8-phosphate	ST001204	AN002004	1.280E-35	1.240E-33	cell_type;iRBC;unRBC
Methyl palmitate	ST000586	AN000901	1.720E-35	1.100E-34	Plasma Volume;0 uL;150 uL;700 uL
tartrazine	ST001202	AN002001	1.910E-35	3.490E-34	cell_type;iRBC;unRBC
m-hydroxybenzoic acid	ST001325	AN002207	2.036E-35	2.300E-34	Sample type;batch pool;chear plasma;master pool;red cross pl...
Benzyl tetradecyl dimethylammonium cation (disinfectant)	ST000089	AN000141	2.130E-35	1.900E-34	Treatment;Human Adipocytes grown in the ABSENCE of SKOV3ip1 ...
glycine-d5 deuterated	ST000865	AN001390	2.310E-35	6.470E-34	Patient group;CIRR;HCC;Pool CIRR;Pool HCC;POSSIBLE CASE;-
NMMA	ST001237	AN002055	3.030E-35	3.100E-33	CRF_MSKCC_Risk_Group;FAVORABLE;INTERMEDIATE;POOR
glycine-d5 deuterated	ST000865	AN001390	3.090E-35	4.540E-34	RACE;AA;Asian;EA;Hisp;Other;-
3-(4-hydroxyphenyl)propionate	ST000974	AN001595	4.120E-35	1.440E-33	REGION;AHRI;MRC;SUN
Pyroglutamate/Oxoproline	ST001317	AN002192	5.592E-35	3.914E-34	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Pyroglutamate/Oxoproline	ST001317	AN002192	5.592E-35	3.914E-34	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Gluconic acid or similar sugar acid 2	ST000586	AN000901	9.870E-35	5.810E-34	Plasma Volume;0 uL;150 uL;700 uL
[13C]-VALINE	ST000016	AN000033	2.750E-34	6.550E-33	Material;Cells;Media
13C-aminoadipic	ST000947	AN001555	3.560E-34	3.560E-34	Time point;120;135;150;-15;165;180;-30;-45;-60;60;baseline
C8-Ceramide m+7	ST000644	AN000976	4.830E-34	4.570E-33	tracer;13C-glucose;13C-glutamine;No label
Galactose-N-acetylgalactosamine-SL	ST001104	AN001796	9.310E-34	2.330E-33	Sample Type;Enriched SLC1G;Enriched SLC1G after treatment wi...
IS Ceramide;[M-H20]+	ST000661	AN001009	1.000E-33	7.770E-33	Study;CHOICE;CSU-143;POOLED
IS Ceramide;[M-H20]+	ST000661	AN001009	1.000E-33	7.770E-33	Type;Clinical;Preclinical;POOLED
Ala-Glu-Glu-His	ST001201	AN001998	1.660E-33	2.410E-32	cell_type;iRBC;unRBC
D-erythro-L-galacto-Nonulose	ST001202	AN002001	2.540E-33	3.430E-32	cell_type;iRBC;unRBC
L-Ala-L-Glu	ST001202	AN002001	4.390E-33	5.110E-32	cell_type;iRBC;unRBC
Galactose-N-acetylgalactosamine	ST001104	AN001796	4.990E-33	7.630E-33	Sample Type;Enriched SLC1G;Enriched SLC1G after treatment wi...
6-Deoxyhexose	ST000586	AN000901	6.940E-33	3.420E-32	Plasma Volume;0 uL;150 uL;700 uL
Asn-Lys-Gly-Pro	ST001201	AN001998	7.230E-33	9.430E-32	cell_type;iRBC;unRBC
alloxanoic acid	ST000608	AN000931	7.420E-33	3.190E-32	Sample_Type;blotter;serum
C-132-Carboxypyropheophorbide a-13C0[+QDA adduct+Na]+	ST000142	AN000225	7.880E-33	6.130E-31	Treatment;13C-Glc;unlabeled
2-Oxo-8-methylthiooctanoate-13C0[+Na]+	ST000142	AN000225	7.960E-33	6.130E-31	Treatment;13C-Glc;unlabeled
Flavonol 3-O-xylosylglycoside-13C0[+13CD3 QDA]+	ST000142	AN000225	9.430E-33	6.130E-31	Treatment;13C-Glc;unlabeled
Aniline-2-Sulfonate	ST001048	AN001716	1.130E-32	6.240E-32	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
isohydroxybutyric acid	ST000092	AN000146	1.320E-32	1.070E-31	Gender;N/A;Female;Male
Deoxyribose phosphate	ST000450	AN000706	1.510E-32	3.070E-31	gender;Female;Male
Oxopropyl-CoM-13C0[+QDA adduct+Na]+	ST000142	AN000225	1.690E-32	6.130E-31	Treatment;13C-Glc;unlabeled
5-Methyl-2-furaldehyde-13C0[+QDA adduct]+	ST000142	AN000225	1.840E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Ala-Met-Asp-Tyr	ST001202	AN002001	1.860E-32	1.980E-31	cell_type;iRBC;unRBC
Chloroacetoacetanilide-13C0[+QDA adduct]+	ST000142	AN000225	1.900E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Chalcomycin-13C0[+QDA adduct]+	ST000142	AN000225	1.950E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Decanoyl acetaldehyde-13C0[+13CD3 QDA]+	ST000142	AN000225	1.970E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Oxononanoate-13C8[+QDA adduct]+	ST000142	AN000225	2.010E-32	6.130E-31	Treatment;13C-Glc;unlabeled
4-Ketoanhydrochlortetracycline-13C0[+H]+	ST000142	AN000225	2.100E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Hydroxyretinal-13C0[+H]+	ST000142	AN000225	2.100E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Sedoheptulose phosphate-13C0[+Na]+	ST000142	AN000225	2.130E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Hydroxyabscisate-13C4[+H]+	ST000142	AN000225	2.140E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Cyclopiazonate-13C0[+Na]+	ST000142	AN000225	2.290E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Cys-Leu-Cys-Tyr	ST001202	AN002001	2.310E-32	2.360E-31	cell_type;iRBC;unRBC
2-Succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-carboxylate-13C0[+QDA adduct+Na]+	ST000142	AN000225	2.340E-32	6.130E-31	Treatment;13C-Glc;unlabeled
N-Methyl-2-oxoglutaramate-13C0[+Na]+	ST000142	AN000225	2.340E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Hydroxyabscisate-13C8[+H]+	ST000142	AN000225	2.480E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Rifamycin S-13C0[+QDA adduct]+	ST000142	AN000225	2.520E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Dehydropantoate-13C0[+Na]+	ST000142	AN000225	2.530E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Oxopropyl-CoM-13C4[+QDA adduct+Na]+	ST000142	AN000225	2.580E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Methyl-isopropylhexadienal-13C0[+Na]+	ST000142	AN000225	2.650E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Aquayamycin-13C0[+13CD3 QDA]+	ST000142	AN000225	2.660E-32	6.130E-31	Treatment;13C-Glc;unlabeled
6-Hydroxykynurenate-13C0[+Na]+	ST000142	AN000225	2.680E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Methylthioribulose phosphate-13C1[+QDA adduct]+	ST000142	AN000225	2.700E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Ala-Ala-Ala-Ser	ST001202	AN002000	2.710E-32	2.060E-31	cell_type;iRBC;unRBC
Vinylbacteriochlorophyllide a-13C1[+Na]+	ST000142	AN000225	2.720E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Prohydrojasmon-13C0[+H]+	ST000142	AN000225	2.740E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Nigakilactone K-13C0[+13CD3 QDA]+	ST000142	AN000225	2.760E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Hydroxy-naphthoquinone-13C0[+H]+	ST000142	AN000225	2.770E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Cyclopiazonate-13C20[+QDA adduct]+	ST000142	AN000225	2.810E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Decanoyl acetaldehyde-13C0[+Na]+	ST000142	AN000225	2.850E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Oxalomalate-13C1[+H]+	ST000142	AN000225	2.920E-32	6.130E-31	Treatment;13C-Glc;unlabeled
3-Hydroxyethylbacteriochlorophyllide a-13C0[+Na]+	ST000142	AN000225	2.980E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Atheroline-13C1[+H]+	ST000142	AN000225	3.130E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Vinylbacteriochlorophyllide a-13C0[+Na]+	ST000142	AN000225	3.150E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Picrasin F-13C20[+13CD3 QDA]+	ST000142	AN000225	3.170E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Peonidin 3-O-glucoside-13C12[+QDA adduct]+	ST000142	AN000225	3.270E-32	6.130E-31	Treatment;13C-Glc;unlabeled
7-Methylhypoxanthine-13C2[+Na]+	ST000142	AN000225	3.280E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Vinylbacteriochlorophyllide a-13C9[+Na]+	ST000142	AN000225	3.510E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Dihydroxanthommatin-13C0[+13CD3 QDA]+	ST000142	AN000225	3.550E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Hydroxykynurenamine-13C0[+QDA adduct]+	ST000142	AN000225	3.570E-32	6.130E-31	Treatment;13C-Glc;unlabeled
GQ1c (34:1)-13C0[+13CD3 QDA]+	ST000142	AN000225	3.610E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Cyclopiazonate-13C1[+QDA adduct]+	ST000142	AN000225	3.800E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Hydrocortisone sodium succinate-13C0[+13CD3 QDA]+	ST000142	AN000225	3.900E-32	6.130E-31	Treatment;13C-Glc;unlabeled
7-Methylhypoxanthine-13C0[+Na]+	ST000142	AN000225	4.060E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Stanolone benzoate-13C0[+Na]+	ST000142	AN000225	4.070E-32	6.130E-31	Treatment;13C-Glc;unlabeled
4-Keto-ATC-13C0[+13CD3 QDA]+	ST000142	AN000225	4.080E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Peonidin 3-O-glucoside-13C1[+QDA adduct]+	ST000142	AN000225	4.080E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Nanchangmycin-13C0[+Na]+	ST000142	AN000225	4.090E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Cinncassiol C1-13C0[+QDA adduct+Na]+	ST000142	AN000225	4.100E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Hydroxykynurenamine-13C0[+QDA adduct+Na]+	ST000142	AN000225	4.120E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Tepraloxydim-13C0[+13CD3 QDA]+	ST000142	AN000225	4.220E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Bacteriochlorophyllide a-13C0[+QDA adduct]+	ST000142	AN000225	4.230E-32	6.130E-31	Treatment;13C-Glc;unlabeled
1-Palmitoyl-2-(5-hydroxy-8-oxo-6-octenoyl)-sn-glycero-3-phosphatidylcholine-13C0[+Na]+	ST000142	AN000225	4.740E-32	6.130E-31	Treatment;13C-Glc;unlabeled
1-Palmitoyl-2-(5-keto-8-oxo-6-octenoyl)-sn-glycero-3-phosphatidylcholine-13C3[+QDA adduct+Na]+	ST000142	AN000225	4.760E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Lankamycin-13C0[+QDA adduct]+	ST000142	AN000225	4.800E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Oxopropyl-CoM-13C5[+QDA adduct+Na]+	ST000142	AN000225	4.840E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Sodium equilin sulfate-13C0[+13CD3 QDA]+	ST000142	AN000225	5.060E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Cyclopiazonate-13C0[+QDA adduct]+	ST000142	AN000225	5.160E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Sialyllactosamine-13C0[+QDA adduct+Na]+	ST000142	AN000225	5.350E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Hydroxyamoorstatin-13C0[+QDA adduct]+	ST000142	AN000225	5.380E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Ketoetiocholanolone-13C0[+Na]+	ST000142	AN000225	5.390E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Nitrophenyl-ketovalidamine-13C0[+H]+	ST000142	AN000225	5.450E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Nigakilactone M-13C0[+QDA adduct+Na]+	ST000142	AN000225	5.520E-32	6.130E-31	Treatment;13C-Glc;unlabeled
N-tert-Butyloxycarbonyl-deacetyl-leupeptin-13C0[+13CD3 QDA]+	ST000142	AN000225	5.550E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Delphinidin 3-O-glucoside-13C1[+QDA adduct+Na]+	ST000142	AN000225	5.610E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Isophenoxazine-13C10[+QDA adduct+Na]+	ST000142	AN000225	5.620E-32	6.130E-31	Treatment;13C-Glc;unlabeled
B-Norcholest-4-en-3-one-13C0[+Na]+	ST000142	AN000225	5.690E-32	6.130E-31	Treatment;13C-Glc;unlabeled
3-Deoxy-glycero-galacto-2-nonulosonic acid-13C0[+QDA adduct+Na]+	ST000142	AN000225	5.830E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Propiomazine hydrochloride-13C0[+13CD3 QDA]+	ST000142	AN000225	5.850E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Abscisic acid GLC ester-13C0[+QDA adduct]+	ST000142	AN000225	5.900E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Isophenoxazine-13C0[+H]+	ST000142	AN000225	5.900E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Hydroxycinnamyl aldehyde-13C0[+Na]+	ST000142	AN000225	5.910E-32	6.130E-31	Treatment;13C-Glc;unlabeled
16a-Hydroxyestrone-13C0[+QDA adduct+Na]+	ST000142	AN000225	5.980E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Oxopropyl-CoM-13C1[+QDA adduct+Na]+	ST000142	AN000225	5.980E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Quinoclamin-13C0[+H]+	ST000142	AN000225	6.030E-32	6.130E-31	Treatment;13C-Glc;unlabeled
YC-17-13C0[+Na]+	ST000142	AN000225	6.070E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Testosterone isocaproate-13C9[+Na]+	ST000142	AN000225	6.080E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Chalcomycin-13C1[+QDA adduct]+	ST000142	AN000225	6.120E-32	6.130E-31	Treatment;13C-Glc;unlabeled
N2-Succinyl-glutamic acid 5-semialdehyde-13C1[+H]+	ST000142	AN000225	6.150E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Dihydrocarminomycin-13C0[+13CD3 QDA]+	ST000142	AN000225	6.170E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Aloinoside A-13C0[+13CD3 QDA]+	ST000142	AN000225	6.210E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Oleoylglycerone phosphate-13C0[+QDA adduct+Na]+	ST000142	AN000225	6.230E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Rhodamine 6G-13C1[+13CD3 QDA]+	ST000142	AN000225	6.260E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Candletoxin A-13C0[+13CD3 QDA]+	ST000142	AN000225	6.320E-32	6.130E-31	Treatment;13C-Glc;unlabeled
1-Palmitoyl-2-(5-keto-8-oxo-6-octenoyl)-sn-glycero-3-phosphatidylcholine-13C0[+QDA adduct+Na]+	ST000142	AN000225	6.330E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Picrasin F-13C0[+13CD3 QDA]+	ST000142	AN000225	6.350E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Uracil 5-carbaldehyde-13C1[+QDA adduct]+	ST000142	AN000225	6.390E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Epothilone C-13C0[+H]+	ST000142	AN000225	6.420E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Prephenate-13C0[+H]+	ST000142	AN000225	6.440E-32	6.130E-31	Treatment;13C-Glc;unlabeled
2-Succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-carboxylate-13C2[+QDA adduct+Na]+	ST000142	AN000225	6.480E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Nanchangmycin-13C1[+QDA adduct+Na]+	ST000142	AN000225	6.600E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Kolanone-13C0[+H]+	ST000142	AN000225	6.620E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Dehydro-fructose-13C1[+H]+	ST000142	AN000225	6.630E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Methylthioribulose phosphate-13C0[+QDA adduct]+	ST000142	AN000225	6.680E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Dihydrogossypetin-13C0[+13CD3 QDA]+	ST000142	AN000225	6.730E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Divinylprotochlorophyllide-13C0[+QDA adduct]+	ST000142	AN000225	6.730E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Isopropenyl oxoheptanoate-13C6[+QDA adduct]+	ST000142	AN000225	6.800E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Oxo-4-phosphonobutanoate-13C0[+QDA adduct]+	ST000142	AN000225	6.860E-32	6.130E-31	Treatment;13C-Glc;unlabeled
3-Iodo-4-hydroxyphenylpyruvate-13C0[+QDA adduct+Na]+	ST000142	AN000225	6.910E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Methylthioribulose phosphate-13C6[+QDA adduct]+	ST000142	AN000225	6.950E-32	6.130E-31	Treatment;13C-Glc;unlabeled
dihydro-keto-PGF2a-13C0[+Na]+	ST000142	AN000225	6.970E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Rhodamine 6G-13C0[+13CD3 QDA]+	ST000142	AN000225	7.020E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Picrasin F-13C19[+13CD3 QDA]+	ST000142	AN000225	7.080E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Phenylpyruviate-13C6[+QDA adduct]+	ST000142	AN000225	7.140E-32	6.130E-31	Treatment;13C-Glc;unlabeled
6-Azaequilenin-13C0[+H]+	ST000142	AN000225	7.200E-32	6.130E-31	Treatment;13C-Glc;unlabeled
PD116740-13C1[+QDA adduct]+	ST000142	AN000225	7.280E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Prednisolone 21-all-cis-farnesylate-13C0[+QDA adduct]+	ST000142	AN000225	7.370E-32	6.130E-31	Treatment;13C-Glc;unlabeled
7-Methylhypoxanthine-13C4[+Na]+	ST000142	AN000225	7.430E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Deoxycarminomycin-13C0[+QDA adduct]+	ST000142	AN000225	7.550E-32	6.130E-31	Treatment;13C-Glc;unlabeled
FA oxo(19:0)	ST001201	AN001998	7.550E-32	8.440E-31	cell_type;iRBC;unRBC
4-Sulfobenzaldehyde-13C0[+Na]+	ST000142	AN000225	7.600E-32	6.130E-31	Treatment;13C-Glc;unlabeled
2-Succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-carboxylate-13C1[+QDA adduct+Na]+	ST000142	AN000225	7.740E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Oxalomalate-13C0[+H]+	ST000142	AN000225	7.760E-32	6.130E-31	Treatment;13C-Glc;unlabeled
PD116740-13C0[+QDA adduct]+	ST000142	AN000225	7.770E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Rehmaionoside C-13C0[+Na]+	ST000142	AN000225	7.870E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Hydroxystreptomycin-13C0[+H]+	ST000142	AN000225	7.880E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Flavonol 3-O-beta-glucosyl-(1->2)-beta-glucoside-13C0[+QDA adduct]+	ST000142	AN000225	8.050E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Triamcinolone diacetate-13C0[+QDA adduct+Na]+	ST000142	AN000225	8.050E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Nanchangmycin-13C0[+QDA adduct+Na]+	ST000142	AN000225	8.090E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Melengestrol acetate-13C0[+Na]+	ST000142	AN000225	8.110E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Atheroline-13C6[+H]+	ST000142	AN000225	8.280E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Dihydroxychromone-13C1[+H]+	ST000142	AN000225	8.300E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Oxostearate-13C0[+H]+	ST000142	AN000225	8.300E-32	6.130E-31	Treatment;13C-Glc;unlabeled
N2-Succinyl-glutamic acid 5-semialdehyde-13C0[+H]+	ST000142	AN000225	8.310E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Rhodamine 6G-13C2[+13CD3 QDA]+	ST000142	AN000225	8.350E-32	6.130E-31	Treatment;13C-Glc;unlabeled
2-Dehydro-xylonate-13C0[+H]+	ST000142	AN000225	8.530E-32	6.130E-31	Treatment;13C-Glc;unlabeled
2-Heptyl-3-hydroxy-quinolone-13C0[+H]+	ST000142	AN000225	8.630E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Peonidin 3-O-glucoside-13C0[+QDA adduct]+	ST000142	AN000225	8.640E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Trinexapac-ethyl-13C0[+Na]+	ST000142	AN000225	8.640E-32	6.130E-31	Treatment;13C-Glc;unlabeled
1-Palmitoyl-2-(5-keto-8-oxo-6-octenoyl)-sn-glycero-3-phosphatidylcholine-13C1[+QDA adduct+Na]+	ST000142	AN000225	8.660E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Sethoxydim-13C0[+H]+	ST000142	AN000225	8.690E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Naphthoquinone-13C0[+H]+	ST000142	AN000225	8.730E-32	6.130E-31	Treatment;13C-Glc;unlabeled
Dihydroxychromone-13C0[+H]+	ST000142	AN000225	8.780E-32	6.130E-31	Treatment;13C-Glc;unlabeled
2-Demethylmenaquinone-13C0[+Na]+	ST000142	AN000225	8.830E-32	6.150E-31	Treatment;13C-Glc;unlabeled
SC-1271-13C0[+QDA adduct+Na]+	ST000142	AN000225	8.850E-32	6.150E-31	Treatment;13C-Glc;unlabeled
Hinokitiol glucoside-13C0[+H]+	ST000142	AN000225	8.870E-32	6.150E-31	Treatment;13C-Glc;unlabeled
Quinoclamin-13C0[+Na]+	ST000142	AN000225	8.930E-32	6.150E-31	Treatment;13C-Glc;unlabeled
Spectinomycin dihydrochloride-13C0[+QDA adduct+Na]+	ST000142	AN000225	9.010E-32	6.150E-31	Treatment;13C-Glc;unlabeled
AminoDHS-13C0[+H]+	ST000142	AN000225	9.200E-32	6.150E-31	Treatment;13C-Glc;unlabeled
Picrasin F-13C1[+13CD3 QDA]+	ST000142	AN000225	9.220E-32	6.150E-31	Treatment;13C-Glc;unlabeled
Hydroxy-carboxybenzalpyruvate-13C0[+H]+	ST000142	AN000225	9.320E-32	6.180E-31	Treatment;13C-Glc;unlabeled
Testosterone decanoate-13C0[+13CD3 QDA]+	ST000142	AN000225	9.330E-32	6.180E-31	Treatment;13C-Glc;unlabeled
Dehydro-fructose-13C0[+H]+	ST000142	AN000225	9.470E-32	6.250E-31	Treatment;13C-Glc;unlabeled
Cyclopiazonate-13C19[+QDA adduct]+	ST000142	AN000225	9.490E-32	6.250E-31	Treatment;13C-Glc;unlabeled
Peonidin 3-O-glucoside-13C9[+QDA adduct]+	ST000142	AN000225	9.560E-32	6.280E-31	Treatment;13C-Glc;unlabeled
Alisol A-13C0[+13CD3 QDA]+	ST000142	AN000225	9.600E-32	6.300E-31	Treatment;13C-Glc;unlabeled
GD1b (36:2)-13C0[+13CD3 QDA]+	ST000142	AN000225	1.030E-31	6.620E-31	Treatment;13C-Glc;unlabeled
Dihydroxychromone-13C3[+H]+	ST000142	AN000225	1.050E-31	6.700E-31	Treatment;13C-Glc;unlabeled
Aminomuconic acid semialdehyde-13C0[+Na]+	ST000142	AN000225	1.060E-31	6.700E-31	Treatment;13C-Glc;unlabeled
5-Chloro-2-hydroxymuconic semialdehyde-13C0[+Na]+	ST000142	AN000225	1.090E-31	6.860E-31	Treatment;13C-Glc;unlabeled
Phosphohydroxypyruvate-13C0[+H]+	ST000142	AN000225	1.100E-31	6.910E-31	Treatment;13C-Glc;unlabeled
Oxopropyl-CoM-13C0[+H]+	ST000142	AN000225	1.110E-31	6.910E-31	Treatment;13C-Glc;unlabeled
Geranylchrysin-13C0[+13CD3 QDA]+	ST000142	AN000225	1.150E-31	7.100E-31	Treatment;13C-Glc;unlabeled
Hydroxymuconic semialdehyde-13C0[+QDA adduct+Na]+	ST000142	AN000225	1.170E-31	7.200E-31	Treatment;13C-Glc;unlabeled
Cinncassiol C2-13C0[+13CD3 QDA]+	ST000142	AN000225	1.210E-31	7.410E-31	Treatment;13C-Glc;unlabeled
Hygromycin A-13C0[+QDA adduct]+	ST000142	AN000225	1.300E-31	7.850E-31	Treatment;13C-Glc;unlabeled
Hydroxyanthraquinone-13C0[+QDA adduct+Na]+	ST000142	AN000225	1.590E-31	9.480E-31	Treatment;13C-Glc;unlabeled
2-Heptyl-3-hydroxy-quinolone-13C1[+H]+	ST000142	AN000225	1.910E-31	1.130E-30	Treatment;13C-Glc;unlabeled
4-Hydroxyphenylacetylglycine	ST001202	AN002001	2.120E-31	1.940E-30	cell_type;iRBC;unRBC
DIHEXOSE	ST000016	AN000033	2.330E-31	5.060E-30	Material;Cells;Media
IS Ceramide;[M-H20]+	ST000661	AN001009	3.620E-31	2.710E-30	Treatment;Ornish;Southbeach;Baseline;Gainer (ad lib);Loser (...
SDMA/ADMA	ST001142	AN001875	5.730E-31	3.680E-30	Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
Asn-Gly-Pro-Pro	ST001201	AN001998	6.000E-31	6.380E-30	cell_type;iRBC;unRBC
Ala-Asp-Asp-Cys	ST001202	AN002000	6.480E-31	4.150E-30	cell_type;iRBC;unRBC
5?-Androstan-3?-ol-17-one sulfate - 8.185043	ST000566	AN000869	7.010E-31	6.170E-30	Time point;Post;Pre;Baseline
SLC1G	ST001104	AN001796	7.640E-31	7.640E-31	Sample Type;Enriched SLC1G;Enriched SLC1G after treatment wi...
taurodeoxycholate/taurochenodeoxycholate	ST001142	AN001876	7.860E-31	7.730E-30	Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
2-chloro-3-methyl-maleylacetate	ST001204	AN002004	1.120E-30	3.980E-29	cell_type;iRBC;unRBC
isohydroxybutyric acid	ST000092	AN000146	1.360E-30	1.190E-29	Ethnicity;N/A;Asian;Black;Caucasian;Hispanic
Alanine / D-Alanine	ST001048	AN001716	1.750E-30	8.180E-30	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
3-Pyridinebutanoic acid	ST000356	AN000583	1.920E-30	1.100E-28	stage;-;2;3
Asp-Trp-Gly-Gly	ST001204	AN002005	3.370E-30	7.580E-29	cell_type;iRBC;unRBC
HEPES	ST001201	AN001999	3.490E-30	2.080E-29	cell_type;iRBC;unRBC
IS SM 35:1;[M+H]+	ST000661	AN001009	5.210E-30	2.960E-29	Study;CHOICE;CSU-143;POOLED
IS SM 35:1;[M+H]+	ST000661	AN001009	5.210E-30	2.960E-29	Type;Clinical;Preclinical;POOLED
Pregnanolone sulfate	ST000567	AN000871	6.830E-30	1.950E-28	Time point;Post;Pre;Baseline
Asp-Gly-Pro-Ser	ST001201	AN001999	1.360E-29	7.990E-29	cell_type;iRBC;unRBC
Aldopentoses	ST000586	AN000901	1.750E-29	7.450E-29	Plasma Volume;0 uL;150 uL;700 uL
AC1MIY4G	ST000842	AN001361	1.870E-29	5.350E-29	Sample type;Muscles;Plasma;Pooled sample
Cinchonain 1a	ST001204	AN002004	2.120E-29	6.870E-28	cell_type;iRBC;unRBC
Arg-Phe-Phe-Arg	ST001201	AN001999	2.250E-29	1.290E-28	cell_type;iRBC;unRBC
succinate/methylmalonate	ST001142	AN001876	2.420E-29	2.380E-28	Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
IS SM 35:1;[M+H]+	ST000661	AN001009	5.690E-29	3.440E-28	Treatment;Ornish;Southbeach;Baseline;Gainer (ad lib);Loser (...
Hydroxyprolines	ST000589	AN000904	7.190E-29	1.040E-28	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
cyclo-Dopa-glucuronylglucoside	ST000567	AN000871	7.360E-29	1.750E-27	Time point;Post;Pre;Baseline
Ala-Leu-Asn-Pro	ST001201	AN001998	8.510E-29	7.080E-28	cell_type;iRBC;unRBC
Lyso-PAF C-18	ST000089	AN000141	1.340E-28	4.630E-28	Treatment;Human Adipocytes grown in the ABSENCE of SKOV3ip1 ...
IS Ceramide;[M-H20]+	ST000661	AN001009	1.630E-28	1.110E-27	Time_Point;1 Month;6 Months;Baseline;0 Days;27 Days;29 Days;...
3-methyladipate/pimelate	ST001142	AN001876	2.100E-28	1.630E-27	Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
2-oxo-4-methylvaleric acid	ST000356	AN000582	2.670E-28	3.370E-27	Diagnosis;breast cancer;control
3-methoxytyramine sulfate	ST000974	AN001595	3.490E-28	9.040E-27	REGION;AHRI;MRC;SUN
N-Acetyl-D-glucosamine 6-phosphate	ST001202	AN002001	3.590E-28	2.490E-27	cell_type;iRBC;unRBC
PIPES	ST001202	AN002001	3.860E-28	2.600E-27	cell_type;iRBC;unRBC
Montecristin	ST001202	AN002000	4.030E-28	2.030E-27	cell_type;iRBC;unRBC
Ala-Thr-Ala-Ser	ST001202	AN002000	5.630E-28	2.770E-27	cell_type;iRBC;unRBC
C8-Ceramide m+8	ST000644	AN000976	5.670E-28	4.020E-27	tracer;13C-glucose;13C-glutamine;No label
Glu-Glu-Gln-His	ST001201	AN001998	6.800E-28	5.120E-27	cell_type;iRBC;unRBC
Methylnoradrenaline	ST000356	AN000583	6.850E-28	6.890E-27	Diagnosis;breast cancer;control
DG(36:2)>DG(18:1_18:1_0:0)	ST001325	AN002206	7.228E-28	4.437E-27	Sample type;batch pool;chear plasma;master pool;red cross pl...
Ethanol diglycine (EDTA decomposition product)	ST000586	AN000901	7.510E-28	2.800E-27	Plasma Volume;0 uL;150 uL;700 uL
Pentonic acids	ST000589	AN000904	1.050E-27	1.510E-27	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
ZEATIN [ISTD] (M+Cl)-	ST000818	AN001296	1.260E-27	1.190E-25	Country;Ethiopia;Tanzania;Botswana
2-oxo-3-methylvaleric acid	ST000356	AN000582	1.610E-27	1.800E-26	Diagnosis;breast cancer;control
N5-acetyl-N5-hydroxy-L-ornithine	ST001202	AN002000	1.940E-27	8.890E-27	cell_type;iRBC;unRBC
Hexadeceylamin	ST001202	AN002000	2.270E-27	1.030E-26	cell_type;iRBC;unRBC
Benzyl dodecyl dimethylammonium cation (disinfectant)	ST000089	AN000141	2.450E-27	7.240E-27	Treatment;Human Adipocytes grown in the ABSENCE of SKOV3ip1 ...
CL 76:9 (18:0/20:4/18:1/20:4) [M-2H](2-)	ST001111	AN001806	2.700E-27	8.950E-25	Sample;Benign;Cancer;Metastasis
3-Deoxy-D-manno-octulosonate 8-phosphate	ST001201	AN001999	3.960E-27	2.120E-26	cell_type;iRBC;unRBC
CerH2O(d18:1/26:1)	ST000608	AN000929	1.870E-26	3.280E-25	Sample_Type;blotter;serum
Biflorin	ST000356	AN000583	2.050E-26	5.020E-25	stage;-;2;3
CL 76:9 (18:0/16:0/22:5/20:4) [M-2H](2-)	ST001111	AN001806	2.150E-26	1.780E-24	Sample;Benign;Cancer;Metastasis
Tolylacetonitrile	ST001202	AN002000	2.530E-26	1.040E-25	cell_type;iRBC;unRBC
C8-Ceramide m+17	ST000644	AN000976	2.590E-26	1.750E-25	tracer;13C-glucose;13C-glutamine;No label
5-Amino-6-ribitylamino uracil	ST000356	AN000583	2.910E-26	6.220E-25	stage;-;2;3
L-pyroglutamic acid/ glutamic acid	ST000865	AN001390	4.180E-26	1.800E-25	Patient group;CIRR;HCC;Pool CIRR;Pool HCC;POSSIBLE CASE;-
ZEATIN [ISTD] (M-H)-	ST000818	AN001296	4.320E-26	1.370E-24	Country;Ethiopia;Tanzania;Botswana
Bile salt	ST001202	AN002001	5.240E-26	2.690E-25	cell_type;iRBC;unRBC
[13C]-LYSINE	ST000016	AN000033	5.440E-26	7.770E-25	Material;Cells;Media
CerH2O(d18:1/16:0)	ST000608	AN000929	5.650E-26	9.290E-25	Sample_Type;blotter;serum
Laurencione diacetate	ST000567	AN000871	6.200E-26	1.270E-24	Time point;Post;Pre;Baseline
Ala-Phe-Arg-His	ST001204	AN002004	7.830E-26	1.690E-24	cell_type;iRBC;unRBC
Ala-Leu-Thr-Ala	ST001202	AN002000	8.570E-26	3.350E-25	cell_type;iRBC;unRBC
deacetylcolchicine	ST001201	AN001999	9.260E-26	4.660E-25	cell_type;iRBC;unRBC
Ala-Leu-Lys-Asp	ST001202	AN002000	1.050E-25	4.040E-25	cell_type;iRBC;unRBC
psicoselysine	ST001204	AN002004	1.390E-25	2.700E-24	cell_type;iRBC;unRBC
C8-Ceramide m+10	ST000644	AN000976	1.750E-25	1.100E-24	tracer;13C-glucose;13C-glutamine;No label
Octulose-monophosphate	ST000450	AN000706	2.010E-25	1.600E-24	gender;Female;Male
IS SM 35:1;[M+H]+	ST000661	AN001009	2.030E-25	1.030E-24	Time_Point;1 Month;6 Months;Baseline;0 Days;27 Days;29 Days;...
Asn-Leu-Pro-Pro	ST001201	AN001998	2.170E-25	1.410E-24	cell_type;iRBC;unRBC
Cys-Gly-Pro-Ser	ST001202	AN002001	2.450E-25	1.140E-24	cell_type;iRBC;unRBC
5?-Androstan-3?-ol-17-one sulfate - 7.7291727	ST000566	AN000869	2.700E-25	1.830E-24	Time point;Post;Pre;Baseline
2-Benzothiazolesulfonamide	ST001201	AN001999	3.060E-25	1.470E-24	cell_type;iRBC;unRBC
Ala-Asp-Gly-Tyr	ST001202	AN002000	3.130E-25	1.150E-24	cell_type;iRBC;unRBC
Cys-Cys-Pro-Ser	ST001201	AN001998	3.690E-25	2.330E-24	cell_type;iRBC;unRBC
L-pyroglutamic acid/ glutamic acid	ST000865	AN001390	7.370E-25	2.750E-24	RACE;AA;Asian;EA;Hisp;Other;-
Marinobufagenin	ST000567	AN000871	7.610E-25	1.360E-23	Time point;Post;Pre;Baseline
MES	ST001202	AN002000	2.390E-24	7.640E-24	cell_type;iRBC;unRBC
4-Hydroxy-4-(3-pyridyl)butanoic acid	ST001317	AN002192	2.629E-24	7.362E-24	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
4-Hydroxy-4-(3-pyridyl)butanoic acid	ST001317	AN002192	2.629E-24	7.362E-24	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Molybdenum cofactor (sulfide)	ST000241	AN000373	3.530E-24	6.640E-22	Concentration (uM);0;500
octulose 8-phosphate	ST001201	AN001999	3.580E-24	1.700E-23	cell_type;iRBC;unRBC
PC(18:0/9:0(CHO))	ST000608	AN000929	3.670E-24	4.190E-23	Sample_Type;blotter;serum
PC(16:0/11:0(CHO))	ST000608	AN000929	4.250E-24	4.650E-23	Sample_Type;blotter;serum
[13C]-THREONINE	ST000016	AN000033	4.970E-24	6.210E-23	Material;Cells;Media
SM(d18:1/25:0) or SM(d18:1/24:1 OH)	ST000450	AN000706	5.060E-24	3.530E-23	gender;Female;Male
Sulfate	ST001202	AN002001	5.520E-24	2.210E-23	cell_type;iRBC;unRBC
Ala-Lys-Ala-Ala	ST001201	AN001999	6.090E-24	2.760E-23	cell_type;iRBC;unRBC
Ala-Asp-Cys-Ser	ST001201	AN001998	6.320E-24	3.740E-23	cell_type;iRBC;unRBC
Ala-Val-Asp-Ser	ST001202	AN002000	6.450E-24	2.030E-23	cell_type;iRBC;unRBC
glycodeoxycholate/glycochenodeoxycholate	ST001142	AN001876	6.990E-24	3.170E-23	Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
Asp-Val-Gly-Ser	ST001202	AN002000	7.810E-24	2.440E-23	cell_type;iRBC;unRBC
hexoses (HILIC pos)	ST001142	AN001875	9.570E-24	3.350E-23	Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
4-amino-4-deoxy-L-arabinose	ST001201	AN001998	9.770E-24	5.700E-23	cell_type;iRBC;unRBC
Elaidate / Oleate /Petroselinate	ST001048	AN001717	1.250E-23	6.660E-23	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
Avenic acid A	ST001202	AN002001	1.470E-23	5.530E-23	cell_type;iRBC;unRBC
MEVALOLACTONE	ST000105	AN000173	1.480E-23	6.090E-21	Sampling;After SWS onset;Morning fasting
FA methyl (8:1)	ST001202	AN002001	1.540E-23	5.710E-23	cell_type;iRBC;unRBC
FA methyl(6:0)	ST001202	AN002001	3.720E-23	1.320E-22	cell_type;iRBC;unRBC
Procollagen 5-(D-galactosyloxy)-L-lysine	ST001202	AN002000	4.120E-23	1.200E-22	cell_type;iRBC;unRBC
Asn-Met-Thr-Asp	ST001201	AN001999	4.440E-23	1.930E-22	cell_type;iRBC;unRBC
ZEATIN [ISTD] (M+Cl)-	ST000842	AN001356	4.840E-23	3.230E-22	Sample type;Muscles;Plasma;Pooled sample
Phenolsulfonphthalein	ST001202	AN002001	4.920E-23	1.700E-22	cell_type;iRBC;unRBC
Sulfate	ST001204	AN002005	5.160E-23	6.330E-22	cell_type;iRBC;unRBC
Anthranilate/4-Aminobenzoate	ST001317	AN002193	6.526E-23	3.959E-22	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Anthranilate/4-Aminobenzoate	ST001317	AN002193	6.526E-23	3.959E-22	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Tetrasaccharide	ST000589	AN000904	7.160E-23	9.520E-23	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
1-(14-methyl-pentadecanoyl)-2-(8-[3]-ladderane-octanyl)-sn-glycerol	ST001204	AN002004	8.410E-23	1.380E-21	cell_type;iRBC;unRBC
N-Acetyl-O-acetylneuraminate	ST001204	AN002004	8.490E-23	1.380E-21	cell_type;iRBC;unRBC
a Cysteine adduct	ST001204	AN002005	1.310E-22	1.410E-21	cell_type;iRBC;unRBC
Asp-Leu-Lys-Asp	ST001202	AN002000	1.750E-22	4.740E-22	cell_type;iRBC;unRBC
4-Amino-4-deoxychorismate	ST001202	AN002001	1.800E-22	5.830E-22	cell_type;iRBC;unRBC
Decosahexaenoic acid	ST000356	AN000582	2.700E-22	2.280E-21	Diagnosis;breast cancer;control
4-QUINOLINECARBOXYLIC ACID #2 (M+H)+	ST000818	AN001297	3.070E-22	4.100E-21	Categorization;Amhara;Dizi;Hadza_settled;Hadza_traditional;H...
2-S-Glutathionyl acetate	ST001201	AN001998	3.450E-22	1.800E-21	cell_type;iRBC;unRBC
L-a-glutamyl-L-Lysine	ST001201	AN001998	3.910E-22	2.010E-21	cell_type;iRBC;unRBC
D-Galacturonate	ST001202	AN002001	5.920E-22	1.740E-21	cell_type;iRBC;unRBC
MOPS	ST001202	AN002000	6.460E-22	1.660E-21	cell_type;iRBC;unRBC
5?-Androstan-3?-ol-17-one sulfate	ST000567	AN000871	7.040E-22	8.390E-21	Time point;Post;Pre;Baseline
Ala-Thr-Ala-Asp	ST001202	AN002000	7.080E-22	1.800E-21	cell_type;iRBC;unRBC
C9 / C14:1-OH	ST000544	AN000827	9.930E-22	6.360E-20	Sample Type;Control;Replicate
L(-)-Nicotine pestal	ST000241	AN000373	1.010E-21	7.610E-20	Concentration (uM);0;500
CMP-N-trimethyl-2-aminoethylphosphonate	ST001202	AN002000	1.290E-21	3.210E-21	cell_type;iRBC;unRBC
CL 74:9 (18:0/20:4/18:2/18:3) [M-2H](2-)	ST001111	AN001806	1.440E-21	3.410E-20	Sample;Benign;Cancer;Metastasis
AMINOHYDROXYBUTANOIC ACID	ST000016	AN000033	2.720E-21	2.470E-20	Material;Cells;Media
taurodeoxycholate/taurochenodeoxycholate	ST001142	AN001876	2.810E-21	8.730E-21	Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
Hexose Diphosphate Pool	ST000450	AN000706	2.950E-21	1.400E-20	gender;Female;Male
acetophenone NIST	ST000385	AN000620	4.190E-21	1.030E-20	Organ;Plasma;Serum;Serum or Plasma
ZEATIN [ISTD] (M+Cl)-	ST000818	AN001296	5.160E-21	1.630E-19	Occupation;Agriculturalist;Agropastoralist;Hunter-Gatherer;P...
Asn-Thr-Asn-Asn	ST001202	AN002000	6.110E-21	1.490E-20	cell_type;iRBC;unRBC
ZEATIN [ISTD] (M-H)-	ST000818	AN001296	7.320E-21	1.740E-19	Occupation;Agriculturalist;Agropastoralist;Hunter-Gatherer;P...
CerH2O(d18:1/26:0);CerH2O(d20:1/24:0)	ST000608	AN000929	9.130E-21	5.580E-20	Sample_Type;blotter;serum
PC(16:0/5:0(CHO))	ST000608	AN000929	1.080E-20	6.470E-20	Sample_Type;blotter;serum
Asn-Thr-Asn-Asn	ST001204	AN002004	1.170E-20	1.300E-19	cell_type;iRBC;unRBC
octulose 8-phosphate	ST001202	AN002001	1.650E-20	4.440E-20	cell_type;iRBC;unRBC
5?-Androstan-3?-ol-17-one sulfate	ST000566	AN000869	2.100E-20	1.230E-19	Time point;Post;Pre;Baseline
Ala-Leu-Trp-Ser	ST001201	AN001998	3.340E-20	1.430E-19	cell_type;iRBC;unRBC
5-hydroxymethyl-2-furoylcarnitine*	ST000974	AN001595	3.900E-20	7.380E-19	REGION;AHRI;MRC;SUN
Steryl sulfate	ST000566	AN000869	5.390E-20	2.960E-19	Time point;Post;Pre;Baseline
DMGV	ST001237	AN002055	5.980E-20	5.110E-19	CRF_MSKCC_Risk_Group;FAVORABLE;INTERMEDIATE;POOR
D-glycero-L-galacto-Octulose	ST001202	AN002001	6.430E-20	1.630E-19	cell_type;iRBC;unRBC
2-oxo-4-methylvaleric acid	ST000356	AN000582	6.850E-20	9.880E-19	stage;-;2;3
Asp-Leu-Gln-Pro	ST001202	AN002000	7.290E-20	1.660E-19	cell_type;iRBC;unRBC
Asp-Val-Pro-Ser	ST001204	AN002004	7.500E-20	7.890E-19	cell_type;iRBC;unRBC
N-(15Z-tetracosenoyl)-1-.beta.-galactosyl-sphing-4-enine	ST000089	AN000141	7.590E-20	1.510E-19	Treatment;Human Adipocytes grown in the ABSENCE of SKOV3ip1 ...
Arg-Leu-Val-Asn	ST000539	AN000819	8.810E-20	4.720E-17	Cell type;Mature erythrocyte;Reticulocyte
L-Isoleucine / Norleucine	ST001048	AN001716	9.370E-20	2.400E-19	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
[13C]-GLUTAMATE	ST000016	AN000033	1.100E-19	8.850E-19	Material;Cells;Media
2-S-Glutathionyl acetate	ST001204	AN002004	1.190E-19	1.220E-18	cell_type;iRBC;unRBC
6-diazo-5-oxonorleucine	ST001202	AN002000	1.430E-19	3.200E-19	cell_type;iRBC;unRBC
16-Feruloyloxypalmitate	ST000567	AN000871	2.230E-19	1.990E-18	Time point;Post;Pre;Baseline
Ala-Asp-Gly-Arg	ST001201	AN001998	2.320E-19	9.340E-19	cell_type;iRBC;unRBC
8-Amino-7-oxononanoate	ST001202	AN002000	2.410E-19	5.260E-19	cell_type;iRBC;unRBC
Asn-Leu-Pro-Pro	ST001202	AN002000	2.860E-19	6.160E-19	cell_type;iRBC;unRBC
2-oxo-3-methylvaleric acid	ST000356	AN000582	2.980E-19	3.770E-18	stage;-;2;3
Progtaglandin F2a	ST001229	AN002042	3.460E-19	6.910E-19	Sample Source;Feces;Serum;Tissues
2(alpha-D-Mannosyl)-D-glycerate	ST001202	AN002001	3.890E-19	9.570E-19	cell_type;iRBC;unRBC
Coproporphyrin	ST000356	AN000583	3.960E-19	2.260E-18	Diagnosis;breast cancer;control
Ala-Asn-Gln-Gln	ST001204	AN002005	4.090E-19	3.250E-18	cell_type;iRBC;unRBC
Ala-Cys-Pro-Ser	ST001202	AN002001	4.120E-19	9.950E-19	cell_type;iRBC;unRBC
Albendazole sulfone	ST001204	AN002005	5.040E-19	3.890E-18	cell_type;iRBC;unRBC
Dihydrogenphosphate	ST001204	AN002005	5.260E-19	3.950E-18	cell_type;iRBC;unRBC
Methylnoradrenaline	ST000356	AN000583	6.060E-19	6.480E-18	stage;-;2;3
CL 74:10 (16:1/22:5/20:4/16:0) [M-2H](2-)	ST001111	AN001806	7.520E-19	1.360E-17	Sample;Benign;Cancer;Metastasis
6-Acetyl-D-glucose	ST001202	AN002000	7.530E-19	1.540E-18	cell_type;iRBC;unRBC
5-aminovaleric acid lactame	ST000420	AN000662	7.540E-19	9.490E-17	Group;nonsmoker;smoker
13.beta.-Ethyl-3-oximinogon-4-en-17-one 3-TMS	ST000978	AN001602	8.130E-19	1.400E-16	Cox_RRT;.;N;Y
PC(18:0/9:0(COOH))	ST000608	AN000929	8.220E-19	3.860E-18	Sample_Type;blotter;serum
Arg-Asp-Asp-Gly	ST001204	AN002004	8.910E-19	7.530E-18	cell_type;iRBC;unRBC
urobilin - targeted	ST000923	AN001513	9.370E-19	8.800E-17	Diagnosis;CD;nonIBD;UC
Gln-Leu-Lys-Tyr	ST001202	AN002001	1.070E-18	2.440E-18	cell_type;iRBC;unRBC
Pseudo uridine penta-tms	ST000978	AN001602	1.140E-18	1.110E-16	Competitive_RRTvsDeath;.;N;RRT;DEATH
trans-Hexadec-2-enoylcarnitine	ST001201	AN001998	1.260E-18	4.890E-18	cell_type;iRBC;unRBC
4-Hydroxy-4-methylglutamate	ST001202	AN002000	1.500E-18	2.980E-18	cell_type;iRBC;unRBC
3-deoxy-D-galactose	ST001204	AN002005	1.580E-18	1.150E-17	cell_type;iRBC;unRBC
acetyl-galactosamine	ST001237	AN002055	2.020E-18	1.480E-17	CRF_MSKCC_Risk_Group;FAVORABLE;INTERMEDIATE;POOR
Cotinineglucuronide	ST000241	AN000373	2.240E-18	5.270E-17	Concentration (uM);0;500
N5-formyl-N5-hydroxy-L-ornithine	ST001201	AN001999	2.250E-18	8.240E-18	cell_type;iRBC;unRBC
13.beta.-Ethyl-3-oximinogon-4-en-17-one 3-TMS	ST000978	AN001602	2.900E-18	2.120E-16	Competitive_RRTvsDeath;.;N;RRT;DEATH
2OH-MBP (Mono(2-hydroxy-isobutyl)phthalate)	ST001317	AN002193	3.375E-18	1.228E-17	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
2OH-MBP (Mono(2-hydroxy-isobutyl)phthalate)	ST001317	AN002193	3.375E-18	1.228E-17	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Asn-Asn-Gly-His	ST001202	AN002000	3.410E-18	6.670E-18	cell_type;iRBC;unRBC
C9 / C14	ST000544	AN000827	4.120E-18	7.910E-17	Sample Type;Control;Replicate
Glucosamine/Galactosamine	ST000614	AN000939	4.400E-18	6.780E-17	Diagonsis;Benign;Cancer;Normal
P-Hydroxyphenylacetate/2-Hydroxyphenylacetate	ST001317	AN002193	4.515E-18	1.522E-17	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
P-Hydroxyphenylacetate/2-Hydroxyphenylacetate	ST001317	AN002193	4.515E-18	1.522E-17	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
[13C]-TYROSINE	ST000016	AN000033	4.790E-18	3.470E-17	Material;Cells;Media
O-Acetylneuraminic acid	ST001202	AN002000	4.790E-18	9.290E-18	cell_type;iRBC;unRBC
Cholic acid or similar bile acid	ST000589	AN000904	5.310E-18	6.870E-18	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
Beta-alanine methyl ester	ST001317	AN002192	6.364E-18	1.485E-17	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Beta-alanine methyl ester	ST001317	AN002192	6.364E-18	1.485E-17	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
N-Butyl-beta-carboline-3-carboxylate	ST001202	AN002001	9.270E-18	2.010E-17	cell_type;iRBC;unRBC
diacetylspermine	ST001237	AN002055	9.340E-18	5.980E-17	CRF_MSKCC_Risk_Group;FAVORABLE;INTERMEDIATE;POOR
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-	ST000842	AN001356	9.570E-18	3.990E-17	Sample type;Muscles;Plasma;Pooled sample
Pseudo uridine penta-tms	ST000978	AN001602	1.340E-17	9.810E-16	Cox_RRT;.;N;Y
FA hydroxy(10:0)	ST001202	AN002001	1.390E-17	2.980E-17	cell_type;iRBC;unRBC
S-Adenosylmethionimine	ST000241	AN000373	1.420E-17	3.870E-16	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Glucosamine/Galactosamine	ST000614	AN000939	1.670E-17	1.830E-16	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
z dioctylphtalate	ST000054	AN000092	1.740E-17	9.070E-16	treatment;Basal ;DCIS ;HER2 ;LumA ;LumB ;Reduction ;Total Po...
fumarate/maleate/alpha-ketoisovalerate	ST001142	AN001876	1.800E-17	5.300E-17	Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
L-a-glutamyl-L-Lysine	ST000539	AN000818	2.030E-17	5.890E-15	Cell type;Mature erythrocyte;Reticulocyte
3-deoxy-D-galactose	ST001202	AN002001	2.310E-17	4.840E-17	cell_type;iRBC;unRBC
Paraxanthine / Theobromine /Theophylline	ST001048	AN001716	3.790E-17	8.430E-17	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
Glu-Lys-Lys-Phe	ST001202	AN002001	5.360E-17	1.110E-16	cell_type;iRBC;unRBC
CL 76:11 (16:0/18:1/22:6/20:4) [M-2H](2-)	ST001111	AN001806	5.450E-17	9.050E-16	Sample;Benign;Cancer;Metastasis
4-Pyrodixic acid / Xanthurenate	ST001048	AN001716	5.470E-17	1.170E-16	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
Decosahexaenoic acid	ST000356	AN000582	8.270E-17	8.360E-16	stage;-;2;3
C16-OH Sulfatide	ST000567	AN000871	1.030E-16	7.760E-16	Time point;Post;Pre;Baseline
diacetylspermine	ST001237	AN002055	1.060E-16	6.790E-15	OS_Censor (1 means the time is a censoring time and 0 means ...
Molybdenum cofactor (sulfide)	ST000241	AN000373	1.180E-16	2.220E-15	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
NMMA	ST001237	AN002055	1.320E-16	6.790E-15	OS_Censor (1 means the time is a censoring time and 0 means ...
Aminocaproate/Adenine	ST001317	AN002192	1.375E-16	2.800E-16	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Aminocaproate/Adenine	ST001317	AN002192	1.375E-16	2.800E-16	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
5-Deoxy-5-aminoshikimic acid	ST000403	AN000643	1.550E-16	3.490E-14	Cell type;Mature erythrocyte;Reticulocyte
[Fv] Desmosdumotin C	ST000539	AN000818	1.650E-16	9.540E-14	timepoint;1 hour;20 hours
Kyn/Trp	ST001237	AN002055	1.650E-16	9.640E-16	CRF_MSKCC_Risk_Group;FAVORABLE;INTERMEDIATE;POOR
gamma-thiomethyl glutamate	ST001204	AN002004	1.840E-16	1.170E-15	cell_type;iRBC;unRBC
alloxanoic acid NIST	ST000392	AN000628	2.630E-16	2.590E-15	Organ;Plasma;Serum;Serum or Plasma
cotinine1	ST000614	AN000941	2.830E-16	1.700E-15	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Bis(glycerophospho)-glycerol	ST000403	AN000642	2.860E-16	3.380E-14	Cell type;Mature erythrocyte;Reticulocyte
L-beta-aspartyl-L-phenylalanine	ST000356	AN000583	3.470E-16	1.690E-15	Diagnosis;breast cancer;control
Sulforaphane	ST001202	AN002001	3.780E-16	7.440E-16	cell_type;iRBC;unRBC
dihomocitrate	ST000403	AN000643	3.880E-16	3.790E-14	Cell type;Mature erythrocyte;Reticulocyte
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000698	AN001084	3.880E-16	4.790E-14	KD#1;no;yes;Pooled melanoma
sinapoyltyramine	ST000403	AN000643	4.210E-16	3.790E-14	Cell type;Mature erythrocyte;Reticulocyte
CL 74:10 (16:0/22:5/16:1/20:4) [M-2H](2-)	ST001111	AN001806	4.400E-16	5.840E-15	Sample;Benign;Cancer;Metastasis
CL 74:9 (18:2/20:3/18:3/18:1) [M-2H](2-)	ST001111	AN001806	5.670E-16	7.230E-15	Sample;Benign;Cancer;Metastasis
PYRIDINE CARBOXYLIC ACID	ST000016	AN000033	7.130E-16	2.720E-14	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
C38:5 PC	ST001142	AN001877	7.780E-16	2.890E-15	Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
MCPP (Mono (3-carboxpropyl) phthalate)	ST001048	AN001717	8.880E-16	3.770E-15	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
Sucrose and similar disaccharides	ST000586	AN000901	8.950E-16	2.450E-15	Plasma Volume;0 uL;150 uL;700 uL
Ala-Asp-Cys-Ser	ST000539	AN000818	9.050E-16	7.530E-14	Cell type;Mature erythrocyte;Reticulocyte
Arg-Leu-Val-Asn	ST000403	AN000643	9.310E-16	6.290E-14	Cell type;Mature erythrocyte;Reticulocyte
FA methyl(18:0)	ST001202	AN002001	9.430E-16	1.830E-15	cell_type;iRBC;unRBC
Coproporphyrin	ST000356	AN000583	9.540E-16	6.270E-15	stage;-;2;3
4-QUINOLINECARBOXYLIC ACID #2 (M+H)+	ST000818	AN001297	1.090E-15	1.060E-14	Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
trihydroxypyrazine NIST	ST000369	AN000603	1.160E-15	1.750E-14	Organ;Plasma;Serum
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000698	AN001084	1.160E-15	1.440E-13	KD#2;yes;no;Pooled melanoma
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000698	AN001084	1.180E-15	1.460E-13	Condition;no;Pooled melanoma;yes
(R)-2-Ethylmalate	ST001202	AN002000	1.660E-15	2.870E-15	cell_type;iRBC;unRBC
5?-Androstan-3?-ol-17-one sulfate - 7.5459185	ST000566	AN000869	1.700E-15	7.880E-15	Time point;Post;Pre;Baseline
Asp-Met-Cys-Cys	ST000403	AN000643	1.710E-15	9.270E-14	Cell type;Mature erythrocyte;Reticulocyte
D-O-Phosphoserine	ST001202	AN002000	1.800E-15	3.100E-15	cell_type;iRBC;unRBC
6-deoxy-5-ketofructose-1-phosphate	ST001201	AN001998	1.860E-15	6.620E-15	cell_type;iRBC;unRBC
CTAB	ST001202	AN002000	2.130E-15	3.640E-15	cell_type;iRBC;unRBC
P-DPD	ST001204	AN002005	2.190E-15	1.180E-14	cell_type;iRBC;unRBC
Glutaminolysis	ST000544	AN000826	2.320E-15	3.950E-14	Sample Type;Control;Replicate
BOC-HIS-OH	ST000016	AN000033	2.440E-15	1.450E-14	Material;Cells;Media
[13C]-LEUCINE	ST000016	AN000033	2.880E-15	1.680E-14	Material;Cells;Media
2-(Hydroxymethyl)-3-(acetamidomethylene)succinate	ST000403	AN000643	2.890E-15	1.410E-13	Cell type;Mature erythrocyte;Reticulocyte
tetrahydro-beta-carboline-carboxylic acid	ST001000	AN001878	3.160E-15	1.120E-13	Diagnosis;CD;Control;UC
2-deoxytetronic acid NIST	ST000385	AN000620	3.320E-15	6.390E-15	Organ;Plasma;Serum;Serum or Plasma
NMMA	ST001142	AN001875	3.410E-15	7.960E-15	Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
Asp-Leu-Lys-Lys	ST000403	AN000643	3.990E-15	1.660E-13	Cell type;Mature erythrocyte;Reticulocyte
Asparaginyl-Hydroxyproline	ST001202	AN002000	4.400E-15	7.380E-15	cell_type;iRBC;unRBC
L(-)-Nicotine pestal	ST000241	AN000373	4.800E-15	6.450E-14	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
di-n-Undecylamine	ST000403	AN000642	4.980E-15	2.260E-13	Cell type;Mature erythrocyte;Reticulocyte
1-deoxyxylonojirimycin	ST000539	AN000818	5.460E-15	2.870E-13	Cell type;Mature erythrocyte;Reticulocyte
Galabiosylceramide (d18:1/26:0)	ST000241	AN000373	6.080E-15	7.880E-14	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
ADMA / Arg	ST000544	AN000826	6.110E-15	6.930E-14	Sample Type;Control;Replicate
Acetylpseudotropine	ST001202	AN002000	6.310E-15	1.050E-14	cell_type;iRBC;unRBC
PC 34:2 (17:2(9Z.12Z)/17:0) [M-Ac-H]-	ST001111	AN001806	6.350E-15	6.200E-14	Sample;Benign;Cancer;Metastasis
Ala-Asp-Cys-Ser	ST000403	AN000642	6.390E-15	2.510E-13	Cell type;Mature erythrocyte;Reticulocyte
CMP-N-acetylneuraminate	ST000403	AN000643	6.630E-15	2.560E-13	Cell type;Mature erythrocyte;Reticulocyte
C8-Ceramide m+6	ST000644	AN000976	7.860E-15	3.020E-14	tracer;13C-glucose;13C-glutamine;No label
IS D31-TAG	ST000523	AN000800	8.330E-15	3.640E-13	Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
Asp-Leu-Lys-Lys	ST000539	AN000819	8.390E-15	6.420E-13	Cell type;Mature erythrocyte;Reticulocyte
trihydroxypyrazine NIST	ST000386	AN000621	9.980E-15	1.640E-13	Organ;Plasma;Serum
N-ACETYL-D-HEXOSAMINE	ST000016	AN000033	1.020E-14	4.270E-13	Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
PC(18:0/8:0(COOH))	ST000608	AN000929	1.040E-14	2.690E-14	Sample_Type;blotter;serum
PC(16:0/7:0(CHO))	ST000608	AN000929	1.520E-14	3.850E-14	Sample_Type;blotter;serum
C9 / C16:1-OH	ST000544	AN000827	1.600E-14	2.360E-13	Sample Type;Control;Replicate
2-deoxyglucose-6-phosphate	ST001201	AN001999	1.690E-14	5.490E-14	cell_type;iRBC;unRBC
Theobromine /Theophylline/ Paraxanthine	ST001317	AN002192	2.012E-14	3.521E-14	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Theobromine /Theophylline/ Paraxanthine	ST001317	AN002192	2.012E-14	3.521E-14	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
N-Acetyl-D-glucosamine 6-phosphate	ST000539	AN000819	2.410E-14	1.440E-12	Cell type;Mature erythrocyte;Reticulocyte
C8-Ceramide m+12	ST000644	AN000976	2.500E-14	9.210E-14	tracer;13C-glucose;13C-glutamine;No label
S-Methyl-5-thio-D-ribose 1-phosphate	ST001204	AN002005	2.750E-14	1.370E-13	cell_type;iRBC;unRBC
N-ACETYL-D-HEXOSAMINE	ST000016	AN000033	2.810E-14	7.390E-13	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
EICOSATRIENOYLGLYCEROPHOSPHOCHOLINE	ST000016	AN000033	2.920E-14	1.550E-13	Material;Cells;Media
FA methyl(16:1)	ST001202	AN002001	3.220E-14	5.520E-14	cell_type;iRBC;unRBC
trans-Hexadec-2-enoylcarnitine	ST001204	AN002004	3.480E-14	1.850E-13	cell_type;iRBC;unRBC
C38:5 PC	ST001142	AN001877	3.600E-14	1.070E-12	Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
Methyl methoxyacetate	ST000614	AN000941	3.760E-14	1.350E-13	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
3-(1-Pyrrolidinyl)-2-pentanone	ST001202	AN002000	3.990E-14	6.480E-14	cell_type;iRBC;unRBC
Pentonic acids	ST000586	AN000901	4.330E-14	1.120E-13	Plasma Volume;0 uL;150 uL;700 uL
D-1-[(3-Carboxypropyl)amino]-1-deoxyfructose	ST001202	AN002001	4.520E-14	1.930E-12	treatment_duration_(h);-;1.5;3;6;9
1-deoxyxylonojirimycin	ST000403	AN000642	4.600E-14	8.870E-13	Cell type;Mature erythrocyte;Reticulocyte
Arg-Asp-Asp-Gly	ST000403	AN000642	4.660E-14	8.870E-13	Cell type;Mature erythrocyte;Reticulocyte
P-DPD	ST001202	AN002001	5.420E-14	9.060E-14	cell_type;iRBC;unRBC
F1P/F6P/G1P/G6P	ST001142	AN001876	6.960E-14	1.420E-13	Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
4-Imidazolone-5-propanoate	ST000403	AN000642	9.030E-14	1.370E-12	Cell type;Mature erythrocyte;Reticulocyte
Asp-Met-Cys-Cys	ST000539	AN000819	9.280E-14	3.820E-12	Cell type;Mature erythrocyte;Reticulocyte
3-nitro-2-pentanol	ST001202	AN002000	9.710E-14	1.550E-13	cell_type;iRBC;unRBC
N-acetyl -D- glucosaminitol	ST001202	AN002001	1.010E-13	3.710E-12	treatment_duration_(h);-;1.5;3;6;9
FA methyl(8:0)	ST001202	AN002001	1.110E-13	1.820E-13	cell_type;iRBC;unRBC
Sphinganine-phosphate (d18:0)	ST000553	AN000845	1.120E-13	1.210E-12	Sample type;Plasma;Urine
sinapoyltyramine	ST000539	AN000819	1.310E-13	3.910E-12	Cell type;Mature erythrocyte;Reticulocyte
3-(ADP)-2-phosphoglycerate	ST001201	AN001998	1.340E-13	4.580E-13	cell_type;iRBC;unRBC
8-iso-15-keto-PGE2	ST000241	AN000373	1.530E-13	1.480E-12	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
vanilylmandelic acid	ST000420	AN000662	1.530E-13	2.140E-12	Group;nonsmoker;smoker
4-Hydroxypyridine	ST000589	AN000904	1.590E-13	1.880E-13	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
Dihomo-?-Linolenic Acid	ST000553	AN000846	1.740E-13	1.280E-12	Sample type;Plasma;Urine
trans-Hexadec-2-enoylcarnitine	ST000539	AN000818	1.960E-13	5.670E-12	Cell type;Mature erythrocyte;Reticulocyte
CL 82:11 (18:0/20:0/22:6/22:5) [M-2H](2-)	ST001111	AN001806	2.060E-13	1.670E-12	Sample;Benign;Cancer;Metastasis
Asp-Met-Gln-Gln	ST001204	AN002004	2.280E-13	1.110E-12	cell_type;iRBC;unRBC
Bis(glycerophospho)-glycerol	ST000539	AN000818	2.390E-13	6.300E-12	Cell type;Mature erythrocyte;Reticulocyte
5-hydroxymethyl-2-furoic acid nist	ST000420	AN000662	2.880E-13	3.630E-12	Group;nonsmoker;smoker
3-(ADP)-glycerate	ST001201	AN001999	2.990E-13	9.430E-13	cell_type;iRBC;unRBC
3-Butynoate	ST001202	AN002000	3.650E-13	8.640E-12	treatment_duration_(h);-;1.5;3;6;9
CL 78:13 (18:1/20:4/18:2/22:6) [M-2H](2-)	ST001111	AN001806	3.740E-13	2.820E-12	Sample;Benign;Cancer;Metastasis
Asn-Leu-Asn-Tyr	ST000539	AN000818	4.180E-13	9.310E-12	Cell type;Mature erythrocyte;Reticulocyte
FA methyl(14:0)	ST001202	AN002001	4.720E-13	7.470E-13	cell_type;iRBC;unRBC
HWESASXX	ST000553	AN000846	4.720E-13	2.830E-12	Sample type;Plasma;Urine
PC(24:1(15Z)/P-18:1(11Z))	ST000241	AN000373	4.830E-13	4.220E-12	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
F1P/F6P/G1P/G6P	ST001142	AN001876	4.930E-13	1.820E-12	Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
6-Acetyl-D-glucose	ST000539	AN000819	5.090E-13	1.050E-11	Cell type;Mature erythrocyte;Reticulocyte
6-Acetyl-D-glucose 2	ST000539	AN000819	5.090E-13	1.050E-11	Cell type;Mature erythrocyte;Reticulocyte
L-a-glutamyl-L-Lysine	ST000403	AN000642	5.470E-13	5.860E-12	Cell type;Mature erythrocyte;Reticulocyte
Ala-Ala-Ala-Ser	ST001204	AN002004	5.740E-13	2.630E-12	cell_type;iRBC;unRBC
(S)-Methylmalonate semialdehyde	ST000539	AN000819	5.900E-13	3.160E-10	Glucose labelling;C13 glucose;unlabelled
3-phosphoglucarate	ST001202	AN002001	5.990E-13	9.350E-13	cell_type;iRBC;unRBC
Ala-Trp-Gly-Gly	ST001202	AN002000	6.160E-13	9.480E-13	cell_type;iRBC;unRBC
5-6-Dihydrouridine	ST001202	AN002000	6.290E-13	1.410E-11	treatment_duration_(h);-;1.5;3;6;9
Ala-Met-Pro-Tyr	ST000403	AN000642	6.500E-13	6.730E-12	Cell type;Mature erythrocyte;Reticulocyte
Butanoyl-PAF	ST000553	AN000845	6.650E-13	5.980E-12	Sample type;Plasma;Urine
CMP-N-trimethyl-2-aminoethylphosphonate	ST000403	AN000642	6.780E-13	6.900E-12	Cell type;Mature erythrocyte;Reticulocyte
Bisacurone epoxide	ST001202	AN002000	7.010E-13	1.070E-12	cell_type;iRBC;unRBC
Myoinositol-2-phosphate	ST000586	AN000901	7.020E-13	1.790E-12	Plasma Volume;0 uL;150 uL;700 uL
PIP(16:0/20:1(11Z))	ST000241	AN000373	7.200E-13	5.890E-12	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
IS SM 35:1;[M+H]+	ST000661	AN001009	7.300E-13	1.280E-12	Species;Homo sapiens;Rattus
(5-Amino-1H-tetraazol-1-yl)acetic acid	ST000356	AN000582	7.490E-13	3.150E-12	Diagnosis;breast cancer;control
5-Ureido-4-imidazole carboxylate	ST000292	AN000466	7.700E-13	1.790E-10	Treatment ;Baseline plasma;Plasma after drinking apple juice...
plasmenyl-PC 40:2 (18:0/22:2(13Z.16Z)) [M+Na]+	ST001111	AN001805	8.150E-13	5.670E-12	Sample;Benign;Cancer;Metastasis
BOC-PRO-OH	ST000016	AN000033	8.260E-13	2.430E-11	Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
Tetrahydroneopterin	ST000356	AN000583	8.300E-13	3.640E-12	Diagnosis;breast cancer;control
4-Imidazolone-5-propanoate	ST001202	AN002000	8.720E-13	1.330E-12	cell_type;iRBC;unRBC
L-beta-aspartyl-L-phenylalanine	ST000356	AN000583	8.850E-13	4.880E-12	stage;-;2;3
Lys-Lys-Trp-Pro	ST001204	AN002005	9.230E-13	4.080E-12	cell_type;iRBC;unRBC
PC(14:1(9Z)/P-18:1(11Z))	ST000241	AN000373	9.260E-13	6.960E-12	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
4-hydroxypyridine	ST000420	AN000662	9.750E-13	1.020E-11	Group;nonsmoker;smoker
2-(4-sulfophenyl)butyrate	ST001202	AN002000	1.090E-12	1.660E-12	cell_type;iRBC;unRBC
Arg-Asp-Asp-Gly	ST001202	AN002000	1.140E-12	1.730E-12	cell_type;iRBC;unRBC
5-6-Dihydrouridine	ST001201	AN001998	1.220E-12	3.940E-12	cell_type;iRBC;unRBC
N-hydroxyisoleucine	ST000403	AN000643	1.220E-12	1.470E-11	Cell type;Mature erythrocyte;Reticulocyte
Mesaconate	ST001202	AN002001	1.280E-12	1.940E-12	cell_type;iRBC;unRBC
Ganglioside GA1 (d18:1/24:0)	ST001202	AN002000	1.350E-12	2.030E-12	cell_type;iRBC;unRBC
3-dimethylsulfoniopropionaldehyde	ST000539	AN000819	1.450E-12	3.880E-10	Glucose labelling;C13 glucose;unlabelled
nicotinamide guanine dinucleotide	ST001201	AN001999	1.490E-12	4.600E-12	cell_type;iRBC;unRBC
BOC-PRO-OH	ST000016	AN000033	1.520E-12	3.310E-11	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
SALICYLATE #2 (M-H)-	ST000748	AN001172	1.580E-12	4.630E-12	Sample type;Cells;Culture Media
N2-(D-1-Carboxyethyl)-L-arginine	ST001204	AN002004	1.710E-12	7.390E-12	cell_type;iRBC;unRBC
omega-Cyclohexylundecanoic acid	ST000539	AN000819	1.720E-12	2.800E-11	Cell type;Mature erythrocyte;Reticulocyte
Vanilloylglycine	ST000292	AN000467	1.970E-12	8.460E-11	Treatment ;Baseline plasma;Plasma after drinking apple juice...
hydrogen iodide	ST000403	AN000643	2.040E-12	2.250E-11	Cell type;Mature erythrocyte;Reticulocyte
undecanedionate	ST001000	AN001880	2.230E-12	6.230E-11	Diagnosis;CD;Control;UC
[PI (18:0)] 1-octadecanoyl-sn-glycero-3-phospho-(1-myo-inositol)	ST000403	AN000643	2.240E-12	2.420E-11	Cell type;Mature erythrocyte;Reticulocyte
MUFA (PC) / SFA (PC)	ST000545	AN000830	2.270E-12	2.170E-10	Sample Type;Control;Replicate
Putrescine / Orn	ST000544	AN000826	2.420E-12	2.060E-11	Sample Type;Control;Replicate
4-Imidazolone-5-propanoate	ST000539	AN000818	2.430E-12	3.810E-11	Cell type;Mature erythrocyte;Reticulocyte
PE(14:1(9Z)/P-16:0)	ST000241	AN000373	2.680E-12	3.250E-11	Concentration (uM);0;500
Eicosapentaenoyl PAF C-16	ST000553	AN000846	2.740E-12	1.210E-11	Sample type;Plasma;Urine
IDP-D-mannose	ST001201	AN001999	2.860E-12	8.780E-12	cell_type;iRBC;unRBC
Eicosapentaenoyl PAF C-16	ST000553	AN000845	2.900E-12	1.570E-11	Sample type;Plasma;Urine
Marinobufagenin	ST000566	AN000869	3.080E-12	1.230E-11	Time point;Post;Pre;Baseline
3-Phosphonopyruvate	ST001202	AN002001	3.090E-12	4.540E-12	cell_type;iRBC;unRBC
Asn-Leu-Asn-Tyr	ST000403	AN000642	3.160E-12	2.620E-11	Cell type;Mature erythrocyte;Reticulocyte
Kyn/Trp	ST001237	AN002055	3.260E-12	2.230E-10	Time point;baseline;week 4;week 8
HEPES	ST000539	AN000819	3.360E-12	4.860E-11	Cell type;Mature erythrocyte;Reticulocyte
C4 / C5	ST000544	AN000827	3.530E-12	4.520E-11	Sample Type;Control;Replicate
dXMP	ST000403	AN000643	3.910E-12	3.710E-11	Cell type;Mature erythrocyte;Reticulocyte
1-thio-beta-D-glucose	ST001204	AN002005	3.940E-12	1.690E-11	cell_type;iRBC;unRBC
Cotine	ST000614	AN000943	4.370E-12	4.260E-11	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Ala-Phe-Tyr-Tyr	ST001204	AN002005	4.420E-12	1.860E-11	cell_type;iRBC;unRBC
3-Phosphonopyruvate	ST000403	AN000643	4.440E-12	4.140E-11	Cell type;Mature erythrocyte;Reticulocyte
Met-Trp-OH	ST000242	AN000375	4.610E-12	6.640E-11	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
DL-Methionine sulfone	ST000403	AN000642	4.960E-12	3.840E-11	Cell type;Mature erythrocyte;Reticulocyte
PC(18:0/P-18:1(11Z))	ST000539	AN000818	4.990E-12	6.720E-11	Cell type;Mature erythrocyte;Reticulocyte
PUFA (PC) / SFA (PC)	ST000545	AN000830	5.060E-12	3.220E-10	Sample Type;Control;Replicate
20cooh AA	ST000916	AN001491	5.140E-12	3.960E-10	Diagnosis;Cirrhosis;NASH;Normal;Steatosis
Ala-Lys-Asn-His	ST000403	AN000642	5.150E-12	3.900E-11	Cell type;Mature erythrocyte;Reticulocyte
CL 82:11 (18:0/20:0/22:5/22:6) [M-2H](2-)	ST001111	AN001806	5.690E-12	3.570E-11	Sample;Benign;Cancer;Metastasis
D-Galacturonate	ST000403	AN000643	5.830E-12	5.260E-11	Cell type;Mature erythrocyte;Reticulocyte
dibenzothiophene-5-oxide	ST001202	AN002000	5.880E-12	8.590E-12	cell_type;iRBC;unRBC
Methylprednisone	ST000567	AN000871	5.880E-12	3.000E-11	Time point;Post;Pre;Baseline
Met-Trp-Trp-Tyr	ST000403	AN000642	5.900E-12	3.480E-9	Glucose labelling;C13 glucose;unlabelled
3-(ADP)-glycerate	ST000403	AN000643	6.160E-12	5.460E-11	Cell type;Mature erythrocyte;Reticulocyte
Ala-Phe-Tyr-Tyr	ST001201	AN001999	6.290E-12	1.840E-11	cell_type;iRBC;unRBC
5-Taurinomethyl-2-thiouridine	ST000241	AN000373	6.310E-12	3.760E-11	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Arg-Asn-Pro-His	ST000403	AN000642	6.410E-12	4.720E-11	Cell type;Mature erythrocyte;Reticulocyte
Ala-Met-Pro-Tyr	ST000539	AN000818	7.510E-12	8.390E-11	Cell type;Mature erythrocyte;Reticulocyte
epibrassinolide+HCOOH	ST001325	AN002207	7.898E-12	7.437E-11	Gender;-;female;male
3-Butynoate	ST001201	AN001998	8.210E-12	2.570E-11	cell_type;iRBC;unRBC
CerH2O(d19:1/24:0)	ST000608	AN000929	8.300E-12	1.670E-11	Sample_Type;blotter;serum
Clitidine 5-phosphate	ST000539	AN000819	8.300E-12	9.670E-11	Cell type;Mature erythrocyte;Reticulocyte
Taurine Dimer	ST000380	AN000614	8.550E-12	6.600E-11	Treatment;10.5mM Glu;5.5mM Glu 5mM Fru;5.5mM Glu;Glucosamine
glucosylglycerol	ST000092	AN000146	9.150E-12	6.130E-11	Urease Treatment;No treatment;Urease pre-treatment;Water pre...
IS SM 35:1;[M+H]+	ST000661	AN001009	9.430E-12	2.960E-11	Sample_Source;Plasma;POOLED;Mammary gland
4-oxo-Retinoic acid	ST000241	AN000373	9.630E-12	5.570E-11	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
3-Butynoate	ST000403	AN000642	1.050E-11	7.380E-11	Cell type;Mature erythrocyte;Reticulocyte
2-O-ethyl PAF C-16	ST000553	AN000845	1.140E-11	4.390E-11	Sample type;Plasma;Urine
3-(ADP)-glycerate	ST001202	AN002001	1.150E-11	1.640E-10	treatment_duration_(h);-;1.5;3;6;9
[PC (7:0/8:0)] 1-heptanoyl-2-octanoyl-sn-glycero-3-phosphocholine	ST000403	AN000643	1.170E-11	9.150E-11	Cell type;Mature erythrocyte;Reticulocyte
D/L Glucosamine / D/L Galactosamine / D-Mannosamine	ST001048	AN001716	1.190E-11	1.950E-11	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
[PC acetyl(16:1)] 1-(9Z-hexadecenoyl)-2-acetyl-sn-glycero-3-phosphocholine	ST000403	AN000642	1.290E-11	8.880E-11	Cell type;Mature erythrocyte;Reticulocyte
1-Oleoyl Lysophosphatidic Acid	ST000553	AN000846	1.430E-11	5.590E-11	Sample type;Plasma;Urine
Total DMA / Arg	ST000544	AN000826	1.430E-11	1.080E-10	Sample Type;Control;Replicate
Ala-Leu-Lys-Pro	ST000403	AN000642	1.580E-11	1.070E-10	Cell type;Mature erythrocyte;Reticulocyte
dXMP	ST000539	AN000819	1.580E-11	1.590E-10	Cell type;Mature erythrocyte;Reticulocyte
Trihexosylceramide (d18:1/9Z-18:1)	ST000241	AN000373	1.590E-11	8.670E-11	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Asn-Cys-Pro-Ser	ST000403	AN000642	1.650E-11	1.090E-10	Cell type;Mature erythrocyte;Reticulocyte
N-Acetyl-D-glucosamine 6-phosphate	ST000403	AN000643	1.650E-11	1.260E-10	Cell type;Mature erythrocyte;Reticulocyte
farnesol	ST000568	AN000874	1.660E-11	2.850E-11	Genotype;AA;AC;CC
Cotinineglucuronide	ST000241	AN000373	1.750E-11	9.140E-11	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Lactosylceramide(d18	ST001202	AN002000	1.770E-11	2.540E-11	cell_type;iRBC;unRBC
Cyclo(leucylprolyl)	ST000553	AN000845	1.890E-11	6.380E-11	Sample type;Plasma;Urine
D-Galacturonate	ST000539	AN000819	2.110E-11	2.060E-10	Cell type;Mature erythrocyte;Reticulocyte
CL 82:11 (18:0/22:5/20:0/22:6) [M-2H](2-)	ST001111	AN001806	2.120E-11	1.280E-10	Sample;Benign;Cancer;Metastasis
z dioctylphtalate	ST000054	AN000092	2.330E-11	1.030E-9	pool aliquot;no;yes
Methyl Guanine	ST000614	AN000943	2.650E-11	1.720E-10	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Methylhippurate	ST000553	AN000847	2.750E-11	7.880E-11	Sample type;Plasma;Urine
octulose 8-phosphate	ST001204	AN002004	2.890E-11	1.150E-10	cell_type;iRBC;unRBC
DMGV	ST001237	AN002055	2.960E-11	3.370E-10	OS_Censor (1 means the time is a censoring time and 0 means ...
PC 24:2 (2:0/22:2(13Z.16Z)) [M+HCOO]-	ST001111	AN001806	3.190E-11	1.860E-10	Sample;Benign;Cancer;Metastasis
n-acetyl-d-hexosamine	ST001322	AN002198	3.197E-11	1.321E-9	treatment;expecting 2 month - human breast milk;expecting 2 ...
HWESASXX	ST000553	AN000845	3.470E-11	1.100E-10	Sample type;Plasma;Urine
SDMA/ADMA	ST001142	AN001875	3.570E-11	7.220E-11	Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
dihomocitrate	ST000539	AN000819	3.710E-11	3.480E-10	Cell type;Mature erythrocyte;Reticulocyte
A-Ketoglutaricacidoxime	ST000539	AN000819	4.150E-11	3.830E-10	Cell type;Mature erythrocyte;Reticulocyte
ribitol (likely)	ST000420	AN000662	4.220E-11	2.210E-10	Group;nonsmoker;smoker
3-methyladipate/pimelate	ST001142	AN001876	4.270E-11	1.400E-10	Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
hydrogen iodide	ST000539	AN000819	4.480E-11	4.070E-10	Cell type;Mature erythrocyte;Reticulocyte
DL-Methionine sulfone	ST001202	AN002000	5.570E-11	7.480E-10	treatment_duration_(h);-;1.5;3;6;9
2-Deoxyinosine	ST000553	AN000847	5.700E-11	1.470E-10	Sample type;Plasma;Urine
CMP-N-acetylneuraminate	ST000539	AN000819	5.770E-11	4.910E-10	Cell type;Mature erythrocyte;Reticulocyte
Asn-Lys-Gly-Pro	ST001204	AN002004	6.050E-11	2.380E-10	cell_type;iRBC;unRBC
3-Methylglutarate/Adipate	ST001317	AN002193	6.165E-11	1.368E-10	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
3-Methylglutarate/Adipate	ST001317	AN002193	6.165E-11	1.368E-10	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
IS Ceramide;[M-H20]+	ST000661	AN001009	6.350E-11	1.760E-10	Sample_Source;Plasma;POOLED;Mammary gland
di-n-Undecylamine	ST000539	AN000818	6.430E-11	5.390E-10	Cell type;Mature erythrocyte;Reticulocyte
4-amino-4-deoxy-L-arabinose	ST001202	AN002000	6.470E-11	8.420E-10	treatment_duration_(h);-;1.5;3;6;9
IS Ceramide;[M-H20]+	ST000661	AN001009	6.530E-11	9.870E-11	Species;Homo sapiens;Rattus
Beta-alanine methyl ester	ST000553	AN000847	7.090E-11	1.740E-10	Sample type;Plasma;Urine
3-dimethylsulfoniopropionaldehyde	ST000403	AN000643	7.120E-11	1.930E-8	Glucose labelling;C13 glucose;unlabelled
Asn-Asp-Asp-Pro	ST000539	AN000819	7.460E-11	6.060E-10	Cell type;Mature erythrocyte;Reticulocyte
nicotinamide guanine dinucleotide	ST001202	AN002001	7.590E-11	8.830E-10	treatment_duration_(h);-;1.5;3;6;9
DIHEXOSE	ST000105	AN000174	7.890E-11	1.510E-8	Sampling;After SWS onset;Morning fasting
Ala-Lys-Asn-His	ST000539	AN000818	7.940E-11	6.390E-10	Cell type;Mature erythrocyte;Reticulocyte
p-Toluic acid-M+0	ST001167	AN001930	7.990E-11	4.020E-10	Time points;0.25h;0h;12h;24h;4h;6days
1-AG b	ST000096	AN000154	8.250E-11	1.070E-9	Timepoint;18 hours;4 hours;NA
Xylobiose	ST001201	AN001999	8.800E-11	2.830E-8	treatment;DHA;DMSO;OZ277;OZ439
melibionate	ST000539	AN000819	8.950E-11	7.060E-10	Cell type;Mature erythrocyte;Reticulocyte
1-O-Methyl-myo-inositol	ST001204	AN002005	9.040E-11	3.440E-10	cell_type;iRBC;unRBC
m-hydroxybenzoic acid	ST001325	AN002207	9.617E-11	7.245E-10	Gender;-;female;male
D/L Glucosamine / D/L Galactosamine	ST001048	AN001716	9.910E-11	1.540E-10	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
5-hydroxynorvaline NIST	ST000385	AN000620	1.060E-10	1.600E-10	Organ;Plasma;Serum;Serum or Plasma
CMP-N-trimethyl-2-aminoethylphosphonate	ST000539	AN000818	1.090E-10	8.460E-10	Cell type;Mature erythrocyte;Reticulocyte
nonulose 9-phosphate	ST000403	AN000643	1.100E-10	7.600E-10	Cell type;Mature erythrocyte;Reticulocyte
1-arachidonoylglyercophosphate	ST000974	AN001595	1.190E-10	1.280E-9	REGION;AHRI;MRC;SUN
sulfate of piperine metabolite C16H19NO3 (3)*	ST000974	AN001595	1.190E-10	1.280E-9	REGION;AHRI;MRC;SUN
Asn-Asp-Asp-Pro	ST000403	AN000643	1.240E-10	8.360E-10	Cell type;Mature erythrocyte;Reticulocyte
Flavonol 3-O-xylosylglycoside-13C1[+QDA adduct]+	ST000148	AN000235	1.250E-10	5.430E-7	Treatment;13C-Glc;unlabeled
L-Ala-L-Glu	ST000403	AN000643	1.320E-10	8.580E-10	Cell type;Mature erythrocyte;Reticulocyte
dibenzothiophene-5-oxide	ST001202	AN002000	1.330E-10	1.460E-9	treatment_duration_(h);-;1.5;3;6;9
Pentosidine	ST000355	AN000581	1.370E-10	3.400E-9	Diagnosis;Breast cancer;Control
CL 72:10 (18:3/14:0/20:3/20:4) [M-2H](2-)	ST001111	AN001806	1.580E-10	7.820E-10	Sample;Benign;Cancer;Metastasis
DIHEXOSE	ST000105	AN000173	1.710E-10	1.760E-8	Sampling;After SWS onset;Morning fasting
Met-Trp-Trp-Tyr	ST000539	AN000818	1.780E-10	1.030E-7	Glucose labelling;C13 glucose;unlabelled
Ganglioside GT3 (d18:1/18:1(11Z))	ST000241	AN000373	1.830E-10	7.660E-10	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
2-Amino-3-methyl-1-butanol	ST000242	AN000375	1.860E-10	1.670E-9	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Dimethylallylaminopurine	ST000553	AN000846	1.920E-10	4.880E-10	Sample type;Plasma;Urine
Unknown_742.54(-)@6.25	ST000818	AN001298	2.110E-10	4.500E-10	Categorization;Amhara;Dizi;Hadza_settled;Hadza_traditional;H...
mildronate	ST000539	AN000818	2.150E-10	1.540E-9	Cell type;Mature erythrocyte;Reticulocyte
plasmenyl-PE 34:1 (16:0/18:1(11E)) [M+H]+	ST001111	AN001805	2.650E-10	1.050E-9	Sample;Benign;Cancer;Metastasis
trans-Hexadec-2-enoylcarnitine	ST000403	AN000642	2.680E-10	1.440E-9	Cell type;Mature erythrocyte;Reticulocyte
PC(18:0/P-18:1(11Z))	ST000403	AN000642	2.770E-10	1.470E-9	Cell type;Mature erythrocyte;Reticulocyte
metabolite 2	ST000539	AN000819	2.780E-10	1.860E-8	Glucose labelling;C13 glucose;unlabelled
gamma-Muricholic acid	ST000553	AN000846	3.000E-10	7.080E-10	Sample type;Plasma;Urine
Methyl deoxyadenosine	ST000614	AN000943	3.230E-10	1.260E-9	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
4-Nitrophenyl-3-ketovalidamine	ST000403	AN000643	3.260E-10	1.890E-9	Cell type;Mature erythrocyte;Reticulocyte
2-Ketovaline	ST000586	AN000901	3.340E-10	7.630E-10	Plasma Volume;0 uL;150 uL;700 uL
gamma-Muricholic acid	ST000553	AN000845	3.390E-10	8.720E-10	Sample type;Plasma;Urine
4-AMINOBUTANOATE (GABA);2-AMINO-2-METHYLPROPANOATE;3-AMINOISOBUTANOATE	ST000956	AN001568	3.600E-10	5.560E-9	Treatment;Condition-1;Condition-2;Condition-3;Control
Hexose Pool	ST000450	AN000706	3.650E-10	8.670E-10	gender;Female;Male
Docosahexaenoyl PAF C-16	ST000553	AN000845	3.720E-10	9.140E-10	Sample type;Plasma;Urine
DOCOSAPENTAENOATE (*)	ST000106	AN000176	4.020E-10	2.320E-8	Sampling time;0 min;60 min
Phosphatidyl glycerol	ST000242	AN000377	4.150E-10	1.590E-8	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
o-toluidene2	ST000614	AN000941	4.200E-10	7.550E-10	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Cysteinyl-Hydroxyproline	ST001202	AN002000	4.210E-10	3.950E-9	treatment_duration_(h);-;1.5;3;6;9
PE(16:1(9Z)/P-18:1(11Z))	ST000241	AN000373	4.310E-10	1.710E-9	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
epibrassinolide+HCOOH	ST001325	AN002207	4.327E-10	1.577E-9	Sample type;batch pool;chear plasma;master pool;red cross pl...
N-hydroxyisoleucine	ST000539	AN000819	4.350E-10	3.030E-9	Cell type;Mature erythrocyte;Reticulocyte
Tris(2-chloroethyl)phosphate	ST000566	AN000869	4.530E-10	1.590E-9	Time point;Post;Pre;Baseline
FMLP	ST000403	AN000642	5.010E-10	2.570E-9	Cell type;Mature erythrocyte;Reticulocyte
4-Phosphopantothenoylcysteine	ST000241	AN000373	5.210E-10	2.020E-9	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Asp-Thr-Cys-Cys	ST001201	AN001998	5.370E-10	1.520E-9	cell_type;iRBC;unRBC
beta-Nicotinamide adenine dinucleotide	ST001211	AN002017	5.470E-10	3.760E-8	Group;Control;Methotrexate
N-Acetyl-D-glucosamine 6-phosphate	ST001204	AN002005	5.480E-10	2.000E-9	cell_type;iRBC;unRBC
3-Phosphonopyruvate	ST001202	AN002001	5.500E-10	5.420E-9	treatment_duration_(h);-;1.5;3;6;9
FKGK 11	ST000242	AN000375	5.550E-10	3.630E-9	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
MANDELIC ACID #2 (M-H)-	ST000842	AN001356	5.800E-10	9.350E-10	Sample type;Muscles;Plasma;Pooled sample
Azythromycin	ST000241	AN000374	6.490E-10	1.640E-9	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Sesaminol glucosyl-(1->2)-[glucosyl-(1->6)]-glucoside	ST001202	AN002000	6.560E-10	8.720E-10	cell_type;iRBC;unRBC
Threonine /Homoserine	ST000553	AN000847	7.040E-10	1.510E-9	Sample type;Plasma;Urine
[PI (18:0)] 1-octadecanoyl-sn-glycero-3-phospho-(1-myo-inositol)	ST000539	AN000819	7.170E-10	4.740E-9	Cell type;Mature erythrocyte;Reticulocyte
(5-Amino-1H-tetraazol-1-yl)acetic acid	ST000356	AN000582	7.550E-10	2.930E-9	stage;-;2;3
Arg-Asp-Asp-Gly	ST000539	AN000818	7.570E-10	4.760E-9	Cell type;Mature erythrocyte;Reticulocyte
IS SM 35:1; [M+H]+	ST000523	AN000800	7.780E-10	5.810E-9	Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
Dolichyl beta-D-mannosyl phosphate	ST000241	AN000373	8.010E-10	2.980E-9	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
N-acetylglycine NIST	ST000385	AN000620	8.230E-10	1.200E-9	Organ;Plasma;Serum;Serum or Plasma
tetranor 12-HETE	ST000916	AN001491	8.660E-10	3.330E-8	Diagnosis;Cirrhosis;NASH;Normal;Steatosis
N-ACETYL-L-ALANINE;3-AMINO-5-HYDROXYBENZOIC ACID	ST000956	AN001568	8.720E-10	9.320E-9	Treatment;Condition-1;Condition-2;Condition-3;Control
SB N-(hexadecanoyl)-sphing-4-enine (d18:1(4E)/16:0) [M-H]-	ST001111	AN001806	9.140E-10	4.100E-9	Sample;Benign;Cancer;Metastasis
Asp-Leu-Lys-Lys	ST001202	AN002000	9.150E-10	1.210E-9	cell_type;iRBC;unRBC
C-GLYCOSYLTRYPTOPHAN	ST000016	AN000033	9.220E-10	3.340E-9	Material;Cells;Media
Pseudo uridine penta-tms	ST000978	AN001602	9.440E-10	9.220E-8	Cox_Composite_DeathRRT;.;N;Y
MANDELIC ACID #2 (M-H)-	ST000763	AN001201	9.540E-10	2.200E-8	Type;Cath;Non-invasive
ribose-5-P/ribulose5-P	ST001142	AN001876	9.640E-10	1.350E-9	Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
5-iPF2a-VI	ST001214	AN002025	9.870E-10	8.960E-9	BMI group;lean;obese;overweight
HEPTADECENOATE (*)	ST000106	AN000176	1.070E-9	4.310E-8	Sampling time;0 min;60 min
Sertraline	ST000356	AN000583	1.090E-9	4.250E-9	Diagnosis;breast cancer;control
4-(Trimethylammonio)but-2-enoate	ST001201	AN001998	1.120E-9	1.460E-7	treatment;DHA;DMSO;OZ277;OZ439
[FA methyl(14:0)] 12-methyl-tetradecanoic acid	ST000539	AN000819	1.120E-9	7.330E-9	Cell type;Mature erythrocyte;Reticulocyte
methylhexadecanoic acid	ST000368	AN000602	1.210E-9	9.110E-9	Organ;Plasma;Serum;Serum or Plasma
C-glycosyltryptophan	ST000899	AN001464	1.220E-9	1.890E-7	Type;Control;Crohn disease;Ulcerative Colitis
(S)-Methylmalonate semialdehyde	ST000403	AN000643	1.300E-9	1.170E-7	Glucose labelling;C13 glucose;unlabelled
Theobromine /Theophylline	ST000553	AN000847	1.330E-9	2.680E-9	Sample type;Plasma;Urine
[GP (16:0/18:1)] 1-hexadecanoyl-2-(11Z-octadecenoyl)-sn-glycero-3-phosphate	ST000539	AN000819	1.340E-9	8.540E-9	Cell type;Mature erythrocyte;Reticulocyte
5?-Androstan-3?-ol-17-one sulfate - 8.185043	ST000566	AN000869	1.360E-9	1.990E-8	group;Old-Curcumin;Old-Placebo;young
Ala-Lys-Asp-Pro	ST001204	AN002004	1.420E-9	4.920E-9	cell_type;iRBC;unRBC
Disialyllacto-N-tetraose	ST000241	AN000373	1.430E-9	5.060E-9	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
N-dimethylethanolamine	ST001202	AN002000	1.470E-9	1.930E-9	cell_type;iRBC;unRBC
glucuronide of piperine metabolite C17H21NO3 (4)*	ST000974	AN001595	1.530E-9	1.570E-8	REGION;AHRI;MRC;SUN
Lyso-PAF C18	ST001223	AN002036	1.530E-9	1.990E-8	Sample Type;Early Disseminated Lyme;Early Localized Lyme;Hea...
Ovothiol disulfide	ST001202	AN002000	1.590E-9	2.060E-9	cell_type;iRBC;unRBC
glucuronide of piperine metabolite C17H21NO3 (3)*	ST000974	AN001595	1.610E-9	1.630E-8	REGION;AHRI;MRC;SUN
N-acetyl-D-hexosamine	ST000412	AN000652	1.640E-9	6.370E-8	Collection Time;1 Hr;2 Hr;3 Hr;-
ACETAMINOPHEN (TN TYLENOL) (M-H)-	ST000713	AN001113	1.660E-9	7.930E-8	malignant transformation;No;yes;Yes
Ala-Glu-Glu-His	ST001204	AN002004	1.690E-9	5.770E-9	cell_type;iRBC;unRBC
SC-514	ST000567	AN000871	1.690E-9	6.710E-9	Time point;Post;Pre;Baseline
Ala-Asp-Cys-Ser	ST001204	AN002004	1.720E-9	5.830E-9	cell_type;iRBC;unRBC
Ala-Asp-Asp-Gln	ST000539	AN000818	1.810E-9	9.710E-9	Cell type;Mature erythrocyte;Reticulocyte
3-methyl-3-hydroxybutyric acid	ST000092	AN000146	1.980E-9	3.760E-9	Gender;N/A;Female;Male
PAF C-18	ST000553	AN000845	2.050E-9	4.250E-9	Sample type;Plasma;Urine
Sphinganine-phosphate (d18:0)	ST000553	AN000846	2.200E-9	4.400E-9	Sample type;Plasma;Urine
ZEATIN [ISTD] (M+CL)-	ST000726	AN001138	2.250E-9	7.500E-9	Timepoint;-;270;120;30;90
4-Aminobenzoate / Anthranilate	ST001048	AN001716	2.360E-9	3.460E-9	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
2-C-Methyl-D-erythritol 4-phosphate	ST001201	AN001999	2.780E-9	7.280E-9	cell_type;iRBC;unRBC
C8-Ceramide m+14	ST000644	AN000976	2.780E-9	6.630E-9	tracer;13C-glucose;13C-glutamine;No label
NMMA	ST001142	AN001875	2.820E-9	5.050E-9	Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
Kanokoside D	ST000242	AN000375	2.860E-9	1.140E-8	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
MG(18:0e/0:0/0:0)	ST000241	AN000373	2.910E-9	9.670E-9	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Laurencione diacetate	ST000567	AN000871	3.070E-9	1.460E-7	groups;Old-Curcumin;Old-Placebo;young
ZEATIN [ISTD] (M+CL)-	ST000748	AN001172	3.110E-9	6.040E-9	Sample type;Cells;Culture Media
Cotinine-good	ST000614	AN000943	3.160E-9	9.490E-9	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Boc-Asn	ST000403	AN000642	3.390E-9	1.530E-8	Cell type;Mature erythrocyte;Reticulocyte
[6]-Paradol	ST001202	AN002001	3.620E-9	4.780E-9	cell_type;iRBC;unRBC
Benzyl dodecyl dimethylammonium cation	ST000077	AN000123	3.660E-9	4.910E-9	Timepoint;0 hours;12 hours;24 hours;2 hours;48 hours;4 hours...
melibionate	ST000403	AN000643	3.670E-9	1.870E-8	Cell type;Mature erythrocyte;Reticulocyte
Galactinoldihydrate	ST000403	AN000643	3.700E-9	1.870E-8	Cell type;Mature erythrocyte;Reticulocyte
mildronate	ST000403	AN000642	3.930E-9	1.760E-8	Cell type;Mature erythrocyte;Reticulocyte
ZEATIN [ISTD] (M-H)-	ST000748	AN001172	4.000E-9	7.450E-9	Sample type;Cells;Culture Media
L-Arabinonate	ST000539	AN000819	4.330E-9	2.580E-8	Cell type;Mature erythrocyte;Reticulocyte
Malyngamide J	ST000242	AN000375	4.670E-9	1.530E-8	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
ethanedisulfonate	ST000539	AN000819	4.700E-9	2.770E-8	Cell type;Mature erythrocyte;Reticulocyte
Asp-Gly-Arg 2	ST000539	AN000818	5.020E-9	2.570E-8	Cell type;Mature erythrocyte;Reticulocyte
1-Hexadecylpyridinium cation	ST000089	AN000141	5.230E-9	6.570E-9	Treatment;Human Adipocytes grown in the ABSENCE of SKOV3ip1 ...
Tetrahydroneopterin	ST000356	AN000583	5.290E-9	2.260E-8	stage;-;2;3
nonulose 9-phosphate	ST000539	AN000819	5.380E-9	3.070E-8	Cell type;Mature erythrocyte;Reticulocyte
nonulose 9-phosphate 2	ST000539	AN000819	5.380E-9	3.070E-8	Cell type;Mature erythrocyte;Reticulocyte
GC(18:2/16:0)	ST000450	AN000705	5.570E-9	2.170E-8	gender;Female;Male
Hydroxyibuprofen	ST000566	AN000869	5.680E-9	1.850E-8	Time point;Post;Pre;Baseline
Crotetamide	ST000913	AN001483	5.870E-9	6.810E-7	Diagnosis;MECFS;MS;ND
2-(Acetamidomethylene)succinate	ST000403	AN000643	5.950E-9	2.900E-8	Cell type;Mature erythrocyte;Reticulocyte
Erythrulose 1-phosphate	ST000403	AN000642	6.160E-9	2.620E-8	Cell type;Mature erythrocyte;Reticulocyte
Fibrinopeptide B (1-9)**	ST000974	AN001595	6.390E-9	5.880E-8	REGION;AHRI;MRC;SUN
Docosahexaenoyl PAF C-16	ST000553	AN000846	6.510E-9	1.260E-8	Sample type;Plasma;Urine
Arg-Phe-Phe-Arg	ST001202	AN002001	6.640E-9	8.720E-9	cell_type;iRBC;unRBC
Triterpenoid	ST000241	AN000373	6.640E-9	2.030E-8	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
N-Stearoyl-4-sphingenyl-1-O-phosphorylcholine	ST000089	AN000141	6.750E-9	8.450E-9	Treatment;Human Adipocytes grown in the ABSENCE of SKOV3ip1 ...
Digitoxigenin bisdigitoxoside	ST000242	AN000375	6.820E-9	2.040E-8	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Arachidonoyl PAF C-16	ST000553	AN000846	7.090E-9	1.340E-8	Sample type;Plasma;Urine
4-Hydroxy-4-methylglutamate	ST000539	AN000818	7.380E-9	3.650E-8	Cell type;Mature erythrocyte;Reticulocyte
Arg-Asn-Pro-His	ST000539	AN000818	7.740E-9	3.800E-8	Cell type;Mature erythrocyte;Reticulocyte
PE(16:0/P-18:1(11Z))	ST000241	AN000373	7.990E-9	2.420E-8	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
trans-Hexadec-2-enoylcarnitine	ST001202	AN002000	8.190E-9	5.410E-8	treatment_duration_(h);-;1.5;3;6;9
5-?-Hydroxybutyl Hydantoin	ST000567	AN000871	8.440E-9	3.020E-8	Time point;Post;Pre;Baseline
PE(14:1(9Z)/P-16:0)	ST000241	AN000373	8.460E-9	2.510E-8	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
3-(ADP)-2-phosphoglycerate	ST001202	AN002001	8.470E-9	1.110E-8	cell_type;iRBC;unRBC
L-Aspartyl-4-phosphate	ST000241	AN000373	9.100E-9	2.650E-8	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Ala-Lys-Lys-Asp	ST001204	AN002004	9.370E-9	2.960E-8	cell_type;iRBC;unRBC
o-toluidene	ST000614	AN000943	9.800E-9	2.730E-8	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
hydrogen iodide	ST001202	AN002001	1.050E-8	1.350E-8	cell_type;iRBC;unRBC
Unknown_742.54(-)@6.25	ST000818	AN001298	1.050E-8	5.050E-8	Country;Ethiopia;Tanzania;Botswana
succinate/methylmalonate	ST001142	AN001876	1.080E-8	2.890E-8	Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
PAF C-16	ST000553	AN000845	1.110E-8	2.000E-8	Sample type;Plasma;Urine
plasmenyl-PC 37:0 (20:0/17:0) [M+Na]+	ST001111	AN001805	1.140E-8	3.470E-8	Sample;Benign;Cancer;Metastasis
N2-Acetyl-L-aminoadipyl-delta-phosphate	ST001202	AN002000	1.160E-8	1.480E-8	cell_type;iRBC;unRBC
C8-Ceramide m0	ST000644	AN000976	1.180E-8	2.610E-8	tracer;13C-glucose;13C-glutamine;No label
GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))	ST001202	AN002001	1.180E-8	1.510E-8	cell_type;iRBC;unRBC
benzi(ghi)perylene	ST000614	AN000943	1.200E-8	3.120E-8	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
2-Hydroxyiminodibenzyl glucuronide	ST000242	AN000375	1.220E-8	3.370E-8	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
1-OG b	ST000096	AN000154	1.230E-8	5.310E-8	Timepoint;18 hours;4 hours;NA
Epoxomicin	ST000567	AN000871	1.250E-8	4.370E-8	Time point;Post;Pre;Baseline
Asparaginyl-Hydroxyproline	ST001202	AN002000	1.260E-8	7.840E-8	treatment_duration_(h);-;1.5;3;6;9
L-VALINE/5-AMINOPENTANOATE/L-NORVALINE;BETAINE	ST000956	AN001568	1.330E-8	9.260E-8	Treatment;Condition-1;Condition-2;Condition-3;Control
Mono-N-depropylprobenecid	ST000421	AN000664	1.400E-8	5.570E-6	treatment;ND;T1D poor glycemic control
4-Hydroxy-4-methylglutamate	ST001202	AN002000	1.410E-8	8.620E-8	treatment_duration_(h);-;1.5;3;6;9
CL 82:12 (20:1/18:0/22:5/22:6) [M-2H](2-)	ST001111	AN001806	1.480E-8	5.660E-8	Sample;Benign;Cancer;Metastasis
N-BOC-D-GLUCOSAMINE	ST000016	AN000033	1.540E-8	5.010E-8	Material;Cells;Media
dibenzothiophene-5-oxide	ST001204	AN002004	1.580E-8	4.930E-8	cell_type;iRBC;unRBC
3-methyladipate-pimelate	ST001000	AN001879	1.660E-8	2.420E-7	Diagnosis;CD;Control;UC
glucuronide of piperine metabolite C17H21NO3 (5)*	ST000974	AN001595	1.670E-8	1.430E-7	REGION;AHRI;MRC;SUN
Phe-Ala-Phe-Ala	ST000553	AN000845	1.670E-8	2.830E-8	Sample type;Plasma;Urine
3-nitro-2-pentanol	ST001202	AN002000	1.700E-8	1.030E-7	treatment_duration_(h);-;1.5;3;6;9
FA hydroxy(16:0)] hexadecanoic acid	ST001202	AN002001	1.750E-8	2.210E-8	cell_type;iRBC;unRBC
Ala-Asp-Asp-Gln	ST000403	AN000642	1.850E-8	7.370E-8	Cell type;Mature erythrocyte;Reticulocyte
2-(Acetamidomethylene)succinate	ST000539	AN000819	1.910E-8	9.860E-8	Cell type;Mature erythrocyte;Reticulocyte
ACETAMINOPHEN (TN TYLENOL) (M-H)-	ST000523	AN000799	1.920E-8	2.090E-7	Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
Sertraline	ST000356	AN000583	1.960E-8	8.160E-8	stage;-;2;3
Dihydro Cer (d18:0/16:0)	ST000553	AN000846	1.990E-8	3.120E-8	Sample type;Plasma;Urine
isohydroxybutyric acid	ST000092	AN000146	1.990E-8	7.830E-8	Urease Treatment;No treatment;Urease pre-treatment;Water pre...
L-Erythrulose	ST000403	AN000643	2.060E-8	8.490E-8	Cell type;Mature erythrocyte;Reticulocyte
ARACHIDONOYLGLYCEROPHOSPHOETHANOLAMINE (*)	ST000105	AN000174	2.070E-8	9.870E-7	Sampling;After SWS onset;Morning fasting
EPC(d33:1)	ST001202	AN002000	2.220E-8	1.280E-7	treatment_duration_(h);-;1.5;3;6;9
N-Acetyl-D-glucosaminate	ST000539	AN000819	2.220E-8	1.120E-7	Cell type;Mature erythrocyte;Reticulocyte
[PC (15:1)] 1-(1Z-pentadecenyl)-sn-glycero-3-phosphocholine	ST000403	AN000643	2.250E-8	9.220E-8	Cell type;Mature erythrocyte;Reticulocyte
Mesaconate	ST001202	AN002001	2.310E-8	1.600E-7	treatment_duration_(h);-;1.5;3;6;9
4-hydroxy-3-methylacetophenone	ST001237	AN002055	2.350E-8	8.010E-7	Time point;baseline;week 4;week 8
Na-methylhistamine	ST000553	AN000847	2.390E-8	4.360E-8	Sample type;Plasma;Urine
OLEANANOICACIDACETATE	ST000046	AN000076	2.520E-8	1.430E-6	Cognitive Status;AD;CN;MCI
Pentosidine	ST000355	AN000581	2.550E-8	6.320E-7	Stage;1;2;3;4;-
6-Acetyl-D-glucose	ST001202	AN002000	2.570E-8	1.400E-7	treatment_duration_(h);-;1.5;3;6;9
O-(N-acetyl-a-neuraminosyl)-(2->3)-O-b-D-galactopyranosyl-(1->4)-O-2-(acetylamino)-2-deoxy-b-D-glucopyranosyl-(1->3)-O-b-D-galactopyranosyl-(1->4)-O-2-(acetylamino)-2-deoxy-b-D-glucopyranosyl-(1->3)-O-b-D-galactopyranosyl-(1->4)- D-Gluc	ST000241	AN000373	2.600E-8	6.890E-8	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
C12 / C10	ST000544	AN000827	2.610E-8	2.790E-7	Sample Type;Control;Replicate
CerH2O(d18:2/22:0)	ST000608	AN000929	2.710E-8	4.340E-8	Sample_Type;blotter;serum
sulfate of piperine metabolite C16H19NO3 (2)*	ST000974	AN001595	2.720E-8	2.260E-7	REGION;AHRI;MRC;SUN
HETE	ST001223	AN002036	2.760E-8	1.200E-7	Sample Type;Early Disseminated Lyme;Early Localized Lyme;Hea...
KG M+5	ST000507	AN000776	2.890E-8	1.380E-7	Time (incubation);24 hours;72 hours
melibionate	ST001201	AN001999	2.950E-8	7.550E-8	cell_type;iRBC;unRBC
D-Erythronic acid ?-lactone	ST000614	AN000943	3.050E-8	7.420E-8	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Phenylacetonitrile	ST001201	AN001998	3.100E-8	8.030E-8	cell_type;iRBC;unRBC
ArachidonoylPAF-C16	ST000553	AN000845	3.110E-8	5.090E-8	Sample type;Plasma;Urine
Benzyl dodecyl dimethylammonium cation	ST000077	AN000123	3.160E-8	9.430E-8	Treatment;100uM Met ;370uM Hcy ;quality check
ketoconazol	ST000403	AN000642	3.180E-8	1.230E-7	Cell type;Mature erythrocyte;Reticulocyte
SB N-(15Z-tetracosenoyl)-sphing-4-enine (d18:1(4E)/24:1(15Z)) [M-H]-	ST001111	AN001806	3.190E-8	1.150E-7	Sample;Benign;Cancer;Metastasis
Estriol 3-sulfate 16-glucuronide	ST000241	AN000373	3.370E-8	8.730E-8	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
nocardicin G	ST000403	AN000643	3.450E-8	1.350E-7	Cell type;Mature erythrocyte;Reticulocyte
SDMA / Arg	ST000544	AN000826	3.530E-8	2.180E-7	Sample Type;Control;Replicate
N2-Acetyl-L-aminoadipyl-delta-phosphate	ST001202	AN002000	3.560E-8	1.860E-7	treatment_duration_(h);-;1.5;3;6;9
Se-Methylselenocysteine	ST000356	AN000583	3.580E-8	1.180E-7	Diagnosis;breast cancer;control
N2-Acetyl-L-aminoadipyl-delta-phosphate	ST001201	AN001998	3.780E-8	9.720E-8	cell_type;iRBC;unRBC
D-Erythronic acid ?-lactone	ST000614	AN000943	3.870E-8	3.770E-7	Diagonsis;Benign;Cancer;Normal
PENTADECANOYLGLYCEROPHOSPHOCHOLINE/STEAROYLGLYCEROPHOSPHOETHANOLAMINE	ST000016	AN000033	3.970E-8	1.220E-7	Material;Cells;Media
Allopregnanalone sulfate	ST000566	AN000869	3.980E-8	3.500E-7	group;Old-Curcumin;Old-Placebo;young
acetyl-galactosamine	ST001237	AN002055	4.080E-8	2.980E-7	OS_Censor (1 means the time is a censoring time and 0 means ...
N-(octanoyl)-L-homoserine	ST000403	AN000642	4.270E-8	1.610E-7	Cell type;Mature erythrocyte;Reticulocyte
C7 N O6 S	ST000567	AN000872	4.500E-8	1.860E-6	Time point;Post;Pre;Baseline
3-(ADP)-2-phosphoglycerate	ST001202	AN002001	4.520E-8	2.890E-7	treatment_duration_(h);-;1.5;3;6;9
3-methyl-3-hydroxybutyric acid	ST000092	AN000146	4.530E-8	8.470E-8	Ethnicity;N/A;Asian;Black;Caucasian;Hispanic
Unknown_742.54(-)@5.61	ST000818	AN001298	4.840E-8	8.070E-8	Categorization;Amhara;Dizi;Hadza_settled;Hadza_traditional;H...
Ala-Leu-Trp-Ser	ST001204	AN002004	4.910E-8	1.490E-7	cell_type;iRBC;unRBC
Asn-Leu-Lys-Asp	ST001201	AN001998	4.920E-8	1.250E-7	cell_type;iRBC;unRBC
6-Acetyl-D-glucose	ST000403	AN000643	5.010E-8	1.900E-7	Cell type;Mature erythrocyte;Reticulocyte
AC1MIY4G	ST000842	AN001360	5.020E-8	5.220E-8	Sample type;Muscles;Plasma;Pooled sample
3-deoxy-D-galactose	ST001205	AN002006	5.070E-8	2.310E-5	treatment_duration_(h);1;5;3
Asymmetrical dimethylarginine	ST001040	AN001702	5.170E-8	1.830E-6	Sample Type/Matrix;Pooled quality control sample;urine;Water...
MethoxsalenMetabolite	ST000047	AN000083	5.660E-8	4.540E-6	Cognitive Status;AD;CN;MCI
C4 N O4 S	ST000566	AN000870	5.760E-8	7.450E-7	Time point;Post;Pre;Baseline
Erucate	ST001317	AN002193	5.968E-8	1.073E-7	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Erucate	ST001317	AN002193	5.968E-8	1.073E-7	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Butanoyl-PAF	ST000553	AN000846	6.370E-8	8.950E-8	Sample type;Plasma;Urine
heptadecanoic acid NIST	ST000385	AN000620	6.370E-8	8.650E-8	Organ;Plasma;Serum;Serum or Plasma
N-HISTIDYL-2-AMINONAPHTHALENE(betaNA)	ST000046	AN000076	6.580E-8	2.850E-6	Cognitive Status;AD;CN;MCI
Dehydro-L-(+)-ascorbic acid dimer	ST000567	AN000871	6.820E-8	2.270E-7	Time point;Post;Pre;Baseline
Ovothiol disulfide	ST000539	AN000818	6.860E-8	2.880E-7	Cell type;Mature erythrocyte;Reticulocyte
C12 / C10	ST000545	AN000830	7.060E-8	9.800E-7	Sample Type;Control;Replicate
4Alpha-hydroxymethyl-5alpha-cholesta-8-en-3beta-ol	ST000241	AN000373	7.190E-8	1.800E-7	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Imazosulfuron	ST000291	AN000464	7.570E-8	1.350E-4	Treatment ;Baseline urine;Urine after drinking apple juice;U...
C7 N O6 S	ST000566	AN000870	8.060E-8	7.450E-7	Time point;Post;Pre;Baseline
Methylpicolinate	ST000553	AN000847	8.070E-8	1.360E-7	Sample type;Plasma;Urine
[Fv] Ovalitenin A	ST000539	AN000818	8.120E-8	9.410E-6	timepoint;1 hour;20 hours
Trisaccharide	ST000586	AN000901	8.180E-8	1.580E-7	Plasma Volume;0 uL;150 uL;700 uL
beta-mannosylglycerate	ST000385	AN000620	8.300E-8	1.120E-7	Organ;Plasma;Serum;Serum or Plasma
Phenolsulfonphthalein	ST000403	AN000643	8.450E-8	3.130E-7	Cell type;Mature erythrocyte;Reticulocyte
4aminobenzaldehyde1	ST000614	AN000941	8.690E-8	1.300E-7	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Boc-Asn	ST000539	AN000818	8.790E-8	3.660E-7	Cell type;Mature erythrocyte;Reticulocyte
G3P	ST000301	AN000479	8.830E-8	8.240E-7	Cell Line;L229;LN18;Pooled glioblastoma;U-138
Malyngamide J	ST000242	AN000377	8.870E-8	1.420E-6	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
metabolite 3	ST000539	AN000818	9.090E-8	1.750E-5	Glucose labelling;C13 glucose;unlabelled
MANDELIC ACID #2 (M-H)-	ST000763	AN001201	9.180E-8	1.810E-6	Group;Borderline Pressures;Healthy;LowRisk;Normal Pressures;...
Glu-Cys-Cys 2	ST000539	AN000819	9.280E-8	4.400E-7	Cell type;Mature erythrocyte;Reticulocyte
2-C-Methyl-D-erythritol 4-phosphate	ST001202	AN002001	9.320E-8	5.300E-7	treatment_duration_(h);-;1.5;3;6;9
2-ketoglucose dimethylacetal NIST	ST000392	AN000628	9.840E-8	4.570E-7	Organ;Plasma;Serum;Serum or Plasma
C4 N O4 S	ST000567	AN000872	9.850E-8	1.860E-6	Time point;Post;Pre;Baseline
Unknown_742.54(-)@6.25	ST000818	AN001298	9.880E-8	2.210E-7	Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
3-Methylglutaconic acid	ST000356	AN000583	1.110E-7	3.460E-7	Diagnosis;breast cancer;control
Diethyl adipate	ST000539	AN000819	1.120E-7	6.010E-5	timepoint;1 hour;20 hours
5-HETrE	ST001214	AN002025	1.140E-7	5.890E-7	BMI group;lean;obese;overweight
Digitoxigenin bisdigitoxoside	ST000242	AN000377	1.140E-7	1.490E-6	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Hydroxytetrabenazine glucuronide	ST000242	AN000377	1.160E-7	1.490E-6	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000741	AN001155	1.220E-7	1.790E-5	subject type;Healthy control;Mild disease;POOLED;Severe dise...
[PR] 9-Hydroxy-helminthosporol	ST000403	AN000643	1.300E-7	4.620E-7	Cell type;Mature erythrocyte;Reticulocyte
glyoxalurea NIST	ST000386	AN000621	1.320E-7	7.960E-7	Organ;Plasma;Serum
HYDROXYACETAMINOPHEN SULFATE (*)	ST000106	AN000176	1.350E-7	3.030E-6	Sampling time;0 min;60 min
L-Ascorbate 6-phosphate	ST001204	AN002005	1.350E-7	4.110E-7	cell_type;iRBC;unRBC
2-amino-2-deoxyglucitol-6-phosphate	ST001204	AN002004	1.360E-7	3.920E-7	cell_type;iRBC;unRBC
4-Nitrophenyl-3-ketovalidamine	ST000539	AN000819	1.470E-7	6.740E-7	Cell type;Mature erythrocyte;Reticulocyte
5-6-Dihydrouridine	ST001202	AN002000	1.510E-7	1.830E-7	cell_type;iRBC;unRBC
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000775	AN001222	1.520E-7	1.770E-5	Treatment response;No;Yes;Pooled
Methylpicolinate	ST001317	AN002192	1.629E-7	2.225E-7	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Methylpicolinate	ST001317	AN002192	1.629E-7	2.225E-7	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
PAF C-18	ST000553	AN000846	1.650E-7	2.100E-7	Sample type;Plasma;Urine
Se-Methylselenocysteine	ST000356	AN000583	1.660E-7	6.310E-7	stage;-;2;3
2-deoxytetronic acid nist	ST000420	AN000662	1.670E-7	4.790E-7	Group;nonsmoker;smoker
3-hydroxyacyl group of bacterial toxin	ST000539	AN000819	1.670E-7	7.590E-7	Cell type;Mature erythrocyte;Reticulocyte
Oxonitine	ST000242	AN000376	1.670E-7	6.660E-7	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
L-beta-aspartyl-L-leucine	ST001204	AN002004	1.700E-7	4.840E-7	cell_type;iRBC;unRBC
Methyl methoxyacetate	ST000614	AN000941	1.750E-7	1.050E-6	Diagonsis;Benign;Cancer;Normal
17?-Ethinyl estradiol	ST000553	AN000846	1.860E-7	2.320E-7	Sample type;Plasma;Urine
Lys-Ser-Ser-Ser	ST000403	AN000642	1.860E-7	2.170E-5	Glucose labelling;C13 glucose;unlabelled
(-)-jasmonoyl-L-valine	ST000403	AN000643	1.880E-7	6.500E-7	Cell type;Mature erythrocyte;Reticulocyte
[FA hydroxy(18:0)] 2S-hydroxy-octadecanoic acid	ST000403	AN000643	2.190E-7	7.510E-7	Cell type;Mature erythrocyte;Reticulocyte
Fructoselysine	ST000403	AN000642	2.200E-7	2.170E-5	Glucose labelling;C13 glucose;unlabelled
Adrenaline(Epinephrine)	ST001040	AN001702	2.240E-7	5.670E-6	Sample Type/Matrix;Pooled quality control sample;urine;Water...
CerH2O(d18:2/23:0)	ST000608	AN000929	2.340E-7	3.570E-7	Sample_Type;blotter;serum
4-Amino-4-deoxychorismate	ST001204	AN002005	2.350E-7	6.900E-7	cell_type;iRBC;unRBC
[GP (16:0/18:1)] 1-hexadecanoyl-2-(11Z-octadecenoyl)-sn-glycero-3-phosphate	ST000403	AN000643	2.350E-7	7.960E-7	Cell type;Mature erythrocyte;Reticulocyte
Total lysoPC	ST000545	AN000830	2.360E-7	1.880E-6	Sample Type;Control;Replicate
2-Amino-3-methyl-1-butanol	ST000566	AN000870	2.430E-7	1.220E-6	Time point;Post;Pre;Baseline
DIMETHYLCAFFEIC ACID	ST000421	AN000664	2.570E-7	5.100E-5	treatment;ND;T1D poor glycemic control
ACETAMINOPHEN (TN TYLENOL) (M-H)-	ST000523	AN000799	2.590E-7	5.180E-6	Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
13C-aminoadipic	ST000947	AN001555	2.680E-7	8.040E-7	Group;control;PCOS
Benzyl tetradecyl dimethylammonium cation	ST000077	AN000123	2.750E-7	3.060E-7	Timepoint;0 hours;12 hours;24 hours;2 hours;48 hours;4 hours...
Steryl sulfate	ST000566	AN000869	2.790E-7	2.230E-6	group;Old-Curcumin;Old-Placebo;young
D-Arabino-Hexonic acid	ST001037	AN001698	2.800E-7	1.640E-5	Description ;Blank;Reagent Blank;Serum Sample;Solvent
ACETAMINOPHEN (TN TYLENOL) (M+H)+	ST000713	AN001114	2.910E-7	5.500E-6	malignant transformation;No;yes;Yes
Senecivernine	ST000566	AN000870	2.910E-7	1.330E-6	Time point;Post;Pre;Baseline
Clitidine 5-phosphate	ST000403	AN000643	3.150E-7	1.060E-6	Cell type;Mature erythrocyte;Reticulocyte
Tolylacetonitrile	ST001202	AN002000	3.260E-7	1.260E-6	treatment_duration_(h);-;1.5;3;6;9
Asn-Leu-Pro-Pro	ST001204	AN002004	3.270E-7	9.150E-7	cell_type;iRBC;unRBC
ACETAMINOPHEN (TN TYLENOL) (M-H)-	ST000523	AN000799	3.330E-7	4.990E-6	Timing of Sample Collection;CHEAR_REFERENCE;1st trimester;te...
N-Didesethylquinagolide	ST000047	AN000082	3.420E-7	4.270E-5	Cognitive Status;AD;CN;MCI
FA hydroxy(18:0)	ST001202	AN002001	3.520E-7	4.210E-7	cell_type;iRBC;unRBC
Methyl eicosatrienoate	ST000586	AN000901	3.530E-7	6.670E-7	Plasma Volume;0 uL;150 uL;700 uL
Phenolsulfonphthalein	ST000539	AN000819	3.570E-7	1.580E-6	Cell type;Mature erythrocyte;Reticulocyte
2-C-Methyl-D-erythritol 4-phosphate	ST001202	AN002001	3.610E-7	4.300E-7	cell_type;iRBC;unRBC
C18:0e MAG	ST001000	AN001881	3.710E-7	1.140E-5	Diagnosis;CD;Control;UC
2-Methylbutanal	ST000567	AN000872	3.780E-7	2.890E-6	Time point;Post;Pre;Baseline
[13C]-HISTIDINE	ST000016	AN000033	3.800E-7	2.920E-6	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
D-glycero-L-galacto-Octulose	ST001202	AN002001	3.810E-7	1.690E-6	treatment_duration_(h);-;1.5;3;6;9
3-Sulfolactate	ST000403	AN000643	3.860E-7	1.280E-6	Cell type;Mature erythrocyte;Reticulocyte
Cyclopiazonic Acid	ST000242	AN000375	4.050E-7	8.580E-7	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
3-hydroxyoxyisovaleric acid	ST000356	AN000582	4.060E-7	1.140E-6	Diagnosis;breast cancer;control
glyoxalurea NIST	ST000369	AN000603	4.070E-7	2.210E-6	Organ;Plasma;Serum
7b-Hydroxydehydroepiandrosterone	ST000356	AN000583	4.100E-7	1.250E-6	Diagnosis;breast cancer;control
FA oxo(18:0)	ST001202	AN002001	4.220E-7	4.980E-7	cell_type;iRBC;unRBC
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000775	AN001222	4.240E-7	2.470E-5	Treatment response;No;Yes;Pooled
1-LG b	ST000096	AN000154	4.250E-7	1.110E-6	Timepoint;18 hours;4 hours;NA
Erythrotetrofuranose	ST000356	AN000582	4.360E-7	1.190E-6	Diagnosis;breast cancer;control
Cys-Met-Tyr-Tyr	ST000403	AN000642	4.440E-7	2.620E-4	timepoint;1 hour;20 hours
N-Succinyl-L-diaminopimelic acid	ST000242	AN000376	4.500E-7	1.350E-6	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Istamycin C	ST000242	AN000377	4.540E-7	4.840E-6	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
D-O-Phosphoserine	ST001202	AN002000	4.550E-7	1.710E-6	treatment_duration_(h);-;1.5;3;6;9
DIOLEOYLPHOSPHATIDYLCHOLINE	ST000016	AN000033	4.600E-7	1.260E-6	Material;Cells;Media
2-Aminomalonate semialdehyde	ST000539	AN000819	4.620E-7	2.010E-6	Cell type;Mature erythrocyte;Reticulocyte
2(alpha-D-Mannosyl)-D-glycerate	ST000539	AN000819	4.830E-7	1.990E-5	Glucose labelling;C13 glucose;unlabelled
2-hydroxymethanesulfonate	ST000539	AN000819	4.850E-7	2.100E-6	Cell type;Mature erythrocyte;Reticulocyte
C12 / C8	ST000544	AN000827	4.990E-7	4.560E-6	Sample Type;Control;Replicate
4-hydroxy-3-methylacetophenone	ST001000	AN001878	5.060E-7	4.130E-6	Diagnosis;CD;Control;UC
omega-Cyclohexylundecanoic acid	ST000403	AN000643	5.130E-7	1.660E-6	Cell type;Mature erythrocyte;Reticulocyte
beta-DIHYDROROTENONE	ST000422	AN000667	5.140E-7	1.420E-4	treatment;ND;T1D good glycemic control
C29 N O20 S2	ST000567	AN000872	5.290E-7	3.620E-6	Time point;Post;Pre;Baseline
nocardicin G	ST000539	AN000819	5.290E-7	2.270E-6	Cell type;Mature erythrocyte;Reticulocyte
para-toluidene	ST000614	AN000943	5.340E-7	9.060E-7	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
Hydroxyprolines	ST000586	AN000901	5.510E-7	1.020E-6	Plasma Volume;0 uL;150 uL;700 uL
PC(18:0/5:0(COOH))	ST000608	AN000929	5.650E-7	8.540E-7	Sample_Type;blotter;serum
GLUCARIC/GULARIC/SACCHARIC ACID	ST000016	AN000033	5.850E-7	1.580E-6	Material;Cells;Media
Tyrphostin B44 (-)	ST000242	AN000376	5.890E-7	1.410E-6	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
N-ACETYL-HEXOSAMINE	ST000475	AN000739	6.130E-7	4.910E-6	Treatment;-;MDH inhib
Asp-Leu-Ser-His	ST000403	AN000642	6.180E-7	4.560E-5	Glucose labelling;C13 glucose;unlabelled
N-(5-Methyl-3-oxohexyl)alanine	ST001202	AN002000	6.190E-7	7.420E-7	cell_type;iRBC;unRBC
ALPHA-AMINOADIPATE/N-METHYL-L-GLUTAMATE;L-2-Aminoadipic Acid	ST000956	AN001568	6.230E-7	3.090E-6	Treatment;Condition-1;Condition-2;Condition-3;Control
2-O-methyl PAF C-16	ST000553	AN000846	6.290E-7	7.410E-7	Sample type;Plasma;Urine
Kyn/Trp	ST001237	AN002055	6.290E-7	3.790E-6	OS_Censor (1 means the time is a censoring time and 0 means ...
D-glycero-L-galacto-Octulose	ST001205	AN002007	6.310E-7	6.650E-5	parasite_line;Cam3.IIR539T;Cam3.IIrev
4-Imidazolone-5-propanoate	ST001202	AN002000	6.530E-7	2.350E-6	treatment_duration_(h);-;1.5;3;6;9
7?-Hydroxy-3-oxo-4-cholestenoate	ST000567	AN000872	6.540E-7	4.050E-6	Time point;Post;Pre;Baseline
PC(16:0/P-18:1(11Z))	ST000403	AN000642	6.570E-7	2.140E-6	Cell type;Mature erythrocyte;Reticulocyte
Tyr-OEt	ST000403	AN000642	6.600E-7	2.140E-6	Cell type;Mature erythrocyte;Reticulocyte
Ala-Asp-Pro-Ser	ST000403	AN000642	6.650E-7	2.140E-6	Cell type;Mature erythrocyte;Reticulocyte
Elaidate / Oleate /Petroselinate	ST001040	AN001703	6.700E-7	5.360E-6	Sample Type/Matrix;Pooled quality control sample;urine;Water...
isodeoxytetronic acid	ST000396	AN000633	6.810E-7	7.350E-5	Sex;Male;Female
Antheridiogen-An	ST001204	AN002004	6.890E-7	1.860E-6	cell_type;iRBC;unRBC
Diphenylmethylphosphine	ST000567	AN000871	6.890E-7	2.140E-6	Time point;Post;Pre;Baseline
Very low density lipoprotein	ST001038	AN001699	6.960E-7	2.200E-6	Placenta_Surface;Fetal;Maternal
HBA	ST000567	AN000872	7.050E-7	4.160E-6	Time point;Post;Pre;Baseline
3-methyladipate/pimelate	ST000923	AN001514	7.130E-7	6.840E-6	Diagnosis;CD;nonIBD;UC
8-Amino-7-oxononanoate	ST001205	AN002006	7.190E-7	9.120E-5	parasite_line;Cam3.IIR539T;Cam3.IIrev
3-Butynoate	ST000539	AN000818	7.200E-7	2.740E-6	Cell type;Mature erythrocyte;Reticulocyte
saccharic acid	ST000412	AN000652	7.370E-7	2.380E-6	Treatment;fresh liver;nonwarm ischemic liver;steatotic liver...
delta-Guanidinovaleric acid	ST000567	AN000872	7.390E-7	3.200E-5	groups;Old-Curcumin;Old-Placebo;young
Trihexosylceramide (d18:1/24:0)	ST000241	AN000373	7.560E-7	1.680E-6	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Arg-Trp-Asp-Cys	ST001204	AN002005	7.570E-7	5.110E-5	treatment_duration_(h);-;3;6;9
GQ1 d18:1 N18:0	ST000362	AN000594	7.670E-7	8.820E-6	Gender;1;2
C36:5 PC plasmalogen-A	ST001000	AN001881	8.270E-7	1.860E-5	Diagnosis;CD;Control;UC
Xylobiose	ST000403	AN000643	9.020E-7	3.050E-5	Glucose labelling;C13 glucose;unlabelled
5-Formiminotetrahydrofolic acid	ST000566	AN000870	9.050E-7	3.060E-6	Time point;Post;Pre;Baseline
Benzylserine	ST000553	AN000847	9.400E-7	1.400E-6	Sample type;Plasma;Urine
3-Deoxy-D-manno-octulosonate 8-phosphate	ST001202	AN002001	1.000E-6	3.880E-6	treatment_duration_(h);-;1.5;3;6;9
Avenic acid A	ST001205	AN002006	1.000E-6	9.120E-5	parasite_line;Cam3.IIR539T;Cam3.IIrev
L-Erythrulose	ST000539	AN000819	1.020E-6	4.290E-6	Cell type;Mature erythrocyte;Reticulocyte
[PR] Citronellyl acetate	ST000403	AN000643	1.030E-6	3.220E-6	Cell type;Mature erythrocyte;Reticulocyte
2(alpha-D-Mannosyl)-D-glycerate	ST001201	AN001999	1.040E-6	5.590E-5	treatment;DHA;DMSO;OZ277;OZ439
4-QUINOLINECARBOXYLIC ACID #2 (M+H)+	ST000818	AN001297	1.050E-6	8.560E-6	Country;Ethiopia;Tanzania;Botswana
L-Glutamic acid n-butyl ester + 1.5990624	ST000566	AN000870	1.050E-6	3.340E-6	Time point;Post;Pre;Baseline
Ethylmalonate/Methyl Malonate	ST000614	AN000939	1.140E-6	1.720E-6	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
L-Glutamic acid n-butyl ester	ST000566	AN000870	1.160E-6	3.590E-6	Time point;Post;Pre;Baseline
(7R)-7-(5-Carboxy-5-oxopentanoyl)aminocephalosporinate	ST000291	AN000464	1.170E-6	6.990E-4	Treatment ;Baseline urine;Urine after drinking apple juice;U...
4-(Trimethylammonio)but-2-enoate	ST001202	AN002000	1.200E-6	1.410E-6	cell_type;iRBC;unRBC
PE(14:0/P-18:1(11Z))	ST000241	AN000373	1.200E-6	2.630E-6	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Furmecyclox	ST000567	AN000871	1.210E-6	3.700E-6	Time point;Post;Pre;Baseline
N(alpha)-t-Butoxycarbonyl-L-leucine	ST000567	AN000872	1.230E-6	6.070E-6	Time point;Post;Pre;Baseline
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000775	AN001222	1.230E-6	1.430E-4	Timepoint;T0;T2;Pooled
N2-Acetyl-L-aminoadipate 2	ST000539	AN000819	1.240E-6	4.990E-6	Cell type;Mature erythrocyte;Reticulocyte
2E-Eicosenoic acid	ST001191	AN001983	1.280E-6	1.310E-5	Treatment;Control;QC;Sample
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000775	AN001223	1.290E-6	6.460E-5	Treatment response;No;Yes;Pooled
L-VALINE/5-AMINOPENTANOATE/L-NORVALINE	ST000475	AN000739	1.300E-6	8.480E-6	Treatment;-;MDH inhib
Dimethylarsinous acid	ST000241	AN000373	1.330E-6	2.860E-6	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
2-Aminomalonate semialdehyde	ST000403	AN000643	1.360E-6	4.210E-6	Cell type;Mature erythrocyte;Reticulocyte
Ganglioside GM3 (d18:0/16:0)	ST000241	AN000373	1.360E-6	2.910E-6	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
SARCOSINE/BETA-ALANINE	ST000475	AN000740	1.370E-6	9.790E-6	Treatment;-;MDH inhib
Total SM-OH	ST000545	AN000830	1.400E-6	6.860E-6	Sample Type;Control;Replicate
N-(15Z-tetracosenoyl)-1-.beta.-galactosyl-sphing-4-enine	ST000077	AN000123	1.410E-6	1.530E-6	Timepoint;0 hours;12 hours;24 hours;2 hours;48 hours;4 hours...
POV-PC	ST000553	AN000845	1.410E-6	2.000E-6	Sample type;Plasma;Urine
3-Indolelactic acid/tryptophan	ST000586	AN000901	1.420E-6	2.530E-6	Plasma Volume;0 uL;150 uL;700 uL
bOHbutyrate-13C0	ST000114	AN000194	1.440E-6	6.660E-5	Treatment;None;Tetracycline
[13C]-ARGININE	ST000016	AN000033	1.460E-6	3.740E-6	Material;Cells;Media
4-Nitroestrone-13C0[+QDA adduct]+	ST000148	AN000235	1.460E-6	7.450E-4	Treatment;13C-Glc;unlabeled
PC(16:0/5:0(CHO))	ST000403	AN000642	1.480E-6	4.550E-6	Cell type;Mature erythrocyte;Reticulocyte
Heptadecanoic acid/Octadecanol 2	ST000586	AN000901	1.530E-6	2.630E-6	Plasma Volume;0 uL;150 uL;700 uL
Asp-Gly-Pro-Ser	ST000403	AN000642	1.540E-6	4.700E-6	Cell type;Mature erythrocyte;Reticulocyte
Galactinoldihydrate	ST000539	AN000819	1.590E-6	6.250E-6	Cell type;Mature erythrocyte;Reticulocyte
1-docosapentaenoylglycerophosphocholine (22:5n3)*	ST000975	AN001596	1.600E-6	2.650E-5	GENDER;F;M
FA oxo(16:0)	ST001202	AN002001	1.630E-6	1.910E-6	cell_type;iRBC;unRBC
Hydromorphone (anesthetic)	ST000089	AN000141	1.660E-6	1.870E-6	Treatment;Human Adipocytes grown in the ABSENCE of SKOV3ip1 ...
N-Glycolyl-D-mannosamine	ST001201	AN001998	1.680E-6	3.840E-6	cell_type;iRBC;unRBC
2(alpha-D-Mannosyl)-D-glycerate	ST001202	AN002001	1.690E-6	6.080E-6	treatment_duration_(h);-;1.5;3;6;9
URACIL;Uracil	ST000956	AN001568	1.700E-6	8.170E-6	Treatment;Condition-1;Condition-2;Condition-3;Control
Assymetrical dimethylarginine	ST000553	AN000847	1.730E-6	2.430E-6	Sample type;Plasma;Urine
Asn-Cys-Pro-Ser	ST000539	AN000818	1.740E-6	6.360E-6	Cell type;Mature erythrocyte;Reticulocyte
Sucrose monopalmitate	ST001205	AN002007	1.750E-6	9.200E-5	parasite_line;Cam3.IIR539T;Cam3.IIrev
8-HETrE	ST001214	AN002025	1.820E-6	5.830E-6	BMI group;lean;obese;overweight
Myxothiazol Z	ST000566	AN000870	1.830E-6	5.050E-6	Time point;Post;Pre;Baseline
ribose-5-P/ribulose5-P	ST001142	AN001876	1.850E-6	3.640E-6	Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
MUFA (PC)	ST000545	AN000830	1.860E-6	7.970E-6	Sample Type;Control;Replicate
acetophenone NIST	ST000385	AN000620	1.910E-6	2.230E-5	Health State;Adenocarcinoma;Healthy;NA
Total SM-non OH	ST000545	AN000830	1.920E-6	7.970E-6	Sample Type;Control;Replicate
Xylobiose	ST000539	AN000819	1.920E-6	7.360E-5	Glucose labelling;C13 glucose;unlabelled
Total SM	ST000545	AN000830	1.960E-6	7.970E-6	Sample Type;Control;Replicate
SALICYLATE #2 (M-H)-	ST000713	AN001113	2.000E-6	3.580E-5	level of dysplasia;HGD;HGD & PDA;LGD;N/A
SALICYLATE #2 (M-H)-	ST000523	AN000799	2.030E-6	2.710E-5	Timing of Sample Collection;CHEAR_REFERENCE;1st trimester;te...
4-Amino-4-deoxychorismate	ST001202	AN002001	2.080E-6	7.200E-6	treatment_duration_(h);-;1.5;3;6;9
8-Amino-7-oxononanoate	ST001202	AN002000	2.130E-6	6.100E-6	treatment_duration_(h);-;1.5;3;6;9
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-	ST000721	AN001128	2.190E-6	1.260E-5	Injury;1 month;3 months
Flavonoid or short-chain cholesterol ester	ST000586	AN000901	2.210E-6	3.710E-6	Plasma Volume;0 uL;150 uL;700 uL
Ginsenoside Re	ST001191	AN001983	2.220E-6	1.780E-5	Treatment;Control;QC;Sample
13.beta.-Ethyl-3-oximinogon-4-en-17-one 3-TMS	ST000978	AN001602	2.240E-6	5.470E-5	Cox_Composite_DeathRRT;.;N;Y
lysoPC a C16:0 / lysoPC a C16:1	ST000545	AN000830	2.270E-6	8.290E-6	Sample Type;Control;Replicate
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000775	AN001223	2.280E-6	1.370E-4	Timepoint;T0;T2;Pooled
N-(15Z-tetracosenoyl)-1-.beta.-galactosyl-sphing-4-enine	ST000077	AN000123	2.290E-6	4.590E-6	Treatment;100uM Met ;370uM Hcy ;quality check
Total PC ae	ST000545	AN000830	2.340E-6	8.290E-6	Sample Type;Control;Replicate
PUFA (PC)	ST000545	AN000830	2.420E-6	8.290E-6	Sample Type;Control;Replicate
ketodeoxycholate	ST001000	AN001880	2.460E-6	9.860E-6	Diagnosis;CD;Control;UC
PUFA	ST001223	AN002036	2.500E-6	5.420E-6	Sample Type;Early Disseminated Lyme;Early Localized Lyme;Hea...
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000695	AN001075	2.530E-6	1.330E-4	Race;Black;White;POOLED
Citiolone	ST000242	AN000375	2.550E-6	4.590E-6	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Hydroxyglutaric acid	ST000356	AN000582	2.620E-6	6.620E-6	Diagnosis;breast cancer;control
cefamandole nafate + 2.0600944	ST000421	AN000663	2.640E-6	2.470E-4	treatment;ND;T1D poor glycemic control
D-2-Amino-hexano-6-lactam	ST000567	AN000872	2.680E-6	1.130E-5	Time point;Post;Pre;Baseline
5?-Androstan-3?-ol-17-one sulfate - 7.7291727	ST000566	AN000869	2.730E-6	1.720E-5	group;Old-Curcumin;Old-Placebo;young
GLYCODEOXYCHOLATE / GLYCOCHENODEOXYCHOLATE	ST000010	AN000026	2.840E-6	2.000E-5	FCS;FCS;NO_FCS
Ile-Met-Met-Thr	ST000403	AN000642	2.850E-6	1.680E-4	Glucose labelling;C13 glucose;unlabelled
Total (PC+SM)	ST000545	AN000830	2.900E-6	8.880E-6	Sample Type;Control;Replicate
N-(octanoyl)-L-homoserine	ST000539	AN000818	2.910E-6	1.030E-5	Cell type;Mature erythrocyte;Reticulocyte
bOHbutyrate-ALL	ST000114	AN000194	3.010E-6	1.050E-4	Treatment;None;Tetracycline
GLYCERALDEHYDE/LACTATE	ST000475	AN000740	3.080E-6	1.400E-5	Treatment;-;MDH inhib
Total PC	ST000545	AN000830	3.140E-6	8.880E-6	Sample Type;Control;Replicate
L-4-Hydroxy-3-methoxy-a-methylphenylalanine	ST000421	AN000663	3.170E-6	2.470E-4	treatment;ND;T1D poor glycemic control
acetophenone NIST	ST000385	AN000620	3.190E-6	5.400E-5	Smoking Status;Current;Former;NA
Total SM / Total PC	ST000545	AN000830	3.210E-6	8.880E-6	Sample Type;Control;Replicate
acetophenone NIST	ST000385	AN000620	3.230E-6	4.920E-5	Gender;F;M;NA
Total PC aa	ST000545	AN000830	3.250E-6	8.880E-6	Sample Type;Control;Replicate
ARACHIDONOYLGLYCEROPHOSPHOINOSITOL (*)	ST000105	AN000174	3.270E-6	5.680E-5	Sampling;After SWS onset;Morning fasting
Undecanone-13C6[+QDA adduct]+	ST000148	AN000235	3.280E-6	1.080E-3	Treatment;13C-Glc;unlabeled
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000775	AN001222	3.350E-6	1.950E-4	Timepoint;T0;T2;Pooled
Trifloxystrobin	ST001037	AN001698	3.430E-6	1.010E-4	Description ;Blank;Reagent Blank;Serum Sample;Solvent
4-Hydroxy-4-methylglutamate	ST001204	AN002004	3.460E-6	8.970E-6	cell_type;iRBC;unRBC
Adenosine 35-diphosphate	ST001091	AN001777	3.740E-6	7.180E-6	Sample.Matrix;Colon Mucosal Tissue;Plasma
DL-Methionine sulfone	ST000539	AN000818	3.750E-6	1.320E-5	Cell type;Mature erythrocyte;Reticulocyte
L-1-Pyrroline-3-hydroxy-5-carboxylate	ST001205	AN002007	3.820E-6	1.510E-4	parasite_line;Cam3.IIR539T;Cam3.IIrev
Methylbutyric aid / Valeric / Isovaleric	ST001000	AN001879	3.820E-6	2.670E-5	Diagnosis;CD;Control;UC
MEVALOLACTONE	ST000016	AN000033	3.840E-6	3.050E-5	Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
N-Methylalanine/2-Aminobutanoic acid/N-Ethylglycine	ST000586	AN000901	3.900E-6	6.490E-6	Plasma Volume;0 uL;150 uL;700 uL
N-Acetyl-D-glucosamine 6-phosphate	ST001201	AN001999	3.920E-6	1.580E-4	treatment;DHA;DMSO;OZ277;OZ439
1-3-7-trimethylurate	ST001000	AN001879	3.930E-6	2.670E-5	Diagnosis;CD;Control;UC
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000695	AN001075	4.010E-6	2.630E-4	Tamoxyfen;N;Y;-
Pro258-13C2	ST000076	AN000122	4.320E-6	9.390E-5	Labeling;13C/15N-Gln;13C-Glc;unlabeled
Penicilloic G acid	ST000242	AN000376	4.330E-6	7.430E-6	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
azelate	ST001000	AN001880	4.340E-6	1.620E-5	Diagnosis;CD;Control;UC
2-deoxycytidine	ST001142	AN001875	4.440E-6	6.840E-6	Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
BOC-ASN	ST000016	AN000033	4.550E-6	1.130E-5	Material;Cells;Media
O-6-deoxy-a-galactopyranosyl-(1->2)-O-b-D-galactopyranosyl-(1->3)-2-(acetylamino)-2-deoxy-D-Galactose-13C0[+13CD3 QDA]+	ST000148	AN000235	4.660E-6	1.310E-3	Treatment;13C-Glc;unlabeled
PC aa C40:5 / PC aa C42:5	ST000545	AN000830	4.960E-6	1.210E-5	Sample Type;Control;Replicate
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000695	AN001075	4.980E-6	3.280E-4	Drug;Exemestane;Letrozole;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000695	AN001075	5.030E-6	3.310E-4	Taxane;N;Y;-
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000695	AN001075	5.100E-6	2.850E-4	TIMEPOINT;3 Month;Baseline;POOLED
METHYL7-DESHYDROXYPYROGALLIN-4-CARBOXYLATE	ST000046	AN000078	5.140E-6	5.100E-4	Cognitive Status;AD;CN;MCI
ALANINE/SARCOSINE	ST000475	AN000739	5.190E-6	1.780E-5	Treatment;-;MDH inhib
Galacto-N-biose	ST001211	AN002017	5.240E-6	6.260E-5	Group;Control;Methotrexate
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000695	AN001075	5.320E-6	3.500E-4	Chemotherapy;N;Y;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000775	AN001222	5.340E-6	3.110E-4	Pair;Pair 1;Pair 2;Pair 3;Pair 4;Pair 5;Pair 6;Pair 7;Pair 8...
3-phosphoglucarate	ST001202	AN002001	5.350E-6	1.690E-5	treatment_duration_(h);-;1.5;3;6;9
Urethane	ST000403	AN000642	5.350E-6	1.540E-5	Cell type;Mature erythrocyte;Reticulocyte
GLYCODEOXYCHOLATE / GLYCOCHENODEOXYCHOLATE	ST000009	AN000024	5.500E-6	3.500E-5	AFTER_MEAL_TIME;30_MIN;NO_WAIT
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000695	AN001075	5.580E-6	3.670E-4	CASE_CONTROL;Case;Control;POOLED
Desmethylmianserin glucuronide	ST000566	AN000870	5.590E-6	1.200E-5	Time point;Post;Pre;Baseline
Ala-Asp-Cys-Gly	ST000539	AN000818	5.680E-6	3.650E-4	timepoint;1 hour;20 hours
L-1-Pyrroline-3-hydroxy-5-carboxylate	ST000403	AN000642	5.780E-6	1.650E-5	Cell type;Mature erythrocyte;Reticulocyte
Indanofan	ST000291	AN000464	5.960E-6	2.050E-3	Treatment ;Baseline urine;Urine after drinking apple juice;U...
DIHYDROFISSINOLIDE	ST000046	AN000076	6.010E-6	1.680E-4	Cognitive Status;AD;CN;MCI
ACETAMINOPHEN (TN TYLENOL) (M+NA)+	ST000713	AN001114	6.100E-6	9.600E-5	malignant transformation;No;yes;Yes
6-Hydroxy flavin adenine dinucleotide	ST000241	AN000373	6.150E-6	5.140E-5	Concentration (uM);0;500
3-ureidoacrylate	ST001201	AN001999	6.250E-6	1.380E-5	cell_type;iRBC;unRBC
(-)-Medicocarpin	ST000403	AN000643	6.330E-6	1.860E-5	Cell type;Mature erythrocyte;Reticulocyte
Ethylmalonate/Methyl Malonate	ST000614	AN000939	6.340E-6	1.060E-5	Diagonsis;Benign;Cancer;Normal
4-(Trimethylammonio)but-2-enoate	ST001201	AN001998	6.350E-6	1.400E-5	cell_type;iRBC;unRBC
Pantathonicacid	ST000614	AN000942	6.430E-6	1.160E-5	Diagonsis;Benign;Cancer;Normal
azelate	ST000923	AN001514	6.440E-6	4.630E-5	Diagnosis;CD;nonIBD;UC
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-	ST000748	AN001172	6.440E-6	8.550E-6	Sample type;Cells;Culture Media
1-stearoyl-rac-glycerol	ST000356	AN000582	6.550E-6	1.580E-5	Diagnosis;breast cancer;control
delta-Guanidinovaleric acid	ST000567	AN000872	6.660E-6	2.060E-5	Time point;Post;Pre;Baseline
Ginsenoside Rg3	ST001191	AN001983	6.790E-6	3.920E-5	Treatment;Control;QC;Sample
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000695	AN001075	6.870E-6	2.590E-4	Race;Black;White;POOLED
Asp-Leu-Lys-Lys	ST001202	AN002000	6.940E-6	1.820E-5	treatment_duration_(h);-;1.5;3;6;9
Man6GlcNAc-VI	ST001037	AN001698	7.210E-6	1.770E-4	Description ;Blank;Reagent Blank;Serum Sample;Solvent
Total SM / Total (SM+PC)	ST000545	AN000830	7.360E-6	1.550E-5	Sample Type;Control;Replicate
PUFA (PC) / MUFA (PC)	ST000545	AN000830	7.370E-6	1.550E-5	Sample Type;Control;Replicate
S-Budesonide	ST001317	AN002193	7.378E-6	1.164E-5	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
S-Budesonide	ST001317	AN002193	7.378E-6	1.164E-5	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
Pregnanolone sulfate	ST000567	AN000871	7.860E-6	9.360E-5	groups;Old-Curcumin;Old-Placebo;young
D/L N-Acetylgalactosamine / D/L N-Acetylglucosamine / D/L N-Acetylmannosamine	ST001040	AN001702	7.970E-6	9.900E-5	Sample Type/Matrix;Pooled quality control sample;urine;Water...
N-(5-Methyl-3-oxohexyl)alanine	ST001202	AN002000	7.990E-6	2.040E-5	treatment_duration_(h);-;1.5;3;6;9
N-Acetyl-D-glucosamine 6-phosphate	ST001202	AN002001	8.070E-6	2.400E-5	treatment_duration_(h);-;1.5;3;6;9
3-(ADP)-glycerate	ST000539	AN000819	8.120E-6	2.830E-5	Cell type;Mature erythrocyte;Reticulocyte
Ala-Leu-Lys-Pro	ST000539	AN000818	8.160E-6	2.680E-5	Cell type;Mature erythrocyte;Reticulocyte
2-keto-l-gluconic acid	ST000092	AN000146	8.360E-6	1.220E-5	Gender;N/A;Female;Male
4-Aminobenzoate / Anthranilate	ST001040	AN001702	8.390E-6	9.900E-5	Sample Type/Matrix;Pooled quality control sample;urine;Water...
2-Dehydro-D-xylonate	ST000403	AN000643	8.500E-6	2.450E-5	Cell type;Mature erythrocyte;Reticulocyte
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000695	AN001075	8.590E-6	3.770E-4	Tamoxyfen;N;Y;-
psicoselysine	ST000403	AN000642	8.630E-6	3.920E-4	Glucose labelling;C13 glucose;unlabelled
UDP-GLCUR-13C0+15N0	ST000076	AN000121	8.720E-6	3.370E-3	Labeling;13C/15N-Gln;13C-Glc;unlabeled
16-Feruloyloxypalmitate	ST000567	AN000871	8.750E-6	9.630E-5	groups;Old-Curcumin;Old-Placebo;young
phthalate ester	ST000417	AN001448	8.910E-6	9.890E-5	Group;AIR;NO2PM;PM
Sulforaphane	ST001202	AN002001	8.990E-6	2.650E-5	treatment_duration_(h);-;1.5;3;6;9
sulfate*	ST000974	AN001595	9.000E-6	1.910E-4	GENDER;F;M
ADMA/SDMA	ST000923	AN001513	9.040E-6	1.450E-4	Diagnosis;CD;nonIBD;UC
SARCOSINE/BETA-ALANINE	ST000919	AN001507	9.210E-6	5.430E-4	Gender;Female;Male
cefamandole nafate	ST000421	AN000663	9.560E-6	6.530E-4	treatment;ND;T1D poor glycemic control
3-Methoxyanthranilate	ST000403	AN000642	9.590E-6	2.590E-5	Cell type;Mature erythrocyte;Reticulocyte
P-DPD	ST001202	AN002001	9.650E-6	2.810E-5	treatment_duration_(h);-;1.5;3;6;9
Plasmalogen(20:4/p18:1)	ST000450	AN000706	9.850E-6	1.620E-5	gender;Female;Male
azelate	ST000923	AN001515	1.000E-5	6.070E-5	Diagnosis;CD;nonIBD;UC
IS Ceramide; [M-H2O]+	ST000523	AN000800	1.000E-5	2.540E-5	Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
Istamycin C1	ST000242	AN000377	1.010E-5	7.770E-5	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (PROBABLY)	ST000016	AN000033	1.020E-5	2.430E-5	Material;Cells;Media
methylnaphthyl sulfate (2)*	ST000975	AN001596	1.020E-5	1.730E-3	REGION;MAK;SUN
MOPS	ST001202	AN002000	1.020E-5	2.560E-5	treatment_duration_(h);-;1.5;3;6;9
N-acetyl-isoputrenine*	ST000975	AN001596	1.040E-5	1.770E-3	GROUP;case;control
HEPTADECENOATE (*)	ST000044	AN000069	1.050E-5	2.480E-3	Pancreas tissue type;Normal area of the pancreas with tumor;...
Sulfate	ST001202	AN002001	1.070E-5	3.010E-5	treatment_duration_(h);-;1.5;3;6;9
Trp-Trp-Tyr-Tyr	ST000539	AN000818	1.070E-5	3.400E-5	Cell type;Mature erythrocyte;Reticulocyte
[13C]-ASPARTIC ACID	ST000016	AN000033	1.080E-5	6.010E-5	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
Marinobufagenin	ST000567	AN000871	1.090E-5	1.120E-4	groups;Old-Curcumin;Old-Placebo;young
Total AC-DC / Total AC	ST000545	AN000830	1.100E-5	2.190E-5	Sample Type;Control;Replicate
Ac-Tyr-OEt	ST000403	AN000642	1.110E-5	2.990E-5	Cell type;Mature erythrocyte;Reticulocyte
1-stearoyl-rac-glycerol	ST000356	AN000582	1.140E-5	3.190E-5	stage;-;2;3
2-Oxo-7-methylthioheptanoic acid	ST000567	AN000872	1.150E-5	3.050E-5	Time point;Post;Pre;Baseline
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000695	AN001075	1.180E-5	4.450E-4	Chemotherapy;N;Y;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000695	AN001075	1.180E-5	4.450E-4	Taxane;N;Y;-
4-methylcatechol sulfate	ST000899	AN001464	1.190E-5	9.760E-5	Type;Control;Crohn disease;Ulcerative Colitis
PC(16:0/15:1(14))	ST000624	AN000956	1.190E-5	1.290E-4	Condition;Control;Glaucomatous
Uscharidin	ST000242	AN000377	1.210E-5	8.960E-5	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
2-Deoxymugineic acid	ST000539	AN000819	1.230E-5	4.150E-5	Cell type;Mature erythrocyte;Reticulocyte
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000695	AN001075	1.230E-5	5.390E-4	Drug;Exemestane;Letrozole;POOLED
Succcinate	ST001038	AN001699	1.250E-5	3.640E-5	Timepoint;15 min;1 hr;24 hr;30 min;<5 min
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000775	AN001222	1.260E-5	4.880E-4	Pair;Pair 1;Pair 2;Pair 3;Pair 4;Pair 5;Pair 6;Pair 7;Pair 8...
Octonyl Carnitine	ST000614	AN000939	1.340E-5	1.840E-5	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000695	AN001075	1.350E-5	5.960E-4	CASE_CONTROL;Case;Control;POOLED
cyano-L-alanine	ST000369	AN000603	1.380E-5	1.670E-4	Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
Asp-Leu-Gln-Pro	ST001202	AN002000	1.400E-5	3.400E-5	treatment_duration_(h);-;1.5;3;6;9
cyclo-Dopa-glucuronylglucoside	ST000567	AN000871	1.400E-5	1.250E-4	groups;Old-Curcumin;Old-Placebo;young
(Z)-N-(2-hydroxyethyl)hexadec-7-enamide	ST000566	AN000870	1.410E-5	2.910E-5	Time point;Post;Pre;Baseline
Octonyl Carnitine	ST000614	AN000939	1.430E-5	2.240E-5	Diagonsis;Benign;Cancer;Normal
5?-Androstan-3?-ol-17-one sulfate	ST000566	AN000869	1.460E-5	8.030E-5	group;Old-Curcumin;Old-Placebo;young
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000695	AN001075	1.460E-5	5.490E-4	TIMEPOINT;3 Month;Baseline;POOLED
protocatechualdehyde	ST001201	AN001998	1.470E-5	3.170E-5	cell_type;iRBC;unRBC
3-hydroxyoxyisovaleric acid	ST000356	AN000582	1.550E-5	4.220E-5	stage;-;2;3
ALANINE/SARCOSINE	ST000956	AN001568	1.550E-5	6.340E-5	Treatment;Condition-1;Condition-2;Condition-3;Control
[PR] Citronellyl acetate	ST000539	AN000819	1.560E-5	5.150E-5	Cell type;Mature erythrocyte;Reticulocyte
diacetylspermine	ST001236	AN002054	1.580E-5	8.080E-4	OS_Censor (1 means the time is a censoring time and 0 means ...
[FA (10:1/2:0)] 2E-Decenedioic acid	ST000403	AN000643	1.600E-5	1.980E-3	timepoint;1 hour;20 hours
Flavonol 3-O-xylosylglycoside-13C23[+QDA adduct]+	ST000148	AN000235	1.610E-5	2.710E-3	Treatment;13C-Glc;unlabeled
[6]-Paradol	ST001205	AN002007	1.640E-5	3.980E-4	parasite_line;Cam3.IIR539T;Cam3.IIrev
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000741	AN001156	1.660E-5	3.600E-4	subject type;Healthy control;Mild disease;POOLED;Severe dise...
HYDROXYISOVALERATE (*)	ST000106	AN000176	1.680E-5	6.810E-3	Visit;1;2
ARACHIDONATE #2 (M-H)-	ST000818	AN001296	1.820E-5	4.940E-5	Categorization;Amhara;Dizi;Hadza_settled;Hadza_traditional;H...
3-Sulfolactate	ST000539	AN000819	1.840E-5	6.010E-5	Cell type;Mature erythrocyte;Reticulocyte
3-(ADP)-2-phosphoglycerate	ST000403	AN000642	1.860E-5	4.880E-5	Cell type;Mature erythrocyte;Reticulocyte
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000697	AN001081	1.870E-5	5.430E-4	Cell Type;BS4;HAHA;PAK;POOLED
sulfa d18:1 N22:0	ST000362	AN000594	1.910E-5	1.220E-4	Gender;1;2
phe-FMDP	ST001201	AN001999	1.930E-5	4.060E-5	cell_type;iRBC;unRBC
[13C]-ASPARTIC ACID	ST000016	AN000033	1.940E-5	1.430E-4	Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
sulfate	ST000899	AN001464	1.940E-5	1.370E-4	Type;Control;Crohn disease;Ulcerative Colitis
gamma-glutamyl-2-aminobutyrate	ST000899	AN001462	1.960E-5	3.930E-4	Type;Control;Crohn disease;Ulcerative Colitis
PC(22:0/P-18:1(11Z))	ST000241	AN000373	1.980E-5	3.600E-5	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
L-Arabinonate	ST000403	AN000643	1.990E-5	5.450E-5	Cell type;Mature erythrocyte;Reticulocyte
DG(36:2)>DG(18:1_18:1_0:0)	ST001325	AN002206	2.022E-5	5.999E-5	Gender;-;female;male
Ala-Cys-Pro-Ser	ST001204	AN002005	2.030E-5	1.100E-3	treatment_duration_(h);-;3;6;9
Ala-Leu-Lys-Asp	ST001202	AN002000	2.040E-5	4.770E-5	treatment_duration_(h);-;1.5;3;6;9
iSTD iSTD Ceramide (d18:1/17:0)	ST000342	AN000554	2.100E-5	2.950E-4	Treatment;Quality Control;PRBC;PRBC-FST;PRBC+FST;WB
Ala-Asp-Gly-Tyr	ST001202	AN002000	2.150E-5	4.990E-5	treatment_duration_(h);-;1.5;3;6;9
Pantathonicacid	ST000614	AN000942	2.170E-5	3.250E-5	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
C4 / C5	ST000545	AN000830	2.180E-5	4.120E-5	Sample Type;Control;Replicate
[FA methyl(14:0)] 12-methyl-tetradecanoic acid	ST000403	AN000643	2.180E-5	5.920E-5	Cell type;Mature erythrocyte;Reticulocyte
2-Oxo-10-methylthiodecanoic acid	ST000566	AN000870	2.280E-5	4.430E-5	Time point;Post;Pre;Baseline
Total AC-OH / Total AC	ST000544	AN000827	2.280E-5	1.810E-4	Sample Type;Control;Replicate
Total AC-OH / Total AC	ST000545	AN000830	2.280E-5	4.240E-5	Sample Type;Control;Replicate
S-(3-hydroxypropyl)mercapturic acid (HPMA)	ST000975	AN001596	2.290E-5	3.120E-3	GROUP;case;control
Total SM / Total PC	ST000544	AN000827	2.350E-5	1.810E-4	Sample Type;Control;Replicate
Convallasaponin A	ST000437	AN000687	2.380E-5	3.760E-5	Sample type;Spiked;Unknown
GLYCOCHENODEOXYCHOLATE / GLYCODEOXYCHOLATE (*)	ST000105	AN000174	2.380E-5	3.130E-4	Sampling;After SWS onset;Morning fasting
PAF C-16	ST000553	AN000846	2.400E-5	2.510E-5	Sample type;Plasma;Urine
Asp-Leu-Lys-Asp	ST001202	AN002000	2.410E-5	5.470E-5	treatment_duration_(h);-;1.5;3;6;9
Lys-Lys-Met-Pro	ST000539	AN000818	2.430E-5	2.340E-3	Glucose labelling;C13 glucose;unlabelled
phthalate ester	ST000420	AN000662	2.430E-5	5.280E-5	Group;nonsmoker;smoker
3-Methylglutaconic acid	ST000356	AN000583	2.460E-5	7.640E-5	stage;-;2;3
Cys-Lys-Met-Gln	ST000403	AN000642	2.490E-5	7.330E-4	Glucose labelling;C13 glucose;unlabelled
2-OG b	ST000096	AN000154	2.510E-5	5.430E-5	Timepoint;18 hours;4 hours;NA
2-oxo-3-methylvaleric acid	ST000566	AN000870	2.520E-5	4.640E-5	Time point;Post;Pre;Baseline
OH-monohexcer d18:1 N16:0	ST000362	AN000594	2.520E-5	1.340E-4	Gender;1;2
Hexose Disaccharide Pool	ST000450	AN000706	2.540E-5	4.020E-5	gender;Female;Male
cis Aconitate M0	ST000507	AN000776	2.560E-5	7.230E-5	Time (incubation);24 hours;72 hours
Sulfacetamide sodium anhydrous	ST000292	AN000466	2.570E-5	2.380E-3	Treatment ;Baseline plasma;Plasma after drinking apple juice...
Arg-Met-Val-Asp	ST000403	AN000642	2.610E-5	7.330E-4	Glucose labelling;C13 glucose;unlabelled
Crotanecine	ST001205	AN002006	2.610E-5	4.950E-4	parasite_line;Cam3.IIR539T;Cam3.IIrev
Benzyl tetradecyl dimethylammonium cation	ST000077	AN000123	2.640E-5	4.460E-5	Treatment;100uM Met ;370uM Hcy ;quality check
Unknown_742.54(-)@5.61	ST000818	AN001298	2.650E-5	4.310E-5	Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
nonulose 9-phosphate	ST001205	AN002007	2.670E-5	5.630E-4	parasite_line;Cam3.IIR539T;Cam3.IIrev
creatine major dehydrated TMS3	ST000417	AN001448	2.680E-5	1.950E-4	Group;AIR;NO2PM;PM
gamma-CEHC glucuronide*	ST000974	AN001595	2.690E-5	1.720E-4	REGION;AHRI;MRC;SUN
Sucrose / Trehalose	ST001048	AN001716	2.700E-5	3.290E-5	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
DIHEXOSE	ST000106	AN000176	2.710E-5	4.980E-4	Sampling time;0 min;60 min
maltotriose minor	ST000058	AN000096	2.720E-5	2.390E-4	Treatment;Group 1;Group 2;Group 3;Group 4;Group 5;Group 6;Gr...
Cys-Thr-Cys-Cys	ST000539	AN000818	2.800E-5	8.280E-5	Cell type;Mature erythrocyte;Reticulocyte
O-PHOSPHONOHEXOPYRANOSE	ST000016	AN000033	2.890E-5	6.440E-5	Material;Cells;Media
4-hydroxychlorothalonil	ST000899	AN001464	2.970E-5	1.920E-4	Type;Control;Crohn disease;Ulcerative Colitis
lysoPC a C20:4 / lysoPC a C20:3	ST000545	AN000830	3.020E-5	5.450E-5	Sample Type;Control;Replicate
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000695	AN001076	3.040E-5	3.870E-3	Taxane;N;Y;-
Glucocerebrosides	ST000242	AN000377	3.060E-5	2.020E-4	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
DOCOSADIENOATE	ST000009	AN000024	3.130E-5	4.140E-4	gender;female;male
Spectinomycin adenylate	ST000242	AN000377	3.160E-5	2.020E-4	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Total lysoPC / Total PC	ST000545	AN000830	3.160E-5	5.630E-5	Sample Type;Control;Replicate
2-deoxycytidine	ST001142	AN001875	3.170E-5	4.010E-5	Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
Picrasin C-13C1[+13CD3 QDA]+	ST000148	AN000235	3.230E-5	3.240E-3	Treatment;13C-Glc;unlabeled
Adenosylcobimide-GDP	ST000241	AN000373	3.240E-5	5.790E-5	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Ala-Thr-Ala-Ser	ST001205	AN002006	3.240E-5	5.410E-4	parasite_line;Cam3.IIR539T;Cam3.IIrev
Asn-Asn-Pro-His	ST000403	AN000642	3.260E-5	8.690E-4	Glucose labelling;C13 glucose;unlabelled
Total SM / Total (SM+PC)	ST000544	AN000827	3.260E-5	2.320E-4	Sample Type;Control;Replicate
3-Methyglutarate	ST001048	AN001717	3.270E-5	4.880E-5	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
Mono-N-depropylprobenecid	ST000422	AN000668	3.300E-5	2.520E-3	treatment;ND;T1D good glycemic control
4-Methylene-L-glutamate	ST000403	AN000643	3.370E-5	8.930E-5	Cell type;Mature erythrocyte;Reticulocyte
O-Acetylneuraminic acid	ST000403	AN000642	3.390E-5	8.690E-4	Glucose labelling;C13 glucose;unlabelled
succinic acid2	ST000417	AN001448	3.390E-5	2.020E-4	Group;AIR;NO2PM;PM
acisoga	ST000899	AN001464	3.410E-5	2.170E-4	Type;Control;Crohn disease;Ulcerative Colitis
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (PROBABLY)	ST000105	AN000173	3.480E-5	8.440E-4	Sampling;After SWS onset;Morning fasting
KINETIN RIBOSIDE	ST000422	AN000668	3.480E-5	2.520E-3	treatment;ND;T1D good glycemic control
MANDELIC ACID #2 (M-H)-	ST000763	AN001201	3.480E-5	1.600E-3	Exercise;No;Yes
PC 28:2 (2:0/26:2(5E.9Z)) [M+HCOO]-	ST001111	AN001806	3.500E-5	9.510E-5	Sample;Benign;Cancer;Metastasis
Hydroxyglutaric acid	ST000356	AN000582	3.590E-5	9.300E-5	stage;-;2;3
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000697	AN001081	3.700E-5	2.950E-3	Stimulation;IFN-G;IL-17A;TNF-alpha;TNF-alpha+IL-17A;Untreate...
Erythrulose 1-phosphate	ST000539	AN000818	3.740E-5	1.090E-4	Cell type;Mature erythrocyte;Reticulocyte
2-hydroxybutyrate/2-hydroxyisobutyrate	ST000899	AN001465	3.890E-5	4.480E-4	Type;Control;Crohn disease;Ulcerative Colitis
ARACHIDONATE #2 (M-H)-	ST000818	AN001296	3.950E-5	1.140E-4	Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
FA hydroxy(10:0)	ST001202	AN002001	3.990E-5	1.060E-4	treatment_duration_(h);-;1.5;3;6;9
SM (d18:1/17:0) iSTD	ST001211	AN002019	4.140E-5	1.870E-4	Group;Control;Methotrexate
2-acetamidoglucal	ST001201	AN001998	4.220E-5	1.310E-3	treatment;DHA;DMSO;OZ277;OZ439
Glu-Cys-Gly-Ser	ST001205	AN002006	4.260E-5	6.260E-4	parasite_line;Cam3.IIR539T;Cam3.IIrev
urea (partial derivative)	ST000092	AN000146	4.290E-5	9.970E-5	Urease Treatment;No treatment;Urease pre-treatment;Water pre...
His-Met-Trp-Ser	ST000403	AN000643	4.330E-5	1.110E-3	Glucose labelling;C13 glucose;unlabelled
14-demethyl-14-dehydrolanosterol	ST000916	AN001492	4.350E-5	3.690E-4	Diagnosis;Cirrhosis;NASH;Normal;Steatosis
d1-piperidine-dicarboxylate	ST000403	AN000642	4.350E-5	1.090E-4	Cell type;Mature erythrocyte;Reticulocyte
a Cysteine adduct	ST001202	AN002000	4.380E-5	9.350E-5	treatment_duration_(h);-;1.5;3;6;9
A-Ketoglutaricacidoxime	ST001201	AN001999	4.400E-5	1.180E-3	treatment;DHA;DMSO;OZ277;OZ439
creatine major dehydrated TMS3	ST000416	AN000658	4.400E-5	2.380E-3	Gender;Female;Male
threosphingosine	ST001000	AN001878	4.590E-5	2.590E-4	Diagnosis;CD;Control;UC
CMP-N-trimethyl-2-aminoethylphosphonate	ST001202	AN002000	4.700E-5	9.980E-5	treatment_duration_(h);-;1.5;3;6;9
DIACYL-GLYCEROPHOSPHOCHOLINE (C50H82NO8P PROBABLY)	ST000016	AN000033	4.810E-5	1.040E-4	Material;Cells;Media
[FA hydroxy(13:0)] 2-hydroxy-tridecanoic acid	ST000403	AN000643	4.990E-5	3.380E-3	timepoint;1 hour;20 hours
2-LG b	ST000096	AN000154	5.090E-5	9.460E-5	Timepoint;18 hours;4 hours;NA
Ala-Thr-Ala-Ser	ST001202	AN002000	5.100E-5	1.080E-4	treatment_duration_(h);-;1.5;3;6;9
KG M+1	ST000507	AN000776	5.130E-5	1.270E-4	Time (incubation);24 hours;72 hours
DIMETHYLXANTHINE	ST000016	AN000033	5.180E-5	3.460E-4	Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
B-Sulfinyl pyruvate	ST000356	AN000583	5.230E-5	1.300E-4	Diagnosis;breast cancer;control
11-Hydroxyeicosatetraenoate glyceryl ester	ST000241	AN000373	5.360E-5	9.230E-5	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
DOCOSAPENTAENOATE (*)	ST000105	AN000174	5.380E-5	6.630E-4	Sampling;After SWS onset;Morning fasting
Histidylproline diketopiperazine	ST000356	AN000583	5.410E-5	1.320E-4	Diagnosis;breast cancer;control
Westiellamide	ST000242	AN000375	5.420E-5	8.300E-5	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
N-hydroxyisoleucine	ST001202	AN002000	5.440E-5	6.180E-5	cell_type;iRBC;unRBC
octulose 8-phosphate	ST001202	AN002001	5.470E-5	1.420E-4	treatment_duration_(h);-;1.5;3;6;9
Ala-Leu-Thr-Ala	ST001202	AN002000	5.480E-5	1.150E-4	treatment_duration_(h);-;1.5;3;6;9
C8-Ceramide m+1	ST000644	AN000976	5.500E-5	9.300E-5	tracer;13C-glucose;13C-glutamine;No label
3-ethylphenylsulfate	ST000975	AN001596	5.510E-5	5.860E-4	GENDER;F;M
[FA oxo(8:0)] 3-oxo-octanoic acid	ST000539	AN000819	5.530E-5	1.700E-4	Cell type;Mature erythrocyte;Reticulocyte
N-ACETYL-HEXOSAMINE	ST000956	AN001568	5.580E-5	1.990E-4	Treatment;Condition-1;Condition-2;Condition-3;Control
(-)-Medicocarpin	ST000539	AN000819	5.600E-5	1.720E-4	Cell type;Mature erythrocyte;Reticulocyte
BOC-LYS-OH	ST000043	AN000070	5.680E-5	3.630E-4	Cell line;MDA-MB-231;MDA-MB-231 p38 gamma knockdown;MDA-MB-2...
Corey PG-Lactone Diol	ST000566	AN000870	5.840E-5	9.890E-5	Time point;Post;Pre;Baseline
Phosphonic acid	ST001037	AN001698	5.960E-5	7.300E-4	Description ;Blank;Reagent Blank;Serum Sample;Solvent
PC aa C40:3 / PC aa C42:5	ST000545	AN000830	6.050E-5	1.050E-4	Sample Type;Control;Replicate
Fluroxypyr	ST000566	AN000869	6.080E-5	1.530E-4	Time point;Post;Pre;Baseline
diacetylspermine	ST000923	AN001513	6.100E-5	5.680E-4	Diagnosis;CD;nonIBD;UC
N5-acetyl-N5-hydroxy-L-ornithine	ST001201	AN001998	6.110E-5	1.280E-4	cell_type;iRBC;unRBC
TROMETHAMINE+5.4366517	ST000046	AN000076	6.150E-5	1.540E-3	Cognitive Status;AD;CN;MCI
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000697	AN001081	6.190E-5	1.200E-3	Cell Type;BS4;HAHA;PAK;POOLED
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000775	AN001223	6.260E-5	2.350E-3	Pair;Pair 1;Pair 2;Pair 3;Pair 4;Pair 5;Pair 6;Pair 7;Pair 8...
ZEATIN [ISTD] (M+H)+	ST000726	AN001139	6.280E-5	1.660E-3	DISEASE_STATE;Control;PCOS
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000697	AN001081	6.500E-5	2.970E-3	Stimulation;IFN-G;IL-17A;TNF-alpha;TNF-alpha+IL-17A;Untreate...
X3.Methylhistidine.	ST000435	AN000685	6.610E-5	4.740E-4	treatment;ND;T1D good glycemic control;T1D poor glycemic con...
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000695	AN001076	6.690E-5	1.090E-2	Drug;Exemestane;Letrozole;POOLED
4-tert-Octylphenol	ST001037	AN001698	6.700E-5	7.880E-4	Description ;Blank;Reagent Blank;Serum Sample;Solvent
ZAPA	ST000539	AN000818	6.880E-5	1.950E-4	Cell type;Mature erythrocyte;Reticulocyte
methanofuran biosynththesis intermediate MF1	ST001205	AN002007	6.960E-5	8.460E-4	parasite_line;Cam3.IIR539T;Cam3.IIrev
5?-Androstan-3?-ol-17-one sulfate	ST000567	AN000871	7.010E-5	5.570E-4	groups;Old-Curcumin;Old-Placebo;young
Ala-Thr-Ala-Gly	ST001205	AN002006	7.240E-5	9.780E-4	parasite_line;Cam3.IIR539T;Cam3.IIrev
OHPro-ALL	ST000110	AN000185	7.300E-5	3.400E-3	Oxygen Condition;hypoxia;normoxia
N-Acetylanthranilate	ST001201	AN001999	7.360E-5	7.900E-3	treatment_duration_(h);-;0.5;1.5;3
ketodeoxycholate	ST000923	AN001515	7.390E-5	3.830E-4	Diagnosis;CD;nonIBD;UC
Bile salt	ST001202	AN002001	7.480E-5	1.880E-4	treatment_duration_(h);-;1.5;3;6;9
MALATE;OXALOACETATE+2H-H	ST000956	AN001569	7.480E-5	3.740E-4	Treatment;Condition-1;Condition-2;Condition-3;Control
N-Oleoyl-L-Serine	ST000566	AN000870	7.520E-5	1.250E-4	Time point;Post;Pre;Baseline
Ala-Val-Asp-Ser	ST001202	AN002000	7.590E-5	1.540E-4	treatment_duration_(h);-;1.5;3;6;9
2OH-MBP (Mono(2-hydroxy-isobutyl)phthalate) / 3OH-MBP (Mono-(3-hydroxy-n-butyl) phthalate)	ST001048	AN001717	7.600E-5	1.110E-4	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
Ovothiol disulfide	ST000403	AN000642	7.720E-5	1.840E-4	Cell type;Mature erythrocyte;Reticulocyte
PC ae C44:5 / PC ae C42:5	ST000545	AN000830	7.720E-5	1.300E-4	Sample Type;Control;Replicate
sulfate of piperine metabolite C16H19NO3 (2)*	ST000975	AN001596	7.780E-5	5.210E-3	REGION;MAK;SUN
5-hydroxynorvaline NIST	ST000368	AN000602	7.800E-5	1.500E-4	Organ;Plasma;Serum;Serum or Plasma
pyroglutamylisoleucine	ST000975	AN001596	7.810E-5	6.650E-3	GROUP;case;control
Arg-Asp-Asp-Gly	ST001202	AN002000	8.010E-5	1.610E-4	treatment_duration_(h);-;1.5;3;6;9
17-phenyl trinor Prostaglandin E2 serinol amide	ST000567	AN000872	8.050E-5	1.660E-4	Time point;Post;Pre;Baseline
2-(acetylamino)-1-5-anhydro-2-deoxy-3-O-b-D-galactopyranosyl-D-arabino-Hex-1-enitol	ST001204	AN002004	8.160E-5	1.910E-4	cell_type;iRBC;unRBC
arachidiic acid	ST000416	AN000658	8.170E-5	5.520E-4	Treatment;Day1_antiperspirant;Day1_deodorant;Day1_noproduct;...
GQ1 d18:1 N20:0	ST000362	AN000594	8.170E-5	3.130E-4	Gender;1;2
DIOLEOYLPHOSPHATIDYLCHOLINE	ST000106	AN000175	8.250E-5	4.530E-3	Sampling time;0 min;60 min
Cotine	ST000614	AN000943	8.500E-5	3.320E-4	Diagonsis;Benign;Cancer;Normal
SALICYLATE #2 (M-H)-	ST000842	AN001356	8.540E-5	1.080E-4	Sample type;Muscles;Plasma;Pooled sample
2-keto-l-gluconic acid	ST000092	AN000146	8.660E-5	1.220E-4	Ethnicity;N/A;Asian;Black;Caucasian;Hispanic
6-Acetamido-2-oxohexanoate	ST000403	AN000642	8.680E-5	1.830E-3	Glucose labelling;C13 glucose;unlabelled
PC 40:3 (20:0/20:3(5Z.8Z.11Z)) [M-Ac-H]-	ST001111	AN001806	8.690E-5	2.200E-4	Sample;Benign;Cancer;Metastasis
t-aconitate-13C0	ST000076	AN000122	8.690E-5	1.270E-3	Labeling;13C/15N-Gln;13C-Glc;unlabeled
2-(sulfomethyl)thiazolidine-4-carboxylate	ST000539	AN000819	8.730E-5	2.550E-4	Cell type;Mature erythrocyte;Reticulocyte
N-ACETYL-D-HEXOSAMINE	ST000016	AN000033	8.760E-5	1.820E-4	Material;Cells;Media
alloxanoic acid NIST	ST000392	AN000628	8.830E-5	2.740E-3	Gender;F;M;-
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000695	AN001076	8.830E-5	8.600E-3	TIMEPOINT;3 Month;Baseline;POOLED
3-methoxytyramine sulfate	ST000975	AN001596	9.000E-5	5.210E-3	REGION;MAK;SUN
Pro258-13C6	ST000076	AN000122	9.020E-5	1.270E-3	Labeling;13C/15N-Gln;13C-Glc;unlabeled
uridine-5-diphosphate bromoacetol	ST000539	AN000819	9.140E-5	2.210E-2	timepoint;1 hour;20 hours
o-toluidene2	ST000614	AN000941	9.180E-5	1.840E-4	Diagonsis;Benign;Cancer;Normal
valerate/isovalerate	ST000923	AN001514	9.270E-5	5.910E-4	Diagnosis;CD;nonIBD;UC
BOC-ALA (+NA)	ST000105	AN000173	9.340E-5	1.670E-3	Sampling;After SWS onset;Morning fasting
PC 40:3 (20:1(11E)/20:2(11Z.14Z)) [M-Ac-H]-	ST001111	AN001806	9.500E-5	2.390E-4	Sample;Benign;Cancer;Metastasis
Asp-Met-Pro-Pro	ST000403	AN000642	9.620E-5	2.270E-4	Cell type;Mature erythrocyte;Reticulocyte
Arg-Met-Asn-His	ST000403	AN000642	9.720E-5	2.280E-4	Cell type;Mature erythrocyte;Reticulocyte
IS SM 35:1;[M+H]+	ST000661	AN001009	9.830E-5	1.240E-4	Sample type;Plasma;Tissues
GLYCOCHENODEOXYCHOLATE / GLYCODEOXYCHOLATE (*)	ST000106	AN000176	9.850E-5	1.660E-3	Sampling time;0 min;60 min
5-HETrE	ST000916	AN001491	9.860E-5	6.320E-4	Diagnosis;Cirrhosis;NASH;Normal;Steatosis
1-dihomo-linoleoylglycerophosphocholine (20:2n6)*	ST000975	AN001596	9.970E-5	9.560E-4	GENDER;F;M
Bis(2-hydroxypropyl)amine+5.4374814	ST000047	AN000081	9.990E-5	9.760E-3	Cognitive Status;AD;CN;MCI
Lys-Lys-Met-Pro	ST000539	AN000818	1.000E-4	4.840E-3	timepoint;1 hour;20 hours
5-Deoxy-5-aminoshikimic acid	ST000539	AN000819	1.020E-4	2.940E-4	Cell type;Mature erythrocyte;Reticulocyte
Lys-Lys-Met-Pro	ST000403	AN000642	1.020E-4	2.080E-3	Glucose labelling;C13 glucose;unlabelled
Ala-Glu-Glu-His	ST001205	AN002006	1.030E-4	1.120E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
CerH2O(d18:1/24:0)	ST000608	AN000929	1.030E-4	1.390E-4	Sample_Type;blotter;serum
N-acetyl-2-aminoctanoate	ST000975	AN001596	1.030E-4	9.590E-4	GENDER;F;M
PIPES	ST001202	AN002001	1.030E-4	2.540E-4	treatment_duration_(h);-;1.5;3;6;9
2-(Hydroxymethyl)-3-(acetamidomethylene)succinate	ST000539	AN000819	1.040E-4	2.990E-4	Cell type;Mature erythrocyte;Reticulocyte
penem CGP31608	ST001204	AN002004	1.040E-4	2.340E-4	cell_type;iRBC;unRBC
N-Ace-Asp-13C2	ST001049	AN001864	1.050E-4	5.840E-3	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
Azaserine	ST000566	AN000870	1.060E-4	1.680E-4	Time point;Post;Pre;Baseline
UDP-GNAc-13C0+15N0	ST000076	AN000121	1.070E-4	2.070E-2	Labeling;13C/15N-Gln;13C-Glc;unlabeled
Trp-Trp-Tyr-Tyr	ST000403	AN000642	1.080E-4	2.520E-4	Cell type;Mature erythrocyte;Reticulocyte
Pregnetriol	ST000241	AN000373	1.090E-4	1.780E-4	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000695	AN001076	1.100E-4	1.460E-2	Chemotherapy;N;Y;POOLED
Gal?1-3Gal?1-4GlcNAc?-Sp	ST000242	AN000377	1.120E-4	6.330E-4	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
6-Acetamido-2-oxohexanoate	ST001201	AN001998	1.130E-4	2.770E-3	treatment;DHA;DMSO;OZ277;OZ439
MES	ST001202	AN002000	1.130E-4	2.210E-4	treatment_duration_(h);-;1.5;3;6;9
3-Methoxyanthranilate	ST000539	AN000818	1.150E-4	3.100E-4	Cell type;Mature erythrocyte;Reticulocyte
N-acetyl -D- glucosaminitol	ST000539	AN000818	1.200E-4	3.220E-4	Cell type;Mature erythrocyte;Reticulocyte
N-acetyl -D- glucosaminitol 2	ST000539	AN000818	1.200E-4	3.220E-4	Cell type;Mature erythrocyte;Reticulocyte
PC(16:0/5:0(COOH))	ST000403	AN000642	1.200E-4	2.750E-4	Cell type;Mature erythrocyte;Reticulocyte
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000695	AN001076	1.200E-4	1.210E-2	CASE_CONTROL;Case;Control;POOLED
N-METHYL-L-GLUTAMATE;ALPHA-AMINOADIPATE;L-2-Aminoadipic Acid	ST000956	AN001569	1.210E-4	5.480E-4	Treatment;Condition-1;Condition-2;Condition-3;Control
Yamogenin 3-O-neohesperidoside	ST000242	AN000377	1.210E-4	6.640E-4	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
2-hydroxymethanesulfonate	ST000403	AN000643	1.240E-4	3.020E-4	Cell type;Mature erythrocyte;Reticulocyte
FMLP	ST000539	AN000818	1.260E-4	3.360E-4	Cell type;Mature erythrocyte;Reticulocyte
GLUCOSE/FRUCTOSE-PHOSPHATE	ST000956	AN001568	1.260E-4	4.070E-4	Treatment;Condition-1;Condition-2;Condition-3;Control
O-Acetylneuraminic acid	ST001202	AN002000	1.260E-4	2.430E-4	treatment_duration_(h);-;1.5;3;6;9
[13C]-LEUCINE	ST000009	AN000023	1.290E-4	3.200E-3	AFTER_MEAL_TIME;30_MIN;NO_WAIT
Cysteinyl-Hydroxyproline	ST001202	AN002000	1.300E-4	1.460E-4	cell_type;iRBC;unRBC
Diacetylhydrazine	ST000403	AN000642	1.330E-4	3.020E-4	Cell type;Mature erythrocyte;Reticulocyte
Asp-Val-Gly-Ser	ST001202	AN002000	1.340E-4	2.580E-4	treatment_duration_(h);-;1.5;3;6;9
HEPES	ST000403	AN000643	1.340E-4	3.250E-4	Cell type;Mature erythrocyte;Reticulocyte
Tiletamine	ST000566	AN000870	1.350E-4	2.060E-4	Time point;Post;Pre;Baseline
PC(16:0/5:0(CHO))	ST000539	AN000818	1.360E-4	3.590E-4	Cell type;Mature erythrocyte;Reticulocyte
alloxanoic acid NIST	ST000392	AN000628	1.370E-4	3.620E-3	Smoking Status;Current;Former;-
C8-Ceramide m+13	ST000644	AN000976	1.370E-4	8.430E-4	time;48 hr;0 hr
Methyl deoxyadenosine	ST000614	AN000943	1.370E-4	4.440E-4	Diagonsis;Benign;Cancer;Normal
ACETAMINOPHEN (TN TYLENOL) (M+Na)+	ST000523	AN000798	1.380E-4	8.810E-4	Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
alloxanoic acid NIST	ST000392	AN000628	1.380E-4	1.360E-3	Disease State;cancer;control;-
Procollagen 5-(D-galactosyloxy)-L-lysine	ST001202	AN002000	1.380E-4	2.650E-4	treatment_duration_(h);-;1.5;3;6;9
2-Dehydro-3-deoxy-L-rhamnonate	ST000403	AN000642	1.390E-4	2.560E-3	Glucose labelling;C13 glucose;unlabelled
C8-Ceramide m+15	ST000644	AN000976	1.390E-4	8.430E-4	time;48 hr;0 hr
EPICATECHINPENTAACETATE	ST000047	AN000081	1.410E-4	1.000E-2	Cognitive Status;AD;CN;MCI
acisoga	ST000975	AN001596	1.420E-4	8.210E-3	GROUP;case;control
Pyroglutamylglycine	ST000553	AN000847	1.420E-4	1.670E-4	Sample type;Plasma;Urine
3-deoxy-D-galactose	ST001202	AN002001	1.430E-4	3.420E-4	treatment_duration_(h);-;1.5;3;6;9
bOHbutyrate-ALL	ST000076	AN000122	1.430E-4	1.710E-3	Labeling;13C/15N-Gln;13C-Glc;unlabeled
3-Phosphonopyruvate	ST000539	AN000819	1.440E-4	4.100E-4	Cell type;Mature erythrocyte;Reticulocyte
Aminophosphovaleric acid	ST000614	AN000943	1.460E-4	1.900E-4	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
C8-Ceramide m+11	ST000644	AN000976	1.460E-4	8.430E-4	time;48 hr;0 hr
CL 72:10 (18:2/18:3/18:2/18:3) [M-2H](2-)	ST001111	AN001806	1.460E-4	3.520E-4	Sample;Benign;Cancer;Metastasis
FA methyl(6:0)	ST001202	AN002001	1.460E-4	3.470E-4	treatment_duration_(h);-;1.5;3;6;9
Ganglioside GM3 (d18:0/24:0)	ST000241	AN000373	1.470E-4	2.350E-4	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
glucuronide of piperine metabolite C17H21NO3 (4)*	ST000975	AN001596	1.490E-4	6.320E-3	REGION;MAK;SUN
S-(3-hydroxypropyl)mercapturic acid (HPMA)	ST000975	AN001596	1.500E-4	1.300E-3	GENDER;F;M
monohexsph	ST000362	AN000594	1.510E-4	5.210E-4	Gender;1;2
PALMITOYLGLYCEROPHOSPHOETHANOLAMINE / PALMITOYLPLASMENYLETHANOLAMINE (*)	ST000105	AN000174	1.510E-4	1.640E-3	Sampling;After SWS onset;Morning fasting
Cys-Met-Tyr-Tyr	ST000539	AN000818	1.520E-4	1.100E-2	Glucose labelling;C13 glucose;unlabelled
Dehydrocholic acid	ST001211	AN002017	1.520E-4	1.090E-3	Group;Control;Methotrexate
19/20-OH PGE2	ST001214	AN002025	1.550E-4	2.520E-4	BMI group;lean;obese;overweight
Adenosine 35-diphosphate	ST001193	AN001989	1.550E-4	2.860E-4	Plasma;Cord blood;Plasma
Kinetensin 4-7	ST000241	AN000373	1.550E-4	2.490E-4	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Arg-Leu-Asn-Asp	ST000539	AN000818	1.560E-4	4.090E-4	Cell type;Mature erythrocyte;Reticulocyte
C8-Ceramide m+9	ST000644	AN000976	1.560E-4	8.430E-4	time;48 hr;0 hr
(R)-3-Hydroxy-Octadecanoic acid	ST000241	AN000373	1.570E-4	2.500E-4	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000695	AN001076	1.570E-4	1.100E-2	Race;Black;White;POOLED
Cys-Met-Met-Phe	ST000403	AN000643	1.590E-4	3.800E-4	Cell type;Mature erythrocyte;Reticulocyte
Neomenthyl acetate	ST000567	AN000872	1.590E-4	2.950E-4	Time point;Post;Pre;Baseline
2-Dehydro-D-xylonate	ST001205	AN002007	1.610E-4	1.540E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
DIHEXOSE	ST000106	AN000175	1.620E-4	7.560E-3	Sampling time;0 min;60 min
Arg-Leu-Asn-Asp	ST000403	AN000642	1.640E-4	3.650E-4	Cell type;Mature erythrocyte;Reticulocyte
Bis(2-hydroxypropyl)amine	ST000047	AN000080	1.650E-4	1.570E-2	Cognitive Status;AD;CN;MCI
Cys-Leu-Cys-Tyr	ST001202	AN002001	1.660E-4	3.870E-4	treatment_duration_(h);-;1.5;3;6;9
Diethyl Oxalpropionate	ST000566	AN000870	1.670E-4	8.790E-3	group;Old-Curcumin;Old-Placebo;young
methylnaphthyl sulfate (2)*	ST000975	AN001596	1.670E-4	1.390E-3	GENDER;F;M
2-deoxyglucose-6-phosphate	ST000450	AN000706	1.680E-4	2.490E-4	gender;Female;Male
cis/trans-hydroxyproline	ST001142	AN001875	1.690E-4	1.950E-4	Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
melibionate	ST001204	AN002005	1.730E-4	4.330E-4	cell_type;iRBC;unRBC
D-erythro-L-galacto-Nonulose	ST001202	AN002001	1.740E-4	3.980E-4	treatment_duration_(h);-;1.5;3;6;9
Arsenobetaine	ST001202	AN002000	1.750E-4	1.960E-4	cell_type;iRBC;unRBC
butyrate / isobutytare	ST001000	AN001879	1.750E-4	6.880E-4	Diagnosis;CD;Control;UC
mannose-6-phosphate NIST	ST000379	AN000613	1.780E-4	8.390E-4	Treatment;10.5mM Glu;5.5mM Glu 5mM Fru;5.5mM Glu;Glucosamine
DIMETHYLXANTHINE	ST000016	AN000033	1.790E-4	3.600E-4	Material;Cells;Media
3-deoxy-D-galactose	ST001204	AN002005	1.800E-4	8.080E-3	treatment_duration_(h);-;3;6;9
3-Ethylmalate	ST001205	AN002006	1.830E-4	1.490E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
L-Glutamate methylester	ST000403	AN000642	1.830E-4	4.040E-4	Cell type;Mature erythrocyte;Reticulocyte
C8-Ceramide m+7	ST000644	AN000976	1.850E-4	8.470E-4	time;48 hr;0 hr
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000695	AN001076	1.890E-4	1.840E-2	Tamoxyfen;N;Y;-
Euparin	ST000567	AN000871	1.910E-4	1.240E-3	groups;Old-Curcumin;Old-Placebo;young
N-acetyl-isoputrenine*	ST000974	AN001595	1.960E-4	4.560E-3	TIMEPOINT;BL;M06;M18
Fisher ratio	ST000545	AN000829	1.970E-4	1.470E-2	Sample Type;Control;Replicate
N-Hydroxy-1-aminonaphthalene	ST000539	AN000819	1.990E-4	5.500E-4	Cell type;Mature erythrocyte;Reticulocyte
2-pyrrolidone-5-carboxylic acid	ST000356	AN000582	2.020E-4	4.160E-4	Diagnosis;breast cancer;control
PGF2a ethanolamide	ST000241	AN000373	2.030E-4	3.160E-4	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
pyroglutamylphenylalanine*	ST000974	AN001595	2.040E-4	1.120E-3	REGION;AHRI;MRC;SUN
Icosatrienoic acid	ST000403	AN000643	2.050E-4	4.810E-4	Cell type;Mature erythrocyte;Reticulocyte
Erythrotetrofuranose	ST000356	AN000582	2.070E-4	4.870E-4	stage;-;2;3
N2-Fructopyranosylarginine	ST001205	AN002006	2.080E-4	1.580E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
octulose 8-phosphate	ST001205	AN002007	2.100E-4	1.900E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
MEVALOLACTONE	ST000016	AN000033	2.130E-4	9.020E-4	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
N-.alpha.-(tert-Butoxycarbonyl)-L-histidine	ST001211	AN002017	2.130E-4	1.430E-3	Group;Control;Methotrexate
4-Amino-4-deoxychorismate	ST000403	AN000643	2.190E-4	5.100E-4	Cell type;Mature erythrocyte;Reticulocyte
[Fv] Ovalitenin A	ST000403	AN000642	2.200E-4	4.840E-4	Cell type;Mature erythrocyte;Reticulocyte
ACETAMINOPHEN (TN TYLENOL) (M+H)+	ST000523	AN000798	2.220E-4	1.310E-3	Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
Cholic acid or similar bile acid	ST000586	AN000901	2.220E-4	3.260E-4	Plasma Volume;0 uL;150 uL;700 uL
glycodeoxycholate/glycochenodeoxycholate	ST001236	AN002054	2.220E-4	4.570E-3	Time point;baseline;week 4;week 9
SB N-(eicosanoyl)-sphing-4-enine (d18:1(4E)/20:0) [M-H]-	ST001111	AN001806	2.230E-4	5.180E-4	Sample;Benign;Cancer;Metastasis
2-deoxytetronic acid NIST	ST000368	AN000602	2.240E-4	4.050E-4	Organ;Plasma;Serum;Serum or Plasma
N-Acetyl-D-glucosaminate	ST000403	AN000643	2.250E-4	5.210E-4	Cell type;Mature erythrocyte;Reticulocyte
Ala-Thr-Ala-Asp	ST001202	AN002000	2.260E-4	4.220E-4	treatment_duration_(h);-;1.5;3;6;9
Cys-Met-Tyr-Tyr	ST000539	AN000818	2.260E-4	1.010E-2	timepoint;1 hour;20 hours
FA (14:1) (physeteric acid)	ST001211	AN002019	2.260E-4	7.630E-4	Group;Control;Methotrexate
C12 GALACTOSYL(BETA) CERAMIDE (D18:1/12:0) (CAS# 41613-14-3); (M+H)+	ST000775	AN001223	2.270E-4	4.790E-3	Pair;Pair 1;Pair 2;Pair 3;Pair 4;Pair 5;Pair 6;Pair 7;Pair 8...
L-Hypoglycin	ST000539	AN000819	2.270E-4	5.700E-3	Glucose labelling;C13 glucose;unlabelled
methylhexadecanoic acid	ST000385	AN000620	2.270E-4	1.340E-3	Gender;F;M;NA
aminoisobutyric acid/GABA	ST000923	AN001513	2.290E-4	1.310E-3	Diagnosis;CD;nonIBD;UC
Total AC-DC / Total AC	ST000544	AN000827	2.290E-4	1.570E-3	Sample Type;Control;Replicate
Procollagen 5-(D-galactosyloxy)-L-lysine	ST001201	AN001998	2.300E-4	4.530E-4	cell_type;iRBC;unRBC
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000689	AN001064	2.320E-4	2.250E-3	Construct;-;Control lentivirus;Noxa knockdown
glucuronide of piperine metabolite C17H21NO3 (5)*	ST000975	AN001596	2.330E-4	8.250E-3	REGION;MAK;SUN
(2S)-2-{[1-(R)-Carboxyethyl]amino}pentanoate	ST000539	AN000819	2.340E-4	5.700E-3	Glucose labelling;C13 glucose;unlabelled
(2S)-2-{[1-(R)-Carboxyethyl]amino}pentanoate 2	ST000539	AN000819	2.340E-4	5.700E-3	Glucose labelling;C13 glucose;unlabelled
CTAB	ST000539	AN000818	2.340E-4	5.910E-4	Cell type;Mature erythrocyte;Reticulocyte
2-ethylphenylsulfate	ST000975	AN001596	2.360E-4	8.250E-3	REGION;MAK;SUN
P-DPD	ST000403	AN000643	2.360E-4	5.440E-4	Cell type;Mature erythrocyte;Reticulocyte
2-oxogluconic acid NIST	ST000369	AN000603	2.370E-4	1.590E-3	Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
C5-SUGAR ALCOHOL	ST000954	AN001564	2.390E-4	4.610E-2	ethnicity;1;2;-
DIMETHYLXANTHINE (*)	ST000105	AN000173	2.400E-4	3.800E-3	Sampling;After SWS onset;Morning fasting
4-Aminomethylcyclohexane carboxylic acid	ST001037	AN001698	2.420E-4	1.780E-3	Description ;Blank;Reagent Blank;Serum Sample;Solvent
4-QUINOLINECARBOXYLIC ACID #2 (M+H)+	ST000523	AN000798	2.450E-4	2.160E-3	Timing of Sample Collection;CHEAR_REFERENCE;1st trimester;te...
A-Ketoglutaricacidoxime	ST000403	AN000643	2.470E-4	5.660E-4	Cell type;Mature erythrocyte;Reticulocyte
4-Hydroxyphenylacetylglycine	ST001202	AN002001	2.500E-4	5.510E-4	treatment_duration_(h);-;1.5;3;6;9
C8-Ceramide m+8	ST000644	AN000976	2.550E-4	1.050E-3	time;48 hr;0 hr
L-Glutamic acid dibutyl ester	ST000566	AN000870	2.610E-4	3.750E-4	Time point;Post;Pre;Baseline
bOHbutyrate-13C4	ST000076	AN000122	2.650E-4	2.430E-3	Labeling;13C/15N-Gln;13C-Glc;unlabeled
4-hydroxy-3-methylacetophenone	ST000923	AN001513	2.670E-4	1.470E-3	Diagnosis;CD;nonIBD;UC
Cycloleucine	ST000567	AN000872	2.700E-4	4.340E-4	Time point;Post;Pre;Baseline
Diphenylmethylphosphineoxide	ST000046	AN000078	2.700E-4	7.070E-3	Cognitive Status;AD;CN;MCI
o-cresol sulfate	ST000975	AN001596	2.700E-4	2.040E-3	GENDER;F;M
sulfate of piperine metabolite C16H19NO3 (3)*	ST000974	AN001595	2.710E-4	1.890E-2	GROUP;case;control
Methyl Guanine	ST000614	AN000943	2.730E-4	6.650E-4	Diagonsis;Benign;Cancer;Normal
Tyr-OEt	ST000539	AN000818	2.780E-4	6.990E-4	Cell type;Mature erythrocyte;Reticulocyte
C8-Ceramide m+17	ST000644	AN000976	2.890E-4	1.100E-3	time;48 hr;0 hr
Anthranilate / 4-Aminobenzoate	ST001040	AN001703	2.920E-4	1.400E-3	Sample Type/Matrix;Pooled quality control sample;urine;Water...
[FA hydroxy(11:1)] 2-hydroxy-10-undecenoic acid	ST000403	AN000643	2.930E-4	6.690E-4	Cell type;Mature erythrocyte;Reticulocyte
XHWESASXXR*	ST000974	AN001595	2.950E-4	1.540E-3	REGION;AHRI;MRC;SUN
D5-L-Glutamine iSTD	ST001211	AN002017	2.960E-4	1.770E-3	Group;Control;Methotrexate
3-methyl catechol sulfate (2)	ST000974	AN001595	2.990E-4	1.550E-3	REGION;AHRI;MRC;SUN
Deoxydaunorubicin-13C0[+QDA adduct]+	ST000148	AN000235	3.020E-4	7.150E-3	Treatment;13C-Glc;unlabeled
indole-3-acetyl-valine	ST000539	AN000819	3.020E-4	8.210E-4	Cell type;Mature erythrocyte;Reticulocyte
ACETAMINOPHEN (TN TYLENOL) (M+Na)+	ST000523	AN000798	3.040E-4	6.130E-3	Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
Heptopyranosides	ST001201	AN001999	3.060E-4	4.930E-3	treatment;DHA;DMSO;OZ277;OZ439
PC 40:5 (20:2(5Z.8Z)/20:3(5Z.8Z.11Z)) [M+HCOO]-	ST001111	AN001806	3.060E-4	7.060E-4	Sample;Benign;Cancer;Metastasis
Cys-Cys-Pro-Ser	ST001201	AN001998	3.070E-4	4.610E-3	treatment;DHA;DMSO;OZ277;OZ439
Pro258-ALL	ST000114	AN000194	3.070E-4	6.100E-3	Treatment;None;Tetracycline
C8-Ceramide m+10	ST000644	AN000976	3.090E-4	1.150E-3	time;48 hr;0 hr
AMINOHYDROXYBUTANOIC ACID	ST000016	AN000033	3.110E-4	1.260E-3	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
Sesaminol glucosyl-(1->2)-[glucosyl-(1->6)]-glucoside	ST001202	AN002000	3.120E-4	5.650E-4	treatment_duration_(h);-;1.5;3;6;9
Hyppuric Acid	ST000284	AN000452	3.160E-4	4.460E-3	Patient group;CRC;Healthy;Polyp
C8-Ceramide m+1	ST000644	AN000976	3.200E-4	1.170E-3	time;48 hr;0 hr
(-)-jasmonoyl-L-isoleucine	ST000403	AN000642	3.200E-4	6.830E-4	Cell type;Mature erythrocyte;Reticulocyte
B-Sulfinyl pyruvate	ST000356	AN000583	3.230E-4	8.510E-4	stage;-;2;3
C3 / C4	ST000544	AN000827	3.230E-4	2.070E-3	Sample Type;Control;Replicate
cis-Cyclo[L-ala-L-Pro]	ST000975	AN001596	3.230E-4	2.410E-3	GENDER;F;M
gamma-CEHC glucuronide	ST000899	AN001464	3.230E-4	1.380E-3	Type;Control;Crohn disease;Ulcerative Colitis
CAI-1	ST000403	AN000643	3.240E-4	7.330E-4	Cell type;Mature erythrocyte;Reticulocyte
CL 76:12 (18:3/20:3/20:4/18:2) [M-2H](2-)	ST001111	AN001806	3.250E-4	7.440E-4	Sample;Benign;Cancer;Metastasis
N2-(D-1-Carboxyethyl)-L-arginine	ST000539	AN000818	3.330E-4	8.350E-4	Cell type;Mature erythrocyte;Reticulocyte
iSTD iSTD FA (16:0)-d3	ST000342	AN000554	3.350E-4	1.480E-3	Treatment;Quality Control;PRBC;PRBC-FST;PRBC+FST;WB
MECPP (Mono-2-ethyl-5-carboxypentyl phthalate)	ST001048	AN001717	3.350E-4	4.180E-4	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
Dipropylene glycol	ST000583	AN000894	3.360E-4	2.620E-2	caries status;caries-active;caries-free
tetrahydrogeranylgeranyl-bacteriopheophytin	ST001204	AN002005	3.400E-4	8.270E-4	cell_type;iRBC;unRBC
Icosadienoic acid	ST000403	AN000643	3.440E-4	7.750E-4	Cell type;Mature erythrocyte;Reticulocyte
nonulose 9-phosphate	ST001204	AN002005	3.450E-4	8.310E-4	cell_type;iRBC;unRBC
BOC-LYS-OH	ST000016	AN000033	3.470E-4	6.790E-4	Material;Cells;Media
ACETAMINOPHEN (TN TYLENOL) (M+H)+	ST000523	AN000798	3.490E-4	6.160E-3	Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
CAI-1	ST000539	AN000819	3.490E-4	2.230E-2	timepoint;1 hour;20 hours
5-Acetamidopentanoate 2	ST000539	AN000819	3.570E-4	7.970E-3	Glucose labelling;C13 glucose;unlabelled
2-deoxytetronic acid NIST	ST000385	AN000620	3.660E-4	1.800E-3	Gender;F;M;NA
(E)-2-Butenyl-4-methyl-threonine	ST000567	AN000872	3.670E-4	5.310E-3	groups;Old-Curcumin;Old-Placebo;young
Bisnorcholic acid	ST000355	AN000581	3.690E-4	2.610E-3	Stage;1;2;3;4;-
Kyn/Trp	ST001237	AN002055	3.690E-4	3.600E-3	Treatment;EVEROLIMUS;NIVOLUMAB
methyl8-[2-(2-formyl-vinyl)-3-hydroxy-5-oxo-cyclopentyl]-octanoate	ST000046	AN000078	3.710E-4	8.410E-3	Cognitive Status;AD;CN;MCI
Caffeine-D3	ST000919	AN001507	3.770E-4	4.200E-3	Response;NR;R
HEPTADECENOATE (*)	ST000105	AN000174	3.780E-4	3.520E-3	Sampling;After SWS onset;Morning fasting
(E)-2-Butenyl-4-methyl-threonine	ST000567	AN000872	3.790E-4	5.730E-4	Time point;Post;Pre;Baseline
glycodeoxycholate/glycochenodeoxycholate	ST001237	AN002055	3.790E-4	9.130E-4	CRF_MSKCC_Risk_Group;FAVORABLE;INTERMEDIATE;POOR
sulfate of piperine metabolite C16H19NO3 (3)*	ST000975	AN001596	3.820E-4	1.240E-2	REGION;MAK;SUN
DIMETHYLXANTHINE	ST000016	AN000033	3.890E-4	1.480E-3	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
3-methyl-3-hydroxybutyric acid	ST000092	AN000146	3.920E-4	5.590E-4	Volume Urine (µL);100;10;25;50;5
Ala-Trp-Gly-Gly	ST001202	AN002000	3.980E-4	7.040E-4	treatment_duration_(h);-;1.5;3;6;9
[Fv] Homoflemingin	ST000539	AN000818	4.010E-4	1.660E-2	timepoint;1 hour;20 hours
400671 carbohydrate	ST000386	AN000621	4.030E-4	3.840E-3	Gender;F;M;NA
B-ureidoisobutyric acid	ST000422	AN000667	4.030E-4	2.240E-2	treatment;ND;T1D good glycemic control
CALCIDIOL (M+H)+[-H2O]	ST000818	AN001297	4.040E-4	1.120E-3	Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
L-4-Hydroxy-3-methoxy-a-methylphenylalanine	ST000422	AN000667	4.050E-4	2.240E-2	treatment;ND;T1D good glycemic control
L-Leucine-D10	ST000919	AN001506	4.190E-4	5.590E-3	Gender;Female;Male
Pro258-13C4	ST000076	AN000122	4.200E-4	3.460E-3	Labeling;13C/15N-Gln;13C-Glc;unlabeled
Propionylglycinemethylester	ST000046	AN000077	4.200E-4	2.090E-2	Cognitive Status;AD;CN;MCI
pyroglutamylglycine	ST000975	AN001596	4.210E-4	3.140E-2	TIMEPOINT;BL;M06;M18
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000698	AN001083	4.260E-4	2.410E-2	KD#1;no;yes;Pooled melanoma
DOCOSAHEXAENOYLGLYCEROPHOSPHOETHANOLAMINE	ST000016	AN000033	4.350E-4	8.360E-4	Material;Cells;Media
4-ethylphenylsulfate	ST000974	AN001595	4.380E-4	7.460E-3	TIMEPOINT;BL;M06;M18
[FA oxo(7:0)] 2-oxo-heptanoic acid	ST000403	AN000643	4.420E-4	8.060E-3	Glucose labelling;C13 glucose;unlabelled
methiin	ST000539	AN000818	4.420E-4	1.090E-3	Cell type;Mature erythrocyte;Reticulocyte
Asn-Asn-Gly-His	ST001201	AN001999	4.500E-4	6.300E-3	treatment;DHA;DMSO;OZ277;OZ439
HBA	ST000566	AN000870	4.510E-4	6.080E-4	Time point;Post;Pre;Baseline
2-keto-l-gluconic acid	ST000092	AN000146	4.570E-4	7.140E-4	Solution Added;N/A;None;Urease;Water
CerH2O(d18:1/24:0);CerH2O(d19:1/23:0)	ST000608	AN000929	4.620E-4	2.250E-3	Factor;case;control
ethylpyruvate	ST000539	AN000819	4.670E-4	1.250E-3	Cell type;Mature erythrocyte;Reticulocyte
PC 36:4 (16:0/20:4(5E.8E.11E.14E)) [M+HCOO]-	ST001111	AN001806	4.820E-4	1.080E-3	Sample;Benign;Cancer;Metastasis
4-Hydroxyphenylacetylglycine	ST001204	AN002005	4.870E-4	1.140E-3	cell_type;iRBC;unRBC
CL 78:12 (18:1/20:4/18:1/22:6) [M-2H](2-)	ST001111	AN001806	4.880E-4	1.090E-3	Sample;Benign;Cancer;Metastasis
N-acetyl -D- glucosaminitol	ST001204	AN002004	4.890E-4	1.030E-3	cell_type;iRBC;unRBC
glucuronide of piperine metabolite C17H21NO3 (5)*	ST000974	AN001595	4.970E-4	2.480E-2	GROUP;case;control
Ala-Lys-Asp-Pro	ST001204	AN002004	5.050E-4	3.360E-2	treatment;DHA;DMSO;OZ277;OZ439
CL 76:11 (18:2/18:2/20:4/20:3) [M-2H](2-)	ST001111	AN001806	5.070E-4	1.110E-3	Sample;Benign;Cancer;Metastasis
Arsenobetaine	ST001202	AN002000	5.080E-4	8.780E-4	treatment_duration_(h);-;1.5;3;6;9
[13C]-HISTIDINE	ST000016	AN000033	5.170E-4	9.710E-4	Material;Cells;Media
Asn-Leu-Pro-Pro	ST001204	AN002004	5.180E-4	3.360E-2	treatment;DHA;DMSO;OZ277;OZ439
N2-(D-1-Carboxyethyl)-L-arginine	ST000403	AN000642	5.190E-4	1.070E-3	Cell type;Mature erythrocyte;Reticulocyte
threo-sphingosine	ST001236	AN002054	5.220E-4	1.780E-2	OS_Censor (1 means the time is a censoring time and 0 means ...
Pro258-13C5	ST000076	AN000122	5.230E-4	4.150E-3	Labeling;13C/15N-Gln;13C-Glc;unlabeled
D-Ribose;ALDOPENTOSE	ST000956	AN001568	5.250E-4	1.460E-3	Treatment;Condition-1;Condition-2;Condition-3;Control
Heterocladol	ST000291	AN000465	5.270E-4	2.810E-2	Treatment ;Baseline urine;Urine after drinking apple juice;U...
OHPro-13C0	ST000114	AN000194	5.280E-4	6.620E-3	Treatment;None;Tetracycline
3-methyl catechol sulfate (2)	ST000975	AN001596	5.330E-4	1.580E-2	REGION;MAK;SUN
Decylubiquinol	ST000567	AN000872	5.330E-4	7.870E-4	Time point;Post;Pre;Baseline
N-acetyl -D- glucosaminitol	ST001201	AN001998	5.380E-4	1.030E-3	cell_type;iRBC;unRBC
1.2.3.4-tetrahydro-beta-carboline-1.3-dicarboxylate	ST000923	AN001515	5.430E-4	2.080E-3	Diagnosis;CD;nonIBD;UC
F-Honaucin A	ST000242	AN000376	5.440E-4	5.930E-4	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
D-Galacturonate	ST001202	AN002001	5.560E-4	1.170E-3	treatment_duration_(h);-;1.5;3;6;9
L-Glutamic acid dibutyl ester	ST000566	AN000870	5.570E-4	1.400E-2	group;Old-Curcumin;Old-Placebo;young
4aminobenzaldehyde1	ST000614	AN000941	5.580E-4	9.120E-4	Diagonsis;Benign;Cancer;Normal
pyroglutamylglycine	ST000974	AN001595	5.620E-4	2.640E-3	REGION;AHRI;MRC;SUN
4-Hydroxy-4-methylglutamate	ST000403	AN000642	5.640E-4	1.160E-3	Cell type;Mature erythrocyte;Reticulocyte
D-Alanyl-D-alanine	ST000356	AN000583	5.720E-4	1.170E-3	Diagnosis;breast cancer;control
IDP-D-mannose	ST001201	AN001999	5.750E-4	7.720E-3	treatment;DHA;DMSO;OZ277;OZ439
GLYCEROL 2-PHOSPHATE/SN-GLYCEROL 3-PHOSPHATE	ST000956	AN001569	5.770E-4	2.210E-3	Treatment;Condition-1;Condition-2;Condition-3;Control
Furamizole	ST000291	AN000465	5.790E-4	2.890E-2	Treatment ;Baseline urine;Urine after drinking apple juice;U...
IDP-D-mannose	ST001205	AN002006	5.790E-4	3.220E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
3-(4-Hydroxyphenyl)Pyruvate / Caffeate	ST001040	AN001702	5.800E-4	2.630E-3	Sample Type/Matrix;Pooled quality control sample;urine;Water...
Ammonia	ST000435	AN000685	5.840E-4	2.790E-3	treatment;ND;T1D good glycemic control;T1D poor glycemic con...
2-hydroxyglutarate+Na	ST000956	AN001568	5.930E-4	1.620E-3	Treatment;Condition-1;Condition-2;Condition-3;Control
undecanedionate	ST000923	AN001515	5.970E-4	2.170E-3	Diagnosis;CD;nonIBD;UC
[calc GSH-13C]	ST000114	AN000194	5.980E-4	6.620E-3	Treatment;None;Tetracycline
Dimethylallylpyrophosphate	ST000356	AN000583	5.980E-4	1.200E-3	Diagnosis;breast cancer;control
o-toluidene	ST000614	AN000943	5.980E-4	1.170E-3	Diagonsis;Benign;Cancer;Normal
EPC(d37:1)	ST001205	AN002006	5.990E-4	3.250E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
lathosterol NIST	ST000369	AN000603	6.010E-4	4.350E-3	Gender;F;M;NA
glucuronide of piperine metabolite C17H21NO3 (4)*	ST000974	AN001595	6.040E-4	2.820E-2	GROUP;case;control
4-Hydroxy-4-methylglutamate	ST001205	AN002007	6.090E-4	4.090E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
TROMETHAMINE+5.1856112	ST000046	AN000076	6.090E-4	1.160E-2	Cognitive Status;AD;CN;MCI
undecanedicarboxylic acid	ST001000	AN001880	6.110E-4	1.710E-3	Diagnosis;CD;Control;UC
cis-Acetylacrylate	ST001205	AN002007	6.270E-4	4.950E-2	treatment_duration_(h);1;5;3
Ritodrineglucuronide	ST000046	AN000078	6.490E-4	1.100E-2	Cognitive Status;AD;CN;MCI
24-Dihydroxyacetophenone	ST001193	AN001989	6.530E-4	1.080E-3	Plasma;Cord blood;Plasma
Alpha-acetyllysine	ST001039	AN001712	6.560E-4	3.900E-3	Sample.Matrix;Plasma;Urine
Ala-Met-Asp-Tyr	ST001202	AN002001	6.660E-4	1.360E-3	treatment_duration_(h);-;1.5;3;6;9
Bis(2-hydroxypropyl)amine+5.6003766	ST000046	AN000077	6.660E-4	3.000E-2	Cognitive Status;AD;CN;MCI
715929 carbohydrate	ST000369	AN000603	6.670E-4	2.050E-3	Organ;Plasma;Serum
N-Acetylanthranilate	ST001201	AN001999	6.670E-4	1.310E-3	cell_type;iRBC;unRBC
BOC-PHE-OH	ST000043	AN000070	6.690E-4	3.550E-3	Cell line;MDA-MB-231;MDA-MB-231 p38 gamma knockdown;MDA-MB-2...
p-Toluic acid-M+1	ST001167	AN001930	6.730E-4	1.310E-3	Time points;0.25h;0h;12h;24h;4h;6days
citraconic acid major TMS2	ST000420	AN000662	6.740E-4	1.180E-3	Group;nonsmoker;smoker
22:1 (n-9)	ST001098	AN001786	6.750E-4	1.150E-2	Treatment;Non-obese control;Obese control;Schizophrenia dx
P-DPD	ST001201	AN001999	6.760E-4	8.700E-3	treatment;DHA;DMSO;OZ277;OZ439
lysopalmitoyl monogalactosylglycerol	ST001322	AN002198	6.850E-4	2.740E-3	treatment;expecting 2 month - human breast milk;expecting 2 ...
VALERYLSALYCILATE	ST000047	AN000081	6.920E-4	2.450E-2	Cognitive Status;AD;CN;MCI
N6-carboxymethyllysine	ST000899	AN001462	7.020E-4	4.880E-3	Type;Control;Crohn disease;Ulcerative Colitis
Dide-O-methylsimmondsin	ST001205	AN002007	7.030E-4	4.530E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
pantothete	ST001000	AN001879	7.050E-4	2.320E-3	Diagnosis;CD;Control;UC
OHPro-ALL	ST000114	AN000194	7.080E-4	6.620E-3	Treatment;None;Tetracycline
(2-Butylbenzofuran-3-yl)(4-hydroxyphenyl)ketone-13C0[+Na]+	ST000142	AN000225	7.120E-4	4.200E-3	Treatment;13C-Glc;unlabeled
Pro258-13C1	ST000114	AN000194	7.140E-4	6.620E-3	Treatment;None;Tetracycline
Phenolsulfonphthalein	ST001202	AN002001	7.220E-4	1.460E-3	treatment_duration_(h);-;1.5;3;6;9
Ascorbate 2-sulfate	ST000567	AN000871	7.270E-4	3.540E-3	groups;Old-Curcumin;Old-Placebo;young
OHPro-13C5	ST000076	AN000122	7.330E-4	5.150E-3	Labeling;13C/15N-Gln;13C-Glc;unlabeled
CMP-N-trimethyl-2-aminoethylphosphonate	ST001201	AN001999	7.340E-4	9.090E-3	treatment;DHA;DMSO;OZ277;OZ439
2-deoxytetronic acid NIST	ST000385	AN000620	7.350E-4	4.860E-3	Smoking Status;Current;Former;NA
GLUCOSAMINE/MANNOSAMINE	ST000475	AN000739	7.440E-4	1.370E-3	Treatment;-;MDH inhib
4-QUINOLINECARBOXYLIC ACID #2 (M+H)+	ST000523	AN000798	7.460E-4	1.050E-2	Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000698	AN001083	7.460E-4	1.120E-2	KD#2;yes;no;Pooled melanoma
2-(Hydroxymethyl)-3-(acetamidomethylene)succinate	ST001201	AN001999	7.480E-4	1.460E-3	cell_type;iRBC;unRBC
Calcium salicylate	ST000292	AN000466	7.670E-4	3.090E-2	Treatment ;Baseline plasma;Plasma after drinking apple juice...
N-hydroxyisoleucine	ST001202	AN002000	7.670E-4	1.240E-3	treatment_duration_(h);-;1.5;3;6;9
L-4-Hydroxy-3-methoxy-a-methylphenylalanine + 2.0514681	ST000421	AN000663	7.690E-4	2.330E-2	treatment;ND;T1D poor glycemic control
19/20-OH PGF2a	ST001214	AN002025	7.720E-4	1.140E-3	BMI group;lean;obese;overweight
[FA (8:1)] 2Z-octenoic acid	ST000539	AN000819	7.730E-4	1.990E-3	Cell type;Mature erythrocyte;Reticulocyte
2-O-methyl PAF C16	ST000553	AN000845	7.740E-4	8.890E-4	Sample type;Plasma;Urine
BOC-SER-OH	ST000044	AN000069	7.750E-4	1.090E-2	Pancreas tissue type;Normal area of the pancreas with tumor;...
ethylpyruvate	ST000403	AN000643	7.770E-4	1.640E-3	Cell type;Mature erythrocyte;Reticulocyte
UDP-GLCUR-13C13+15N0	ST000076	AN000121	7.780E-4	1.000E-1	Labeling;13C/15N-Gln;13C-Glc;unlabeled
3-S-cysteinyl-2-methylpropanoate*	ST000974	AN001595	7.790E-4	3.600E-3	REGION;AHRI;MRC;SUN
L-Ala-L-Glu	ST000539	AN000819	7.920E-4	2.010E-3	Cell type;Mature erythrocyte;Reticulocyte
L-Ala-L-Glu 2	ST000539	AN000819	7.920E-4	2.010E-3	Cell type;Mature erythrocyte;Reticulocyte
Hydroxyibuprofen	ST000567	AN000871	7.970E-4	2.000E-3	Time point;Post;Pre;Baseline
indole-3-acetyl-valine	ST000403	AN000643	7.980E-4	1.680E-3	Cell type;Mature erythrocyte;Reticulocyte
2-ethylphenylsulfate	ST000975	AN001596	8.000E-4	5.090E-3	GENDER;F;M
Cys-Gly-Pro-Ser	ST001202	AN002001	8.010E-4	1.580E-3	treatment_duration_(h);-;1.5;3;6;9
asparagylisoleucine	ST000974	AN001595	8.020E-4	1.170E-2	TIMEPOINT;BL;M06;M18
[FA hydroxy(13:0)] 2-hydroxy-tridecanoic acid	ST000539	AN000819	8.060E-4	4.320E-2	timepoint;1 hour;20 hours
sulfate of piperine metabolite C16H19NO3 (2)*	ST000974	AN001595	8.070E-4	3.160E-2	GROUP;case;control
9-myristoleate	ST001322	AN002198	8.071E-4	3.127E-3	treatment;expecting 2 month - human breast milk;expecting 2 ...
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (PROBABLY)	ST000016	AN000033	8.090E-4	2.710E-3	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
HWESASXX*	ST000974	AN001595	8.140E-4	3.160E-2	GROUP;case;control
ACETAMINOPHEN (TN TYLENOL) (M+H)+	ST000713	AN001114	8.160E-4	1.040E-2	level of dysplasia;HGD;HGD & PDA;LGD;N/A
Bisnorcholic acid	ST000355	AN000581	8.200E-4	6.110E-3	Diagnosis;Breast cancer;Control
ACETAMINOPHEN (TN TYLENOL) (M+NA)+	ST000713	AN001114	8.230E-4	1.040E-2	level of dysplasia;HGD;HGD & PDA;LGD;N/A
3-hydroxybutyroylglycine**	ST000975	AN001596	8.260E-4	2.560E-2	GROUP;case;control
[FA methyl(6:0)] 2-methyl-hexanoic acid	ST000403	AN000643	8.260E-4	2.530E-2	timepoint;1 hour;20 hours
threosphingosine	ST000923	AN001513	8.280E-4	3.460E-3	Diagnosis;CD;nonIBD;UC
715929 carbohydrate	ST000386	AN000621	8.300E-4	2.550E-3	Organ;Plasma;Serum
DIACYL-PHOSPHATIDYLCHOLINE	ST000044	AN000068	8.300E-4	2.810E-2	Pancreas tissue type;Normal area of the pancreas with tumor;...
3-deoxy-D-galactose	ST001205	AN002006	8.310E-4	1.410E-1	treatment;DHA;DMSO;OZ277;OZ439
glycol	ST000355	AN000580	8.320E-4	3.950E-3	Stage;1;2;3;4;-
Galacturonate / Glucuronate	ST001040	AN001702	8.370E-4	3.610E-3	Sample Type/Matrix;Pooled quality control sample;urine;Water...
Cotinine-good	ST000614	AN000943	8.400E-4	1.550E-3	Diagonsis;Benign;Cancer;Normal
3-Butynoate	ST000566	AN000870	8.460E-4	1.100E-3	Time point;Post;Pre;Baseline
C8-Ceramide m0	ST000644	AN000976	8.590E-4	2.490E-3	time;48 hr;0 hr
3-methyl catechol sulfate (1)	ST000976	AN001597	8.690E-4	2.400E-1	TIMEPOINT;BL;M06
Ala-Lys-Lys-Asp	ST001204	AN002004	8.700E-4	4.230E-2	treatment;DHA;DMSO;OZ277;OZ439
Tyrphostin B44 (-)	ST000242	AN000375	8.710E-4	1.180E-3	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
3-Ethylmalate	ST001201	AN001998	8.810E-4	1.620E-3	cell_type;iRBC;unRBC
O-(N-acetyl-a-neuraminosyl)-(2->3)-O-b-D-galactopyranosyl-(1->4)-O-2-(acetylamino)-2-deoxy-b-D-glucopyranosyl-(1->3)-O-b-D-galactopyranosyl-(1->4)-O-2-(acetylamino)-2-deoxy-b-D-glucopyranosyl-(1->3)-O-b-D-galactopyranosyl-(1->4)- D-Gluc	ST000241	AN000373	8.810E-4	6.020E-3	Concentration (uM);0;500
2(alpha-D-Mannosyl)-D-glycerate	ST000403	AN000643	8.890E-4	1.850E-3	Cell type;Mature erythrocyte;Reticulocyte
Azelate	ST001048	AN001717	8.970E-4	1.100E-3	Analysis type;CHEAR 2016-1407 Study Sample;CHEAR Pooled Urin...
ACETAMINOPHEN (TN TYLENOL) (M+Na)+	ST000523	AN000798	9.000E-4	5.520E-3	Timing of Sample Collection;CHEAR_REFERENCE;1st trimester;te...
3-Hydroxyhexdecanedioyl-CoA	ST000241	AN000373	9.070E-4	1.330E-3	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
4-QUINOLINECARBOXYLIC ACID #2 (M+H)+	ST000523	AN000798	9.070E-4	4.410E-3	Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
4-allylphenol sulfate	ST000975	AN001596	9.110E-4	5.690E-3	GENDER;F;M
Corey PG-Lactone Diol + 6.739769	ST000566	AN000870	9.270E-4	1.190E-3	Time point;Post;Pre;Baseline
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000741	AN001155	9.450E-4	2.990E-2	subject type;Healthy control;Mild disease;POOLED;Severe dise...
Naloxone-3-glucuronide	ST000242	AN000377	9.460E-4	4.330E-3	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
cx-MiDP (MCNP) (Mono(2,7-dimethyl-7-carboxyheptyl) phthalate)	ST001317	AN002193	9.596E-4	1.343E-3	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
cx-MiDP (MCNP) (Mono(2,7-dimethyl-7-carboxyheptyl) phthalate)	ST001317	AN002193	9.596E-4	1.343E-3	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
5-hydroxynorvaline NIST	ST000392	AN000628	9.640E-4	5.440E-3	Disease State;cancer;control;-
Acetyphenylalanine	ST001039	AN001712	9.670E-4	4.130E-3	Sample.Matrix;Plasma;Urine
2-Amino-2-methyl-1-propanol+3.3926477	ST000047	AN000080	9.720E-4	3.870E-2	Cognitive Status;AD;CN;MCI
C-GLYCOSYLTRYPTOPHAN	ST000016	AN000033	9.840E-4	3.130E-3	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
ACETAMINOPHEN (TN TYLENOL) (M+H)+	ST000523	AN000798	1.010E-3	5.910E-3	Timing of Sample Collection;CHEAR_REFERENCE;1st trimester;te...
a Cysteine adduct	ST000539	AN000818	1.010E-3	2.380E-3	Cell type;Mature erythrocyte;Reticulocyte
a Cysteine adduct 2	ST000539	AN000818	1.010E-3	2.380E-3	Cell type;Mature erythrocyte;Reticulocyte
Gln-Leu-Lys-His	ST000403	AN000642	1.010E-3	1.980E-3	Cell type;Mature erythrocyte;Reticulocyte
glucuronide of piperine metabolite C17H21NO3 (3)*	ST000974	AN001595	1.010E-3	3.270E-2	GROUP;case;control
5-(3-Pyridyl)-2-hydroxytetrahydrofuran	ST000567	AN000872	1.020E-3	1.190E-2	groups;Old-Curcumin;Old-Placebo;young
Bile salt	ST001201	AN001999	1.020E-3	1.970E-3	cell_type;iRBC;unRBC
melibionate	ST001202	AN002001	1.020E-3	1.960E-3	treatment_duration_(h);-;1.5;3;6;9
Phenyl beta-D-glucopyranoside	ST000566	AN000869	1.020E-3	4.490E-3	group;Old-Curcumin;Old-Placebo;young
Arg-Phe-Phe-Arg	ST001202	AN002001	1.030E-3	1.960E-3	treatment_duration_(h);-;1.5;3;6;9
D1-2-Hydroxymethylethisterone-11.471997	ST000046	AN000078	1.030E-3	1.520E-2	Cognitive Status;AD;CN;MCI
2E-methyl-glutaconic acid	ST000567	AN000872	1.040E-3	1.500E-3	Time point;Post;Pre;Baseline
Citrate source fragment (+H and + NH3)	ST000956	AN001568	1.050E-3	2.700E-3	Treatment;Condition-1;Condition-2;Condition-3;Control
ethanedisulfonate	ST000403	AN000643	1.050E-3	2.150E-3	Cell type;Mature erythrocyte;Reticulocyte
7b-Hydroxydehydroepiandrosterone	ST000356	AN000583	1.060E-3	2.590E-3	stage;-;2;3
Ala-Asp-Pro-Ser	ST000539	AN000818	1.070E-3	2.510E-3	Cell type;Mature erythrocyte;Reticulocyte
L-beta-aspartyl-L-serine	ST001201	AN001998	1.070E-3	1.190E-2	treatment;DHA;DMSO;OZ277;OZ439
Acetylpseudotropine	ST001202	AN002000	1.080E-3	1.710E-3	treatment_duration_(h);-;1.5;3;6;9
ADMA/SDMA	ST001000	AN001878	1.100E-3	4.170E-3	Diagnosis;CD;Control;UC
indole-3-acetonitrile oxide	ST000403	AN000642	1.100E-3	2.140E-3	Cell type;Mature erythrocyte;Reticulocyte
3-methyl catechol sulfate (1)	ST000899	AN001464	1.130E-3	3.830E-3	Type;Control;Crohn disease;Ulcerative Colitis
HWESASXX*	ST000974	AN001595	1.140E-3	5.050E-3	REGION;AHRI;MRC;SUN
Valacyclovir	ST000291	AN000465	1.140E-3	5.000E-2	Treatment ;Baseline urine;Urine after drinking apple juice;U...
z mstfa artifact	ST000420	AN000662	1.140E-3	1.950E-3	Group;nonsmoker;smoker
2-Deoxymugineic acid	ST000403	AN000643	1.160E-3	2.350E-3	Cell type;Mature erythrocyte;Reticulocyte
DL-?-Lipoic Acid	ST000566	AN000870	1.160E-3	1.470E-3	Time point;Post;Pre;Baseline
1-(14-methyl-pentadecanoyl)-2-(8-[3]-ladderane-octanyl)-sn-glycerol	ST001205	AN002006	1.170E-3	5.670E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
10-oxogeranial	ST000403	AN000643	1.180E-3	1.730E-2	Glucose labelling;C13 glucose;unlabelled
Acetylneuraminic acid	ST001039	AN001713	1.180E-3	4.070E-3	Sample.Matrix;Plasma;Urine
NMMA	ST001236	AN002054	1.180E-3	2.900E-2	OS_Censor (1 means the time is a censoring time and 0 means ...
4-Aminophenyl 1-thio-beta-D-glucuronide	ST000422	AN000667	1.190E-3	4.380E-2	treatment;ND;T1D good glycemic control
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000689	AN001063	1.190E-3	7.300E-3	Construct;-;Control lentivirus;Noxa knockdown
acetophenone NIST	ST000368	AN000602	1.200E-3	1.880E-3	Organ;Plasma;Serum;Serum or Plasma
EPC(d37:2)	ST001205	AN002006	1.200E-3	5.780E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
ARACHIDONATE #2 (M-H)-	ST000818	AN001296	1.220E-3	3.860E-3	Occupation;Agriculturalist;Agropastoralist;Hunter-Gatherer;P...
nicotinamide guanine dinucleotide	ST001205	AN002007	1.220E-3	6.750E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
Bile salt	ST001201	AN001999	1.230E-3	7.900E-2	treatment_duration_(h);-;0.5;1.5;3
isolinoleic acid NIST	ST000369	AN000603	1.230E-3	3.600E-3	Organ;Plasma;Serum
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000689	AN001063	1.230E-3	7.300E-3	Construct;-;Control lentivirus;Noxa knockdown
16b-Hydroxystanozolol	ST000241	AN000373	1.240E-3	1.770E-3	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Putreanine	ST001205	AN002006	1.240E-3	5.890E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
Furfural diethyl acetal	ST000539	AN000819	1.250E-3	3.030E-3	Cell type;Mature erythrocyte;Reticulocyte
N-Acetyl Lysine	ST000614	AN000939	1.250E-3	1.560E-3	Diagonsis;Benign;Cancer;Normal
Histidylproline diketopiperazine	ST000356	AN000583	1.260E-3	3.030E-3	stage;-;2;3
sulfate*	ST000975	AN001596	1.260E-3	7.480E-3	GENDER;F;M
2-pyrrolidone-5-carboxylic acid	ST000356	AN000582	1.270E-3	2.780E-3	stage;-;2;3
Citrate+Na;CITRATE	ST000956	AN001568	1.270E-3	3.160E-3	Treatment;Condition-1;Condition-2;Condition-3;Control
isolinoleic acid NIST	ST000386	AN000621	1.270E-3	3.640E-3	Organ;Plasma;Serum
Phenyl beta-D-glucopyranoside	ST000567	AN000871	1.270E-3	5.030E-3	groups;Old-Curcumin;Old-Placebo;young
urobilin - targeted	ST000923	AN001513	1.270E-3	1.180E-2	sex;Female;Male
Napthyl amine	ST000614	AN000943	1.280E-3	1.560E-3	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
p-Toluic acid-M+3	ST001167	AN001930	1.280E-3	8.600E-3	Cell lines;RWPE1;VCaP
Diacetylhydrazine	ST000539	AN000818	1.290E-3	3.450E-2	timepoint;1 hour;20 hours
[13C]-LEUCINE	ST000106	AN000175	1.310E-3	3.210E-2	Sampling time;0 min;60 min
IS D31-TAG	ST000523	AN000800	1.310E-3	8.170E-3	Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
oleamide NIST	ST000412	AN000652	1.310E-3	2.050E-3	Treatment;fresh liver;nonwarm ischemic liver;steatotic liver...
DISACCHARIDE (6C/6C)/2-alpha-D-glucosyl-D-glucose	ST000956	AN001569	1.320E-3	4.000E-3	Treatment;Condition-1;Condition-2;Condition-3;Control
2-AG b	ST000096	AN000154	1.340E-3	1.580E-3	Timepoint;18 hours;4 hours;NA
C6H12O6-HEXOSE/KETOSE/INOSITOL	ST000292	AN000467	1.350E-3	1.450E-2	Treatment ;Baseline plasma;Plasma after drinking apple juice...
1-3-7-trimethylurate	ST000923	AN001514	1.360E-3	4.870E-3	Diagnosis;CD;nonIBD;UC
4-Hydroxy-6-methylpyran-2-one	ST000567	AN000872	1.370E-3	1.930E-3	Time point;Post;Pre;Baseline
[6]-Shogaol-13C0[+H]+	ST000148	AN000235	1.370E-3	1.450E-2	Treatment;13C-Glc;unlabeled
EthosuximideM7	ST000046	AN000077	1.370E-3	5.240E-2	Cognitive Status;AD;CN;MCI
Icosatrienoic acid	ST000539	AN000819	1.370E-3	3.290E-3	Cell type;Mature erythrocyte;Reticulocyte
[PC (15:1)] 1-(1Z-pentadecenyl)-sn-glycero-3-phosphocholine	ST000539	AN000819	1.370E-3	3.290E-3	Cell type;Mature erythrocyte;Reticulocyte
Hydroxybutyrate3	ST000137	AN000219	1.380E-3	1.140E-2	Sample Group;Control;Patient
P-DPD	ST000539	AN000819	1.380E-3	3.290E-3	Cell type;Mature erythrocyte;Reticulocyte
ZEATIN [ISTD] (M+CL)-	ST000711	AN001110	1.380E-3	8.610E-2	NTM pulmonary disease;no;yes
C14:1-OH / C10	ST000545	AN000830	1.390E-3	2.170E-3	Sample Type;Control;Replicate
C8-Ceramide m+6	ST000644	AN000976	1.390E-3	3.710E-3	time;48 hr;0 hr
1-(2-(3-CYCLOHEXENYL)ETHYL)SILATRANE	ST001037	AN001698	1.400E-3	7.830E-3	Description ;Blank;Reagent Blank;Serum Sample;Solvent
ARACHIDONOYLGLYCEROPHOSPHOINOSITOL (*)	ST000106	AN000176	1.410E-3	1.840E-2	Sampling time;0 min;60 min
BOC-PHE-OH	ST000105	AN000173	1.410E-3	1.660E-2	Sampling;After SWS onset;Morning fasting
[FA oxo(8:0)] 3-oxo-octanoic acid	ST000403	AN000643	1.410E-3	1.870E-2	Glucose labelling;C13 glucose;unlabelled
Fibrinopeptide B (1-9)**	ST000975	AN001596	1.410E-3	3.550E-2	GROUP;case;control
PC 40:4 (18:0/22:4(7Z.10Z.13Z.16Z)) [M-Ac-H]-	ST001111	AN001806	1.430E-3	2.860E-3	Sample;Benign;Cancer;Metastasis
SB N-(9Z-octadecenoyl)-sphinganine (d18:0/18:1(9Z)) [M-H]-	ST001111	AN001806	1.430E-3	2.860E-3	Sample;Benign;Cancer;Metastasis
Ala-Asp-Asp-His	ST001201	AN001998	1.450E-3	1.460E-2	treatment;DHA;DMSO;OZ277;OZ439
L-proline amide	ST000539	AN000818	1.450E-3	3.450E-2	timepoint;1 hour;20 hours
N-acetylmannosamine minor	ST000087	AN000139	1.450E-3	2.830E-3	Time Point;18 hours;4 hours
sulfa d18:1 N22:0	ST000362	AN000594	1.450E-3	4.880E-2	Chronic_Bronchitis;1;-
ZEATIN [ISTD] (M+H)+	ST000711	AN001111	1.470E-3	4.130E-2	NTM pulmonary disease;no;yes
gamma-thiomethyl glutamate	ST001205	AN002006	1.480E-3	6.620E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
methylhexadecanoic acid	ST000369	AN000603	1.480E-3	8.350E-3	Smoker;Current;Former;NA
Very low density lipoprotein	ST001038	AN001699	1.480E-3	2.970E-3	Timepoint;15 min;1 hr;24 hr;30 min;<5 min
[Fv] Homoflemingin	ST000403	AN000642	1.490E-3	2.860E-3	Cell type;Mature erythrocyte;Reticulocyte
3-methyl catechol sulfate (1)	ST000975	AN001596	1.500E-3	8.580E-3	GENDER;F;M
methylhexadecanoic acid	ST000385	AN000620	1.500E-3	7.660E-3	Smoking Status;Current;Former;NA
methylhexadecanoic acid	ST000369	AN000603	1.510E-3	8.550E-3	Gender;F;M;NA
D-MANNOSAMINE (CAS# 14307-02-9); (M+H)+[-H2O]	ST000689	AN001064	1.520E-3	7.720E-3	Construct;-;Control lentivirus;Noxa knockdown
L-proline amide	ST000403	AN000642	1.520E-3	2.040E-2	Glucose labelling;C13 glucose;unlabelled
6-Acetyl-D-glucose	ST001204	AN002004	1.530E-3	3.040E-3	cell_type;iRBC;unRBC
VALERYLSALYCILATE	ST000047	AN000080	1.530E-3	5.600E-2	Cognitive Status;AD;CN;MCI
C8-Ceramide m+12	ST000644	AN000976	1.550E-3	4.070E-3	time;48 hr;0 hr
methylhexadecanoic acid	ST000385	AN000620	1.550E-3	5.630E-3	Health State;Adenocarcinoma;Healthy;NA
plasmenyl-PE 38:4 (16:0/22:4(7Z.10Z.13Z.16Z)) [M+H]+	ST001111	AN001805	1.570E-3	2.250E-3	Sample;Benign;Cancer;Metastasis
trans-OH-Pro	ST000783	AN001239	1.570E-3	2.920E-1	RACE;AA;EA
2-deoxyerythritol NIST	ST000383	AN000618	1.580E-3	2.790E-2	Health Status;diabetic;non-diabetic
3-acetyl pyridine adenine dinucleotide	ST000539	AN000819	1.580E-3	3.030E-2	Glucose labelling;C13 glucose;unlabelled
EPC(d39:1)	ST001205	AN002006	1.580E-3	6.780E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
Furfural diethyl acetal	ST000403	AN000643	1.580E-3	1.940E-2	Glucose labelling;C13 glucose;unlabelled
C4 / C0	ST000545	AN000830	1.590E-3	2.470E-3	Sample Type;Control;Replicate
D-Mannose /D-Allose	ST000980	AN001606	1.600E-3	3.060E-2	Classification;Mild;Moderate;Non-allergic;Severe
phosphinomethylisomalate	ST001205	AN002007	1.600E-3	8.280E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
3-Hydroxyphenytoin	ST000047	AN000083	1.620E-3	2.090E-2	Cognitive Status;AD;CN;MCI
Ala-Cys-Pro-Ser	ST001204	AN002005	1.640E-3	3.790E-3	cell_type;iRBC;unRBC
N-Oleoyl-L-Serine	ST000566	AN000870	1.640E-3	2.150E-2	group;Old-Curcumin;Old-Placebo;young
SM(d18:1/25:0) or SM(d18:1/24:1 OH)	ST000465	AN000726	1.640E-3	5.870E-2	Treatment;Control;Englerin (100 nM)
lathosterol NIST	ST000369	AN000603	1.650E-3	9.080E-3	Smoker;Current;Former;NA
Oleandrosyl-oleandolide-13C0[+QDA adduct]+	ST000148	AN000235	1.650E-3	1.610E-2	Treatment;13C-Glc;unlabeled
ZEATIN [ISTD] (CAS# 13114-27-7); (M-H)-	ST000698	AN001083	1.650E-3	2.490E-2	Condition;no;Pooled melanoma;yes
2-AMINOETHYL DIHYDROGEN PHOSPHATE;ETHANOLAMINE PHOSPHATE	ST000956	AN001569	1.660E-3	4.880E-3	Treatment;Condition-1;Condition-2;Condition-3;Control
Asn-Leu-Pro-Pro	ST001205	AN002006	1.660E-3	1.410E-1	treatment;DHA;DMSO;OZ277;OZ439
Casein K	ST000403	AN000642	1.660E-3	5.620E-2	timepoint;1 hour;20 hours
17a-Ethynylestradiol2-glucuronide	ST000046	AN000079	1.670E-3	2.380E-2	Cognitive Status;AD;CN;MCI
7-Deoxyadriamycinone	ST000422	AN000668	1.670E-3	7.360E-2	treatment;ND;T1D good glycemic control
Asp-Gly-Pro-Ser	ST000539	AN000818	1.670E-3	3.750E-3	Cell type;Mature erythrocyte;Reticulocyte
PALMITOYLGLYCEROPHOSPHOETHANOLAMINE / PALMITOYLPLASMENYLETHANOLAMINE (*)	ST000044	AN000069	1.670E-3	1.610E-2	Pancreas tissue type;Normal area of the pancreas with tumor;...
valine ion	ST000975	AN001596	1.670E-3	3.640E-2	GROUP;case;control
Fummarate M+4	ST000507	AN000776	1.680E-3	3.690E-3	Time (incubation);24 hours;72 hours
c-aconitate-13C5	ST001049	AN001864	1.700E-3	2.980E-2	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
N-Ace-Asp-13C3	ST001049	AN001864	1.710E-3	2.980E-2	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
t-aconitate-13C0	ST001045	AN001709	1.710E-3	3.910E-2	protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
[13C]-ARGININE	ST000016	AN000033	1.720E-3	5.170E-3	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
ADSGEGDFXAEGGGVR*	ST000974	AN001595	1.720E-3	7.270E-3	REGION;AHRI;MRC;SUN
2-Pyridylthioamide	ST000566	AN000869	1.730E-3	3.390E-3	Time point;Post;Pre;Baseline
methiin	ST000403	AN000642	1.730E-3	3.310E-3	Cell type;Mature erythrocyte;Reticulocyte
Mesaconate	ST001205	AN002007	1.740E-3	8.850E-3	parasite_line;Cam3.IIR539T;Cam3.IIrev
O-methylcatechol sulfate	ST000899	AN001464	1.740E-3	5.470E-3	Type;Control;Crohn disease;Ulcerative Colitis
glucose-6-phosphate minor	ST000420	AN000662	1.750E-3	2.890E-3	Group;nonsmoker;smoker
6-deoxyglucitol NIST	ST000369	AN000603	1.760E-3	9.370E-3	Smoker;Current;Former;NA
GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))	ST001202	AN002001	1.760E-3	3.230E-3	treatment_duration_(h);-;1.5;3;6;9
3-S-cysteinyl-2-methylpropanoate*	ST000974	AN001595	1.770E-3	2.240E-2	TIMEPOINT;BL;M06;M18
[FA (8:1)] 2Z-octenoic acid	ST000403	AN000643	1.770E-3	3.540E-3	Cell type;Mature erythrocyte;Reticulocyte
SB N-(octadecanoyl)-sphing-4-enine (d18:1(4E)/18:0) [M-H]-	ST001111	AN001806	1.790E-3	3.500E-3	Sample;Benign;Cancer;Metastasis
5?-Androstan-3?-ol-17-one sulfate - 7.5459185	ST000566	AN000869	1.810E-3	7.580E-3	group;Old-Curcumin;Old-Placebo;young
Unknown_742.54(-)@6.25	ST000818	AN001298	1.810E-3	2.940E-3	Occupation;Agriculturalist;Agropastoralist;Hunter-Gatherer;P...
methylsuccinoylcarnitine (1)	ST000975	AN001596	1.820E-3	3.750E-2	GROUP;case;control
Labriformidin	ST000242	AN000377	1.830E-3	7.970E-3	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Casein K	ST000539	AN000818	1.850E-3	4.130E-3	Cell type;Mature erythrocyte;Reticulocyte
Casein K 2	ST000539	AN000818	1.850E-3	4.130E-3	Cell type;Mature erythrocyte;Reticulocyte
L-Sorbose/Fructose	ST000980	AN001606	1.860E-3	3.060E-2	Classification;Mild;Moderate;Non-allergic;Severe
Aminophosphovaleric acid	ST000614	AN000943	1.870E-3	2.920E-3	Diagonsis;Benign;Cancer;Normal
Citrate+NH3	ST000956	AN001568	1.870E-3	4.180E-3	Treatment;Condition-1;Condition-2;Condition-3;Control
bOHbutyrate-13C1	ST000114	AN000194	1.880E-3	1.340E-2	Treatment;None;Tetracycline
6-oxopiperidine-2-carboxylic acid	ST000974	AN001595	1.890E-3	2.280E-2	TIMEPOINT;BL;M06;M18
heptadecanoic acid NIST	ST000369	AN000603	1.890E-3	5.180E-3	Organ;Plasma;Serum
U 0521-13C0[+QDA adduct]+NH4	ST000148	AN000235	1.890E-3	1.700E-2	Treatment;13C-Glc;unlabeled
Cys-Met-Met-Phe	ST000539	AN000819	1.900E-3	4.450E-3	Cell type;Mature erythrocyte;Reticulocyte
Phorbol butanoate-13C0[+QDA adduct]+	ST000148	AN000235	1.900E-3	1.700E-2	Treatment;13C-Glc;unlabeled
acetytyrosine	ST001192	AN001986	1.920E-3	4.260E-2	Diet;-;Omnivore;Vegetarian
L-Asparticacidb-semialdehyde	ST000047	AN000082	1.920E-3	3.430E-2	Cognitive Status;AD;CN;MCI
L-beta-aspartyl-L-leucine	ST001204	AN002004	1.920E-3	4.380E-2	treatment_duration_(h);-;3;6;9
ZEATIN [ISTD] (M-H)-	ST000711	AN001110	1.930E-3	8.610E-2	NTM pulmonary disease;no;yes
gamma-Hydroxyphenylbutazone glucuronide	ST000421	AN000666	1.940E-3	1.900E-1	treatment;ND;T1D poor glycemic control
ACETAMINOPHEN (TN TYLENOL) (M+Na)+	ST000818	AN001297	1.960E-3	8.470E-3	Country;Ethiopia;Tanzania;Botswana
Fluoresceinmonoglucuronide	ST000047	AN000081	1.960E-3	4.190E-2	Cognitive Status;AD;CN;MCI
furoylglycine NIST	ST000381	AN000615	1.960E-3	9.540E-3	Cohort;CSMC;INHA
saccharic acid	ST000087	AN000139	1.960E-3	3.430E-3	Time Point;18 hours;4 hours
N-ACETYL-D-HEXOSAMINE	ST000106	AN000175	1.970E-3	1.060E-1	Constitution;Lean;Obese
Spermidine / Putrescine	ST000545	AN000829	1.970E-3	3.560E-2	Sample Type;Control;Replicate
2-ketoglucose dimethylacetal NIST	ST000392	AN000628	1.980E-3	1.960E-2	Gender;F;M;-
4-Methylumbelliferyl ?-D-glucuronide	ST000566	AN000869	1.990E-3	7.970E-3	group;Old-Curcumin;Old-Placebo;young
D-Alanyl-D-alanine	ST000356	AN000583	2.010E-3	4.650E-3	stage;-;2;3
Desmethylnimodipine	ST000047	AN000081	2.020E-3	4.190E-2	Cognitive Status;AD;CN;MCI
Hydroxycholesterol Species	ST000465	AN000727	2.030E-3	4.330E-2	Treatment;Control;Englerin (100 nM)
4-Hydroxylevamisole Glucuronide	ST000566	AN000869	2.040E-3	3.820E-3	Time point;Post;Pre;Baseline
[13C]-PHENYLALANINE	ST000016	AN000033	2.070E-3	3.550E-3	Material;Cells;Media
N-Acetylphenylalanine / Indole-3-Ethanol	ST001040	AN001703	2.080E-3	8.340E-3	Sample Type/Matrix;Pooled quality control sample;urine;Water...
C-GLYCOSYLTRYPTOPHAN (*)	ST000106	AN000175	2.100E-3	1.060E-1	Constitution;Lean;Obese
Ceramide(d18:1/23:0) or Ceramide(d18:1/22:1 OH)	ST000450	AN000705	2.110E-3	1.700E-2	Disease;CFS;Normal
lathosterol NIST	ST000379	AN000613	2.120E-3	5.090E-3	Time;10min;1hr;24hr;6hr
OH-monohexcer d18:1 N18:0	ST000362	AN000594	2.120E-3	4.880E-2	Chronic_Bronchitis;1;-
6-diazo-5-oxonorleucine	ST001202	AN002000	2.130E-3	3.250E-3	treatment_duration_(h);-;1.5;3;6;9
Cys-Gly-Pro-Ser	ST001201	AN001999	2.130E-3	2.040E-2	treatment;DHA;DMSO;OZ277;OZ439
docosahexaenoylcholine	ST000899	AN001463	2.130E-3	6.650E-3	Type;Control;Crohn disease;Ulcerative Colitis
N-methylundec-10-enamide	ST000242	AN000377	2.130E-3	8.880E-3	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
ALDO/KETO-HEXOSE	ST000475	AN000739	2.150E-3	3.600E-3	Treatment;-;MDH inhib
[13C]-LYSINE	ST000016	AN000033	2.160E-3	6.230E-3	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
sulfa d18:1 N16:0	ST000362	AN000594	2.160E-3	6.220E-3	Gender;1;2
Ala-Asp-Asp-His	ST001201	AN001998	2.190E-3	3.850E-3	cell_type;iRBC;unRBC
XHWESASXXR*	ST000974	AN001595	2.190E-3	4.850E-2	GROUP;case;control
hydroxyisovaleric acid	ST001000	AN001879	2.200E-3	6.320E-3	Diagnosis;CD;Control;UC
o-cresol sulfate	ST000974	AN001595	2.200E-3	2.480E-2	TIMEPOINT;BL;M06;M18
Lactosylceramide (d18:1/12:0)	ST000241	AN000374	2.210E-3	9.300E-3	Concentration (uM);0;500
arachidiic acid	ST000417	AN001448	2.230E-3	5.260E-3	Group;AIR;NO2PM;PM
PC 40:8 (20:4(5E.8E.11E.14E)/20:4(5E.8E.11E.14E)) [M-Ac-H]-	ST001111	AN001806	2.230E-3	4.250E-3	Sample;Benign;Cancer;Metastasis
5b-Pregnediol	ST000241	AN000373	2.240E-3	3.130E-3	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
DIHYDROMUNDULETONE	ST000046	AN000078	2.240E-3	2.630E-2	Cognitive Status;AD;CN;MCI
diacetylspermine	ST001000	AN001878	2.250E-3	7.240E-3	Diagnosis;CD;Control;UC
2-Dehydro-D-xylonate	ST000539	AN000819	2.270E-3	3.790E-2	Glucose labelling;C13 glucose;unlabelled
2-Dehydro-D-xylonate 2	ST000539	AN000819	2.270E-3	3.790E-2	Glucose labelling;C13 glucose;unlabelled
2-oxosuberate	ST000539	AN000819	2.270E-3	3.790E-2	Glucose labelling;C13 glucose;unlabelled
PC(14:1(9Z)/P-16:0)	ST000241	AN000373	2.280E-3	1.380E-2	Concentration (uM);0;500
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (PROBABLY)	ST000016	AN000033	2.300E-3	1.040E-2	Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
1-(6-[3]-ladderane-hexanyl)-2-(8-[3]-ladderane-octanyl)-sn-glycerophosphocholine	ST000445	AN000696	2.320E-3	1.670E-2	Treatment;FSH;LH
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-	ST000689	AN001063	2.330E-3	9.890E-3	Construct;-;Control lentivirus;Noxa knockdown
3-hydroxybenzoic acid (likely)	ST000420	AN000662	2.340E-3	3.820E-3	Group;nonsmoker;smoker
CPT-I ratio	ST000544	AN000827	2.360E-3	1.370E-2	Sample Type;Control;Replicate
CPT-I ratio	ST000545	AN000830	2.360E-3	3.580E-3	Sample Type;Control;Replicate
heptadecanoic acid NIST	ST000386	AN000621	2.360E-3	6.380E-3	Organ;Plasma;Serum
c-aconitate-13C0	ST001049	AN001864	2.370E-3	3.440E-2	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
Oxostearate-13C0[+Na]+	ST000148	AN000235	2.370E-3	1.850E-2	Treatment;13C-Glc;unlabeled
D1-2-Hydroxymethylethisterone	ST000046	AN000078	2.380E-3	2.700E-2	Cognitive Status;AD;CN;MCI
OH-dihexcer d18:1 N18:0	ST000362	AN000594	2.380E-3	6.540E-3	Gender;1;2
isohexonic acid	ST001211	AN002016	2.390E-3	5.680E-3	Group;Control;Methotrexate
Tecomine-13C0[+13CD3 QDA]+NH4	ST000148	AN000235	2.390E-3	1.850E-2	Treatment;13C-Glc;unlabeled
ACETAMINOPHEN (TN TYLENOL) (M-H)-	ST000713	AN001113	2.400E-3	1.810E-2	level of dysplasia;HGD;HGD & PDA;LGD;N/A
EPC(d33:1)	ST001202	AN002000	2.410E-3	2.640E-3	cell_type;iRBC;unRBC
glyoxalurea NIST	ST000386	AN000621	2.410E-3	1.450E-2	Gender;F;M;NA
1-(11Z-octadecenyl)-sn-glycero-3-phosphocholine	ST001204	AN002004	2.430E-3	4.600E-3	cell_type;iRBC;unRBC
2-oxo-4-methylvaleric acid	ST000355	AN000580	2.430E-3	1.070E-2	Diagnosis;Breast cancer;Control
3-S-cysteinyl-2-methylpropanoate*	ST000975	AN001596	2.430E-3	1.020E-1	TIMEPOINT;BL;M06;M18
YM-201636	ST000567	AN000871	2.430E-3	8.260E-3	groups;Old-Curcumin;Old-Placebo;young
BOC-ASN	ST000010	AN000025	2.440E-3	7.520E-3	FCS;FCS;NO_FCS
Aspidofractine	ST000539	AN000818	2.450E-3	5.340E-3	Cell type;Mature erythrocyte;Reticulocyte
Levobunolol glucuronide	ST000566	AN000870	2.450E-3	2.960E-3	Time point;Post;Pre;Baseline
6C-SUGAR ALCOHOL	ST000954	AN001564	2.490E-3	1.160E-1	ethnicity;1;2;-
Marinobufagenin	ST000566	AN000869	2.490E-3	9.530E-3	group;Old-Curcumin;Old-Placebo;young
N-Acetyl Lysine	ST000614	AN000939	2.490E-3	2.870E-3	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
4-Methylumbelliferylbeta-D-glucuronide	ST000047	AN000082	2.500E-3	3.670E-2	Cognitive Status;AD;CN;MCI
2-Hydroxy-3-(4-methoxyethylphenoxy)-propanoicacid	ST000047	AN000083	2.510E-3	2.980E-2	Cognitive Status;AD;CN;MCI
5-hydroxynorvaline NIST	ST000385	AN000620	2.510E-3	7.950E-3	Health State;Adenocarcinoma;Healthy;NA
L-Hypoglycin	ST000403	AN000643	2.510E-3	4.820E-3	Cell type;Mature erythrocyte;Reticulocyte
Ala-Thr-Ala-Gly	ST001201	AN001999	2.520E-3	2.130E-2	treatment;DHA;DMSO;OZ277;OZ439
(R)-AMAA	ST000539	AN000819	2.540E-3	5.690E-3	Cell type;Mature erythrocyte;Reticulocyte
AMINOPENTANOIC ACID	ST000044	AN000069	2.560E-3	2.080E-2	Pancreas tissue type;Normal area of the pancreas with tumor;...
PC 36:2 (18:0/18:2(2E.4E)) [M+HCOO]-	ST001111	AN001806	2.560E-3	4.860E-3	Sample;Benign;Cancer;Metastasis
Sodiumtetradecylsulfate	ST000046	AN000078	2.560E-3	2.730E-2	Cognitive Status;AD;CN;MCI
hexanoylglutamine	ST000975	AN001596	2.570E-3	4.570E-2	GROUP;case;control
Abscisic acid glucose ester	ST000403	AN000643	2.580E-3	4.940E-3	Cell type;Mature erythrocyte;Reticulocyte
HYDROXYISOVALERATE (*)	ST000105	AN000174	2.580E-3	1.410E-1	PCOS;No PCOS;PCOS
Source Fragment TRP	ST000919	AN001506	2.580E-3	2.420E-2	Gender;Female;Male
3-methyl catechol sulfate (1)	ST000974	AN001595	2.590E-3	2.740E-2	TIMEPOINT;BL;M06;M18
ADMA / Arg	ST000545	AN000829	2.590E-3	3.560E-2	Sample Type;Control;Replicate
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M+H)+	ST000689	AN001064	2.610E-3	1.200E-2	Construct;-;Control lentivirus;Noxa knockdown
Serotonin / Trp	ST000545	AN000829	2.620E-3	3.560E-2	Sample Type;Control;Replicate
a Cysteine adduct	ST000403	AN000642	2.630E-3	4.970E-3	Cell type;Mature erythrocyte;Reticulocyte
D-Alanyl-D-alanine	ST000539	AN000819	2.630E-3	9.520E-2	timepoint;1 hour;20 hours
Spermidine / Putrescine	ST000544	AN000826	2.630E-3	1.030E-2	Sample Type;Control;Replicate
[13C]-ASPARTIC ACID	ST000106	AN000175	2.650E-3	1.100E-1	Constitution;Lean;Obese
glutathione-sulfite	ST000539	AN000819	2.660E-3	9.520E-2	timepoint;1 hour;20 hours
isoamylnitrite	ST000047	AN000081	2.660E-3	4.560E-2	Cognitive Status;AD;CN;MCI
Taurine Dimer	ST000380	AN000614	2.660E-3	4.350E-3	Time;10min;1hr;24hr;6hr
21-hydroxypregnenolone monosulfate (1)	ST000974	AN001595	2.670E-3	1.080E-2	REGION;AHRI;MRC;SUN
D1-2-Hydroxymethylethisterone	ST000422	AN000668	2.670E-3	8.430E-2	treatment;ND;T1D good glycemic control
4-QUINOLINECARBOXYLIC ACID #2 (M+H)+	ST000725	AN001137	2.680E-3	5.560E-1	gender;Female;Male
C16-OH Sulfatide	ST000567	AN000871	2.730E-3	8.860E-3	groups;Old-Curcumin;Old-Placebo;young
tetcyclacis	ST001204	AN002005	2.730E-3	6.140E-3	cell_type;iRBC;unRBC
CL 80:14 (18:0/20:4/20:4/22:6) [M-2H](2-)	ST001111	AN001806	2.740E-3	5.110E-3	Sample;Benign;Cancer;Metastasis
DOPA/Tyr	ST000544	AN000826	2.740E-3	1.030E-2	Sample Type;Control;Replicate
DOPA/Tyr	ST000545	AN000829	2.740E-3	3.560E-2	Sample Type;Control;Replicate
ZEATIN [ISTD] (M+CL)-	ST000713	AN001113	2.770E-3	2.480E-2	malignant transformation;No;yes;Yes
Fummarate M0	ST000507	AN000776	2.780E-3	5.790E-3	Time (incubation);24 hours;72 hours
2-Oxovalericacid	ST000045	AN000075	2.790E-3	4.820E-2	Treatment;Insulin Withdrawal;Saline Infusion
1_iSTD PG (17:0/17:0)	ST000342	AN000554	2.830E-3	6.330E-3	Treatment;Quality Control;PRBC;PRBC-FST;PRBC+FST;WB
Cys-Leu-Cys-Tyr	ST001201	AN001999	2.830E-3	5.260E-3	cell_type;iRBC;unRBC
SALICYLATE #2 (M-H)-	ST000841	AN001349	2.830E-3	3.280E-2	Subject group;HIGH-FA;LOW-FA;MID-FA;N/A
Putrescine / Orn	ST000545	AN000829	2.850E-3	3.560E-2	Sample Type;Control;Replicate
N-Acetylanthranilate	ST001201	AN001999	2.880E-3	2.320E-2	treatment;DHA;DMSO;OZ277;OZ439
[13C]-TYROSINE	ST000106	AN000175	2.890E-3	5.130E-2	Sampling time;0 min;60 min
Phosphoagmatine	ST000291	AN000464	2.910E-3	1.420E-1	Treatment ;Baseline urine;Urine after drinking apple juice;U...
Cys-Met-Pro-His	ST000403	AN000643	2.930E-3	3.230E-2	Glucose labelling;C13 glucose;unlabelled
Asn-Leu-Pro-Pro	ST001201	AN001998	2.950E-3	2.260E-2	treatment;DHA;DMSO;OZ277;OZ439
O-methylcatechol sulfate	ST000974	AN001595	2.970E-3	3.090E-2	TIMEPOINT;BL;M06;M18
2-ketoglucose dimethylacetal NIST	ST000392	AN000628	2.990E-3	3.370E-2	Smoking Status;Current;Former;-
2-ketoglucose dimethylacetal NIST	ST000063	AN000101	3.000E-3	1.350E-2	Source;Group 1 - Score 0;Group 2 - Score 50
N-Acetyl-p-benzoquinonimine	ST000047	AN000081	3.000E-3	4.820E-2	Cognitive Status;AD;CN;MCI
ZEATIN [ISTD] (M+H)+	ST000763	AN001202	3.000E-3	1.730E-2	Group;Borderline Pressures;Healthy;LowRisk;Normal Pressures;...
aminoisobutyric acid/GABA	ST000923	AN001513	3.010E-3	2.130E-2	sex;Female;Male
Asn-Lys-Gly-Gly	ST001205	AN002006	3.010E-3	1.110E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
2-Formaminobenzoylacetate	ST000539	AN000819	3.020E-3	4.620E-2	Glucose labelling;C13 glucose;unlabelled
BOC-ASP-OH	ST000043	AN000070	3.020E-3	1.310E-2	Cell line;MDA-MB-231;MDA-MB-231 p38 gamma knockdown;MDA-MB-2...
para-toluidene	ST000614	AN000943	3.050E-3	4.110E-3	Diagonsis;Benign;Cancer;Normal
Ala-Leu-Thr-Pro	ST000403	AN000642	3.070E-3	5.730E-3	Cell type;Mature erythrocyte;Reticulocyte
ethyl-(2R)-methyl-(3S)-hydroxybutanoate	ST000403	AN000643	3.080E-3	5.960E-2	timepoint;1 hour;20 hours
N-Ace-Asp-13C1	ST001049	AN001864	3.090E-3	4.110E-2	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
N-acetyl -D- glucosaminitol	ST001202	AN002001	3.110E-3	3.390E-3	cell_type;iRBC;unRBC
2-ketoglucose dimethylacetal NIST	ST000392	AN000628	3.120E-3	1.370E-2	Disease State;cancer;control;-
3-hydroxybutyroylglycine**	ST000976	AN001597	3.130E-3	2.090E-1	GROUP;case;control
Cit / Orn	ST000405	AN000645	3.130E-3	5.630E-1	Vaginal Bleeding;N;UNK;Y;-
Billirubin	ST000919	AN001507	3.150E-3	2.370E-2	Response;NR;R
pyroglutamylglycine	ST000975	AN001596	3.150E-3	4.850E-2	GROUP;case;control
Monoethyl phthalate (mEP)	ST000954	AN001565	3.160E-3	7.280E-2	daily_dose;2;3;4;1
Source Fragment TRP	ST000954	AN001564	3.170E-3	1.020E-1	race;1;2
PC(14:1(9Z)/P-16:0)	ST000241	AN000373	3.180E-3	4.350E-3	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Fibrinopeptide B (1-11)**	ST000975	AN001596	3.190E-3	1.610E-2	GENDER;F;M
glucuronide of piperine metabolite C17H21NO3 (3)*	ST000975	AN001596	3.190E-3	6.400E-2	REGION;MAK;SUN
BOC-ASN	ST000044	AN000069	3.200E-3	2.440E-2	Pancreas tissue type;Normal area of the pancreas with tumor;...
Gln-Leu-Lys-Tyr	ST001202	AN002001	3.230E-3	5.630E-3	treatment_duration_(h);-;1.5;3;6;9
6-(2-CHLORO-5-(TRIFLUOROMETHYL)PHENYL)-1-PHENYL-2-THIOBIUREA-0.88713235	ST000046	AN000078	3.260E-3	3.160E-2	Cognitive Status;AD;CN;MCI
L-2-Aminoadipate 6-semialdehyde	ST000539	AN000819	3.270E-3	4.870E-2	Glucose labelling;C13 glucose;unlabelled
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-	ST000775	AN001222	3.290E-3	1.630E-2	Treatment response;No;Yes;Pooled
20:3 (n-6)	ST001098	AN001786	3.310E-3	2.650E-2	Treatment;Non-obese control;Obese control;Schizophrenia dx
cefamandole nafate	ST000422	AN000667	3.310E-3	1.020E-1	treatment;ND;T1D good glycemic control
2-(sulfomethyl)thiazolidine-4-carboxylate	ST000403	AN000643	3.320E-3	3.460E-2	Glucose labelling;C13 glucose;unlabelled
Lys-Lys-Met-Pro	ST000403	AN000642	3.330E-3	7.850E-2	timepoint;1 hour;20 hours
Texanol	ST000583	AN000894	3.330E-3	7.050E-2	caries status;caries-active;caries-free
Dihydrodaunorubicin-13C0[+13CD3 QDA]+	ST000148	AN000235	3.340E-3	2.300E-2	Treatment;13C-Glc;unlabeled
iSTD iSTD PE (17:0/17:0)	ST000342	AN000554	3.350E-3	6.870E-3	Treatment;Quality Control;PRBC;PRBC-FST;PRBC+FST;WB
Furfuryl alcohol	ST000292	AN000466	3.370E-3	8.440E-2	Treatment ;Baseline plasma;Plasma after drinking apple juice...
inositol 1-phosphate (I1P)	ST000974	AN001595	3.390E-3	6.770E-2	GROUP;case;control
3-hydroxyoxyisovaleric acid	ST000355	AN000580	3.400E-3	1.360E-2	Stage;1;2;3;4;-
5-guanidino-3-methyl-2-oxo-pentanoate	ST000539	AN000818	3.400E-3	6.160E-2	timepoint;1 hour;20 hours
Asn-Asn-Gly-His	ST001202	AN002000	3.400E-3	5.060E-3	treatment_duration_(h);-;1.5;3;6;9
Urethane	ST000539	AN000818	3.420E-3	7.180E-3	Cell type;Mature erythrocyte;Reticulocyte
Urethane 2	ST000539	AN000818	3.420E-3	7.180E-3	Cell type;Mature erythrocyte;Reticulocyte
N2-(D-1-Carboxyethyl)-L-arginine	ST001201	AN001998	3.440E-3	2.370E-2	treatment;DHA;DMSO;OZ277;OZ439
Frctose-6-Phosphate	ST000614	AN000940	3.460E-3	5.100E-3	Diagonsis;Benign;Cancer;Normal
L-thiazolidine-4-carboxylate	ST000403	AN000642	3.460E-3	7.850E-2	timepoint;1 hour;20 hours
OH-monohexcer d18:1 N16:0	ST000362	AN000594	3.460E-3	1.630E-1	GoldStage;3;4;2;1;-
Gentianaine	ST000539	AN000818	3.480E-3	7.280E-3	Cell type;Mature erythrocyte;Reticulocyte
PGE2-d4	ST001000	AN001880	3.480E-3	8.480E-3	Diagnosis;CD;Control;UC
12-OPDA	ST000539	AN000818	3.500E-3	7.280E-3	Cell type;Mature erythrocyte;Reticulocyte
EDOXUDINE	ST000422	AN000668	3.500E-3	8.430E-2	treatment;ND;T1D good glycemic control
4-Aminophenyl1-thio-beta-D-glucuronide	ST000047	AN000081	3.510E-3	5.470E-2	Cognitive Status;AD;CN;MCI
5-Hydroxycotinine	ST000403	AN000643	3.550E-3	6.670E-3	Cell type;Mature erythrocyte;Reticulocyte
3-Ethyl-3-methylheptane	ST001037	AN001698	3.560E-3	1.500E-2	Description ;Blank;Reagent Blank;Serum Sample;Solvent
cyclo(leu-pro)	ST000974	AN001595	3.560E-3	6.900E-2	GROUP;case;control
Gulonolactone	ST001039	AN001713	3.570E-3	7.750E-3	Sample.Matrix;Plasma;Urine
2-C-Methyl-D-erythritol 4-phosphate	ST001201	AN001999	3.590E-3	2.660E-2	treatment;DHA;DMSO;OZ277;OZ439
2-oxogluconic acid NIST	ST000369	AN000603	3.590E-3	9.150E-3	Organ;Plasma;Serum
C-GLYCOSYLTRYPTOPHAN	ST000016	AN000033	3.590E-3	1.480E-2	Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
SAPPANONE A 7-METHYL ETHER	ST000421	AN000664	3.590E-3	1.710E-1	treatment;ND;T1D poor glycemic control
benzi(ghi)perylene1	ST000614	AN000941	3.600E-3	3.600E-3	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
GUANOSINE 5`-DIPHOSPHO-D-MANNOSE	ST000044	AN000069	3.600E-3	2.500E-2	Pancreas tissue type;Normal area of the pancreas with tumor;...
Hydroxykynurenamine-13C0[+13CD3 QDA]+	ST000148	AN000235	3.600E-3	2.410E-2	Treatment;13C-Glc;unlabeled
hexadecylglycerol NIST	ST001211	AN002016	3.630E-3	8.280E-3	Group;Control;Methotrexate
Geranylgeranylacetone-13C0[+QDA adduct]+	ST000148	AN000235	3.640E-3	2.440E-2	Treatment;13C-Glc;unlabeled
N-Acetyl-5-hydroxysulfapyridine	ST000421	AN000664	3.640E-3	1.710E-1	treatment;ND;T1D poor glycemic control
plasmenyl-PC 42:1 (18:0/24:1(15Z)) [M+Na]+	ST001111	AN001805	3.640E-3	4.990E-3	Sample;Benign;Cancer;Metastasis
2-oxogluconic acid NIST	ST000386	AN000621	3.650E-3	1.830E-2	Gender;F;M;NA
8-keto-7-aminoperlagonate	ST000403	AN000643	3.650E-3	3.590E-2	Glucose labelling;C13 glucose;unlabelled
DIHYDROSPATHELIACHROMENE	ST000422	AN000668	3.650E-3	8.430E-2	treatment;ND;T1D good glycemic control
8-Amino-7-oxononanoate	ST000046	AN000076	3.660E-3	3.960E-2	Cognitive Status;AD;CN;MCI
400671 carbohydrate	ST000369	AN000603	3.670E-3	1.670E-2	Gender;F;M;NA
glyoxalurea NIST	ST000369	AN000603	3.670E-3	1.410E-2	Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
beta-Homophenylalanine	ST001211	AN002017	3.680E-3	1.410E-2	Group;Control;Methotrexate
penem CGP31608	ST000539	AN000819	3.680E-3	7.790E-3	Cell type;Mature erythrocyte;Reticulocyte
penem CGP31608 2	ST000539	AN000819	3.680E-3	7.790E-3	Cell type;Mature erythrocyte;Reticulocyte
AMINOHYDROXYBUTANOIC ACID	ST000016	AN000033	3.740E-3	1.520E-2	Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
2-Aceto-2-hydroxybutanoate	ST000292	AN000466	3.760E-3	9.180E-2	Treatment ;Baseline plasma;Plasma after drinking apple juice...
7-hydroxyTetranorIloprost	ST000047	AN000083	3.810E-3	3.830E-2	Cognitive Status;AD;CN;MCI
IS SM 35:1; [M+H]+	ST000523	AN000800	3.810E-3	1.790E-2	Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
gamma-Hydroxyphenylbutazoneglucuronide	ST000047	AN000083	3.820E-3	3.830E-2	Cognitive Status;AD;CN;MCI
IsoquinolineN-oxide	ST000046	AN000079	3.820E-3	3.530E-2	Cognitive Status;AD;CN;MCI
Cys-Met-Tyr-Tyr	ST000403	AN000642	3.830E-3	4.190E-2	Glucose labelling;C13 glucose;unlabelled
Lovastatin Hydroxy Acid	ST000553	AN000845	3.850E-3	4.330E-3	Sample type;Plasma;Urine
Asn-Leu-Pro-Pro	ST001202	AN002000	3.860E-3	7.780E-1	treatment;DHA;DMSO;OZ277;OZ439
[PR] 9-Hydroxy-helminthosporol	ST000539	AN000819	3.870E-3	8.130E-3	Cell type;Mature erythrocyte;Reticulocyte
Ala-Lys-Ala-Ala	ST001201	AN001999	3.880E-3	2.710E-2	treatment;DHA;DMSO;OZ277;OZ439
[FA hydroxy(9:1)] 4-hydroxy-2-nonenal	ST000403	AN000642	3.890E-3	7.200E-3	Cell type;Mature erythrocyte;Reticulocyte
Ala-Leu-Asn-Pro	ST001201	AN001998	3.900E-3	2.430E-2	treatment;DHA;DMSO;OZ277;OZ439
ETHYL 3-INDOLE ACETATE	ST000016	AN000033	3.900E-3	6.500E-3	Material;Cells;Media
(3-Arylcarbonyl)-alanine	ST000291	AN000465	3.910E-3	1.330E-1	Treatment ;Baseline urine;Urine after drinking apple juice;U...
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (PROBABLY)	ST000105	AN000173	3.920E-3	7.680E-2	Gender;Female;Male
[FA hydroxy(9:1)] 4-hydroxy-2-nonenal	ST000539	AN000818	3.970E-3	6.760E-2	timepoint;1 hour;20 hours
ZAPA	ST000403	AN000642	3.970E-3	4.260E-2	Glucose labelling;C13 glucose;unlabelled
lathosterol NIST	ST000369	AN000603	3.990E-3	1.500E-2	Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
Gl-OH3P	ST000301	AN000479	4.000E-3	8.300E-3	Cell Line;L229;LN18;Pooled glioblastoma;U-138
Asp-Met-Pro-Pro	ST000539	AN000818	4.020E-3	8.230E-3	Cell type;Mature erythrocyte;Reticulocyte
C3 / C4	ST000545	AN000830	4.040E-3	5.980E-3	Sample Type;Control;Replicate
[13C]-ARGININE	ST000016	AN000033	4.050E-3	1.610E-2	Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
(3-Arylcarbonyl)-alanine	ST000291	AN000464	4.050E-3	1.690E-1	Treatment ;Baseline urine;Urine after drinking apple juice;U...
400671 carbohydrate	ST000369	AN000603	4.060E-3	1.500E-2	Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
Ala-Leu-Trp-Ser	ST001201	AN001998	4.090E-3	2.430E-2	treatment;DHA;DMSO;OZ277;OZ439
2-oxosuberate	ST000403	AN000643	4.130E-3	3.920E-2	Glucose labelling;C13 glucose;unlabelled
methylhexadecanoic acid	ST000386	AN000621	4.130E-3	2.210E-2	Smoker;Current;Former;NA
creatine major dehydrated TMS3	ST000416	AN000658	4.150E-3	1.270E-2	Treatment;Day1_antiperspirant;Day1_deodorant;Day1_noproduct;...
Ala-Asp-Asp-Asp	ST001201	AN001998	4.170E-3	2.430E-2	treatment;DHA;DMSO;OZ277;OZ439
GLYCEROL 2-PHOSPHATE/SN-GLYCEROL 3-PHOSPHATE	ST000583	AN000895	4.180E-3	7.350E-2	time;12-weeks;baseline
2-oxogluconic acid NIST	ST000386	AN000621	4.190E-3	1.100E-2	Organ;Plasma;Serum
PALMITOYLGLYCEROPHOSPHOETHANOLAMINE / PALMITOYLPLASMENYLETHANOLAMINE (*)	ST000105	AN000174	4.190E-3	2.000E-1	OSA;Negative;Positive
beta-hydroxymyristic acid	ST001133	AN001858	4.210E-3	2.540E-2	CENPF;Control;KO
3-sulfopropanoate	ST000539	AN000819	4.220E-3	8.840E-3	Cell type;Mature erythrocyte;Reticulocyte
PALMITOYLGLYCEROPHOSPHOETHANOLAMINE / PALMITOYLPLASMENYLETHANOLAMINE (*)	ST000105	AN000174	4.230E-3	7.690E-2	Gender;Female;Male
PENTADECANOYLGLYCEROPHOSPHOCHOLINE/STEAROYLGLYCEROPHOSPHOETHANOLAMINE	ST000016	AN000033	4.250E-3	1.160E-2	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-	ST000775	AN001222	4.260E-3	3.110E-2	Timepoint;T0;T2;Pooled
Ala-Leu-Lys-Pro	ST001205	AN002006	4.270E-3	1.510E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
Ovothiol disulfide	ST001201	AN001999	4.270E-3	2.920E-2	treatment;DHA;DMSO;OZ277;OZ439
Hydroxyhexanone-13C0[+QDA adduct]+	ST000142	AN000225	4.300E-3	2.500E-2	Treatment;13C-Glc;unlabeled
2-HB (2-hydroxybutyric acid)	ST000166	AN000259	4.310E-3	1.410E-2	Group;3M;Control;HF
isoamylnitrite	ST000046	AN000076	4.320E-3	4.370E-2	Cognitive Status;AD;CN;MCI
plasmenyl-PE 36:2 (18:0/18:2(2E.4E)) [M+H]+	ST001111	AN001805	4.340E-3	5.870E-3	Sample;Benign;Cancer;Metastasis
3-dimethylsulfoniopropionaldehyde	ST000403	AN000643	4.350E-3	7.140E-2	timepoint;1 hour;20 hours
sodium dodecyl sulfate	ST000403	AN000643	4.350E-3	7.140E-2	timepoint;1 hour;20 hours
UDP-GNAc-13C6+15N0	ST000076	AN000121	4.360E-3	2.640E-1	Labeling;13C/15N-Gln;13C-Glc;unlabeled
BOC-ASN	ST000009	AN000023	4.370E-3	1.260E-2	SURGERY;GASTRIC_BAND;ROUX_EN_Y;LEAN_CONTROL
Hexazinone	ST000242	AN000377	4.390E-3	1.650E-2	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
B-ureidoisobutyricacid-6.84278	ST000046	AN000079	4.420E-3	3.930E-2	Cognitive Status;AD;CN;MCI
3-acetyl pyridine adenine dinucleotide	ST000403	AN000643	4.440E-3	8.280E-3	Cell type;Mature erythrocyte;Reticulocyte
isoamylnitrite	ST000046	AN000078	4.440E-3	3.600E-2	Cognitive Status;AD;CN;MCI
C5-SUGAR ALCOHOL	ST000956	AN001569	4.470E-3	1.120E-2	Treatment;Condition-1;Condition-2;Condition-3;Control
2-oxo-4-methylvaleric acid	ST000355	AN000580	4.490E-3	1.740E-2	Stage;1;2;3;4;-
N-Acetylanthranilate	ST001205	AN002007	4.490E-3	7.090E-1	treatment;DHA;DMSO;OZ277;OZ439
Cys-Thr-Cys-Cys	ST000403	AN000642	4.500E-3	4.660E-2	Glucose labelling;C13 glucose;unlabelled
enolpyruvate NIST	ST000381	AN000615	4.500E-3	1.700E-2	Cohort;CSMC;INHA
(R)-AMAA	ST000403	AN000643	4.500E-3	8.360E-3	Cell type;Mature erythrocyte;Reticulocyte
BOC-PHE-OH	ST000044	AN000069	4.540E-3	2.860E-2	Pancreas tissue type;Normal area of the pancreas with tumor;...
bOHbutyrate-13C2	ST000076	AN000122	4.570E-3	2.100E-2	Labeling;13C/15N-Gln;13C-Glc;unlabeled
ETHYL 3-UREIDOPROPIONATE (M+H)+	ST000726	AN001139	4.570E-3	4.400E-2	DISEASE_STATE;Control;PCOS
dihydrogeranylgeranyl-bacteriopheophytin	ST001205	AN002007	4.590E-3	1.770E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
ACETAMINOPHEN (TN TYLENOL) (M+H)+	ST000763	AN001202	4.600E-3	2.350E-2	Group;Borderline Pressures;Healthy;LowRisk;Normal Pressures;...
Plasmalogen(p18:0/20:4)	ST000450	AN000706	4.610E-3	6.190E-3	gender;Female;Male
3-O-Methyl-myo-inositol	ST000566	AN000870	4.660E-3	4.450E-2	group;Old-Curcumin;Old-Placebo;young
nonulose 9-phosphate	ST001202	AN002001	4.680E-3	7.990E-3	treatment_duration_(h);-;1.5;3;6;9
N-Acetyl-5-hydroxysulfapyridine	ST000046	AN000079	4.690E-3	3.950E-2	Cognitive Status;AD;CN;MCI
[FA (10:1/2:0)] 2E-Decenedioic acid	ST000403	AN000643	4.700E-3	4.360E-2	Glucose labelling;C13 glucose;unlabelled
heptadecanoic acid NIST	ST000385	AN000620	4.730E-3	1.260E-2	Health State;Adenocarcinoma;Healthy;NA
Methoxytyramine	ST001039	AN001712	4.730E-3	1.150E-2	Sample.Matrix;Plasma;Urine
sodium dodecyl sulfate	ST000539	AN000819	4.740E-3	1.070E-1	timepoint;1 hour;20 hours
FA methyl(18:0)	ST001202	AN002001	4.770E-3	8.080E-3	treatment_duration_(h);-;1.5;3;6;9
1-Methyladenosine B	ST001211	AN002017	4.790E-3	1.810E-2	Group;Control;Methotrexate
benzi(ghi)perylene	ST000614	AN000943	4.790E-3	6.030E-3	Diagonsis;Benign;Cancer;Normal
4-(Trimethylammonio)but-2-enoate	ST001202	AN002000	4.820E-3	7.080E-3	treatment_duration_(h);-;1.5;3;6;9
Methylitaconate	ST001205	AN002006	4.840E-3	1.700E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
Ovothiol B	ST001204	AN002005	4.840E-3	1.050E-2	cell_type;iRBC;unRBC
5-guanidino-3-methyl-2-oxo-pentanoate	ST000403	AN000642	4.850E-3	1.060E-1	timepoint;1 hour;20 hours
Anaferine-13C0[+13CD3 QDA]+	ST000148	AN000235	4.860E-3	2.940E-2	Treatment;13C-Glc;unlabeled
A-Ketoglutaricacidoxime	ST001201	AN001999	4.870E-3	8.810E-3	cell_type;iRBC;unRBC
lathosterol NIST	ST000386	AN000621	4.890E-3	2.460E-2	Smoker;Current;Former;NA
uridine-5-diphosphate bromoacetol	ST000403	AN000643	4.900E-3	9.080E-3	Cell type;Mature erythrocyte;Reticulocyte
lathosterol NIST	ST000386	AN000621	4.940E-3	2.290E-2	Gender;F;M;NA
Glu-Met-Met-His	ST000403	AN000643	4.950E-3	4.460E-2	Glucose labelling;C13 glucose;unlabelled
trimethylbenzene	ST000923	AN001513	4.950E-3	1.460E-2	Diagnosis;CD;nonIBD;UC
Galabiosylceramide (d18:1/16:0)	ST000567	AN000872	4.960E-3	5.940E-3	Time point;Post;Pre;Baseline
(-)-jasmonoyl-L-valine	ST000539	AN000819	4.970E-3	1.030E-2	Cell type;Mature erythrocyte;Reticulocyte
6-deoxyglucitol NIST	ST000369	AN000603	5.020E-3	1.810E-2	Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
plasmenyl-PC 19:0; [M+Na]+@2.31	ST000665	AN001017	5.020E-3	4.350E-2	Cell line;HepG2;HuH-7
400671 carbohydrate	ST000386	AN000621	5.050E-3	2.690E-2	Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
[6]-Paradol	ST001202	AN002001	5.060E-3	8.520E-3	treatment_duration_(h);-;1.5;3;6;9
Meradimate	ST000047	AN000080	5.080E-3	1.260E-1	Cognitive Status;AD;CN;MCI
Ivermectin B1a	ST000421	AN000665	5.140E-3	1.530E-1	treatment;ND;T1D poor glycemic control
metabolite 2	ST000539	AN000818	5.140E-3	7.400E-2	timepoint;1 hour;20 hours
valine ion	ST000974	AN001595	5.140E-3	4.240E-2	TIMEPOINT;BL;M06;M18
D1-2-Hydroxymethylethisterone - 1.9729741	ST000421	AN000664	5.170E-3	1.710E-1	treatment;ND;T1D poor glycemic control
Sucrose / Trehalose / Lactose	ST001040	AN001702	5.180E-3	1.480E-2	Sample Type/Matrix;Pooled quality control sample;urine;Water...
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000698	AN001083	5.200E-3	4.890E-2	KD#1;no;yes;Pooled melanoma
hydroxy-CMPF*	ST000975	AN001596	5.210E-3	9.850E-2	REGION;MAK;SUN
Laudanosine	ST000539	AN000819	5.220E-3	7.360E-2	Glucose labelling;C13 glucose;unlabelled
1-5-diazabicyclononane	ST000539	AN000818	5.240E-3	7.400E-2	timepoint;1 hour;20 hours
1-5-diazabicyclononane 2	ST000539	AN000818	5.240E-3	7.400E-2	timepoint;1 hour;20 hours
2-deoxypentitol NIST	ST001211	AN002016	5.250E-3	1.110E-2	Group;Control;Methotrexate
[Fv] Desmosdumotin C	ST000403	AN000642	5.260E-3	1.110E-1	timepoint;1 hour;20 hours
4-oxo-4-(3-pyridyl)-butanoate	ST001205	AN002007	5.280E-3	1.960E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
MEVALOLACTONE	ST000016	AN000033	5.280E-3	8.620E-3	Material;Cells;Media
Phenolsulfonphthalein	ST001205	AN002007	5.280E-3	1.960E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
BOC-HIS-OH	ST000016	AN000033	5.310E-3	2.080E-2	Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
GAB-13C3	ST001046	AN001710	5.330E-3	1.530E-1	protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
desmethylnortriptylineglucuronide	ST000047	AN000083	5.350E-3	4.490E-2	Cognitive Status;AD;CN;MCI
PYRIDINE CARBOXYLIC ACID	ST000106	AN000175	5.350E-3	4.280E-1	Visit;1;2
methylhexadecanoic acid	ST000386	AN000621	5.360E-3	2.430E-2	Gender;F;M;NA
phosphinomethylmalate	ST000403	AN000643	5.360E-3	9.830E-3	Cell type;Mature erythrocyte;Reticulocyte
N-acetyltheanine	ST000974	AN001595	5.370E-3	1.980E-2	REGION;AHRI;MRC;SUN
L-Glutamate methylester	ST000539	AN000818	5.380E-3	7.420E-2	timepoint;1 hour;20 hours
N-Ace-Asp-13C4	ST001049	AN001864	5.390E-3	5.570E-2	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
3-(ADP)-2-phosphoglycerate	ST000539	AN000818	5.400E-3	1.080E-2	Cell type;Mature erythrocyte;Reticulocyte
2-ethylphenylsulfate	ST000974	AN001595	5.410E-3	4.500E-2	GENDER;F;M
Arg-Cys-Gln-Tyr	ST000539	AN000819	5.430E-3	1.110E-2	Cell type;Mature erythrocyte;Reticulocyte
tetrahydro-1-methyl-beta-carboline-3-carboxylate	ST000923	AN001514	5.430E-3	1.420E-2	Diagnosis;CD;nonIBD;UC
L-Glutamate methylester	ST000539	AN000818	5.450E-3	1.080E-2	Cell type;Mature erythrocyte;Reticulocyte
XHWESASXXR*	ST000974	AN001595	5.480E-3	4.240E-2	TIMEPOINT;BL;M06;M18
idonic acid NIST	ST000379	AN000613	5.530E-3	1.690E-2	Treatment;10.5mM Glu;5.5mM Glu 5mM Fru;5.5mM Glu;Glucosamine
2-Amino-2-methyl-1-propanol	ST000421	AN000663	5.550E-3	1.210E-1	treatment;ND;T1D poor glycemic control
Trihydroxybutyric acid	ST000980	AN001606	5.570E-3	4.270E-2	Classification;Mild;Moderate;Non-allergic;Severe
2-docosanamidoethanesulfonicacid	ST000046	AN000076	5.610E-3	4.820E-2	Cognitive Status;AD;CN;MCI
DOCOSADIENOATE (*)	ST000105	AN000174	5.610E-3	3.090E-2	Sampling;After SWS onset;Morning fasting
thioproline	ST000899	AN001462	5.610E-3	2.570E-2	Type;Control;Crohn disease;Ulcerative Colitis
Ala-Leu-Thr-Ala	ST001201	AN001998	5.640E-3	3.110E-2	treatment;DHA;DMSO;OZ277;OZ439
ethyl-(2R)-methyl-(3S)-hydroxybutanoate	ST000403	AN000643	5.640E-3	4.790E-2	Glucose labelling;C13 glucose;unlabelled
N5-acetyl-N5-hydroxy-L-ornithine	ST000539	AN000818	5.650E-3	7.440E-2	timepoint;1 hour;20 hours
URIDINE 5`-DIPHOSPHOGLUCOSE	ST000044	AN000069	5.650E-3	3.340E-2	Pancreas tissue type;Normal area of the pancreas with tumor;...
[PC acetyl(16:1)] 1-(9Z-hexadecenoyl)-2-acetyl-sn-glycero-3-phosphocholine	ST000539	AN000818	5.660E-3	7.440E-2	timepoint;1 hour;20 hours
c-aconitate-13C1	ST001049	AN001864	5.670E-3	5.620E-2	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
methylhexadecanoic acid	ST000369	AN000603	5.670E-3	1.900E-2	Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
CCCP	ST000292	AN000466	5.680E-3	1.200E-1	Treatment ;Baseline plasma;Plasma after drinking apple juice...
Total AC / C0	ST000545	AN000830	5.690E-3	8.170E-3	Sample Type;Control;Replicate
5-O-Feruloylquinic acid	ST000566	AN000869	5.700E-3	9.830E-3	Time point;Post;Pre;Baseline
Pyrazinoicacid	ST000047	AN000081	5.710E-3	7.210E-2	Cognitive Status;AD;CN;MCI
O-Acetylneuraminic acid	ST000539	AN000818	5.740E-3	1.730E-1	Glucose labelling;C13 glucose;unlabelled
Valproate	ST000150	AN000237	5.750E-3	1.740E-1	Patient;Patient 1;Patient 2;Patient 3;Patient 4
Sulfinopyruvate-13C1[+QDA adduct+Na]+	ST000148	AN000235	5.760E-3	3.300E-2	Treatment;13C-Glc;unlabeled
Capillone-13C0[+13CD3 QDA]+	ST000148	AN000235	5.810E-3	3.310E-2	Treatment;13C-Glc;unlabeled
Abscisic acid GLC ester-13C0[+Na]+	ST000148	AN000235	5.820E-3	3.310E-2	Treatment;13C-Glc;unlabeled
Mannitol;HEXOSE ALCOHOL	ST000954	AN001565	5.860E-3	4.360E-1	ethnicity;1;2;-
2-Hydroxy-3-(4-methoxyethylphenoxy)-propanoic acid	ST000567	AN000871	5.870E-3	1.710E-2	groups;Old-Curcumin;Old-Placebo;young
EICOSATRIENOYLGLYCEROPHOSPHOCHOLINE	ST000016	AN000033	5.890E-3	1.560E-2	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
Succcinate	ST001038	AN001699	5.900E-3	8.160E-3	Placenta_Surface;Fetal;Maternal
Chloroacetoacetanilide-13C1[+QDA adduct+Na]+	ST000148	AN000235	5.920E-3	3.340E-2	Treatment;13C-Glc;unlabeled
[13C]-ASPARTIC ACID	ST000016	AN000033	5.930E-3	9.570E-3	Material;Cells;Media
Diacetylmonoxime	ST000539	AN000818	5.930E-3	1.730E-1	Glucose labelling;C13 glucose;unlabelled
1-docosapentaenoylglycerophosphocholine (22:5n6)*	ST000976	AN001597	5.960E-3	2.130E-1	GENDER;F;M
Prohydrojasmon-13C0[+13CD3 QDA]+	ST000148	AN000235	5.970E-3	3.350E-2	Treatment;13C-Glc;unlabeled
SELENOCYSTAMINE	ST000105	AN000173	5.980E-3	5.240E-2	Sampling;After SWS onset;Morning fasting
N-ACETYL-D-HEXOSAMINE	ST000011	AN000028	5.990E-3	3.510E-2	COLLECTION_COUNTRY;ETHIOPIA;TANZANIA
cyclo(leu-pro)	ST000974	AN001595	6.000E-3	4.240E-2	TIMEPOINT;BL;M06;M18
alpha-Amylcinnamaldehyde-13C0[+QDA adduct]+	ST000148	AN000235	6.010E-3	3.370E-2	Treatment;13C-Glc;unlabeled
nonulose 9-phosphate	ST001204	AN002005	6.030E-3	1.090E-1	treatment_duration_(h);-;3;6;9
Diethyl adipate	ST000403	AN000643	6.040E-3	1.100E-2	Cell type;Mature erythrocyte;Reticulocyte
Fibrinopeptide A (4-15)**	ST000975	AN001596	6.060E-3	7.640E-2	GROUP;case;control
2-Phospho-D-glycerate	ST001205	AN002007	6.090E-3	2.410E-1	treatment_duration_(h);1;5;3
ALPHA-AMINOADIPATE/N-METHYL-L-GLUTAMATE	ST000919	AN001506	6.090E-3	4.240E-2	Gender;Female;Male
penem CGP31608	ST000403	AN000643	6.090E-3	4.920E-2	Glucose labelling;C13 glucose;unlabelled
urobilinogen	ST001237	AN002055	6.100E-3	2.360E-2	Time point;baseline;week 4;week 8
Phorbol 12-tiglate 13-decanoate-13C0[+Na]+	ST000148	AN000235	6.110E-3	3.400E-2	Treatment;13C-Glc;unlabeled
Arg-Asp-Asp-Gly	ST001201	AN001998	6.120E-3	1.020E-2	cell_type;iRBC;unRBC
Mannopine	ST000292	AN000466	6.160E-3	1.220E-1	Treatment ;Baseline plasma;Plasma after drinking apple juice...
C-glycosyltryptophan*	ST000974	AN001595	6.170E-3	9.670E-2	GROUP;case;control
Sulfoacetate	ST000539	AN000819	6.190E-3	1.240E-2	Cell type;Mature erythrocyte;Reticulocyte
(Z)-4-Hydroxyphenylacetaldehyde-oxime	ST000403	AN000642	6.210E-3	5.450E-2	Glucose labelling;C13 glucose;unlabelled
hydroxymyristate	ST000923	AN001515	6.220E-3	1.660E-2	Diagnosis;CD;nonIBD;UC
18:3 (n-3)	ST001098	AN001786	6.240E-3	2.650E-2	Treatment;Non-obese control;Obese control;Schizophrenia dx
L-ARGININE-(GUANIDINEIMINO-15N2) [ISTD] (CAS# ); (M+H)+	ST000695	AN001076	6.260E-3	2.270E-1	Taxane;N;Y;-
Oxodecanoate-13C3[+QDA adduct]+	ST000148	AN000235	6.360E-3	3.510E-2	Treatment;13C-Glc;unlabeled
C8-Ceramide m+14	ST000644	AN000976	6.370E-3	1.260E-2	time;48 hr;0 hr
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-	ST000726	AN001138	6.390E-3	1.210E-1	AGE;12;13;14;15;16;17
Abscisic acid GLC ester-13C16[+Na]+	ST000148	AN000235	6.410E-3	3.520E-2	Treatment;13C-Glc;unlabeled
4-(1-methyl-5-hydroxy-2-pyrrolidinyl)-3-oxobutanoate methyl ester	ST000403	AN000642	6.450E-3	5.520E-2	Glucose labelling;C13 glucose;unlabelled
C9 / C10:2	ST000544	AN000827	6.450E-3	3.350E-2	Sample Type;Control;Replicate
glucuronide of piperine metabolite C17H21NO3 (3)*	ST000975	AN001596	6.450E-3	2.970E-2	GENDER;F;M
Phenylpyruviate-13C1[+13CD3 QDA]+	ST000148	AN000235	6.480E-3	3.560E-2	Treatment;13C-Glc;unlabeled
cyclo(L-phe-L-pro)	ST000974	AN001595	6.490E-3	9.670E-2	GROUP;case;control
D-2-Amino-hexano-6-lactam	ST000539	AN000818	6.490E-3	8.070E-2	timepoint;1 hour;20 hours
10-nonadecenoate	ST000923	AN001515	6.500E-3	1.690E-2	Diagnosis;CD;nonIBD;UC
12-OPDA	ST000403	AN000642	6.590E-3	5.550E-2	Glucose labelling;C13 glucose;unlabelled
Neomenthyl acetate	ST000567	AN000872	6.590E-3	3.570E-2	groups;Old-Curcumin;Old-Placebo;young
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000697	AN001082	6.590E-3	9.120E-2	Stimulation;IFN-G;IL-17A;TNF-alpha;TNF-alpha+IL-17A;Untreate...
Lankamycin-13C0[+Na]+	ST000148	AN000235	6.600E-3	3.600E-2	Treatment;13C-Glc;unlabeled
L-beta-aspartyl-L-alanine	ST001201	AN001998	6.600E-3	1.080E-2	cell_type;iRBC;unRBC
glutathione-sulfite	ST000403	AN000643	6.610E-3	1.190E-2	Cell type;Mature erythrocyte;Reticulocyte
N-Hydroxy-1-aminonaphthalene	ST000403	AN000643	6.620E-3	1.190E-2	Cell type;Mature erythrocyte;Reticulocyte
Pro258-13C0	ST000114	AN000194	6.630E-3	3.690E-2	Treatment;None;Tetracycline
(R)-2-Ethylmalate	ST001202	AN002000	6.630E-3	9.340E-3	treatment_duration_(h);-;1.5;3;6;9
BOC-HIS-OH	ST000106	AN000175	6.650E-3	8.940E-2	Sampling time;0 min;60 min
Dihydrogenphosphate	ST001204	AN002005	6.660E-3	1.110E-1	treatment_duration_(h);-;3;6;9
2-amino-6-methylaminohexanoic acid	ST000355	AN000580	6.670E-3	2.440E-2	Stage;1;2;3;4;-
BOC-ALA-OH	ST000041	AN000063	6.680E-3	1.280E-1	Group;Control;NAFLD
Ketohexanoate-13C0[+QDA adduct+Na]+	ST000148	AN000235	6.690E-3	3.630E-2	Treatment;13C-Glc;unlabeled
D1-2-Hydroxymethylethisterone-2.831552	ST000046	AN000079	6.700E-3	5.350E-2	Cognitive Status;AD;CN;MCI
Glu-Met-Cys-His	ST000539	AN000819	6.740E-3	1.330E-2	Cell type;Mature erythrocyte;Reticulocyte
3-Oxotetradecanoate-13C0[+13CD3 QDA]+	ST000148	AN000235	6.750E-3	3.650E-2	Treatment;13C-Glc;unlabeled
gamma-glutamyllysine	ST000975	AN001596	6.800E-3	3.090E-2	GENDER;F;M
cyclo(L-phe-L-pro)	ST000974	AN001595	6.810E-3	5.410E-2	GENDER;F;M
BOC-ALA-OH	ST000105	AN000174	6.830E-3	3.570E-2	Sampling;After SWS onset;Morning fasting
cis-Cyclo[L-ala-L-Pro]	ST000974	AN001595	6.830E-3	4.490E-2	TIMEPOINT;BL;M06;M18
N-BOC-L-Tryptophan	ST000954	AN001564	6.870E-3	1.320E-1	race;1;2
4-Hydroxypyridine	ST000046	AN000077	6.890E-3	9.840E-2	Cognitive Status;AD;CN;MCI
Ile-Ala/Leu-Ala	ST000230	AN000344	6.890E-3	8.710E-2	Tissue Type;HCC (Hepatocellular carcinoma);HCC-NT (surrounde...
Propionylglycinemethylester+6.2598743	ST000046	AN000077	6.910E-3	9.840E-2	Cognitive Status;AD;CN;MCI
thioproline	ST000975	AN001596	6.910E-3	7.640E-2	GROUP;case;control
8-Amino-7-oxononanoate	ST000047	AN000080	6.930E-3	1.370E-1	Cognitive Status;AD;CN;MCI
Oxodecanoate-13C1[+13CD3 QDA]+	ST000148	AN000235	6.930E-3	3.720E-2	Treatment;13C-Glc;unlabeled
SELENOCYSTAMINE	ST000016	AN000033	6.950E-3	1.100E-2	Material;Cells;Media
IsoquinolineN-oxide	ST000046	AN000078	6.960E-3	4.550E-2	Cognitive Status;AD;CN;MCI
myo-Inositol 1-phosphate/myo-Inositol 3-phosphate	ST000230	AN000343	6.990E-3	4.930E-2	Tissue Type;HCC (Hepatocellular carcinoma);HCC-NT (surrounde...
glycol	ST000355	AN000580	7.010E-3	2.720E-2	Diagnosis;Breast cancer;Control
hydroxy-CMPF	ST000975	AN001596	7.060E-3	7.640E-2	GROUP;case;control
C12 GALACTOSYL(BETA) CERAMIDE (D18:1/12:0) (M+NA)+	ST000744	AN001163	7.070E-3	2.000E-1	Gender;female;male
PROCOLLAGEN 5-HYDROXY-L-LYSINE (M+H)+	ST000823	AN001307	7.090E-3	4.330E-1	Dysplasia;LGD;N/A
masilinate	ST000923	AN001515	7.150E-3	1.800E-2	Diagnosis;CD;nonIBD;UC
OBTUSAQUINONE	ST000422	AN000668	7.150E-3	1.290E-1	treatment;ND;T1D good glycemic control
pyroGlu-13C3	ST001045	AN001709	7.170E-3	7.720E-2	protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
tert-Butyl(2-(tert-butyl)-4-methoxyphenoxy)dimethylsilane	ST000978	AN001602	7.170E-3	4.470E-2	Cox_RRT;.;N;Y
Rimocidine-13C0[+H]+	ST000148	AN000235	7.180E-3	3.810E-2	Treatment;13C-Glc;unlabeled
1-LG and 2-LG	ST000977	AN001599	7.190E-3	1.440E-2	Group;Healthy Control;NAFLD
SALICYLATE #2 (M-H)-	ST000523	AN000799	7.210E-3	1.970E-2	Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
4-(Trimethylammonio)but-2-enoate	ST001205	AN002006	7.230E-3	2.260E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
hydroxy-CMPF	ST000975	AN001596	7.240E-3	1.270E-1	REGION;MAK;SUN
400671 carbohydrate	ST000369	AN000603	7.310E-3	2.700E-2	Smoker;Current;Former;NA
nornorcapsaicin	ST000403	AN000642	7.390E-3	6.060E-2	Glucose labelling;C13 glucose;unlabelled
OH-monohexcer d18:1 N24:0	ST000362	AN000594	7.420E-3	1.540E-2	Gender;1;2
Caffeine-D3	ST000956	AN001568	7.430E-3	1.440E-2	Treatment;Condition-1;Condition-2;Condition-3;Control
Undecanone-13C0[+H]+	ST000148	AN000235	7.430E-3	3.890E-2	Treatment;13C-Glc;unlabeled
2-Dehydro-3-deoxy-arabinonate-13C0[+Na]+	ST000148	AN000235	7.440E-3	3.890E-2	Treatment;13C-Glc;unlabeled
Manumycin A-13C0[+H]+	ST000148	AN000235	7.440E-3	3.890E-2	Treatment;13C-Glc;unlabeled
Mycalamide A	ST000566	AN000870	7.440E-3	4.910E-2	group;Old-Curcumin;Old-Placebo;young
Propoxyphene	ST000421	AN000663	7.470E-3	1.460E-1	treatment;ND;T1D poor glycemic control
L-Glutamic acid n-butyl ester + 1.5990624	ST000566	AN000870	7.530E-3	4.910E-2	group;Old-Curcumin;Old-Placebo;young
Chloroacetoacetanilide-13C0[+QDA adduct+Na]+	ST000148	AN000235	7.540E-3	3.930E-2	Treatment;13C-Glc;unlabeled
Methylprednisone	ST000567	AN000871	7.540E-3	2.110E-2	groups;Old-Curcumin;Old-Placebo;young
OH-monohexcer d18:1 N20:0	ST000362	AN000594	7.590E-3	1.540E-2	Gender;1;2
Ovothiol disulfide	ST001204	AN002004	7.590E-3	1.360E-2	cell_type;iRBC;unRBC
UDP-GNAc-13C13+15N0	ST000076	AN000121	7.600E-3	3.500E-1	Labeling;13C/15N-Gln;13C-Glc;unlabeled
Methyltyrosine	ST000356	AN000582	7.610E-3	1.370E-2	Diagnosis;breast cancer;control
Phenylglyoxylate-13C0[+13CD3 QDA]+	ST000148	AN000235	7.610E-3	3.960E-2	Treatment;13C-Glc;unlabeled
iSTD iSTD MAG (17:0/0:0/0:0)	ST000342	AN000554	7.630E-3	1.390E-2	Treatment;Quality Control;PRBC;PRBC-FST;PRBC+FST;WB
Methyl 2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-p-toluate	ST000539	AN000819	7.630E-3	1.230E-1	timepoint;1 hour;20 hours
2-Formaminobenzoylacetate	ST000539	AN000819	7.680E-3	1.230E-1	timepoint;1 hour;20 hours
Ala-Ala-Ala-Ser	ST001202	AN002000	7.700E-3	1.070E-2	treatment_duration_(h);-;1.5;3;6;9
OH-dihexcer d18:1 N16:0	ST000362	AN000594	7.700E-3	1.060E-1	Chronic_Bronchitis;1;-
ZEATIN [ISTD] (M-H)-	ST000726	AN001138	7.700E-3	4.490E-2	Assay;BC TP;OGTT
Asn-Val-Gly-Ser	ST001204	AN002004	7.760E-3	1.390E-2	cell_type;iRBC;unRBC
Trinexapac	ST001037	AN001698	7.790E-3	2.800E-2	Description ;Blank;Reagent Blank;Serum Sample;Solvent
BOC-ALA-OH	ST000044	AN000069	7.820E-3	4.400E-2	Pancreas tissue type;Normal area of the pancreas with tumor;...
DMNT	ST000403	AN000642	7.820E-3	1.370E-2	Cell type;Mature erythrocyte;Reticulocyte
Fisher ratio	ST000544	AN000826	7.830E-3	2.790E-2	Sample Type;Control;Replicate
Cys-Thr-Ser-Tyr	ST000539	AN000819	7.860E-3	1.230E-1	timepoint;1 hour;20 hours
Hydroxyandrosterone-13C0[+Na]+	ST000148	AN000235	7.880E-3	4.060E-2	Treatment;13C-Glc;unlabeled
C12 / C8	ST000545	AN000830	7.890E-3	1.120E-2	Sample Type;Control;Replicate
Hydroxycinnamyl aldehyde-13C0[+Na]+	ST000148	AN000235	7.890E-3	4.060E-2	Treatment;13C-Glc;unlabeled
2-AMINO-2-DEOXYHEXOPYRANOSE	ST000016	AN000033	7.930E-3	1.230E-2	Material;Cells;Media
BOC-ASP-OH	ST000016	AN000033	7.930E-3	2.020E-2	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
Caldarchaeol	ST000445	AN000696	7.930E-3	3.910E-2	Treatment;FSH;LH
GAB-ALL	ST001045	AN001709	7.970E-3	7.720E-2	protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
11-O-Demethylpradimicinone II-13C0[+13CD3 QDA]+	ST000148	AN000235	7.990E-3	4.100E-2	Treatment;13C-Glc;unlabeled
4-Amino-4-deoxychorismate	ST000539	AN000819	7.990E-3	1.550E-2	Cell type;Mature erythrocyte;Reticulocyte
Caffeine-D3	ST000919	AN001507	8.000E-3	5.400E-2	Gender;Female;Male
p-Toluic acid-M+3	ST001167	AN001930	8.090E-3	1.320E-2	Time points;0.25h;0h;12h;24h;4h;6days
thioproline	ST000974	AN001595	8.090E-3	1.110E-1	GROUP;case;control
octulose 8-phosphate	ST000403	AN000643	8.110E-3	6.180E-2	Glucose labelling;C13 glucose;unlabelled
Methyl Caprate	ST000978	AN001602	8.120E-3	5.410E-2	Competitive_RRTvsDeath;.;N;RRT;DEATH
N-acetylglycine NIST	ST000385	AN000620	8.140E-3	1.770E-2	Gender;F;M;NA
urea (partial derivative)	ST000092	AN000146	8.150E-3	1.130E-2	Solution Added;N/A;None;Urease;Water
Asn-Lys-Gly-Pro	ST001204	AN002004	8.160E-3	1.540E-1	treatment;DHA;DMSO;OZ277;OZ439
N2-(D-1-Carboxyethyl)-L-arginine	ST001202	AN002000	8.170E-3	1.120E-2	treatment_duration_(h);-;1.5;3;6;9
2-Hydroxy-3-(4-methoxyethylphenoxy)-propanoic acid	ST000566	AN000869	8.180E-3	2.670E-2	group;Old-Curcumin;Old-Placebo;young
3-Deoxy-D-manno-octulosonate 8-phosphate	ST001205	AN002007	8.180E-3	2.780E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
Arg/(Arg+Orn)	ST000544	AN000826	8.220E-3	2.790E-2	Sample Type;Control;Replicate
trimethylbenzene	ST001000	AN001878	8.220E-3	2.180E-2	Diagnosis;CD;Control;UC
2-(4-sulfophenyl)butyrate	ST001202	AN002000	8.240E-3	1.130E-2	treatment_duration_(h);-;1.5;3;6;9
4-Hydroxypyridine+4.290232	ST000047	AN000081	8.250E-3	9.130E-2	Cognitive Status;AD;CN;MCI
4-METHYL-1-PENTENE	ST001037	AN001698	8.270E-3	2.930E-2	Description ;Blank;Reagent Blank;Serum Sample;Solvent
N-Acetyl-D-glucosaminate	ST001201	AN001999	8.310E-3	1.450E-2	cell_type;iRBC;unRBC
Oxododecanoate-13C0[+QDA adduct]+	ST000148	AN000235	8.390E-3	4.250E-2	Treatment;13C-Glc;unlabeled
DIMETHYLCAFFEIC ACID	ST000422	AN000668	8.490E-3	1.350E-1	treatment;ND;T1D good glycemic control
deacetylcolchicine	ST001202	AN002000	8.500E-3	1.150E-2	treatment_duration_(h);-;1.5;3;6;9
Fibrinopeptide B (1-9)**	ST000975	AN001596	8.510E-3	2.080E-1	TIMEPOINT;BL;M06;M18
Undecanone-13C0[+13CD3 QDA]+	ST000148	AN000235	8.510E-3	4.300E-2	Treatment;13C-Glc;unlabeled
ANGOLENSIN (R)	ST000421	AN000664	8.540E-3	1.730E-1	treatment;ND;T1D poor glycemic control
ZEATIN [ISTD] (CAS# 13114-27-7); (M+H)+	ST000697	AN001082	8.540E-3	5.750E-2	Cell Type;BS4;HAHA;PAK;POOLED
d1-piperidine-dicarboxylate	ST000539	AN000818	8.580E-3	1.640E-2	Cell type;Mature erythrocyte;Reticulocyte
C2 / C0	ST000544	AN000827	8.590E-3	4.180E-2	Sample Type;Control;Replicate
ACETAMINOPHEN (TN TYLENOL) (M+NA)+	ST000763	AN001202	8.610E-3	3.560E-2	Group;Borderline Pressures;Healthy;LowRisk;Normal Pressures;...
PC(16:0/5:0(COOH))	ST000403	AN000642	8.610E-3	1.610E-1	timepoint;1 hour;20 hours
5-hydroxynorvaline NIST	ST000385	AN000620	8.620E-3	2.440E-2	Smoking Status;Current;Former;NA
Abscisic acid glucose ester	ST000403	AN000643	8.620E-3	1.230E-1	timepoint;1 hour;20 hours
5-6-Dihydrouridine	ST001201	AN001998	8.640E-3	4.140E-2	treatment;DHA;DMSO;OZ277;OZ439
4-8dimethylnonanoylcarnitine	ST000403	AN000642	8.670E-3	1.500E-2	Cell type;Mature erythrocyte;Reticulocyte
PENTADECANOYLGLYCEROPHOSPHOCHOLINE/STEAROYLGLYCEROPHOSPHOETHANOLAMINE (*)	ST000106	AN000175	8.680E-3	1.090E-1	Sampling time;0 min;60 min
C14:1-OH / C10	ST000544	AN000827	8.700E-3	4.180E-2	Sample Type;Control;Replicate
TROMETHAMINE	ST000047	AN000081	8.710E-3	9.240E-2	Cognitive Status;AD;CN;MCI
Met-SO / Met	ST000545	AN000829	8.730E-3	7.600E-2	Sample Type;Control;Replicate
Methyl Caprate	ST000978	AN001602	8.750E-3	5.170E-2	Cox_RRT;.;N;Y
Hydroxynonenal-13C0[+13CD3 QDA]+	ST000148	AN000235	8.770E-3	4.400E-2	Treatment;13C-Glc;unlabeled
5-methyluridine NIST	ST001211	AN002016	8.830E-3	1.790E-2	Group;Control;Methotrexate
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000698	AN001083	8.840E-3	4.870E-2	KD#2;yes;no;Pooled melanoma
Aminodipic Acid	ST000876	AN001413	8.870E-3	1.000E-1	L-serine (mg/kg/day);100;200;300;400;50;-
Kinetin-9-riboside	ST001037	AN001698	8.900E-3	3.010E-2	Description ;Blank;Reagent Blank;Serum Sample;Solvent
PC 33:3 (15:1(9Z)/18:2(2E.4E)) [M-Ac-H]-	ST001111	AN001806	8.940E-3	1.590E-2	Sample;Benign;Cancer;Metastasis
Albendazole sulfone	ST001204	AN002005	8.950E-3	1.210E-1	treatment_duration_(h);-;3;6;9
cyclo(L-phe-L-pro)	ST000974	AN001595	8.970E-3	5.360E-2	TIMEPOINT;BL;M06;M18
L-Glutamic acid n-butyl ester	ST000566	AN000870	8.980E-3	5.240E-2	group;Old-Curcumin;Old-Placebo;young
5-hydroxymethyl-2-furoylcarnitine*	ST000974	AN001595	8.990E-3	6.750E-2	GENDER;F;M
Cyclo(deltaAla-L-Val)	ST000539	AN000818	9.080E-3	9.920E-2	timepoint;1 hour;20 hours
2-Hydroxyphenylalanine;L-TYROSINE	ST000956	AN001568	9.100E-3	1.710E-2	Treatment;Condition-1;Condition-2;Condition-3;Control
Kynurenine / Trp	ST000545	AN000829	9.110E-3	7.600E-2	Sample Type;Control;Replicate
Isopropenyl oxoheptanoate-13C1[+13CD3 QDA]+	ST000148	AN000235	9.130E-3	4.540E-2	Treatment;13C-Glc;unlabeled
Frctose-6-Phosphate	ST000614	AN000940	9.140E-3	1.130E-2	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
N5-acetyl-N5-hydroxy-L-ornithine	ST000539	AN000818	9.170E-3	2.120E-1	Glucose labelling;C13 glucose;unlabelled
BOC-ALA-OH (CAS# 15761-38-3); (M-H)-	ST000697	AN001081	9.200E-3	7.550E-2	Stimulation;IFN-G;IL-17A;TNF-alpha;TNF-alpha+IL-17A;Untreate...
FA hydroxy(18:1)]	ST001205	AN002007	9.210E-3	3.060E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
fucose+ rhamnose	ST000390	AN000626	9.210E-3	4.550E-2	Tumor Present;No;Yes;-
IS D31-TAG	ST000669	AN001025	9.210E-3	2.530E-1	Disease;AS-Control-P;AS-Control-S;Coats;JB-Coats-P
[13C]-ISOLEUCINE	ST000009	AN000023	9.230E-3	3.150E-2	gender;female;male
8-Amino-7-oxononanoate	ST000047	AN000081	9.230E-3	9.580E-2	Cognitive Status;AD;CN;MCI
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (???)	ST000016	AN000033	9.240E-3	1.430E-2	Material;Cells;Media
L-VALINE/5-AMINOPENTANOATE/L-NORVALINE	ST000919	AN001506	9.240E-3	5.910E-2	Gender;Female;Male
C12 GALACTOSYL(BETA) CERAMIDE (D18:1/12:0) (CAS# 41613-14-3); (M+HCOO)-	ST000695	AN001075	9.320E-3	4.630E-2	Race;Black;White;POOLED
IBUPROFEN CARBOXYLIC ACID (CAS# 15935-54-3); (M+CL)-	ST000695	AN001075	9.320E-3	4.630E-2	Race;Black;White;POOLED
enolpyruvate NIST	ST000087	AN000139	9.390E-3	1.350E-2	Time Point;18 hours;4 hours
Monodehydroascorbate	ST000292	AN000466	9.390E-3	1.530E-1	Treatment ;Baseline plasma;Plasma after drinking apple juice...
perchlorate	ST000403	AN000643	9.390E-3	1.300E-1	timepoint;1 hour;20 hours
Hydroxyabscisate-13C0[+Na]+	ST000148	AN000235	9.410E-3	4.640E-2	Treatment;13C-Glc;unlabeled
[13C]-GLUTAMATE	ST000016	AN000033	9.460E-3	2.390E-2	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
10-nonadecenoate	ST001192	AN001986	9.500E-3	1.060E-1	Diet;-;Omnivore;Vegetarian
N-dimethylethanolamine	ST000403	AN000642	9.500E-3	1.640E-2	Cell type;Mature erythrocyte;Reticulocyte
400671 carbohydrate	ST000386	AN000621	9.540E-3	3.840E-2	Smoker;Current;Former;NA
4-Sulfobenzyl alcohol	ST000567	AN000871	9.560E-3	2.530E-2	groups;Old-Curcumin;Old-Placebo;young
[PC (16:0/3:0)] 1-hexadecanoyl-2-(2E-propionyl)-sn-glycero-3-phosphocholine	ST000539	AN000818	9.610E-3	1.800E-2	Cell type;Mature erythrocyte;Reticulocyte
Sphingosine(18:0)-13C0[+H]+	ST000148	AN000235	9.610E-3	4.710E-2	Treatment;13C-Glc;unlabeled
URIDINE 5`-DIPHOSPHOGLUCOSE	ST000010	AN000026	9.620E-3	2.220E-1	TGF;NO_TGF;TGF
Hydroxyproline/Aminolevulinate	ST000284	AN000452	9.630E-3	6.800E-2	Patient group;CRC;Healthy;Polyp
glucuronide of piperine metabolite C17H21NO3 (5)*	ST000975	AN001596	9.700E-3	8.800E-2	GROUP;case;control
Total AC / C0	ST000544	AN000827	9.800E-3	4.590E-2	Sample Type;Control;Replicate
C9 / C10:2	ST000545	AN000830	9.810E-3	1.380E-2	Sample Type;Control;Replicate
GLUCARIC/GULARIC/SACCHARIC ACID	ST000041	AN000063	9.810E-3	1.500E-1	Group;Control;NAFLD
ARACHIDONOYLGLYCEROPHOSPHOETHANOLAMINE (*)	ST000106	AN000176	9.850E-3	8.650E-2	Sampling time;0 min;60 min
asparagylisoleucine	ST000974	AN001595	9.860E-3	1.250E-1	GROUP;case;control
19-hydroxy-17-oxoandrost-5-en-3-beta-ylsulfate	ST000046	AN000079	9.910E-3	6.760E-2	Cognitive Status;AD;CN;MCI
acetophenone NIST	ST000369	AN000603	9.910E-3	3.520E-2	Gender;F;M;NA
Ala-Glu-Glu-His	ST001204	AN002004	1.000E-2	1.720E-1	treatment;DHA;DMSO;OZ277;OZ439
N-Ace-Asp-13C5	ST001049	AN001864	1.010E-2	8.270E-2	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
Ala-Asn-Asn-Ser	ST001201	AN001998	1.020E-2	4.530E-2	treatment;DHA;DMSO;OZ277;OZ439
fucose + rhamnose	ST000369	AN000603	1.020E-2	3.300E-2	Smoker;Current;Former;NA
1-octadecanoyl-rac-glycerol+2.8676724	ST000047	AN000081	1.030E-2	1.040E-1	Cognitive Status;AD;CN;MCI
cytidine-5-monophosphate NIST	ST000087	AN000139	1.030E-2	1.450E-2	Time Point;18 hours;4 hours
Gln-Leu-Lys-His	ST000539	AN000818	1.030E-2	1.920E-2	Cell type;Mature erythrocyte;Reticulocyte
Glu-Glu-Gln-His	ST001201	AN001998	1.030E-2	4.530E-2	treatment;DHA;DMSO;OZ277;OZ439
2(alpha-D-Mannosyl)-D-glycerate	ST001201	AN001999	1.040E-2	1.800E-2	cell_type;iRBC;unRBC
3-methoxycatechol sulfate (2)	ST000899	AN001464	1.040E-2	2.550E-2	Type;Control;Crohn disease;Ulcerative Colitis
4-Hydroxybenzyl cyanide	ST000421	AN000664	1.040E-2	1.730E-1	treatment;ND;T1D poor glycemic control
5-guanidino-3-methyl-2-oxo-pentanoate	ST000403	AN000642	1.040E-2	1.780E-2	Cell type;Mature erythrocyte;Reticulocyte
Cys-Gly-Pro-Ser	ST001204	AN002005	1.040E-2	2.080E-2	cell_type;iRBC;unRBC
L-2-Aminoadipate 6-semialdehyde	ST000403	AN000643	1.040E-2	7.310E-2	Glucose labelling;C13 glucose;unlabelled
2-hydroxy-3-methylpentanoic acid / leucinic acid	ST001000	AN001879	1.050E-2	2.420E-2	Diagnosis;CD;Control;UC
IS D31-TAG	ST000669	AN001025	1.050E-2	1.690E-1	Matrix;Plasma;SRF;CB
Leucomycin A3-13C0[+H]+	ST000148	AN000235	1.050E-2	5.070E-2	Treatment;13C-Glc;unlabeled
1-docosapentaenoylglycerophosphocholine (22:5n6)*	ST000975	AN001596	1.060E-2	4.470E-2	GENDER;F;M
3-AP	ST001167	AN001929	1.060E-2	2.280E-2	Time points;0.25h;0h;12h;24h;4h;6days
cyano-L-alanine	ST000369	AN000603	1.060E-2	3.370E-2	Smoker;Current;Former;NA
DIMETHYLXANTHINE	ST000105	AN000173	1.060E-2	7.280E-2	Sampling;After SWS onset;Morning fasting
nitrocyclohexane	ST000539	AN000818	1.060E-2	2.350E-1	Glucose labelling;C13 glucose;unlabelled
Oxodecanoate-13C0[+QDA adduct]+	ST000148	AN000235	1.060E-2	5.080E-2	Treatment;13C-Glc;unlabeled
1-Naphthoicacidglucuronide	ST000046	AN000078	1.070E-2	5.990E-2	Cognitive Status;AD;CN;MCI
5-Dehydro-4-deoxy-D-glucarate	ST000403	AN000643	1.070E-2	1.450E-1	timepoint;1 hour;20 hours
Ala-Leu-Lys-Asp	ST001201	AN001998	1.070E-2	1.700E-2	cell_type;iRBC;unRBC
DIACYL-GLYCEROPHOSPHOCHOLINE (C50H82NO8P PROBABLY)	ST000106	AN000175	1.070E-2	1.200E-1	Sampling time;0 min;60 min
Trihexosylceramide (d18:1/18:0)	ST000241	AN000374	1.070E-2	3.970E-2	Concentration (uM);0;500
[13C]-LYSINE	ST000105	AN000173	1.080E-2	7.280E-2	Sampling;After SWS onset;Morning fasting
Ala-Leu-Trp-Ser	ST001204	AN002004	1.080E-2	1.750E-1	treatment;DHA;DMSO;OZ277;OZ439
ALPHA-AMINOADIPATE/N-METHYL-L-GLUTAMATE	ST000954	AN001564	1.080E-2	1.560E-1	race;1;2
Asn-Leu-Pro-Pro	ST001205	AN002006	1.080E-2	3.100E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
glyoxalurea NIST	ST000386	AN000621	1.080E-2	4.170E-2	Smoker;Current;Former;NA
IS Ceramide; [M-H2O]+	ST000523	AN000800	1.080E-2	3.330E-2	Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
OHPro-13C5	ST001045	AN001709	1.080E-2	8.410E-2	protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
Picrasin C-13C0[+QDA adduct]+	ST000148	AN000235	1.080E-2	5.150E-2	Treatment;13C-Glc;unlabeled
nornorcapsaicin	ST000403	AN000642	1.090E-2	1.830E-1	timepoint;1 hour;20 hours
Thujaplicin-13C0[+13CD3 QDA]+	ST000142	AN000225	1.090E-2	6.280E-2	Treatment;13C-Glc;unlabeled
9-myristoleate	ST001322	AN002198	1.094E-2	8.480E-2	group;OB;NW
[FA oxo(7:0)] 2-oxo-heptanoic acid	ST000403	AN000643	1.100E-2	1.450E-1	timepoint;1 hour;20 hours
Ala-Asp-Asp-Cys	ST001201	AN001998	1.110E-2	1.750E-2	cell_type;iRBC;unRBC
Mannitol;HEXOSE ALCOHOL	ST000956	AN001569	1.110E-2	2.310E-2	Treatment;Condition-1;Condition-2;Condition-3;Control
Manumycin A-13C17[+H]+	ST000148	AN000235	1.110E-2	5.230E-2	Treatment;13C-Glc;unlabeled
N-acetylisoleucine	ST000976	AN001597	1.110E-2	2.940E-1	TIMEPOINT;BL;M06
SB N-(docosanoyl)-sphing-4-enine (d18:1(4E)/22:0) [M-H]-	ST001111	AN001806	1.120E-2	1.960E-2	Sample;Benign;Cancer;Metastasis
[13C]-ARGININE	ST000043	AN000070	1.130E-2	3.880E-2	Cell line;MDA-MB-231;MDA-MB-231 p38 gamma knockdown;MDA-MB-2...
ATP-H2O-13C2+15N0	ST000076	AN000121	1.130E-2	4.230E-1	Labeling;13C/15N-Gln;13C-Glc;unlabeled
Gulonolactone	ST001193	AN001989	1.130E-2	1.500E-2	Plasma;Cord blood;Plasma
N-(4-benzenesulfonamide) arachidonoyl amine	ST000242	AN000375	1.130E-2	1.380E-2	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Asn-Gly-Pro-Pro	ST001201	AN001998	1.140E-2	4.700E-2	treatment;DHA;DMSO;OZ277;OZ439
C-GLYCOSYLTRYPTOPHAN (*)	ST000105	AN000173	1.140E-2	2.920E-1	OSA;Negative;Positive
[FA methyl(6:0)] 2-methyl-hexanoic acid	ST000539	AN000819	1.140E-2	2.110E-2	Cell type;Mature erythrocyte;Reticulocyte
7-ALPHA-HYDROXY-3-OXO-4-CHOLESTENOATE (*)	ST000105	AN000174	1.150E-2	1.690E-1	Gender;Female;Male
Isocitrate M0	ST000507	AN000776	1.150E-2	2.260E-2	Time (incubation);24 hours;72 hours
threo-sphingosine	ST001237	AN002055	1.150E-2	2.130E-2	CRF_MSKCC_Risk_Group;FAVORABLE;INTERMEDIATE;POOR
8-Amino-7-oxononanoate	ST001201	AN001998	1.160E-2	4.700E-2	treatment;DHA;DMSO;OZ277;OZ439
Decylubiquinol	ST000567	AN000872	1.160E-2	5.370E-2	groups;Old-Curcumin;Old-Placebo;young
L-GLUTAMIC ACID;N-METHYL-D-ASPARTIC ACID;O-ACETYL-L-SERINE;O-Acetyl-L-Serine	ST000956	AN001569	1.170E-2	2.330E-2	Treatment;Condition-1;Condition-2;Condition-3;Control
N-Acetyl-D-glucosaminate	ST001204	AN002004	1.170E-2	2.010E-2	cell_type;iRBC;unRBC
N-acetylglycine NIST	ST000386	AN000621	1.170E-2	4.340E-2	Smoker;Current;Former;NA
PC(16:0/5:0(COOH))	ST000539	AN000818	1.170E-2	2.410E-1	Glucose labelling;C13 glucose;unlabelled
ALDO/KETO-HEXOSE	ST000956	AN001568	1.190E-2	2.210E-2	Treatment;Condition-1;Condition-2;Condition-3;Control
[FA hydroxy(18:0)] 2S-hydroxy-octadecanoic acid	ST000539	AN000819	1.190E-2	2.180E-2	Cell type;Mature erythrocyte;Reticulocyte
N-acetylglycine NIST	ST000062	AN000100	1.190E-2	6.800E-2	Source;Group 1 - Score 0;Group 2 - Score 50
[PC (7:0/8:0)] 1-heptanoyl-2-octanoyl-sn-glycero-3-phosphocholine	ST000539	AN000819	1.190E-2	1.410E-1	timepoint;1 hour;20 hours
Val-Tyr-Val iSTD	ST001211	AN002017	1.190E-2	4.060E-2	Group;Control;Methotrexate
7-Deoxyloganetin	ST000291	AN000464	1.200E-2	3.760E-1	Treatment ;Baseline urine;Urine after drinking apple juice;U...
taurodeoxycholate/taurochenodeoxycholate	ST001000	AN001879	1.200E-2	2.670E-2	Diagnosis;CD;Control;UC
beta-mannosylglycerate	ST000368	AN000602	1.210E-2	1.720E-2	Organ;Plasma;Serum;Serum or Plasma
G3P	ST000302	AN000480	1.210E-2	2.740E-2	Labelint time (hours);0;1;24;3;48;72
hydroxy-CMPF*	ST000975	AN001596	1.210E-2	9.890E-2	GROUP;case;control
L-Glutamic-13C4[-H+]-	ST000367	AN000601	1.210E-2	9.070E-2	Tissue type;nontumor;tumor
3alpha-HYDROXY-3-DEOXYANGOLENSICACIDMETHYLESTER	ST000047	AN000083	1.220E-2	8.350E-2	Cognitive Status;AD;CN;MCI
Cys-Thr-Ser-Tyr	ST000539	AN000819	1.220E-2	2.230E-2	Cell type;Mature erythrocyte;Reticulocyte
N-Butyl-beta-carboline-3-carboxylate	ST001202	AN002001	1.220E-2	1.870E-2	treatment_duration_(h);-;1.5;3;6;9
[PC (7:0/8:0)] 1-heptanoyl-2-octanoyl-sn-glycero-3-phosphocholine	ST000539	AN000819	1.220E-2	2.230E-2	Cell type;Mature erythrocyte;Reticulocyte
H2S2O3	ST001201	AN001999	1.230E-2	4.390E-1	treatment_duration_(h);-;0.5;1.5;3
Prunetin or similar isoflavone	ST000586	AN000901	1.230E-2	1.540E-2	Plasma Volume;0 uL;150 uL;700 uL
2(alpha-D-Mannosyl)-D-glycerate	ST000403	AN000643	1.240E-2	7.960E-2	Glucose labelling;C13 glucose;unlabelled
Avenic acid A	ST001202	AN002001	1.240E-2	1.890E-2	treatment_duration_(h);-;1.5;3;6;9
octulose 8-phosphate	ST000403	AN000643	1.240E-2	2.110E-2	Cell type;Mature erythrocyte;Reticulocyte
Sulfate - 1.053629	ST000422	AN000668	1.240E-2	1.690E-1	treatment;ND;T1D good glycemic control
Glu-Met-Met-His	ST000539	AN000819	1.250E-2	1.460E-1	timepoint;1 hour;20 hours
heptadecanoic acid NIST	ST000368	AN000602	1.250E-2	1.760E-2	Organ;Plasma;Serum;Serum or Plasma
Seratonin	ST000490	AN000756	1.250E-2	4.980E-2	Disease;cardiovascular disease;sleep apnea
Undecanone-13C0[+QDA adduct]+	ST000148	AN000235	1.250E-2	5.750E-2	Treatment;13C-Glc;unlabeled
3-hydroxyacyl group of bacterial toxin	ST000403	AN000643	1.260E-2	8.030E-2	Glucose labelling;C13 glucose;unlabelled
4-oxoproline;5-OXO-L-PROLINE	ST000954	AN001565	1.260E-2	1.550E-1	race;1;2
8R-hydroxy-9Z-octadecenoic acid	ST000421	AN000666	1.260E-2	2.190E-1	treatment;ND;T1D poor glycemic control
cyclohexylammonium	ST000046	AN000077	1.260E-2	1.250E-1	Cognitive Status;AD;CN;MCI
[Fv] Desmosdumotin C	ST000403	AN000642	1.260E-2	2.130E-2	Cell type;Mature erythrocyte;Reticulocyte
SALICYLURIC GLUCURONIDE (*)	ST000105	AN000174	1.260E-2	2.400E-1	PCOS;No PCOS;PCOS
ZEATIN [ISTD] (M-H)-	ST000726	AN001138	1.260E-2	1.100E-1	DISEASE_STATE;Control;PCOS
CD 1790	ST000444	AN000695	1.270E-2	5.210E-2	Sample Treatment;Bubbled;Control
HEXANESULFONIC ACID-Sulfate	ST000957	AN001571	1.270E-2	1.380E-1	Milk fraction;fat;skim;whole
MES	ST001201	AN001999	1.270E-2	6.940E-2	treatment;DHA;DMSO;OZ277;OZ439
UDP-GNAc-13C11+15N0	ST000076	AN000121	1.270E-2	4.230E-1	Labeling;13C/15N-Gln;13C-Glc;unlabeled
3-AIB (a-amino[1-(14)C]isobutyric acid)	ST000166	AN000259	1.280E-2	2.860E-2	Group;3M;Control;HF
Dihydroxyacetophenone	ST001039	AN001712	1.280E-2	2.220E-2	Sample.Matrix;Plasma;Urine
DMGV	ST001192	AN001984	1.280E-2	1.780E-1	Diet;-;Omnivore;Vegetarian
lathosterol NIST	ST000379	AN000613	1.280E-2	3.620E-2	Treatment;10.5mM Glu;5.5mM Glu 5mM Fru;5.5mM Glu;Glucosamine
N-Acetylglutamic-13C4[-H+]-	ST000367	AN000601	1.280E-2	9.070E-2	Tissue type;nontumor;tumor
19-hydroxy-17-oxoandrost-5-en-3-beta-ylsulfate	ST000046	AN000078	1.290E-2	6.950E-2	Cognitive Status;AD;CN;MCI
3-Dechloroethylifosfamide	ST000444	AN000695	1.290E-2	5.210E-2	Sample Treatment;Bubbled;Control
5-(3-Pyridyl)-2-hydroxytetrahydrofuran	ST000567	AN000872	1.290E-2	1.410E-2	Time point;Post;Pre;Baseline
Ala-Cys-Pro-Ser	ST001205	AN002007	1.290E-2	4.050E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
Arg-Phe-Phe-Arg	ST001201	AN001999	1.290E-2	6.940E-2	treatment;DHA;DMSO;OZ277;OZ439
C-glycosyltryptophan*	ST000975	AN001596	1.290E-2	5.210E-2	GENDER;F;M
cytidine-5-monophosphate NIST	ST000390	AN000626	1.290E-2	5.640E-2	Tumor Present;No;Yes;-
Ala-Leu-Trp-Ser	ST001204	AN002004	1.300E-2	1.810E-1	treatment_duration_(h);-;3;6;9
L-a-glutamyl-L-Lysine	ST001201	AN001998	1.310E-2	5.130E-2	treatment;DHA;DMSO;OZ277;OZ439
2-oxindole-3-acetate	ST000899	AN001462	1.320E-2	4.930E-2	Type;Control;Crohn disease;Ulcerative Colitis
Bis(2-hydroxypropyl)amine+5.586841	ST000047	AN000081	1.320E-2	1.140E-1	Cognitive Status;AD;CN;MCI
CL 74:10 (16:0/22:5/20:4/16:1) [M-2H](2-)	ST001111	AN001806	1.320E-2	2.240E-2	Sample;Benign;Cancer;Metastasis
[FA hydroxy(11:1)] 2-hydroxy-10-undecenoic acid	ST000539	AN000819	1.320E-2	2.400E-2	Cell type;Mature erythrocyte;Reticulocyte
N-Acetylglutamic-13C6[-H+]-	ST000367	AN000601	1.320E-2	9.070E-2	Tissue type;nontumor;tumor
2-AMINO-2-DEOXYHEXOPYRANOSE	ST000106	AN000175	1.330E-2	4.280E-1	Visit;1;2
2-oxogluconic acid NIST	ST000386	AN000621	1.330E-2	4.720E-2	Smoker;Current;Former;NA
deschlorobenzoylIndomethacin	ST000046	AN000076	1.330E-2	7.650E-2	Cognitive Status;AD;CN;MCI
?-Methyltryptamine (AMT)	ST000242	AN000377	1.330E-2	3.980E-2	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
2-deoxytetronic acid NIST	ST001118	AN001817	1.340E-2	2.620E-2	Treatment Group;Control;Wilson Disease
Bifemelane (M4)	ST000421	AN000664	1.340E-2	1.980E-1	treatment;ND;T1D poor glycemic control
HYDROXYISOVALERATE (*)	ST000044	AN000069	1.340E-2	6.190E-2	Pancreas tissue type;Normal area of the pancreas with tumor;...
isodeoxytetronic acid	ST000396	AN000633	1.340E-2	1.080E-1	Age Group;45-49;50-54;55-59;60-64;65-69;70-74
N-acetylisoleucine	ST000974	AN001595	1.340E-2	7.360E-2	TIMEPOINT;BL;M06;M18
2(alpha-D-Mannosyl)-D-glycerate	ST001205	AN002007	1.350E-2	4.100E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
3-CMPFP**	ST000976	AN001597	1.350E-2	3.710E-1	GROUP;case;control
3-Deoxy-D-manno-octulosonate 8-phosphate	ST001202	AN002001	1.350E-2	1.460E-2	cell_type;iRBC;unRBC
BOC-ASN	ST000009	AN000023	1.350E-2	3.750E-2	POST_SURGERY_TIME;12MO;6MO;NO_SURGERY;PRE_SURGERY
DMGV	ST001236	AN002054	1.350E-2	6.930E-2	OS_Censor (1 means the time is a censoring time and 0 means ...
DMGV	ST001237	AN002055	1.350E-2	8.630E-2	Prior antiangiogenic regimens (≥2);FALSE;TRUE
[PA(18:0)] 1-octadecanoyl-2-sn-glycero-3-phosphate	ST001205	AN002007	1.350E-2	4.100E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
Pro258-13C3	ST000076	AN000122	1.350E-2	4.900E-2	Labeling;13C/15N-Gln;13C-Glc;unlabeled
Acetominophen	ST000913	AN001483	1.360E-2	3.310E-1	Diagnosis;MECFS;MS;ND
Ala-Cys-Pro-Ser	ST001201	AN001999	1.360E-2	7.050E-2	treatment;DHA;DMSO;OZ277;OZ439
HYDROLYSIS PRODUCT OF BUSSEIN + 1.9674853	ST000421	AN000663	1.360E-2	1.910E-1	treatment;ND;T1D poor glycemic control
N-gamma-Acetyl-N-2-formyl-5-methoxykynurenamine	ST000047	AN000081	1.360E-2	1.150E-1	Cognitive Status;AD;CN;MCI
2-Amino-2-methyl-1-propanol+5.1998544	ST000046	AN000077	1.370E-2	1.280E-1	Cognitive Status;AD;CN;MCI
DISACCHARIDE (6C/6C)/2-alpha-D-glucosyl-D-glucose	ST000475	AN000740	1.370E-2	2.160E-2	Treatment;-;MDH inhib
16:1 (n-7)	ST001098	AN001786	1.380E-2	3.360E-2	Treatment;Non-obese control;Obese control;Schizophrenia dx
6-Hydroxy flavin adenine dinucleotide	ST000241	AN000373	1.380E-2	1.700E-2	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Dimethylallylpyrophosphate	ST000356	AN000583	1.380E-2	2.580E-2	stage;-;2;3
PIPES	ST001201	AN001999	1.380E-2	7.050E-2	treatment;DHA;DMSO;OZ277;OZ439
17beta-Hydroxy-2alpha-(hydroxymethyl)-5alpha-androstan-3-one-13C0[+Na]+	ST000148	AN000235	1.390E-2	6.240E-2	Treatment;13C-Glc;unlabeled
Capillone-13C1[+QDA adduct]+	ST000148	AN000235	1.390E-2	6.250E-2	Treatment;13C-Glc;unlabeled
cyclo(pro-arg)*	ST000975	AN001596	1.400E-2	1.770E-1	REGION;MAK;SUN
ACETAMINOPHEN (TN TYLENOL) (M-H)-	ST000763	AN001201	1.410E-2	5.720E-2	Group;Borderline Pressures;Healthy;LowRisk;Normal Pressures;...
Carboxyibuprofen	ST000421	AN000663	1.410E-2	1.910E-1	treatment;ND;T1D poor glycemic control
[FA oxo(7:0)] 2-oxo-heptanoic acid	ST000539	AN000819	1.410E-2	2.550E-2	Cell type;Mature erythrocyte;Reticulocyte
PC(16:0/5:0(COOH))	ST000539	AN000818	1.410E-2	1.410E-1	timepoint;1 hour;20 hours
sn-caldarchaeo-1-phosphoethanolamine	ST000445	AN000696	1.410E-2	5.500E-2	Treatment;FSH;LH
Total DMA / Arg	ST000545	AN000829	1.410E-2	1.060E-1	Sample Type;Control;Replicate
5-Dehydro-4-deoxy-D-glucarate	ST000566	AN000869	1.420E-2	4.310E-2	group;Old-Curcumin;Old-Placebo;young
L-Noradrenaline	ST000403	AN000643	1.420E-2	2.420E-2	Cell type;Mature erythrocyte;Reticulocyte
N-acetyl-isoputrenine*	ST000974	AN001595	1.420E-2	9.430E-2	GENDER;F;M
PYRIDINE CARBOXYLIC ACID	ST000044	AN000069	1.420E-2	6.450E-2	Pancreas tissue type;Normal area of the pancreas with tumor;...
N-Acetylglutamic-13C5[-H+]-	ST000367	AN000601	1.430E-2	9.070E-2	Tissue type;nontumor;tumor
pyroGlu-13C4	ST001049	AN001864	1.430E-2	9.730E-2	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
benzi(ghi)perylene1	ST000614	AN000941	1.440E-2	1.730E-2	Diagonsis;Benign;Cancer;Normal
O-PHOSPHONOHEXOPYRANOSE	ST000016	AN000033	1.440E-2	4.970E-2	Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
epsilon-caprolactam (likely)	ST000420	AN000662	1.450E-2	2.120E-2	Group;nonsmoker;smoker
Oxostearate-13C2[+QDA adduct]+	ST000142	AN000225	1.450E-2	8.270E-2	Treatment;13C-Glc;unlabeled
Methyl butenal-13C0[+13CD3 QDA]+	ST000148	AN000235	1.460E-2	6.480E-2	Treatment;13C-Glc;unlabeled
2-hydroxydecanoate	ST000976	AN001597	1.470E-2	3.710E-1	GROUP;case;control
Ala-Asp-Asp-Cys	ST001202	AN002000	1.470E-2	1.930E-2	treatment_duration_(h);-;1.5;3;6;9
Ala-Thr-Ala-Ser	ST001201	AN001998	1.470E-2	5.630E-2	treatment;DHA;DMSO;OZ277;OZ439
alpha-(Methylenecyclopropyl)glycine	ST000403	AN000643	1.470E-2	9.150E-2	Glucose labelling;C13 glucose;unlabelled
C24:0 PC	ST001000	AN001881	1.470E-2	5.030E-2	Diagnosis;CD;Control;UC
iSTD iSTD PG (17:0/17:0)	ST000346	AN000562	1.470E-2	1.750E-1	Condition;Mild Asthma;No Asthma;Quality Control;Severe Asthm...
PC(O-12:0/O-1:0)	ST000624	AN000956	1.470E-2	6.320E-2	Condition;Control;Glaucomatous
Pro258-13C2	ST000114	AN000194	1.470E-2	7.290E-2	Treatment;None;Tetracycline
z dioctylphtalate	ST000417	AN001448	1.470E-2	2.680E-2	Group;AIR;NO2PM;PM
Bifemelane(M4)	ST000046	AN000079	1.480E-2	8.110E-2	Cognitive Status;AD;CN;MCI
c181hexcerum	ST000433	AN000683	1.480E-2	8.690E-2	Group;Alzheimer disease dementia;Cognitively normal;Dementia...
N-acetylglycine NIST	ST000389	AN000625	1.480E-2	5.000E-1	Emphysema/COPD;No;Yes
Oleoyl amine + 12.276432	ST000421	AN000665	1.480E-2	3.420E-1	treatment;ND;T1D poor glycemic control
Ala-Asp-Gly-Arg	ST001201	AN001998	1.490E-2	5.670E-2	treatment;DHA;DMSO;OZ277;OZ439
FA methyl (8:1)	ST001202	AN002001	1.490E-2	2.220E-2	treatment_duration_(h);-;1.5;3;6;9
2-oxogluconic acid NIST	ST000369	AN000603	1.500E-2	4.690E-2	Gender;F;M;NA
3-phosphoglucarate	ST001201	AN001999	1.500E-2	4.840E-1	treatment_duration_(h);-;0.5;1.5;3
8-HETrE	ST000916	AN001491	1.500E-2	4.110E-2	Diagnosis;Cirrhosis;NASH;Normal;Steatosis
deschlorobenzoyl Indomethacin	ST000422	AN000667	1.500E-2	3.190E-1	treatment;ND;T1D good glycemic control
SucroseAndDischarrides-13C6[-H+]-	ST000367	AN000601	1.500E-2	9.070E-2	Tissue type;nontumor;tumor
D-Phenyllacticacid	ST000046	AN000078	1.510E-2	7.650E-2	Cognitive Status;AD;CN;MCI
N-Acetylglutamic-13C7[-H+]-	ST000367	AN000601	1.510E-2	9.070E-2	Tissue type;nontumor;tumor
PROCOLLAGEN 5-HYDROXY-L-LYSINE (CAS# 1190-94-9); (M+H)+	ST000775	AN001223	1.510E-2	1.160E-1	Pair;Pair 1;Pair 2;Pair 3;Pair 4;Pair 5;Pair 6;Pair 7;Pair 8...
trihexcer d18:1 N16:0	ST000362	AN000594	1.510E-2	2.820E-2	Gender;1;2
FBP	ST000302	AN000480	1.520E-2	2.870E-2	Labelint time (hours);0;1;24;3;48;72
Mono-N-depropylprobenecid	ST000047	AN000083	1.520E-2	9.740E-2	Cognitive Status;AD;CN;MCI
3-hydroxyacyl group of bacterial toxin	ST000403	AN000643	1.530E-2	1.920E-1	timepoint;1 hour;20 hours
HYDROLYSIS PRODUCT OF BUSSEIN + 1.4680848	ST000421	AN000663	1.530E-2	1.980E-1	treatment;ND;T1D poor glycemic control
N-Acetylglutamic-13C2[-H+]-	ST000367	AN000601	1.530E-2	9.070E-2	Tissue type;nontumor;tumor
DIOLEOYLPHOSPHATIDYLCHOLINE	ST000016	AN000033	1.540E-2	5.270E-2	Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
GLUCOSE/FRUCTOSE-PHOSPHATE	ST000424	AN000673	1.540E-2	2.970E-1	DONOR CAUSE OF DEATH;Anoxia;Cerebrovascular/Stroke;CVA;Traum...
isobutene glycol NIST	ST000910	AN001480	1.540E-2	1.610E-1	Diagnosis;MECFS;MS;ND
CL 80:14 (18:0/22:6/18:2/22:6) [M-2H](2-)	ST001111	AN001806	1.550E-2	2.600E-2	Sample;Benign;Cancer;Metastasis
Deamino-alpha-keto-demethylphosphinothricin-13C0[+QDA adduct]+	ST000142	AN000225	1.550E-2	8.770E-2	Treatment;13C-Glc;unlabeled
L-2-Amino-4-(hydroxymethylphosphinyl)butanoate	ST000291	AN000464	1.550E-2	4.620E-1	Treatment ;Baseline urine;Urine after drinking apple juice;U...
N-Amidino-L-glutamate	ST000292	AN000466	1.550E-2	1.970E-1	Treatment ;Baseline plasma;Plasma after drinking apple juice...
Oxidized Latia luciferin-13C10[+QDA adduct]+	ST000148	AN000235	1.550E-2	6.770E-2	Treatment;13C-Glc;unlabeled
15beta-hydroxycyproterone acetate	ST000444	AN000695	1.560E-2	5.210E-2	Sample Treatment;Bubbled;Control
DG 37:2 (18:2/19:0/0:0) [M+NH4]+	ST001111	AN001805	1.560E-2	1.990E-2	Sample;Benign;Cancer;Metastasis
3-hydroxyacyl group of bacterial toxin	ST000403	AN000643	1.570E-2	2.640E-2	Cell type;Mature erythrocyte;Reticulocyte
ACETAMINOPHEN (TN TYLENOL) (M-H)-	ST000721	AN001128	1.570E-2	4.850E-1	GOSE;4;5;6;7;8;NA
Asn-Thr-Asn-Asn	ST001202	AN002000	1.570E-2	2.040E-2	treatment_duration_(h);-;1.5;3;6;9
Heptopyranosides	ST001201	AN001999	1.570E-2	2.600E-2	cell_type;iRBC;unRBC
N5-formyl-N5-hydroxy-L-ornithine	ST001201	AN001999	1.570E-2	7.650E-2	treatment;DHA;DMSO;OZ277;OZ439
N-Acetyl-D-glucosaminate	ST001204	AN002004	1.570E-2	2.340E-1	treatment;DHA;DMSO;OZ277;OZ439
N-Acetyl-D-glucosamine 6-phosphate	ST001201	AN001999	1.570E-2	2.600E-2	cell_type;iRBC;unRBC
pyroglutamylisoleucine	ST000974	AN001595	1.570E-2	5.210E-2	REGION;AHRI;MRC;SUN
7-Hydroxyfluphenazine glucuronide	ST000422	AN000668	1.580E-2	2.020E-1	treatment;ND;T1D good glycemic control
(R)-3-Hydroxybutanoate	ST000403	AN000643	1.580E-2	9.310E-2	Glucose labelling;C13 glucose;unlabelled
6-bromotryptophan	ST000975	AN001596	1.590E-2	1.210E-1	GROUP;case;control
iSTD iSTD FA (16:0)-d3	ST000346	AN000562	1.590E-2	1.750E-1	Condition;Mild Asthma;No Asthma;Quality Control;Severe Asthm...
ketodeoxycholate	ST001192	AN001986	1.590E-2	1.090E-1	Diet;-;Omnivore;Vegetarian
N-acetylglycine NIST	ST000392	AN000628	1.590E-2	4.050E-2	Organ;Plasma;Serum;Serum or Plasma
acisoga	ST000975	AN001596	1.600E-2	6.040E-2	GENDER;F;M
Mono-N-depropylprobenecid	ST000046	AN000079	1.600E-2	8.450E-2	Cognitive Status;AD;CN;MCI
uridine-5-diphosphate bromoacetol	ST000403	AN000643	1.600E-2	9.310E-2	Glucose labelling;C13 glucose;unlabelled
3-(Methylthio)propanoate	ST000292	AN000466	1.610E-2	2.020E-1	Treatment ;Baseline plasma;Plasma after drinking apple juice...
D1-2-Hydroxymethylethisterone - 13.49303	ST000422	AN000670	1.610E-2	5.900E-1	treatment;ND;T1D good glycemic control
o-cresol sulfate	ST000899	AN001464	1.610E-2	3.580E-2	Type;Control;Crohn disease;Ulcerative Colitis
OHPro-13C0	ST001045	AN001709	1.610E-2	1.050E-1	protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
Pyrazinoicacid	ST000046	AN000077	1.610E-2	1.370E-1	Cognitive Status;AD;CN;MCI
DSGEGDFXAEGGGVR*	ST000974	AN001595	1.620E-2	5.340E-2	REGION;AHRI;MRC;SUN
URIDINE 5`-DIPHOSPHOGLUCOSE	ST000010	AN000026	1.620E-2	5.110E-2	FCS;FCS;NO_FCS
Lactosylceramide (d18:1/12:0)	ST000241	AN000374	1.630E-2	1.650E-2	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
[13C]-LYSINE	ST000044	AN000068	1.640E-2	1.380E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
BOC-ASP-OH	ST000105	AN000174	1.640E-2	6.040E-1	CPAP;No CPAP;After CPAP
[13C]-HISTIDINE	ST000042	AN000064	1.660E-2	4.910E-1	Condition;Acute lung injury;Healthy
acetophenone NIST	ST000381	AN000615	1.660E-2	4.550E-2	Cohort;CSMC;INHA
Diacetylmonoxime	ST000403	AN000642	1.660E-2	1.140E-1	Glucose labelling;C13 glucose;unlabelled
Mesaconate	ST000539	AN000819	1.660E-2	1.810E-1	Glucose labelling;C13 glucose;unlabelled
Met-Met-Pro-Tyr	ST000403	AN000643	1.660E-2	9.540E-2	Glucose labelling;C13 glucose;unlabelled
sulfa d18:1 N20:0	ST000362	AN000594	1.660E-2	1.260E-1	Chronic_Bronchitis;1;-
pyroGlu-13C5	ST001049	AN001864	1.670E-2	1.000E-1	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
4-Maleylacetoacetate	ST000292	AN000466	1.680E-2	2.050E-1	Treatment ;Baseline plasma;Plasma after drinking apple juice...
NMMA	ST000923	AN001513	1.680E-2	3.420E-2	Diagnosis;CD;nonIBD;UC
Pinacidil-N-Oxide	ST000047	AN000080	1.680E-2	1.800E-1	Cognitive Status;AD;CN;MCI
OH-dihexcer d18:1 N18:0	ST000362	AN000594	1.690E-2	1.260E-1	Chronic_Bronchitis;1;-
Orn / Ser	ST000544	AN000826	1.690E-2	5.230E-2	Sample Type;Control;Replicate
6-deoxy-5-ketofructose-1-phosphate	ST001201	AN001998	1.700E-2	5.890E-2	treatment;DHA;DMSO;OZ277;OZ439
BOC-HIS-OH	ST000105	AN000174	1.700E-2	7.220E-2	Sampling;After SWS onset;Morning fasting
Capillone-13C0[+QDA adduct]+	ST000148	AN000235	1.700E-2	7.280E-2	Treatment;13C-Glc;unlabeled
OHPro-13C2	ST001046	AN001710	1.700E-2	3.540E-1	protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
UDP-GNAc-13C15+15N0	ST000076	AN000121	1.700E-2	5.030E-1	Labeling;13C/15N-Gln;13C-Glc;unlabeled
Fibrinopeptide B (1-12)**	ST000975	AN001596	1.710E-2	2.840E-1	TIMEPOINT;BL;M06;M18
heptadecanoic acid NIST	ST000385	AN000620	1.710E-2	3.940E-2	Smoking Status;Current;Former;NA
17a-Ethynylestradiol	ST000444	AN000695	1.720E-2	5.210E-2	Sample Treatment;Bubbled;Control
5-Nonanol	ST001037	AN001698	1.720E-2	5.230E-2	Description ;Blank;Reagent Blank;Serum Sample;Solvent
Acitretin	ST000444	AN000695	1.720E-2	5.210E-2	Sample Treatment;Bubbled;Control
Ala-Val-Asp-Ser	ST001201	AN001998	1.720E-2	5.890E-2	treatment;DHA;DMSO;OZ277;OZ439
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-	ST000775	AN001222	1.720E-2	7.160E-2	Pair;Pair 1;Pair 2;Pair 3;Pair 4;Pair 5;Pair 6;Pair 7;Pair 8...
Uscharidin-13C0[+QDA adduct+Na]+	ST000148	AN000235	1.720E-2	7.330E-2	Treatment;13C-Glc;unlabeled
17beta-Hydroxy-2alpha-(hydroxymethyl)-5alpha-androstan-3-one-13C1[+13CD3 QDA]+	ST000148	AN000235	1.730E-2	7.400E-2	Treatment;13C-Glc;unlabeled
BOC-ASP-OH	ST000041	AN000063	1.730E-2	1.960E-1	Group;Control;NAFLD
methyl-4-hydroxybenzoate sulfate	ST000899	AN001464	1.730E-2	3.780E-2	Type;Control;Crohn disease;Ulcerative Colitis
metabolite 1	ST000539	AN000818	1.740E-2	3.050E-2	Cell type;Mature erythrocyte;Reticulocyte
N-acetyltheanine	ST000975	AN001596	1.740E-2	6.460E-2	GENDER;F;M
3-propylphosphoenolpyruvate	ST001205	AN002006	1.750E-2	4.490E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
CTAB	ST001205	AN002006	1.750E-2	4.490E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
indole-3-acetonitrile oxide	ST000539	AN000818	1.750E-2	3.070E-2	Cell type;Mature erythrocyte;Reticulocyte
Asn-Asn-Gly-His	ST001201	AN001999	1.760E-2	2.870E-2	cell_type;iRBC;unRBC
hydroxy-CMPF*	ST000976	AN001597	1.760E-2	2.450E-1	GENDER;F;M
Disialyllacto-N-tetraose	ST000241	AN000373	1.770E-2	8.770E-2	Concentration (uM);0;500
[FA (8:1)] 2Z-octenoic acid	ST000403	AN000643	1.770E-2	9.900E-2	Glucose labelling;C13 glucose;unlabelled
FKGK 11	ST000242	AN000377	1.770E-2	4.940E-2	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
isoamylnitrite	ST000046	AN000077	1.770E-2	1.380E-1	Cognitive Status;AD;CN;MCI
Laudanosine	ST000539	AN000819	1.770E-2	3.090E-2	Cell type;Mature erythrocyte;Reticulocyte
Sulfate	ST000046	AN000079	1.770E-2	9.010E-2	Cognitive Status;AD;CN;MCI
7-hydroxyTetranorIloprost	ST000046	AN000079	1.780E-2	9.010E-2	Cognitive Status;AD;CN;MCI
acetophenone NIST	ST000386	AN000621	1.780E-2	6.200E-2	Smoker;Current;Former;NA
o-Toluenesulfamide	ST000046	AN000077	1.780E-2	1.380E-1	Cognitive Status;AD;CN;MCI
(R)-3-((R)-3-Hydroxybutanoyloxy)butanoate	ST001201	AN001999	1.780E-2	2.890E-2	cell_type;iRBC;unRBC
7-ALPHA-HYDROXY-3-OXO-4-CHOLESTENOATE (*)	ST000105	AN000174	1.790E-2	4.190E-1	OSA;Negative;Positive
A-Ketoglutaricacidoxime	ST001201	AN001999	1.790E-2	4.950E-1	treatment_duration_(h);-;0.5;1.5;3
Celiprolol	ST000566	AN000870	1.790E-2	9.110E-2	group;Old-Curcumin;Old-Placebo;young
34-Dihydroxymandelic acid	ST001039	AN001713	1.800E-2	2.680E-2	Sample.Matrix;Plasma;Urine
cis-Cyclo[L-ala-L-Pro]	ST000975	AN001596	1.800E-2	2.150E-1	REGION;MAK;SUN
Creatine-D3	ST000954	AN001564	1.800E-2	7.810E-1	diplotype;1;2
psicoselysine	ST000539	AN000818	1.800E-2	2.970E-1	Glucose labelling;C13 glucose;unlabelled
Oxidized Latia luciferin-13C0[+13CD3 QDA]+	ST000148	AN000235	1.810E-2	7.610E-2	Treatment;13C-Glc;unlabeled
sodium chlorovulone III	ST000422	AN000668	1.810E-2	2.180E-1	treatment;ND;T1D good glycemic control
EICOSATRIENOYLGLYCEROPHOSPHOCHOLINE (*)	ST000105	AN000173	1.830E-2	1.120E-1	Sampling;After SWS onset;Morning fasting
SucroseAndDischarrides-13C11[-H+]-	ST000367	AN000601	1.830E-2	9.070E-2	Tissue type;nontumor;tumor
1-(14 or 15-methyl)palmitoyl-GPC (a17:0 or i17:0)*	ST000974	AN001595	1.840E-2	1.840E-1	GROUP;case;control
3-O-Methyl-myo-inositol	ST000566	AN000870	1.840E-2	2.020E-2	Time point;Post;Pre;Baseline
5-Guanidino-3-methyl-2-oxopentanoate	ST000292	AN000466	1.840E-2	2.060E-1	Treatment ;Baseline plasma;Plasma after drinking apple juice...
AMINOHYDROXYBUTANOIC ACID	ST000106	AN000176	1.840E-2	1.410E-1	Sampling time;0 min;60 min
Asn-Thr-Trp-His	ST001205	AN002007	1.840E-2	5.160E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
GPEtnNMe(16:0/18:1(9Z))	ST000421	AN000664	1.840E-2	2.150E-1	treatment;ND;T1D poor glycemic control
Levonorgestrel	ST000444	AN000695	1.840E-2	5.210E-2	Sample Treatment;Bubbled;Control
O-Desmethyloxotolrestatsulfate	ST000045	AN000072	1.840E-2	1.440E-1	Treatment;Insulin Withdrawal;Saline Infusion
BOC-ASP-OH	ST000106	AN000176	1.850E-2	3.570E-1	Visit;1;2
C12 / C12:1	ST000405	AN000645	1.850E-2	5.990E-1	Group;No PA;PA;PoolAll
t-aconitate-ALL	ST000076	AN000122	1.850E-2	6.410E-2	Labeling;13C/15N-Gln;13C-Glc;unlabeled
O-Desmethylverapamil (D-702)	ST000444	AN000695	1.860E-2	5.210E-2	Sample Treatment;Bubbled;Control
DMGV	ST001236	AN002054	1.870E-2	1.940E-1	Nivolumab Dose (mg/kg);0.3;10;2
GLYCOLITHOCHOLIC ACID ETHYL ESTER	ST000016	AN000033	1.870E-2	4.420E-2	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
p-Hydroxyphenylbutazoneglucuronide	ST000046	AN000079	1.880E-2	9.110E-2	Cognitive Status;AD;CN;MCI
Myxalamid D	ST001204	AN002004	1.890E-2	2.630E-1	treatment;DHA;DMSO;OZ277;OZ439
iSTD iSTD MAG (17:0/0:0/0:0)	ST000346	AN000562	1.900E-2	1.750E-1	Condition;Mild Asthma;No Asthma;Quality Control;Severe Asthm...
iSTD iSTD PC (12:0/13:0)	ST000346	AN000562	1.900E-2	1.750E-1	Condition;Mild Asthma;No Asthma;Quality Control;Severe Asthm...
z dioctylphtalate	ST000416	AN000658	1.900E-2	4.280E-2	Treatment;Day1_antiperspirant;Day1_deodorant;Day1_noproduct;...
2-hydroxyoctanoate	ST000974	AN001595	1.910E-2	1.180E-1	GENDER;F;M
3-CMPFP**	ST000975	AN001596	1.910E-2	1.340E-1	GROUP;case;control
Chloramphenicolalcohol	ST000047	AN000081	1.910E-2	1.420E-1	Cognitive Status;AD;CN;MCI
metabolite 1	ST000539	AN000819	1.910E-2	1.860E-1	Glucose labelling;C13 glucose;unlabelled
propyl 4-hydroxybenzoate sulfate	ST000899	AN001464	1.910E-2	4.070E-2	Type;Control;Crohn disease;Ulcerative Colitis
L-a-glutamyl-L-Lysine	ST001205	AN002006	1.920E-2	4.380E-1	treatment_duration_(h);1;5;3
nitrocyclohexane	ST000539	AN000818	1.920E-2	3.340E-2	Cell type;Mature erythrocyte;Reticulocyte
12-(2-Cyclopenten-1-yl)-2-dodecanone-13C10[+QDA adduct]+	ST000148	AN000235	1.930E-2	7.980E-2	Treatment;13C-Glc;unlabeled
N-Didesethylquinagolide glucuronide	ST000421	AN000663	1.930E-2	2.080E-1	treatment;ND;T1D poor glycemic control
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronide	ST000444	AN000695	1.940E-2	5.210E-2	Sample Treatment;Bubbled;Control
Cyclopentolate	ST000444	AN000695	1.940E-2	5.210E-2	Sample Treatment;Bubbled;Control
L-Glutamic-13C3[-H+]-	ST000367	AN000601	1.940E-2	9.070E-2	Tissue type;nontumor;tumor
L-Hypoglycin	ST000403	AN000643	1.940E-2	1.060E-1	Glucose labelling;C13 glucose;unlabelled
Pro258-ALL	ST000113	AN000191	1.940E-2	2.590E-1	Treatment;None;Tetracycline
D-Alanyl-D-alanine	ST000539	AN000819	1.950E-2	1.860E-1	Glucose labelling;C13 glucose;unlabelled
N-Acetylglutamic-13C3[-H+]-	ST000367	AN000601	1.950E-2	9.070E-2	Tissue type;nontumor;tumor
4-Amino-4-deoxychorismate	ST001201	AN001999	1.970E-2	3.160E-2	cell_type;iRBC;unRBC
isoamyl nitrite	ST000422	AN000669	1.970E-2	1.000E+0	treatment;ND;T1D good glycemic control
tert-Butyl(2-(tert-butyl)-4-methoxyphenoxy)dimethylsilane	ST000978	AN001602	1.970E-2	1.010E-1	Competitive_RRTvsDeath;.;N;RRT;DEATH
cytidine-5-monophosphate NIST	ST000379	AN000613	1.980E-2	3.850E-2	Time;10min;1hr;24hr;6hr
Ac-Tyr-OEt	ST000539	AN000818	1.990E-2	1.600E-1	timepoint;1 hour;20 hours
Ala-Thr-Ala-Gly	ST001201	AN001999	1.990E-2	3.180E-2	cell_type;iRBC;unRBC
glucuronide of piperine metabolite C17H21NO3 (4)*	ST000975	AN001596	1.990E-2	1.350E-1	GROUP;case;control
N-acetyl-2-aminoctanoate	ST000974	AN001595	1.990E-2	1.180E-1	GENDER;F;M
2-keto-l-gluconic acid	ST000092	AN000146	2.000E-2	2.920E-2	Urease Treatment;No treatment;Urease pre-treatment;Water pre...
tocopherol beta NIST	ST000061	AN000099	2.000E-2	6.190E-2	Source;Group 1 - Subcutaenous Fat;Group 2 - Visceral Fat;Met...
lathosterol NIST	ST000386	AN000621	2.010E-2	7.890E-2	Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
Methoxycinnamaldehyde-13C0[+QDA adduct]+	ST000148	AN000235	2.010E-2	8.250E-2	Treatment;13C-Glc;unlabeled
[13C]-VALINE	ST000044	AN000068	2.020E-2	1.560E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
FA methyl(8:0)	ST001202	AN002001	2.020E-2	2.960E-2	treatment_duration_(h);-;1.5;3;6;9
N2-(D-1-Carboxyethyl)-L-arginine	ST001205	AN002006	2.020E-2	5.050E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
L-proline amide	ST000403	AN000642	2.030E-2	2.720E-1	timepoint;1 hour;20 hours
[PS(18:1)] 1-(9Z-octadecenoyl)-sn-glycero-3-phosphoserine	ST001205	AN002007	2.030E-2	5.570E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
tetrahydrogeranylgeranyl-bacteriopheophytin	ST001204	AN002005	2.040E-2	2.300E-1	treatment_duration_(h);-;3;6;9
N-acetylisoleucine	ST000899	AN001464	2.050E-2	4.340E-2	Type;Control;Crohn disease;Ulcerative Colitis
Sodium ortho-phenylphenate	ST000292	AN000466	2.050E-2	2.180E-1	Treatment ;Baseline plasma;Plasma after drinking apple juice...
t-aconitate-13C4	ST000076	AN000122	2.050E-2	7.010E-2	Labeling;13C/15N-Gln;13C-Glc;unlabeled
Gentamicin	ST000444	AN000695	2.060E-2	5.210E-2	Sample Treatment;Bubbled;Control
6-Acetamido-2-oxohexanoate	ST000403	AN000642	2.070E-2	3.380E-2	Cell type;Mature erythrocyte;Reticulocyte
Lorazepamglucuronide	ST000046	AN000076	2.070E-2	1.070E-1	Cognitive Status;AD;CN;MCI
Cys-Met-Pro-His	ST000539	AN000819	2.080E-2	1.890E-1	Glucose labelling;C13 glucose;unlabelled
ETHYL 3-INDOLE ACETATE	ST000105	AN000173	2.080E-2	2.440E-1	Gender;Female;Male
2-Oxovaleric acid	ST000421	AN000663	2.090E-2	2.140E-1	treatment;ND;T1D poor glycemic control
b-Dihydrotetrabenazine	ST000444	AN000695	2.090E-2	5.210E-2	Sample Treatment;Bubbled;Control
Cys-Phe-Trp-Gly	ST001201	AN001998	2.090E-2	6.980E-2	treatment;DHA;DMSO;OZ277;OZ439
deschlorobenzoyl Indomethacin	ST000422	AN000668	2.090E-2	2.440E-1	treatment;ND;T1D good glycemic control
Fructoselysine	ST000539	AN000818	2.090E-2	3.580E-2	Cell type;Mature erythrocyte;Reticulocyte
Fructoselysine 2	ST000539	AN000818	2.090E-2	3.580E-2	Cell type;Mature erythrocyte;Reticulocyte
IS d5-DAG	ST000523	AN000800	2.090E-2	2.890E-2	Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
Prunetin or similar isoflavone	ST000589	AN000904	2.090E-2	2.160E-2	Plasma Volume Extracted;0 uL;100 uL;150 uL;200 uL;25 uL;300 ...
SALICYLATE #2 (M-H)-	ST000523	AN000799	2.090E-2	7.390E-2	Gender;CHEAR_REFERENCE;Female;LIPIDOMICS_STD;Male;POOL_BATCH...
[13C]-ISOLEUCINE	ST000044	AN000068	2.100E-2	1.570E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
Khellol glucoside-13C0[+13CD3 QDA]+	ST000142	AN000225	2.100E-2	1.180E-1	Treatment;13C-Glc;unlabeled
AMINOHYDROXYBUTANOIC ACID	ST000044	AN000069	2.110E-2	8.660E-2	Pancreas tissue type;Normal area of the pancreas with tumor;...
1-octadecanoyl-2-tetradecanoyl-sn-glycero-3-phosphocholine	ST001205	AN002006	2.120E-2	4.380E-1	treatment_duration_(h);1;5;3
cer160	ST000433	AN000683	2.120E-2	8.690E-2	Group;Alzheimer disease dementia;Cognitively normal;Dementia...
gama-Aminobutyrate	ST000284	AN000452	2.130E-2	1.150E-1	Patient group;CRC;Healthy;Polyp
N-gamma-Acetyl-N-2-formyl-5-methoxykynurenamine	ST000047	AN000082	2.130E-2	1.420E-1	Cognitive Status;AD;CN;MCI
6-Acetamido-2-oxohexanoate	ST001204	AN002005	2.140E-2	4.160E-2	cell_type;iRBC;unRBC
L-1-Pyrroline-3-hydroxy-5-carboxylate	ST000539	AN000818	2.140E-2	3.630E-2	Cell type;Mature erythrocyte;Reticulocyte
L-1-Pyrroline-3-hydroxy-5-carboxylate 2	ST000539	AN000818	2.140E-2	3.630E-2	Cell type;Mature erythrocyte;Reticulocyte
[13C]-TYROSINE	ST000044	AN000068	2.150E-2	1.590E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
CL 74:9 (20:3/18:2/20:4/16:0) [M-2H](2-)	ST001111	AN001806	2.150E-2	3.450E-2	Sample;Benign;Cancer;Metastasis
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-	ST000992	AN001618	2.150E-2	6.470E-1	Smoker;No;Yes
Arg-Asp-Asp-Gly	ST001205	AN002006	2.160E-2	5.290E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
Deoxydihydro-artemisinin	ST000444	AN000695	2.160E-2	5.210E-2	Sample Treatment;Bubbled;Control
Diethyl adipate	ST000403	AN000643	2.170E-2	2.300E-1	timepoint;1 hour;20 hours
glucuronide of piperine metabolite C17H21NO3 (5)*	ST000975	AN001596	2.170E-2	7.920E-2	GENDER;F;M
HEXOSE-DISACCHARIDE	ST000424	AN000673	2.170E-2	3.080E-1	DONOR CAUSE OF DEATH;Anoxia;Cerebrovascular/Stroke;CVA;Traum...
(-)-jasmonoyl-L-isoleucine	ST000539	AN000818	2.170E-2	3.670E-2	Cell type;Mature erythrocyte;Reticulocyte
inositol allo-	ST000396	AN000633	2.180E-2	1.340E-1	Age Group;45-49;50-54;55-59;60-64;65-69;70-74
Prostaglandin E2 ethanolamide	ST000241	AN000373	2.180E-2	2.620E-2	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
SDMA / Arg	ST000545	AN000829	2.180E-2	1.360E-1	Sample Type;Control;Replicate
diacetylspermine	ST001237	AN002055	2.190E-2	7.140E-2	Time point;baseline;week 4;week 8
N-Ace-Asp-13C0	ST001049	AN001864	2.190E-2	1.070E-1	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
TRIDESACETOXYKHIVORIN	ST000421	AN000666	2.190E-2	2.330E-1	treatment;ND;T1D poor glycemic control
1-octadecanoyl-rac-glycerol	ST000046	AN000077	2.210E-2	1.560E-1	Cognitive Status;AD;CN;MCI
3-hydroxykynurenate	ST001192	AN001985	2.210E-2	2.870E-1	Diet;-;Omnivore;Vegetarian
AMINOPENTANOIC ACID	ST000105	AN000174	2.210E-2	4.190E-1	OSA;Negative;Positive
CoQ10H2	ST000450	AN000705	2.210E-2	4.300E-2	gender;Female;Male
DIHYDROSPATHELIACHROMENE	ST000047	AN000080	2.210E-2	1.880E-1	Cognitive Status;AD;CN;MCI
L-GLUTAMIC ACID;N-METHYL-D-ASPARTIC ACID;O-ACETYL-L-SERINE;O-Acetyl-L-Serine	ST000954	AN001565	2.210E-2	4.710E-1	ethnicity;1;2;-
threo-Isocitricacid-1.0347548	ST000047	AN000082	2.220E-2	1.420E-1	Cognitive Status;AD;CN;MCI
Total DMA / Arg	ST000405	AN000645	2.220E-2	5.990E-1	Group;No PA;PA;PoolAll
IS Ceramide;[M-H20]+	ST000669	AN001025	2.230E-2	1.790E-1	Matrix;Plasma;SRF;CB
AMINOHYDROXYBENZOIC ACID	ST000016	AN000033	2.240E-2	3.290E-2	Material;Cells;Media
CBS 113A	ST000291	AN000464	2.240E-2	5.970E-1	Treatment ;Baseline urine;Urine after drinking apple juice;U...
D-Galacturonate	ST001205	AN002007	2.240E-2	5.990E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
Oxononanoate-13C1[+QDA adduct]+	ST000148	AN000235	2.240E-2	9.000E-2	Treatment;13C-Glc;unlabeled
Diacetylmonoxime	ST000539	AN000818	2.250E-2	3.790E-2	Cell type;Mature erythrocyte;Reticulocyte
t-aconitate-13C2	ST000076	AN000122	2.250E-2	7.270E-2	Labeling;13C/15N-Gln;13C-Glc;unlabeled
ZEATIN [ISTD] (CAS# 13114-27-7); (M+CL)-	ST000698	AN001083	2.250E-2	1.080E-1	Condition;no;Pooled melanoma;yes
[13C]-LEUCINE	ST000044	AN000068	2.260E-2	1.640E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-	ST000695	AN001075	2.260E-2	1.350E-1	Chemotherapy;N;Y;POOLED
(3-sulfo)Galbeta-Cer(d18:0/18:0(2OH))	ST000445	AN000696	2.270E-2	6.880E-2	Treatment;FSH;LH
EB1213	ST000047	AN000081	2.270E-2	1.610E-1	Cognitive Status;AD;CN;MCI
Gentianaine	ST000539	AN000818	2.270E-2	1.640E-1	timepoint;1 hour;20 hours
Ketohexanoate-13C1[+QDA adduct+Na]+	ST000148	AN000235	2.270E-2	9.100E-2	Treatment;13C-Glc;unlabeled
t-aconitate-13C1	ST001045	AN001709	2.270E-2	1.140E-1	protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
HEXOSE-DISACCHARIDE	ST000475	AN000739	2.280E-2	3.560E-2	Treatment;-;MDH inhib
C8-Ceramide m0	ST000644	AN000976	2.290E-2	3.600E-1	group ID;PHGDH;PSAT;PSPH
Sulfinopyruvate-13C0[+QDA adduct+Na]+	ST000148	AN000235	2.290E-2	9.160E-2	Treatment;13C-Glc;unlabeled
2-docosanamidoethanesulfonicacid	ST000046	AN000077	2.300E-2	1.560E-1	Cognitive Status;AD;CN;MCI
Ganglioside GA1 (d18:1/24:1(15Z))	ST001205	AN002006	2.300E-2	4.380E-1	treatment_duration_(h);1;5;3
Hydroxynonenal-13C0[+QDA adduct]+	ST000148	AN000235	2.300E-2	9.170E-2	Treatment;13C-Glc;unlabeled
3-acetyl pyridine adenine dinucleotide	ST000403	AN000643	2.310E-2	1.210E-1	Glucose labelling;C13 glucose;unlabelled
Ala-Glu-Glu-His	ST001201	AN001998	2.310E-2	7.580E-2	treatment;DHA;DMSO;OZ277;OZ439
fumarate/maleate/alpha-ketoisovalerate	ST001142	AN001876	2.320E-2	2.680E-2	Cell Culture Media;AMEM + 20% FBS;IMDM + 10% FBS;IMDM + 20% ...
ORTHOTHYMOTINICACID	ST000047	AN000082	2.320E-2	1.450E-1	Cognitive Status;AD;CN;MCI
4-ethylphenylsulfate	ST000899	AN001464	2.330E-2	4.890E-2	Type;Control;Crohn disease;Ulcerative Colitis
ETHYL 3-INDOLE ACETATE	ST000105	AN000173	2.330E-2	2.990E-1	PCOS;No PCOS;PCOS
lathosterol NIST	ST000383	AN000618	2.330E-2	9.680E-1	UCP-3 Polymorphism;g/a;g/g
pyroGlu-ALL	ST001045	AN001709	2.330E-2	1.140E-1	protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
pyroglutamylphenylalanine*	ST000975	AN001596	2.330E-2	1.540E-1	GROUP;case;control
Sphinganine-phosphate	ST000612	AN000937	2.330E-2	2.560E-1	Condition;Control;Glaucomatous
Casein K	ST000539	AN000818	2.340E-2	1.650E-1	timepoint;1 hour;20 hours
Casein K 2	ST000539	AN000818	2.340E-2	1.650E-1	timepoint;1 hour;20 hours
CIS-4-NONENE	ST001037	AN001698	2.340E-2	6.810E-2	Description ;Blank;Reagent Blank;Serum Sample;Solvent
penem CGP31608	ST000539	AN000819	2.340E-2	1.950E-1	timepoint;1 hour;20 hours
penem CGP31608 2	ST000539	AN000819	2.340E-2	1.950E-1	timepoint;1 hour;20 hours
glucuronide of piperine metabolite C17H21NO3 (4)*	ST000975	AN001596	2.350E-2	8.290E-2	GENDER;F;M
Oleoylglycerone phosphate-13C0[+H]+	ST000148	AN000235	2.350E-2	9.320E-2	Treatment;13C-Glc;unlabeled
sulfa d18:1 N20:0	ST000362	AN000594	2.350E-2	4.150E-2	Gender;1;2
[13C]-PROLINE	ST000044	AN000068	2.360E-2	1.690E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
3-Hydroxytetradecanedioic acid	ST000444	AN000695	2.360E-2	5.210E-2	Sample Treatment;Bubbled;Control
beta-mannosylglycerate	ST000389	AN000625	2.360E-2	5.000E-1	Emphysema/COPD;No;Yes
Cerebroside C	ST000421	AN000665	2.360E-2	4.280E-1	treatment;ND;T1D poor glycemic control
Oxononanoate-13C0[+13CD3 QDA]+	ST000148	AN000235	2.360E-2	9.330E-2	Treatment;13C-Glc;unlabeled
4-Aminobenzoate/Anthranilate	ST001317	AN002192	2.367E-2	2.549E-2	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
4-Aminobenzoate/Anthranilate	ST001317	AN002192	2.367E-2	2.549E-2	SampleType;CHEAR Study Sample;Matrix_Blank;NIST_3672;Study S...
3-methoxytyramine sulfate	ST000975	AN001596	2.370E-2	1.540E-1	GROUP;case;control
Buspirone N-oxide	ST000444	AN000695	2.370E-2	5.210E-2	Sample Treatment;Bubbled;Control
Trihexosylceramide (d18:1/18:0)	ST000241	AN000374	2.380E-2	2.380E-2	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Hydroxynonenal-13C5[+QDA adduct]+	ST000148	AN000235	2.390E-2	9.450E-2	Treatment;13C-Glc;unlabeled
1-AG and 2-AG	ST000977	AN001599	2.400E-2	4.200E-2	Group;Healthy Control;NAFLD
2-hydroxyoctanoate	ST000974	AN001595	2.400E-2	7.490E-2	REGION;AHRI;MRC;SUN
GAB-ALL	ST000110	AN000185	2.400E-2	6.370E-2	Oxygen Condition;hypoxia;normoxia
GAB-ALL	ST000113	AN000191	2.400E-2	4.370E-1	Oxygen Condition;hypoxia;normoxia
Gentianaine	ST000539	AN000818	2.400E-2	3.640E-1	Glucose labelling;C13 glucose;unlabelled
Glu-Met-Cys-His	ST000403	AN000643	2.400E-2	3.990E-2	Cell type;Mature erythrocyte;Reticulocyte
Oxytetracycline hydrochloride-13C0[+13CD3 QDA]+	ST000148	AN000235	2.400E-2	9.470E-2	Treatment;13C-Glc;unlabeled
t-aconitate-13C4	ST001045	AN001709	2.400E-2	1.140E-1	protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
t-aconitate-ALL	ST000114	AN000194	2.400E-2	8.780E-2	Treatment;None;Tetracycline
HBA	ST000614	AN000940	2.410E-2	2.670E-2	Diagonsis;Benign;Cancer;Normal
Hexose Pool	ST000465	AN000726	2.410E-2	1.340E-1	Treatment;Control;Englerin (100 nM)
methylhexadecanoic acid	ST000386	AN000621	2.410E-2	9.270E-2	Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
N-ACETYL-D-HEXOSAMINE	ST000011	AN000028	2.410E-2	1.050E-1	gender;male;female
UDP-GNAc-13C7+15N0	ST000076	AN000121	2.410E-2	5.980E-1	Labeling;13C/15N-Gln;13C-Glc;unlabeled
3-(a-Naphthoxy)lactic acid	ST000422	AN000668	2.420E-2	2.680E-1	treatment;ND;T1D good glycemic control
8-hydroxymianseringlucuronide	ST000047	AN000082	2.420E-2	1.480E-1	Cognitive Status;AD;CN;MCI
monohexsph	ST000362	AN000594	2.420E-2	9.440E-1	SmokingStatus;-;1
2-deoxycytidine	ST000923	AN001513	2.430E-2	7.810E-2	sex;Female;Male
6-Dehydrotestosterone glucuronide	ST000355	AN000581	2.430E-2	7.300E-2	Stage;1;2;3;4;-
FAMPRIDINE	ST000422	AN000668	2.430E-2	2.680E-1	treatment;ND;T1D good glycemic control
1-(9Z-octadecenoyl)-2-hexadecanoyl-sn-glycero-3-phosphocholine	ST001205	AN002006	2.440E-2	4.400E-1	treatment_duration_(h);1;5;3
FA methyl(16:1)	ST001205	AN002007	2.440E-2	6.440E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
IS Ceramide;[M-H20]+	ST000661	AN001009	2.440E-2	2.710E-2	Sample type;Plasma;Tissues
L-2-aminobutyric acid	ST000356	AN000582	2.440E-2	3.980E-2	Diagnosis;breast cancer;control
NNAL-N-glucuronide	ST000444	AN000695	2.440E-2	5.210E-2	Sample Treatment;Bubbled;Control
Pro258-13C0	ST000076	AN000122	2.440E-2	7.760E-2	Labeling;13C/15N-Gln;13C-Glc;unlabeled
S-Methyl-5-thio-D-ribose 1-phosphate	ST001204	AN002005	2.440E-2	5.980E-1	treatment;DHA;DMSO;OZ277;OZ439
[13C]-THREONINE	ST000044	AN000068	2.450E-2	1.720E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
7-Hydroxyprochlorperazineglucuronide	ST000045	AN000073	2.450E-2	1.120E-1	Treatment;Insulin Withdrawal;Saline Infusion
butylamine NIST	ST000379	AN000613	2.450E-2	6.030E-2	Treatment;10.5mM Glu;5.5mM Glu 5mM Fru;5.5mM Glu;Glucosamine
Oxodecanoate-13C0[+13CD3 QDA]+	ST000148	AN000235	2.450E-2	9.600E-2	Treatment;13C-Glc;unlabeled
Picrasin C-13C0[+13CD3 QDA]+	ST000148	AN000235	2.450E-2	9.610E-2	Treatment;13C-Glc;unlabeled
SucroseAndDischarrides-13C9[-H+]-	ST000367	AN000601	2.450E-2	9.070E-2	Tissue type;nontumor;tumor
Tafluprost free acid	ST000444	AN000695	2.450E-2	5.210E-2	Sample Treatment;Bubbled;Control
URIDINE 5`-DIPHOSPHOGLUCURONIC ACID	ST000010	AN000026	2.450E-2	2.870E-1	TGF;NO_TGF;TGF
FA methyl(16:1)	ST001202	AN002001	2.460E-2	3.550E-2	treatment_duration_(h);-;1.5;3;6;9
Isopropenyl oxoheptanoate-13C5[+QDA adduct]+	ST000148	AN000235	2.460E-2	9.630E-2	Treatment;13C-Glc;unlabeled
6-Acetyl-D-glucose	ST001204	AN002004	2.470E-2	2.530E-1	treatment_duration_(h);-;3;6;9
D-Allose	ST000980	AN001606	2.470E-2	5.820E-2	Classification;Mild;Moderate;Non-allergic;Severe
6beta-hydroxybudesonide	ST000444	AN000695	2.480E-2	5.210E-2	Sample Treatment;Bubbled;Control
8-Hydroxypromazine	ST000046	AN000077	2.480E-2	1.620E-1	Cognitive Status;AD;CN;MCI
BOC-PHE-OH	ST000105	AN000174	2.480E-2	3.250E-1	PCOS;No PCOS;PCOS
ORTHOTHYMOTINIC ACID	ST000421	AN000664	2.480E-2	2.520E-1	treatment;ND;T1D poor glycemic control
Oxprenolol	ST000421	AN000663	2.480E-2	2.380E-1	treatment;ND;T1D poor glycemic control
Sulfoacetate	ST000403	AN000643	2.480E-2	2.460E-1	timepoint;1 hour;20 hours
TROMETHAMINE+5.9955096	ST000046	AN000076	2.480E-2	1.200E-1	Cognitive Status;AD;CN;MCI
N-gamma-Acetyl-N-2-formyl-5-methoxykynurenamine	ST000047	AN000080	2.490E-2	1.950E-1	Cognitive Status;AD;CN;MCI
HBA	ST000614	AN000940	2.500E-2	2.980E-2	Smoking Status;Smoker;Current Smoker;Former Smoker;Non-Smoke...
N-Hydroxymethylnicotinamide	ST000566	AN000870	2.500E-2	2.670E-2	Time point;Post;Pre;Baseline
bOHbutyrate-13C1	ST001046	AN001710	2.510E-2	4.100E-1	protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
gamma-glutamyllysine	ST000976	AN001597	2.510E-2	2.830E-1	GENDER;F;M
Maleylpyruvate-13C0[+QDA adduct+Na]+	ST000142	AN000225	2.510E-2	1.400E-1	Treatment;13C-Glc;unlabeled
monohexsph	ST000362	AN000594	2.510E-2	1.310E-1	Chronic_Bronchitis;1;-
pyroGlu-13C0	ST001049	AN001864	2.510E-2	1.160E-1	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
Apionicacid	ST000046	AN000079	2.520E-2	1.110E-1	Cognitive Status;AD;CN;MCI
His-Thr-OH	ST000242	AN000377	2.520E-2	6.370E-2	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
?-Tocotrienol	ST000553	AN000845	2.520E-2	2.780E-2	Sample type;Plasma;Urine
glucuronide of piperine metabolite C17H21NO3 (3)*	ST000975	AN001596	2.530E-2	1.600E-1	GROUP;case;control
3-Oxotetradecanoate-13C0[+QDA adduct]+	ST000148	AN000235	2.540E-2	9.830E-2	Treatment;13C-Glc;unlabeled
Xanthoxin-13C0[+QDA adduct]+	ST000148	AN000235	2.540E-2	9.840E-2	Treatment;13C-Glc;unlabeled
Acetominophen	ST000913	AN001483	2.550E-2	4.280E-1	Sex;FEMALE;MALE
GAB-13C0	ST001045	AN001709	2.550E-2	1.140E-1	protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
phenylalanine-d8	ST001192	AN001984	2.550E-2	2.800E-1	Diet;-;Omnivore;Vegetarian
C8-Ceramide m+14	ST000644	AN000976	2.560E-2	3.600E-1	group ID;PHGDH;PSAT;PSPH
4-Amino-4-deoxychorismate	ST001205	AN002007	2.570E-2	5.810E-1	treatment_duration_(h);1;5;3
phenol red	ST000974	AN001595	2.570E-2	7.900E-2	REGION;AHRI;MRC;SUN
2-Isopropyl-5-methyl-1-heptanol	ST000978	AN001602	2.580E-2	1.140E-1	Cox_RRT;.;N;Y
aOHglutarate-13C0	ST001049	AN001864	2.580E-2	1.160E-1	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
Kynorenate	ST000284	AN000452	2.580E-2	1.170E-1	Patient group;CRC;Healthy;Polyp
2-Propylisonicotinic acid	ST000422	AN000669	2.590E-2	1.000E+0	treatment;ND;T1D good glycemic control
SFA (PC)	ST000545	AN000830	2.590E-2	3.560E-2	Sample Type;Control;Replicate
[13C]-GLUTAMATE	ST000044	AN000068	2.600E-2	1.740E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
16-a-Hydroxypregnenolone	ST000444	AN000695	2.600E-2	5.210E-2	Sample Treatment;Bubbled;Control
Methyl Docosanoate	ST000978	AN001602	2.600E-2	1.140E-1	Cox_RRT;.;N;Y
BOC-ALA (+NA)	ST000043	AN000070	2.620E-2	7.870E-2	Cell line;MDA-MB-231;MDA-MB-231 p38 gamma knockdown;MDA-MB-2...
Dicyclohexyl phthalate	ST000583	AN000894	2.620E-2	1.850E-1	time;12-weeks;baseline
DIACYL-GLYCEROPHOSPHOCHOLINE (C50H82NO8P PROBABLY)	ST000016	AN000033	2.630E-2	5.870E-2	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
1-PHENYLETHANOL (CAS# 1445-91-6); (M+H)+[-H2O]	ST000741	AN001156	2.640E-2	1.290E-1	subject type;Healthy control;Mild disease;POOLED;Severe dise...
cyclo(L-phe-L-pro)	ST000974	AN001595	2.640E-2	8.080E-2	REGION;AHRI;MRC;SUN
N-ACETYL-HEXOSAMINE	ST000954	AN001564	2.640E-2	1.820E-1	race;1;2
N-BOC-D-GLUCOSAMINE	ST000016	AN000033	2.640E-2	5.870E-2	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
OHPro-ALL	ST001045	AN001709	2.640E-2	1.140E-1	protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
CocamidopropylBetaine	ST000913	AN001483	2.650E-2	3.990E-1	Diagnosis;MECFS;MS;ND
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-	ST000695	AN001075	2.650E-2	1.780E-1	Taxane;N;Y;-
Phenolsulfonphthalein	ST001204	AN002005	2.650E-2	5.050E-2	cell_type;iRBC;unRBC
[13C]-ARGININE	ST000044	AN000068	2.660E-2	1.750E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
2-oxogluconic acid NIST	ST000369	AN000603	2.660E-2	6.950E-2	Smoker;Current;Former;NA
N-Acetyl-O-acetylneuraminate	ST001204	AN002004	2.660E-2	2.650E-1	treatment_duration_(h);-;3;6;9
Napthyl amine	ST000614	AN000943	2.670E-2	3.060E-2	Diagonsis;Benign;Cancer;Normal
ZEATIN [ISTD] (M+H)+	ST000823	AN001307	2.670E-2	4.330E-1	Dysplasia;LGD;N/A
ketoconazol	ST000539	AN000818	2.680E-2	4.470E-2	Cell type;Mature erythrocyte;Reticulocyte
GLYCODEOXYCHOLATE / GLYCOCHENODEOXYCHOLATE (*)	ST000105	AN000174	2.690E-2	3.320E-1	PCOS;No PCOS;PCOS
3-(ADP)-2-phosphoglycerate	ST000539	AN000818	2.700E-2	1.840E-1	timepoint;1 hour;20 hours
3-dimethylsulfoniopropionaldehyde	ST000539	AN000819	2.700E-2	2.040E-1	timepoint;1 hour;20 hours
4-Methylene-L-glutamate	ST000539	AN000819	2.700E-2	4.570E-2	Cell type;Mature erythrocyte;Reticulocyte
Ala-Leu-Thr-Pro	ST000403	AN000642	2.700E-2	1.620E-1	Glucose labelling;C13 glucose;unlabelled
cyclo(leu-pro)	ST000974	AN001595	2.700E-2	1.470E-1	GENDER;F;M
Sulfinpyrazone sulfone	ST000566	AN000869	2.700E-2	3.970E-2	Time point;Post;Pre;Baseline
Cyanidin-3-rhamnoglucoside chloride-13C0[+Na]+	ST000142	AN000225	2.710E-2	1.500E-1	Treatment;13C-Glc;unlabeled
12-Hydroxynevirapine glucuronide	ST000444	AN000695	2.720E-2	5.210E-2	Sample Treatment;Bubbled;Control
20:2 (n-6)	ST001098	AN001786	2.720E-2	4.210E-2	Treatment;Non-obese control;Obese control;Schizophrenia dx
3-Butynoate	ST001205	AN002006	2.720E-2	4.400E-1	treatment_duration_(h);1;5;3
bOHbutyrate-13C00	ST000951	AN001560	2.720E-2	9.040E-1	cell_type;CD8_T_memory;CD8_T_naive;NK
cyclohexylammonium+5.197659	ST000046	AN000076	2.730E-2	1.210E-1	Cognitive Status;AD;CN;MCI
16-Oxo-palmitate	ST000248	AN000392	2.740E-2	7.260E-1	Cell population;Fast-cycling cells;Slow-cyling cells
2(alpha-D-Mannosyl)-D-glycerate	ST000539	AN000819	2.740E-2	2.040E-1	timepoint;1 hour;20 hours
3-CMPFP**	ST000975	AN001596	2.750E-2	2.930E-1	REGION;MAK;SUN
Betaine / L-Valine/ Norvaline	ST001040	AN001702	2.750E-2	5.600E-2	Sample Type/Matrix;Pooled quality control sample;urine;Water...
N5-acetyl-N5-hydroxy-L-ornithine	ST000539	AN000818	2.750E-2	4.560E-2	Cell type;Mature erythrocyte;Reticulocyte
Arg-Lys-Asp-Asp	ST001204	AN002005	2.760E-2	2.760E-1	treatment_duration_(h);-;3;6;9
isolinoleic acid NIST	ST000369	AN000603	2.760E-2	7.030E-2	Smoker;Current;Former;NA
URSODIOL-2 WATER	ST000691	AN001067	2.780E-2	3.250E-2	Progression;Pooled plasma;Y
3-(a-Naphthoxy)lacticacid	ST000047	AN000083	2.790E-2	1.510E-1	Cognitive Status;AD;CN;MCI
Ala-Asp-Asp-Asp	ST001201	AN001998	2.790E-2	4.070E-2	cell_type;iRBC;unRBC
Cycloleucine	ST000567	AN000872	2.790E-2	1.070E-1	groups;Old-Curcumin;Old-Placebo;young
D-Galacturonate	ST001201	AN001999	2.790E-2	4.350E-2	cell_type;iRBC;unRBC
iSTD iSTD Ceramide (d18:1/17:0)	ST000346	AN000562	2.790E-2	1.750E-1	Condition;Mild Asthma;No Asthma;Quality Control;Severe Asthm...
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-	ST000695	AN001075	2.790E-2	1.850E-1	CASE_CONTROL;Case;Control;POOLED
L-Noradrenaline	ST001205	AN002007	2.790E-2	7.230E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
Arg-Met-Asn-His	ST000539	AN000818	2.800E-2	4.630E-2	Cell type;Mature erythrocyte;Reticulocyte
hydroxy-CMPF	ST000976	AN001597	2.800E-2	2.830E-1	GENDER;F;M
O-methylcatechol sulfate	ST000975	AN001596	2.800E-2	3.780E-1	TIMEPOINT;BL;M06;M18
z dioctylphtalate	ST000417	AN001448	2.800E-2	6.220E-1	Collection Time;24HRPOST;Post;Pre
Fibrinopeptide A (3-15)**	ST000975	AN001596	2.810E-2	3.780E-1	TIMEPOINT;BL;M06;M18
IBUPROFEN CARBOXYLIC ACID (M-H)-	ST000743	AN001160	2.820E-2	5.870E-1	Gender;female;male
N-(3-pyridyl)-Indomethacin amide	ST000242	AN000377	2.820E-2	6.760E-2	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
(R)-3-Methyl-2-oxobutanoate	ST000047	AN000082	2.820E-2	1.590E-1	Cognitive Status;AD;CN;MCI
N-Acetylglutamic-13C1[-H+]-	ST000367	AN000601	2.830E-2	9.640E-2	Tissue type;nontumor;tumor
UDP-GNAc-13C12+15N0	ST000076	AN000121	2.840E-2	5.990E-1	Labeling;13C/15N-Gln;13C-Glc;unlabeled
glyoxalurea NIST	ST000369	AN000603	2.850E-2	7.030E-2	Smoker;Current;Former;NA
Prohydrojasmon-13C0[+13CD3 QDA]+	ST000142	AN000225	2.850E-2	1.570E-1	Treatment;13C-Glc;unlabeled
3-(a-Naphthoxy)lactic acid glucuronide	ST000421	AN000665	2.860E-2	4.500E-1	treatment;ND;T1D poor glycemic control
D1-2-Hydroxymethylethisterone - 14.2670965	ST000422	AN000670	2.860E-2	5.900E-1	treatment;ND;T1D good glycemic control
P-Hydroxydesmethylgliquidone	ST000422	AN000668	2.860E-2	2.930E-1	treatment;ND;T1D good glycemic control
4-8dimethylnonanoylcarnitine	ST000403	AN000642	2.870E-2	1.680E-1	Glucose labelling;C13 glucose;unlabelled
7-Hexadecenoic acid methyl ester	ST001000	AN001881	2.870E-2	8.680E-2	Diagnosis;CD;Control;UC
cer200	ST000433	AN000683	2.870E-2	8.690E-2	Group;Alzheimer disease dementia;Cognitively normal;Dementia...
SALICYLURIC GLUCURONIDE (*)	ST000105	AN000174	2.870E-2	1.130E-1	Sampling;After SWS onset;Morning fasting
ARACHIDONATE #2 (M-H)-	ST000818	AN001296	2.880E-2	9.120E-2	Sex;F;M;nan
VD2716	ST000045	AN000075	2.890E-2	1.530E-1	Treatment;Insulin Withdrawal;Saline Infusion
SC-514	ST000567	AN000871	2.900E-2	6.810E-2	groups;Old-Curcumin;Old-Placebo;young
acetytyrosine	ST001000	AN001880	2.910E-2	4.820E-2	Diagnosis;CD;Control;UC
Asn-Lys-Gly-Pro	ST001201	AN001998	2.910E-2	9.250E-2	treatment;DHA;DMSO;OZ277;OZ439
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-	ST000695	AN001075	2.910E-2	1.850E-1	TIMEPOINT;3 Month;Baseline;POOLED
IS D31-TAG	ST000523	AN000800	2.920E-2	9.930E-2	Timing of Sample Collection;CHEAR_REFERENCE;1st trimester;te...
4-hydroxy-3-methylacetophenone	ST000923	AN001513	2.930E-2	8.360E-2	sex;Female;Male
Fenoterolsulfate	ST000047	AN000082	2.930E-2	1.590E-1	Cognitive Status;AD;CN;MCI
Methyl Caprate	ST000978	AN001602	2.930E-2	1.820E-1	Cox_Composite_DeathRRT;.;N;Y
ALPHA-AMINOADIPATE/N-METHYL-L-GLUTAMATE	ST000957	AN001570	2.940E-2	1.960E-1	Milk fraction;fat;skim;whole
carboxyibuprofen	ST000923	AN001515	2.940E-2	2.430E-1	sex;Female;Male
2-Hydroxy-imipramine glucuronide	ST000444	AN000695	2.950E-2	5.280E-2	Sample Treatment;Bubbled;Control
glycodeoxycholate/glycochenodeoxycholate	ST001237	AN002055	2.950E-2	1.080E-1	Treatment;EVEROLIMUS;NIVOLUMAB
MCOA	ST000301	AN000479	2.950E-2	5.160E-2	Cell Line;L229;LN18;Pooled glioblastoma;U-138
Benzoquinoneacetate-13C1[+QDA adduct+Na]+	ST000142	AN000225	2.960E-2	1.630E-1	Treatment;13C-Glc;unlabeled
L-VALINE/5-AMINOPENTANOATE/L-NORVALINE	ST000954	AN001564	2.960E-2	3.180E-1	ethnicity;1;2;-
N-(6-Aminohexanoyl)-6-aminohexanoate	ST000292	AN000466	2.960E-2	2.550E-1	Treatment ;Baseline plasma;Plasma after drinking apple juice...
N-gamma-Acetyl-N-2-formyl-5-methoxykynurenamine	ST000047	AN000083	2.960E-2	1.530E-1	Cognitive Status;AD;CN;MCI
2-Amino-2-methyl-1-propanol	ST000047	AN000080	2.970E-2	2.150E-1	Cognitive Status;AD;CN;MCI
BOC-HIS-OH	ST000016	AN000033	2.970E-2	6.510E-2	Cell type;293T;DEL;SR786;SUDHL-1;SUPM2
octulose 8-phosphate	ST000539	AN000819	2.980E-2	2.420E-1	Glucose labelling;C13 glucose;unlabelled
Dimenhydrinate	ST000444	AN000695	2.990E-2	5.280E-2	Sample Treatment;Bubbled;Control
[6]-Paradol	ST001201	AN001999	3.000E-2	4.640E-2	cell_type;iRBC;unRBC
cefamandolenafate	ST000047	AN000081	3.000E-2	1.810E-1	Cognitive Status;AD;CN;MCI
4-Hydroxytacrine	ST000047	AN000082	3.010E-2	1.600E-1	Cognitive Status;AD;CN;MCI
GLYCODEOXYCHOLATE / GLYCOCHENODEOXYCHOLATE (*)	ST000105	AN000174	3.010E-2	1.160E-1	Sampling;After SWS onset;Morning fasting
(R)-piperidine-3-carboxylate	ST001205	AN002006	3.010E-2	6.900E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
2-Phospho-D-glycerate	ST001201	AN001999	3.020E-2	6.950E-1	treatment_duration_(h);-;0.5;1.5;3
4-Oxocyclohexanecarboxylate-13C0[+QDA adduct]+	ST000148	AN000235	3.020E-2	1.130E-1	Treatment;13C-Glc;unlabeled
N-gamma-Acetyl-N-2-formyl-5-methoxykynurenamine	ST000046	AN000076	3.020E-2	1.310E-1	Cognitive Status;AD;CN;MCI
13C-aminoadipic	ST000948	AN001557	3.030E-2	4.540E-2	Time point;120;135;150;-15;165;180;-30;-45;-60;60;baseline
Aminofructose 6-phosphate/Glucosamine 6-phosphate-13C3[-H+]-	ST000367	AN000601	3.030E-2	9.720E-2	Tissue type;nontumor;tumor
Oxooctanoate-13C0[+QDA adduct+Na]+	ST000148	AN000235	3.030E-2	1.140E-1	Treatment;13C-Glc;unlabeled
(R)-3-Hydroxybutanoate	ST000539	AN000819	3.030E-2	5.100E-2	Cell type;Mature erythrocyte;Reticulocyte
4-Hydroxyphenylacetylglycine	ST000403	AN000643	3.040E-2	4.920E-2	Cell type;Mature erythrocyte;Reticulocyte
8-Amino-7-oxononanoate+4.7958198	ST000047	AN000080	3.040E-2	2.150E-1	Cognitive Status;AD;CN;MCI
O-Acetyl-L-homoserine 2	ST000539	AN000819	3.040E-2	2.170E-1	timepoint;1 hour;20 hours
Chloramphenicolalcohol	ST000046	AN000077	3.050E-2	1.690E-1	Cognitive Status;AD;CN;MCI
O-PHOSPHONOHEXOPYRANOSE	ST000044	AN000069	3.050E-2	1.150E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
IBUPROFEN CARBOXYLIC ACID (M-H)-	ST000721	AN001128	3.070E-2	3.590E-1	CT findings;Abnormal only;Normal
TROMETHAMINE+5.7465215	ST000046	AN000077	3.070E-2	1.690E-1	Cognitive Status;AD;CN;MCI
4-methylhexanoylglutamine	ST000975	AN001596	3.080E-2	3.160E-1	REGION;MAK;SUN
HYDROLYSIS PRODUCT OF BUSSEIN	ST000421	AN000664	3.080E-2	2.780E-1	treatment;ND;T1D poor glycemic control
BOC-ALA-OH	ST000043	AN000070	3.090E-2	8.790E-2	Cell line;MDA-MB-231;MDA-MB-231 p38 gamma knockdown;MDA-MB-2...
bOHbutyrate-13C0	ST000076	AN000122	3.090E-2	9.100E-2	Labeling;13C/15N-Gln;13C-Glc;unlabeled
6-deoxy-mannose	ST000355	AN000580	3.100E-2	8.090E-2	Stage;1;2;3;4;-
BOC-MET-OH	ST000105	AN000174	3.100E-2	1.190E-1	Sampling;After SWS onset;Morning fasting
BOC-PRO-OH	ST000106	AN000175	3.100E-2	2.460E-1	Sampling time;0 min;60 min
Celiprolol	ST000566	AN000870	3.110E-2	3.260E-2	Time point;Post;Pre;Baseline
D9-Choline iSTD	ST001211	AN002017	3.110E-2	9.160E-2	Group;Control;Methotrexate
N-acetyl-2-aminoctanoate	ST000974	AN001595	3.110E-2	9.200E-2	REGION;AHRI;MRC;SUN
PYRIDINE CARBOXYLIC ACID	ST000044	AN000068	3.110E-2	1.900E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
4-Aminophenyl 1-thio-beta-D-glucuronide + 2.6188798	ST000421	AN000663	3.120E-2	2.630E-1	treatment;ND;T1D poor glycemic control
AMINOPENTANOIC ACID	ST000106	AN000176	3.120E-2	1.880E-1	Sampling time;0 min;60 min
[13C]-ARGININE	ST000105	AN000173	3.130E-2	5.450E-1	CPAP;No CPAP;After CPAP
[13C]-PROLINE	ST000105	AN000173	3.130E-2	3.500E-1	PCOS;No PCOS;PCOS
17beta-Hydroxy-5alpha-androst-2-ene-2-carboxaldehyde-13C1[+QDA adduct]+	ST000148	AN000235	3.130E-2	1.160E-1	Treatment;13C-Glc;unlabeled
Benzoquinoneacetate-13C0[+QDA adduct]+	ST000148	AN000235	3.130E-2	1.160E-1	Treatment;13C-Glc;unlabeled
N-ACETYL-HEXOSAMINE	ST000956	AN001569	3.130E-2	5.580E-2	Treatment;Condition-1;Condition-2;Condition-3;Control
N-Hydroxymethylnicotinamide	ST000566	AN000870	3.130E-2	1.220E-1	group;Old-Curcumin;Old-Placebo;young
Ovothiol disulfide	ST001201	AN001999	3.130E-2	4.820E-2	cell_type;iRBC;unRBC
URETHANE	ST000421	AN000663	3.130E-2	2.630E-1	treatment;ND;T1D poor glycemic control
metabolite 1	ST000539	AN000819	3.140E-2	5.260E-2	Cell type;Mature erythrocyte;Reticulocyte
10-Hydroxy-octadec-12Z-enoate-9-beta-D-glucuronide	ST000444	AN000695	3.150E-2	5.280E-2	Sample Treatment;Bubbled;Control
7-ALPHA-HYDROXY-3-OXO-4-CHOLESTENOATE	ST000011	AN000028	3.150E-2	2.020E-1	ETHNICITY_ASSIGNED;AMHARA;ARGOBBA;MURSI;SABUE;WEYTO;HADZABE;...
cytidine-5-monophosphate NIST	ST000061	AN000099	3.150E-2	8.210E-2	Source;Group 1 - Subcutaenous Fat;Group 2 - Visceral Fat;Met...
AMINOHYDROXYBUTANOIC ACID	ST000041	AN000063	3.160E-2	7.450E-1	Visit;1;2;3;4;5;6;7
Arachidonyl lysolecithin + 10.70548	ST000421	AN000665	3.160E-2	4.500E-1	treatment;ND;T1D poor glycemic control
c241hexcerum	ST000433	AN000683	3.160E-2	8.690E-2	Group;Alzheimer disease dementia;Cognitively normal;Dementia...
FA hydroxy(18:1)]	ST001204	AN002004	3.160E-2	5.060E-2	cell_type;iRBC;unRBC
Glu-Met-Met-His	ST000539	AN000819	3.160E-2	5.270E-2	Cell type;Mature erythrocyte;Reticulocyte
L-Glutamic-13C2[-H+]-	ST000367	AN000601	3.160E-2	9.800E-2	Tissue type;nontumor;tumor
1-deoxyxylonojirimycin	ST001205	AN002006	3.170E-2	7.170E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
aOHglutarate-13C4	ST001049	AN001864	3.170E-2	1.310E-1	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
Diglycolicacid	ST000046	AN000078	3.180E-2	1.220E-1	Cognitive Status;AD;CN;MCI
ETHYL 3-UREIDOPROPIONATE (M+H)+	ST000726	AN001139	3.190E-2	6.770E-2	Timepoint;-;270;120;30;90
C6H12O6-HEXOSE/KETOSE/INOSITOL	ST000919	AN001507	3.200E-2	1.310E-1	Response;NR;R
Mycalamide A	ST000566	AN000870	3.210E-2	3.330E-2	Time point;Post;Pre;Baseline
Oxododecanoate-13C1[+QDA adduct]+	ST000148	AN000235	3.210E-2	1.180E-1	Treatment;13C-Glc;unlabeled
Pro258-13C5	ST000114	AN000194	3.210E-2	2.630E-1	Oxygen Condition;hypoxia;normoxia
3-AP	ST001167	AN001929	3.220E-2	6.260E-2	Cell lines;RWPE1;VCaP
L-gamma-Cyano-gamma-aminobutyricacid+1.2438003	ST000046	AN000077	3.220E-2	1.700E-1	Cognitive Status;AD;CN;MCI
Methyltyrosine	ST000356	AN000582	3.220E-2	5.800E-2	stage;-;2;3
3-S-cysteinyl-2-methylpropanoate*	ST000975	AN001596	3.230E-2	1.870E-1	GROUP;case;control
Edrophonium	ST000444	AN000695	3.230E-2	5.280E-2	Sample Treatment;Bubbled;Control
N-desmethylimatinib	ST000444	AN000695	3.230E-2	5.280E-2	Sample Treatment;Bubbled;Control
O-Acetyl-Lcarnitine:HCl (N-methyl-D3)	ST000552	AN000843	3.230E-2	9.420E-1	VTE;no;yes
trans-Hexadec-2-enoyl carnitine	ST000355	AN000581	3.230E-2	8.950E-2	Stage;1;2;3;4;-
Aspidofractine	ST000539	AN000818	3.250E-2	2.020E-1	timepoint;1 hour;20 hours
glyoxalurea NIST	ST000369	AN000603	3.250E-2	8.530E-2	Gender;F;M;NA
glyoxalurea NIST	ST000386	AN000621	3.250E-2	1.180E-1	Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
TRIDESACETOXYKHIVORIN	ST000046	AN000078	3.260E-2	1.230E-1	Cognitive Status;AD;CN;MCI
Ala-Leu-Trp-Ser	ST001201	AN001998	3.270E-2	5.330E-1	treatment_duration_(h);-;0.5;1.5;3
Desmethylmianserin glucuronide	ST000566	AN000870	3.270E-2	1.230E-1	group;Old-Curcumin;Old-Placebo;young
PO4-ALL	ST001049	AN001864	3.270E-2	1.310E-1	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
24-Dihydroxyacetophenone	ST001193	AN001988	3.280E-2	4.810E-2	Plasma;Cord blood;Plasma
4-Hydroxybenzylcyanide+6.609466	ST000046	AN000076	3.280E-2	1.340E-1	Cognitive Status;AD;CN;MCI
GLUCOSAMINE/MANNOSAMINE	ST000424	AN000673	3.280E-2	3.080E-1	DONOR CAUSE OF DEATH;Anoxia;Cerebrovascular/Stroke;CVA;Traum...
NVP-BEZ235	ST000567	AN000871	3.280E-2	7.570E-2	groups;Old-Curcumin;Old-Placebo;young
5-alpha-Coprostanol or similar oxysterol	ST000586	AN000901	3.290E-2	3.870E-2	Plasma Volume;0 uL;150 uL;700 uL
N-acetylalliin	ST000975	AN001596	3.290E-2	3.250E-1	REGION;MAK;SUN
3-(ADP)-glycerate	ST001202	AN002001	3.300E-2	3.540E-2	cell_type;iRBC;unRBC
fucose + rhamnose	ST000369	AN000603	3.300E-2	8.530E-2	Gender;F;M;NA
3-(4-Hydroxyphenyl)propionic acid	ST000586	AN000901	3.310E-2	3.870E-2	Plasma Volume;0 uL;150 uL;700 uL
Sulfoacetate	ST000403	AN000643	3.310E-2	5.340E-2	Cell type;Mature erythrocyte;Reticulocyte
1-monoheptadecanoyl glyceride NIST	ST000910	AN001480	3.330E-2	2.390E-1	Diagnosis;MECFS;MS;ND
6-oxopiperidine-2-carboxylic acid	ST000975	AN001596	3.330E-2	3.990E-1	TIMEPOINT;BL;M06;M18
M1	ST000291	AN000464	3.330E-2	7.190E-1	Treatment ;Baseline urine;Urine after drinking apple juice;U...
ZEATIN [ISTD] (M+Cl)-	ST000523	AN000799	3.330E-2	7.870E-2	Type of Family Member;CHEAR_REFERENCE;mother;child;LIPIDOMIC...
ACETAMINOPHEN (TN TYLENOL) (M+Na)+	ST000818	AN001297	3.340E-2	6.130E-2	Categorization;Amhara;Dizi;Hadza_settled;Hadza_traditional;H...
Dicyclohexyl phthalate	ST000583	AN000894	3.340E-2	2.650E-1	caries status;caries-active;caries-free
Isobutyrylglycinemethylester	ST000047	AN000083	3.350E-2	1.650E-1	Cognitive Status;AD;CN;MCI
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-	ST000695	AN001075	3.350E-2	1.400E-1	Race;Black;White;POOLED
methylhexadecanoic acid	ST000389	AN000625	3.350E-2	2.910E-1	Group;Benign;Cancer
saccharic acid	ST000369	AN000603	3.350E-2	6.820E-2	Organ;Plasma;Serum
AFN911	ST000444	AN000695	3.360E-2	5.280E-2	Sample Treatment;Bubbled;Control
BOC-ALA (+NA)	ST000105	AN000173	3.360E-2	5.450E-1	CPAP;No CPAP;After CPAP
iodoacetate	ST001204	AN002005	3.360E-2	6.260E-2	cell_type;iRBC;unRBC
Oxononanoate-13C0[+QDA adduct]+	ST000148	AN000235	3.360E-2	1.230E-1	Treatment;13C-Glc;unlabeled
SAPPANONEA7-METHYLETHER	ST000046	AN000079	3.370E-2	1.280E-1	Cognitive Status;AD;CN;MCI
4-Amino-4-deoxychorismate	ST001205	AN002007	3.380E-2	8.690E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
Deoxyartemsinin	ST000444	AN000695	3.380E-2	5.280E-2	Sample Treatment;Bubbled;Control
Lactose+K	ST000954	AN001564	3.380E-2	6.520E-1	daily_dose;2;3;4;1
C16 / C16:1	ST000405	AN000645	3.390E-2	5.630E-1	Vaginal Bleeding;N;UNK;Y;-
ethyl-(2R)-methyl-(3S)-hydroxybutanoate	ST000539	AN000819	3.390E-2	5.620E-2	Cell type;Mature erythrocyte;Reticulocyte
N-acetyphenylalanine	ST001192	AN001984	3.390E-2	2.800E-1	Diet;-;Omnivore;Vegetarian
URIDINE 5`-DIPHOSPHOGLUCOSE	ST000010	AN000026	3.390E-2	8.170E-2	Hours;72;0;12;24;2
2-hydroxyoctanoate	ST000899	AN001464	3.400E-2	6.860E-2	Type;Control;Crohn disease;Ulcerative Colitis
Arg-Met-Asn-His	ST000539	AN000818	3.400E-2	4.110E-1	Glucose labelling;C13 glucose;unlabelled
saccharic acid	ST000386	AN000621	3.400E-2	7.070E-2	Organ;Plasma;Serum
AC1MIY4G	ST000770	AN001217	3.410E-2	1.660E-1	Timepoint;T0;T55
AMINOHYDROXYBUTANOIC ACID	ST000106	AN000175	3.410E-2	2.620E-1	Sampling time;0 min;60 min
cytidine-5-monophosphate NIST	ST000379	AN000613	3.410E-2	7.700E-2	Treatment;10.5mM Glu;5.5mM Glu 5mM Fru;5.5mM Glu;Glucosamine
Dinoterb (herbicide)	ST000583	AN000895	3.410E-2	1.830E-1	time;12-weeks;baseline
Dibucaine0cinchocaine	ST000444	AN000695	3.420E-2	5.280E-2	Sample Treatment;Bubbled;Control
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (POSSIBLY)	ST000041	AN000063	3.420E-2	3.160E-1	Group;Control;NAFLD
4-PIOL	ST000539	AN000818	3.430E-2	2.110E-1	timepoint;1 hour;20 hours
Cit / Arg	ST000544	AN000826	3.430E-2	1.020E-1	Sample Type;Control;Replicate
Oxidized Latia luciferin-13C1[+13CD3 QDA]+	ST000148	AN000235	3.430E-2	1.250E-1	Treatment;13C-Glc;unlabeled
Chlordiazepoxide	ST000913	AN001483	3.440E-2	4.400E-1	Sex;FEMALE;MALE
cis-Acetylacrylate	ST001205	AN002007	3.440E-2	1.000E+0	treatment;DHA;DMSO;OZ277;OZ439
Hydroxycholesterol species	ST000450	AN000705	3.440E-2	1.410E-1	Disease;CFS;Normal
L-Aspartic acid b-semialdehyde	ST000422	AN000668	3.450E-2	3.260E-1	treatment;ND;T1D good glycemic control
PROCOLLAGEN 5-HYDROXY-L-LYSINE (M+H)+	ST000823	AN001307	3.450E-2	7.330E-1	Diagnosis;IPMN;MCN;SCA
SM(d18:1/25:0) or SM(d18:1/24:1 OH)	ST000617	AN000946	3.450E-2	3.110E-1	Treatment;CFS;Control
2-Amino-2-methyl-1-propanol	ST000047	AN000081	3.460E-2	1.970E-1	Cognitive Status;AD;CN;MCI
2-Dehydro-D-xylonate	ST000539	AN000819	3.460E-2	5.700E-2	Cell type;Mature erythrocyte;Reticulocyte
2-Dehydro-D-xylonate 2	ST000539	AN000819	3.460E-2	5.700E-2	Cell type;Mature erythrocyte;Reticulocyte
Bergamottin	ST001037	AN001698	3.460E-2	9.520E-2	Description ;Blank;Reagent Blank;Serum Sample;Solvent
Ferrous lactate	ST000291	AN000465	3.460E-2	6.800E-1	Treatment ;Baseline urine;Urine after drinking apple juice;U...
Manumycin A-13C16[+H]+	ST000148	AN000235	3.460E-2	1.260E-1	Treatment;13C-Glc;unlabeled
N-Acetyl-5-aminosalicylicacid-3.4608338	ST000046	AN000079	3.460E-2	1.280E-1	Cognitive Status;AD;CN;MCI
ZEATIN [ISTD] (M+H)+	ST000744	AN001163	3.470E-2	4.360E-1	Gender;female;male
4-Methyl-5-thiazoleethanol?	ST001211	AN002017	3.480E-2	9.980E-2	Group;Control;Methotrexate
ethyl-(2R)-methyl-(3S)-hydroxybutanoate	ST000539	AN000819	3.480E-2	2.630E-1	Glucose labelling;C13 glucose;unlabelled
bOHbutyrate-13C0	ST001049	AN001864	3.500E-2	1.340E-1	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
N-Acetyl-ala-ala-ala-methylester	ST000403	AN000642	3.510E-2	1.900E-1	Glucose labelling;C13 glucose;unlabelled
Triphosphate	ST000241	AN000373	3.510E-2	4.150E-2	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
Glu-Lys-Lys-Phe	ST001202	AN002001	3.530E-2	5.020E-2	treatment_duration_(h);-;1.5;3;6;9
7-DEACETOXY-7-OXOKHIVORIN	ST000047	AN000080	3.540E-2	2.350E-1	Cognitive Status;AD;CN;MCI
Aspidofractine	ST000403	AN000642	3.540E-2	1.900E-1	Glucose labelling;C13 glucose;unlabelled
CAI-1-13C0[+13CD3 QDA]+	ST000142	AN000225	3.540E-2	1.920E-1	Treatment;13C-Glc;unlabeled
7-ALPHA-HYDROXY-3-OXO-4-CHOLESTENOATE (*)	ST000106	AN000176	3.550E-2	1.990E-1	Sampling time;0 min;60 min
N2-(D-1-Carboxyethyl)-L-arginine	ST001201	AN001998	3.550E-2	5.120E-2	cell_type;iRBC;unRBC
(S)-Methylmalonate semialdehyde	ST000539	AN000819	3.550E-2	2.310E-1	timepoint;1 hour;20 hours
acetytyrosine	ST000923	AN001515	3.560E-2	7.040E-2	Diagnosis;CD;nonIBD;UC
5-hydroxynorvaline NIST	ST000390	AN000626	3.570E-2	2.040E-1	Diagnosis;adenocarcinoma;adenocarcinoma w/ BAC;adenocarcinom...
Nitro-Tyr1)	ST000783	AN001239	3.570E-2	7.020E-1	RACE;AA;EA
FA methyl(14:0)	ST001202	AN002001	3.580E-2	5.060E-2	treatment_duration_(h);-;1.5;3;6;9
Gln-Phe-Gln-His	ST001205	AN002007	3.580E-2	9.130E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
THYMIDINE-5`-DIPHOSPHO-ALPHA-D-GLUCOSE	ST000044	AN000069	3.580E-2	1.290E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
cyclohexylammonium+2.7358363	ST000046	AN000076	3.610E-2	1.430E-1	Cognitive Status;AD;CN;MCI
[13C]-PHENYLALANINE	ST000044	AN000068	3.630E-2	1.940E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
Caffeine-D3	ST000424	AN000673	3.630E-2	7.400E-1	SEX;F;M
Methyl Linocerate	ST000978	AN001602	3.630E-2	1.330E-1	Cox_RRT;.;N;Y
Trimethylsilyl 3-((trimethylsilyl)thio)propanoate	ST000978	AN001602	3.630E-2	1.330E-1	Cox_RRT;.;N;Y
[13C]-ASPARTIC ACID	ST000044	AN000068	3.640E-2	1.940E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
2-amino-2-deoxy-isochorismate	ST001201	AN001999	3.640E-2	5.590E-2	cell_type;iRBC;unRBC
Arachidonyl lysolecithin	ST000422	AN000667	3.640E-2	5.290E-1	treatment;ND;T1D good glycemic control
6-deoxyglucitol NIST	ST000386	AN000621	3.660E-2	1.210E-1	Gender;F;M;NA
2-methylcitrate/homocitrate	ST000899	AN001464	3.670E-2	7.320E-2	Type;Control;Crohn disease;Ulcerative Colitis
Fibrinopeptide B (1-13)**	ST000974	AN001595	3.670E-2	1.060E-1	REGION;AHRI;MRC;SUN
idonic acid NIST	ST000379	AN000613	3.670E-2	6.590E-2	Time;10min;1hr;24hr;6hr
Dityrosine	ST000444	AN000695	3.680E-2	5.570E-2	Sample Treatment;Bubbled;Control
methylnaphthyl sulfate (2)*	ST000974	AN001595	3.680E-2	1.060E-1	REGION;AHRI;MRC;SUN
palmithoylethanolamide	ST000923	AN001516	3.680E-2	5.370E-2	Diagnosis;CD;nonIBD;UC
BOC-HIS-OH	ST000105	AN000174	3.690E-2	5.090E-1	OSA;Negative;Positive
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-	ST000698	AN001083	3.690E-2	1.440E-1	KD#2;yes;no;Pooled melanoma
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-	ST000698	AN001083	3.690E-2	2.040E-1	KD#1;no;yes;Pooled melanoma
N-HISTIDYL-2-AMINONAPHTHALENE (betaNA)	ST000421	AN000665	3.690E-2	4.500E-1	treatment;ND;T1D poor glycemic control
GemfibrozilM2	ST000046	AN000078	3.700E-2	1.320E-1	Cognitive Status;AD;CN;MCI
arachidiic acid	ST000416	AN000658	3.710E-2	1.430E-1	Gender;Female;Male
Asn-Gln-Tyr-His	ST000403	AN000643	3.710E-2	1.680E-1	Glucose labelling;C13 glucose;unlabelled
2-(Hydroxymethyl)-3-(acetamidomethylene)succinate	ST001201	AN001999	3.730E-2	1.540E-1	treatment;DHA;DMSO;OZ277;OZ439
(R)-AMAA	ST000539	AN000819	3.740E-2	2.360E-1	timepoint;1 hour;20 hours
Ivermectin B1a + 11.394018	ST000421	AN000665	3.750E-2	4.500E-1	treatment;ND;T1D poor glycemic control
LACTATE-dimer	ST000954	AN001565	3.750E-2	2.880E-1	race;1;2
4-hydroxy-3-methylacetophenone	ST001236	AN002054	3.760E-2	1.350E-1	OS_Censor (1 means the time is a censoring time and 0 means ...
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-	ST000695	AN001075	3.770E-2	2.060E-1	Tamoxyfen;N;Y;-
N-ACETYL-HEXOSAMINE	ST000583	AN000895	3.780E-2	1.940E-1	time;12-weeks;baseline
[13C]-VALINE	ST000106	AN000175	3.790E-2	4.680E-1	Constitution;Lean;Obese
6-deoxyglucitol NIST	ST000369	AN000603	3.790E-2	9.390E-2	Gender;F;M;NA
aOHglutarate-13C1	ST001049	AN001864	3.790E-2	1.430E-1	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
6-oxopiperidine-2-carboxylic acid	ST000975	AN001596	3.800E-2	3.590E-1	REGION;MAK;SUN
alpha-Methylstyrene	ST000403	AN000642	3.800E-2	4.040E-1	timepoint;1 hour;20 hours
BOC-ASN	ST000044	AN000068	3.800E-2	1.940E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
Propionylglycinemethylester	ST000046	AN000079	3.800E-2	1.350E-1	Cognitive Status;AD;CN;MCI
Abscisic acid glucose ester	ST000403	AN000643	3.810E-2	1.720E-1	Glucose labelling;C13 glucose;unlabelled
Cys-Leu-Cys-Tyr	ST001201	AN001999	3.810E-2	1.540E-1	treatment;DHA;DMSO;OZ277;OZ439
3-(1-Pyrrolidinyl)-2-pentanone	ST001202	AN002000	3.820E-2	4.640E-2	treatment_duration_(h);-;1.5;3;6;9
BOC-ASP-OH	ST000105	AN000174	3.820E-2	5.090E-1	OSA;Negative;Positive
hexanoylglutamine	ST000974	AN001595	3.820E-2	1.830E-1	GENDER;F;M
Lactosylceramide(d18	ST001202	AN002000	3.820E-2	4.640E-2	treatment_duration_(h);-;1.5;3;6;9
5-Formiminotetrahydrofolic acid	ST000566	AN000870	3.830E-2	1.300E-1	group;Old-Curcumin;Old-Placebo;young
BOC-PRO-OH	ST000105	AN000173	3.830E-2	4.040E-1	Gender;Female;Male
GLYCERALDEHYDE 3-PHOSPHATE DIETHYL ACETAL	ST000016	AN000033	3.830E-2	5.380E-2	Material;Cells;Media
3-HB (3-hydroxybutyric acid)	ST000166	AN000259	3.850E-2	6.650E-2	Group;3M;Control;HF
[Fv] Desmosdumotin C	ST000539	AN000818	3.850E-2	4.280E-1	Glucose labelling;C13 glucose;unlabelled
IS Ceramide; [M-H2O]+	ST000523	AN000800	3.850E-2	1.250E-1	Timing of Sample Collection;CHEAR_REFERENCE;1st trimester;te...
Ne-Acetyllysine	ST001037	AN001698	3.850E-2	1.040E-1	Description ;Blank;Reagent Blank;Serum Sample;Solvent
(R)-AMAA	ST000539	AN000819	3.850E-2	2.830E-1	Glucose labelling;C13 glucose;unlabelled
possible sucrose	ST000420	AN000662	3.870E-2	5.480E-2	Group;nonsmoker;smoker
PYRIDINE CARBOXYLIC ACID	ST000016	AN000033	3.870E-2	5.420E-2	Material;Cells;Media
URSINICACID	ST000046	AN000076	3.870E-2	1.510E-1	Cognitive Status;AD;CN;MCI
diacetylspermine	ST001237	AN002055	3.880E-2	1.240E-1	Treatment;EVEROLIMUS;NIVOLUMAB
5-adenosylhomocysteine	ST001142	AN001875	3.890E-2	4.000E-2	Classifications;AML;B-cell_ALL;B-cell_lymphoma_other;bile_du...
6-deoxy-5-ketofructose-1-phosphate	ST001205	AN002006	3.900E-2	8.240E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
acetyl-galactosamine	ST001236	AN002054	3.910E-2	2.310E-1	Nivolumab Dose (mg/kg);0.3;10;2
Ala-Leu-Thr-Pro	ST000539	AN000818	3.910E-2	6.190E-2	Cell type;Mature erythrocyte;Reticulocyte
Pentazocinetransacid	ST000047	AN000080	3.910E-2	2.470E-1	Cognitive Status;AD;CN;MCI
Phenolsulfonphthalein	ST001201	AN001999	3.910E-2	7.400E-1	treatment_duration_(h);-;0.5;1.5;3
BOC-MET-OH	ST000105	AN000174	3.930E-2	6.250E-1	CPAP;No CPAP;After CPAP
N5-acetyl-N5-hydroxy-L-ornithine	ST001201	AN001998	3.930E-2	6.150E-1	treatment_duration_(h);-;0.5;1.5;3
N2-(D-1-Carboxyethyl)-L-arginine	ST001204	AN002004	3.940E-2	3.080E-1	treatment_duration_(h);-;3;6;9
PROCOLLAGEN 5-HYDROXY-L-LYSINE (CAS# 1190-94-9); (M+H)+	ST000741	AN001156	3.950E-2	1.740E-1	subject type;Healthy control;Mild disease;POOLED;Severe dise...
AMINOHYDROXYBUTANOIC ACID	ST000044	AN000068	3.960E-2	1.980E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
18-Hydroxycorticosterone	ST000355	AN000581	3.980E-2	9.380E-2	Stage;1;2;3;4;-
4-Hydroxypyridine+1.305617	ST000046	AN000076	3.990E-2	1.530E-1	Cognitive Status;AD;CN;MCI
isoamyl nitrite	ST000421	AN000665	4.000E-2	4.500E-1	treatment;ND;T1D poor glycemic control
Met-Trp-Trp-Tyr	ST000403	AN000642	4.000E-2	4.140E-1	timepoint;1 hour;20 hours
Diacetylmonoxime	ST000539	AN000818	4.010E-2	2.330E-1	timepoint;1 hour;20 hours
1-tetradecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine	ST001205	AN002006	4.020E-2	5.090E-1	treatment_duration_(h);1;5;3
2-Amino-3-methyl-1-butanol + 5.2393837	ST000421	AN000663	4.020E-2	3.090E-1	treatment;ND;T1D poor glycemic control
C12 GALACTOSYL(BETA) CERAMIDE (D18:1/12:0) (M+Cl)-	ST000818	AN001296	4.020E-2	6.850E-2	Ethnicity;Amhara;Dizi;Hadza;Hamer;Herero/Na;Herero;Ju|Hoan;J...
Oxidized Latia luciferin-13C1[+QDA adduct]+	ST000148	AN000235	4.030E-2	1.420E-1	Treatment;13C-Glc;unlabeled
6-bromotryptophan	ST000976	AN001597	4.050E-2	3.080E-1	GENDER;F;M
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-	ST000726	AN001138	4.060E-2	1.400E-1	Assay;BC TP;OGTT
O-glucosyl-tomatidine	ST001204	AN002005	4.060E-2	7.460E-2	cell_type;iRBC;unRBC
Oxooctanoate-13C1[+QDA adduct]+	ST000148	AN000235	4.060E-2	1.430E-1	Treatment;13C-Glc;unlabeled
Sulfadoxine suflate	ST000421	AN000664	4.070E-2	3.270E-1	treatment;ND;T1D poor glycemic control
4-keto pentadecanoic acid	ST000248	AN000392	4.080E-2	7.260E-1	Cell population;Fast-cycling cells;Slow-cyling cells
ATP-H2O-13C0+15N0	ST000076	AN000121	4.080E-2	5.990E-1	Labeling;13C/15N-Gln;13C-Glc;unlabeled
Dichlorophen	ST000291	AN000464	4.080E-2	8.100E-1	Treatment ;Baseline urine;Urine after drinking apple juice;U...
L-[15N]ANTHRANILIC ACID [ISTD] (CAS# ); (M-H)-	ST000695	AN001075	4.090E-2	2.620E-1	Drug;Exemestane;Letrozole;POOLED
Meradimate+2.886999	ST000047	AN000081	4.090E-2	2.080E-1	Cognitive Status;AD;CN;MCI
EPIAFZELECHINTRIMETHYLETHER	ST000046	AN000079	4.100E-2	1.440E-1	Cognitive Status;AD;CN;MCI
Isohomovanillic acid	ST000356	AN000583	4.110E-2	5.910E-2	Diagnosis;breast cancer;control
Corey PG-Lactone Diol	ST000566	AN000870	4.120E-2	1.350E-1	group;Old-Curcumin;Old-Placebo;young
tartrazine	ST001202	AN002001	4.130E-2	5.740E-2	treatment_duration_(h);-;1.5;3;6;9
Undecanone-13C2[+QDA adduct]+	ST000148	AN000235	4.130E-2	1.450E-1	Treatment;13C-Glc;unlabeled
CerP(t39:1)[M+H]+	ST000992	AN001621	4.140E-2	3.460E-1	Metabolic syndrome;No;Yes
Bis(2-hydroxypropyl)amine+5.481559	ST000046	AN000077	4.150E-2	2.020E-1	Cognitive Status;AD;CN;MCI
HECOGENINACETATE	ST000047	AN000080	4.150E-2	2.500E-1	Cognitive Status;AD;CN;MCI
Oxodecanoate-13C1[+QDA adduct]+	ST000148	AN000235	4.170E-2	1.460E-1	Treatment;13C-Glc;unlabeled
ZEATIN [ISTD] (M+CL)-	ST000726	AN001138	4.170E-2	2.170E-1	DISEASE_STATE;Control;PCOS
L-Leucine-D10	ST000424	AN000673	4.180E-2	3.080E-1	DONOR CAUSE OF DEATH;Anoxia;Cerebrovascular/Stroke;CVA;Traum...
2-AMINO-2-DEOXYHEXOPYRANOSE	ST000106	AN000175	4.190E-2	3.060E-1	Sampling time;0 min;60 min
2-hexacosanamidoethanesulfonicacid	ST000047	AN000081	4.190E-2	2.080E-1	Cognitive Status;AD;CN;MCI
Hydroxynonenal-13C1[+QDA adduct]+	ST000148	AN000235	4.190E-2	1.470E-1	Treatment;13C-Glc;unlabeled
Oxododecanoate-13C0[+13CD3 QDA]+	ST000148	AN000235	4.190E-2	1.470E-1	Treatment;13C-Glc;unlabeled
2-Amino-2-methyl-1-propanol+5.204487	ST000047	AN000081	4.200E-2	2.080E-1	Cognitive Status;AD;CN;MCI
3-Methyglutarate	ST001040	AN001703	4.200E-2	8.820E-2	Sample Type/Matrix;Pooled quality control sample;urine;Water...
DI-LINOLEOYL-3-SN-PHOSPHATIDYLCHOLINE (???)	ST000016	AN000033	4.220E-2	1.170E-1	Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
7-ALPHA-HYDROXY-3-OXO-4-CHOLESTENOATE	ST000009	AN000024	4.230E-2	8.560E-2	SURGERY;GASTRIC_BAND;ROUX_EN_Y;LEAN_CONTROL
Glutamate semialdehyde-13C0[+13CD3 QDA]+	ST000142	AN000225	4.230E-2	2.280E-1	Treatment;13C-Glc;unlabeled
sulfa d18:1 N22:0	ST000362	AN000594	4.230E-2	6.260E-1	Severe_Exacerbations;1;2;3;5;-
Cys-Gly-Pro-Ser	ST001201	AN001999	4.240E-2	6.440E-2	cell_type;iRBC;unRBC
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-	ST000708	AN001100	4.240E-2	1.570E-1	GROUP;POOLED;Standard;VLED
Creatine-D3	ST000424	AN000673	4.250E-2	3.080E-1	DONOR CAUSE OF DEATH;Anoxia;Cerebrovascular/Stroke;CVA;Traum...
25-hydroxyvitaminD225-(beta-glucuronide)/25hydroxyergocalciferol25-(beta-glucuronide)	ST000045	AN000072	4.260E-2	2.380E-1	Treatment;Insulin Withdrawal;Saline Infusion
Methyl-isopropylhexadienal-13C0[+13CD3 QDA]+	ST000142	AN000225	4.260E-2	2.290E-1	Treatment;13C-Glc;unlabeled
PYRIDINE CARBOXYLIC ACID	ST000105	AN000174	4.260E-2	3.540E-1	Gender;Female;Male
L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-	ST000708	AN001100	4.270E-2	1.940E-1	VISIT;POOLED;visit 1;visit 2
[13C]-HISTIDINE	ST000044	AN000068	4.280E-2	2.050E-1	Pancreas tissue type;Normal area of the pancreas with tumor;...
8-Amino-7-oxononanoate	ST001201	AN001998	4.280E-2	6.080E-2	cell_type;iRBC;unRBC
PEUCENIN+7.86186	ST000047	AN000080	4.280E-2	2.500E-1	Cognitive Status;AD;CN;MCI
UDP-GNAc-13C5+15N0	ST000076	AN000121	4.290E-2	5.990E-1	Labeling;13C/15N-Gln;13C-Glc;unlabeled
GLYCODEOXYCHOLATE / GLYCOCHENODEOXYCHOLATE (*)	ST000106	AN000176	4.300E-2	2.210E-1	Sampling time;0 min;60 min
URSINIC ACID	ST000422	AN000668	4.300E-2	3.560E-1	treatment;ND;T1D good glycemic control
t-aconitate-13C2	ST001045	AN001709	4.310E-2	1.510E-1	protocol.id;12CGlc_FASN_shRNA;12CGlc_NTC_shRNA;13CGlc_FASN_s...
Ala-Ala-Ala-Ser	ST001205	AN002006	4.320E-2	9.990E-1	treatment;DHA;DMSO;OZ277;OZ439
Met-Trp-Trp-Tyr	ST000539	AN000818	4.320E-2	2.360E-1	timepoint;1 hour;20 hours
N-acetylglycine NIST	ST001131	AN001856	4.320E-2	1.810E-1	Treatment;Healthy;Trauma
1-deoxynojirimycin	ST000403	AN000642	4.330E-2	2.180E-1	Glucose labelling;C13 glucose;unlabelled
3-nitro-2-pentanol	ST000539	AN000818	4.330E-2	6.750E-2	Cell type;Mature erythrocyte;Reticulocyte
DOCOSAPENTAENOATE (*)	ST000106	AN000176	4.330E-2	5.150E-1	Visit;1;2
16a-hydroxy DHEA 3-sulfate	ST000976	AN001597	4.340E-2	5.670E-1	GROUP;case;control
alpha-Methylstyrene	ST000403	AN000642	4.350E-2	6.580E-2	Cell type;Mature erythrocyte;Reticulocyte
Delphinidin 3-O-glucoside-13C0[+QDA adduct+Na]+	ST000142	AN000225	4.350E-2	2.340E-1	Treatment;13C-Glc;unlabeled
pyroGlu-13C1	ST001049	AN001864	4.350E-2	1.570E-1	protocol.id;12CGlc_shCTL;12CGlc_shP4HA1;13CGlc_shCTL;13CGlc_...
crustecdysone	ST001192	AN001986	4.370E-2	2.160E-1	Diet;-;Omnivore;Vegetarian
L-proline amide	ST000539	AN000818	4.370E-2	6.770E-2	Cell type;Mature erythrocyte;Reticulocyte
Asp-Leu-Lys-Asp	ST001204	AN002004	4.380E-2	4.260E-1	treatment;DHA;DMSO;OZ277;OZ439
Sulfite	ST000421	AN000664	4.380E-2	3.270E-1	treatment;ND;T1D poor glycemic control
ZEATIN [ISTD] (M+H)+	ST000721	AN001127	4.380E-2	2.480E-1	Gender;Male;Female
2-Formaminobenzoylacetate	ST000539	AN000819	4.390E-2	7.140E-2	Cell type;Mature erythrocyte;Reticulocyte
3-OH-DL-KYNURENINE	ST000876	AN001413	4.390E-2	3.200E-1	L-serine (mg/kg/day);100;200;300;400;50;-
Phenylalanine-HCOOH	ST000954	AN001564	4.390E-2	2.340E-1	race;1;2
1-dihomo-linoleoylglycerophosphocholine (20:2n6)*	ST000974	AN001595	4.400E-2	1.980E-1	GENDER;F;M
[13C]-PROLINE	ST000105	AN000173	4.410E-2	2.080E-1	Sampling;After SWS onset;Morning fasting
CAI-1-13C0[+13CD3 QDA]+	ST000148	AN000235	4.410E-2	1.530E-1	Treatment;13C-Glc;unlabeled
Gemeprost + 11.412178	ST000421	AN000665	4.410E-2	4.500E-1	treatment;ND;T1D poor glycemic control
iodoacetate	ST001204	AN002005	4.410E-2	8.320E-1	treatment;DHA;DMSO;OZ277;OZ439
Isopropenyl oxoheptanoate-13C0[+13CD3 QDA]+	ST000148	AN000235	4.430E-2	1.530E-1	Treatment;13C-Glc;unlabeled
Mesaconate	ST000403	AN000643	4.440E-2	3.340E-1	timepoint;1 hour;20 hours
ALPHA-AMINOADIPATE/N-METHYL-L-GLUTAMATE	ST000954	AN001564	4.450E-2	4.160E-1	ethnicity;1;2;-
2-Formaminobenzoylacetate	ST000403	AN000643	4.460E-2	1.870E-1	Glucose labelling;C13 glucose;unlabelled
n-acetyl-d-hexosamine	ST001322	AN002198	4.466E-2	1.870E-1	group;OB;NW
Fumaric	ST000284	AN000452	4.470E-2	1.530E-1	Patient group;CRC;Healthy;Polyp
L-Noradrenaline	ST000539	AN000819	4.470E-2	7.200E-2	Cell type;Mature erythrocyte;Reticulocyte
PC aa C28:1 / PC aa C40:2	ST000405	AN000645	4.470E-2	5.990E-1	Group;No PA;PA;PoolAll
NMMA	ST001237	AN002055	4.480E-2	1.610E-1	Prior antiangiogenic regimens (≥2);FALSE;TRUE
Isohomovanillic acid	ST000356	AN000583	4.490E-2	7.390E-2	stage;-;2;3
PGP(18:0/18:1(11Z))	ST000241	AN000373	4.490E-2	5.140E-2	Treatment_compound;BSA;CB-cis;CB-trans;CK-cis;CK-trans;K-cis...
PEUCENIN	ST000047	AN000080	4.500E-2	2.500E-1	Cognitive Status;AD;CN;MCI
VGAHAGEYGAEALER*	ST000093	AN000149	4.500E-2	2.860E-1	condition;FFA affected ;FFA unaffected ;Scalp biopsy normal
VGAHAGEYGAEALER*	ST000093	AN000149	4.500E-2	2.860E-1	location;frontal scalp;occipital scalp;NA
Diethyl Oxalpropionate	ST000566	AN000870	4.510E-2	4.640E-2	Time point;Post;Pre;Baseline
Tetrahydrothiophene sulfoxide	ST000422	AN000667	4.530E-2	5.950E-1	treatment;ND;T1D good glycemic control
4-Hydroxypyridine+1.305617	ST000046	AN000077	4.540E-2	2.100E-1	Cognitive Status;AD;CN;MCI
Ala-Asp-Cys-Ser	ST001201	AN001998	4.550E-2	1.360E-1	treatment;DHA;DMSO;OZ277;OZ439
1.2.3.4-tetrahydro-beta-carboline-1.3-dicarboxylate	ST000923	AN001515	4.560E-2	2.960E-1	sex;Female;Male
BOC-ASN	ST000009	AN000023	4.560E-2	2.550E-1	AFTER_MEAL_TIME;30_MIN;NO_WAIT
BOC-ASN	ST000106	AN000176	4.560E-2	5.150E-1	Visit;1;2
D/L Glucosamine / D/L Galactosamine	ST001040	AN001702	4.560E-2	8.310E-2	Sample Type/Matrix;Pooled quality control sample;urine;Water...
L-2-Aminoadipate 6-semialdehyde	ST000403	AN000643	4.560E-2	3.380E-1	timepoint;1 hour;20 hours
L-Leucine-D10	ST000954	AN001564	4.560E-2	4.160E-1	ethnicity;1;2;-
saccharic acid	ST000412	AN000652	4.560E-2	1.340E-1	Collection Time;1 Hr;2 Hr;3 Hr;-
BENZOIC ACID #2 (M-H)-	ST000748	AN001172	4.570E-2	4.930E-2	Sample type;Cells;Culture Media
[13C]-GLUTAMATE	ST000043	AN000070	4.580E-2	1.150E-1	Cell line;MDA-MB-231;MDA-MB-231 p38 gamma knockdown;MDA-MB-2...
LACTATE-dimer	ST000956	AN001569	4.590E-2	7.280E-2	Treatment;Condition-1;Condition-2;Condition-3;Control
Digoxigenin bisdigitoxoside	ST000242	AN000377	4.600E-2	1.030E-1	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
L-[15N]ANTHRANILIC ACID [ISTD] (M+H)+	ST000742	AN001158	4.600E-2	8.070E-2	Species;Homo sapiens;Mus musculus;-
ZEATIN [ISTD] (M+H)+	ST000763	AN001202	4.600E-2	1.570E-1	Type;Cath;Non-invasive
BOC-MET-OH	ST000105	AN000174	4.610E-2	5.090E-1	OSA;Negative;Positive
fluphenazineenanthate	ST000047	AN000081	4.610E-2	2.150E-1	Cognitive Status;AD;CN;MCI
Bis(2-hydroxypropyl)amine	ST000047	AN000081	4.630E-2	2.150E-1	Cognitive Status;AD;CN;MCI
PENTADECANOYLGLYCEROPHOSPHOCHOLINE/STEAROYLGLYCEROPHOSPHOETHANOLAMINE	ST000016	AN000033	4.630E-2	1.260E-1	Treatment;K210R NPM-ALK tf;No transfection;WT NPM-ALK tf;CEP...
Hydroxyabscisate-13C1[+H]+	ST000142	AN000225	4.640E-2	2.470E-1	Treatment;13C-Glc;unlabeled
Ketohexanoate-13C5[+QDA adduct]+	ST000142	AN000225	4.640E-2	2.470E-1	Treatment;13C-Glc;unlabeled
Methyl Docosanoate	ST000978	AN001602	4.640E-2	1.700E-1	Competitive_RRTvsDeath;.;N;RRT;DEATH
2-deoxycytidine	ST000923	AN001513	4.660E-2	7.100E-2	Diagnosis;CD;nonIBD;UC
BOC-ASN-OH	ST000106	AN000176	4.660E-2	5.150E-1	Visit;1;2
cis-3-Hexenyllactate	ST000355	AN000580	4.660E-2	1.190E-1	Diagnosis;Breast cancer;Control
Tolmetin sodium	ST000292	AN000466	4.660E-2	3.250E-1	Treatment ;Baseline plasma;Plasma after drinking apple juice...
D-2-Amino-hexano-6-lactam	ST000539	AN000818	4.690E-2	7.220E-2	Cell type;Mature erythrocyte;Reticulocyte
Lys-Lys-Trp-Pro	ST001204	AN002005	4.690E-2	4.030E-1	treatment_duration_(h);-;3;6;9
SucroseAndDischarrides-13C12[-H+]-	ST000367	AN000601	4.690E-2	1.150E-1	Tissue type;nontumor;tumor
2-oxo-3-methylvaleric acid	ST000566	AN000870	4.700E-2	1.410E-1	group;Old-Curcumin;Old-Placebo;young
Gemeprost	ST000421	AN000665	4.710E-2	4.500E-1	treatment;ND;T1D poor glycemic control
Tos-Lys-CH2Cl	ST000292	AN000466	4.730E-2	3.250E-1	Treatment ;Baseline plasma;Plasma after drinking apple juice...
URSINICACID	ST000046	AN000077	4.750E-2	2.140E-1	Cognitive Status;AD;CN;MCI
2-OG b	ST000096	AN000154	4.760E-2	1.770E-1	Sample Type;Adipocyte ;Co-culture ;Control ;Media blank
ACETAMINOPHEN (TN TYLENOL) (M+NA)+	ST000742	AN001158	4.760E-2	8.080E-2	Species;Homo sapiens;Mus musculus;-
Hydroxyprolyl-Asparagine	ST001205	AN002006	4.760E-2	9.690E-2	parasite_line;Cam3.IIR539T;Cam3.IIrev
Oxononanoate-13C1[+13CD3 QDA]+	ST000148	AN000235	4.760E-2	1.620E-1	Treatment;13C-Glc;unlabeled
17beta-Hydroxy-2alpha-(hydroxymethyl)-5alpha-androstan-3-one-13C1[+QDA adduct]+	ST000148	AN000235	4.770E-2	1.620E-1	Treatment;13C-Glc;unlabeled
3-ethylphenylsulfate	ST000974	AN001595	4.770E-2	2.100E-1	GENDER;F;M
BOC-ASN	ST000011	AN000027	4.770E-2	1.770E-1	COLLECTION_COUNTRY;ETHIOPIA;TANZANIA
CerP 21:0; [M-H]-@2.12	ST000775	AN001224	4.770E-2	1.270E-1	Treatment response;No;Yes;Pooled
N-(6-Quinolinyl)phthalimide	ST000978	AN001602	4.770E-2	1.540E-1	Cox_RRT;.;N;Y
L-Glutamate methylester	ST000539	AN000818	4.780E-2	5.120E-1	Glucose labelling;C13 glucose;unlabelled
DIMETHYLXANTHINE (*)	ST000105	AN000173	4.790E-2	4.390E-1	Gender;Female;Male
Gln-Leu-Lys-His	ST000539	AN000818	4.790E-2	2.570E-1	timepoint;1 hour;20 hours
MBzP	ST001040	AN001703	4.790E-2	9.580E-2	Sample Type/Matrix;Pooled quality control sample;urine;Water...
3-methyl catechol sulfate (1)	ST000975	AN001596	4.800E-2	3.890E-1	REGION;MAK;SUN
12-OPDA	ST000403	AN000642	4.810E-2	4.280E-1	timepoint;1 hour;20 hours
ANHYDROBRAZILICACID	ST000046	AN000078	4.840E-2	1.600E-1	Cognitive Status;AD;CN;MCI
L-[15N]ANTHRANILIC ACID [ISTD] (M+H)+	ST000768	AN001215	4.840E-2	3.320E-1	Media;3N media;E8 media
L-[15N]ANTHRANILIC ACID [ISTD] (M+H)+	ST000768	AN001215	4.840E-2	3.320E-1	Type;neurons;stem cells
Allotetrahydrocortisol	ST000421	AN000665	4.870E-2	4.500E-1	treatment;ND;T1D poor glycemic control
4-Hydroxybenzylcyanide	ST000046	AN000077	4.890E-2	2.170E-1	Cognitive Status;AD;CN;MCI
Gln-Leu-Lys-His	ST000403	AN000642	4.890E-2	2.310E-1	Glucose labelling;C13 glucose;unlabelled
succite	ST001000	AN001879	4.890E-2	9.130E-2	Diagnosis;CD;Control;UC
16a-hydroxy DHEA 3-sulfate	ST000974	AN001595	4.900E-2	2.140E-1	GENDER;F;M
Ergine	ST000242	AN000377	4.900E-2	1.070E-1	Sample Status;Whole M1 medium;Whole M2 medium; Whole uncondi...
Spermine / Spermidine	ST000545	AN000829	4.900E-2	2.400E-1	Sample Type;Control;Replicate
L-beta-Homoleucine	ST000913	AN001483	4.910E-2	4.480E-1	Diagnosis;MECFS;MS;ND
nicotinamide guanine dinucleotide	ST001201	AN001999	4.910E-2	1.910E-1	treatment;DHA;DMSO;OZ277;OZ439
thymine-d4	ST001192	AN001985	4.910E-2	3.720E-1	Diet;-;Omnivore;Vegetarian
Xanthumin-13C0[+Na]+	ST000142	AN000225	4.910E-2	2.600E-1	Treatment;13C-Glc;unlabeled
Ala-Asp-Cys-Ser	ST001202	AN002000	4.930E-2	5.930E-2	treatment_duration_(h);-;1.5;3;6;9
Icosadienoic acid	ST000539	AN000819	4.930E-2	7.860E-2	Cell type;Mature erythrocyte;Reticulocyte
Asn-Leu-Lys-Asp	ST001201	AN001998	4.940E-2	1.460E-1	treatment;DHA;DMSO;OZ277;OZ439
BOC-ASN	ST000010	AN000025	4.940E-2	1.120E-1	Hours;72;0;12;24;2
Cit / Orn	ST000544	AN000826	4.950E-2	1.400E-1	Sample Type;Control;Replicate
tthyl hexadecenoate	ST001000	AN001878	4.950E-2	8.890E-2	Diagnosis;CD;Control;UC
[FA (10:1/2:0)] 2E-Decenedioic acid	ST000539	AN000819	4.970E-2	7.880E-2	Cell type;Mature erythrocyte;Reticulocyte
Unknown_742.54(-)@5.61	ST000818	AN001298	4.970E-2	6.530E-2	Country;Ethiopia;Tanzania;Botswana
AMINOHYDROXYBUTANOIC ACID	ST000105	AN000173	4.980E-2	5.620E-1	CPAP;No CPAP;After CPAP
Bis (2-hydroxypropyl) amine + 5.4315743	ST000422	AN000667	4.990E-2	6.020E-1	treatment;ND;T1D good glycemic control
2-oxogluconic acid NIST	ST000386	AN000621	5.000E-2	1.560E-1	Cancer status;Adenocarcinoma;Adenocarcnoma;Adenosquamous;Hea...
Diacetylhydrazine	ST000403	AN000642	5.000E-2	4.280E-1	timepoint;1 hour;20 hours

( Species:Human)
List of studies, analyses, submitted metabolite names, experimental conditions and RSD values

Replicate numbers reflect the number of replicates for each experimental condition where the measured value was not null

Name	Study_id	Analysis_id	Factors	Range(RSD)	Replicates